⚕︎𝜓

Géder Grohs

PSIQUIATRA | FLORIANÓPOLIS

SZ 2022~2023

PMID- 37802615

OWN - NLM

STAT- MEDLINE

DCOM- 20231010

LR - 20231013

IS - 2044-6055 (Electronic)

IS - 2044-6055 (Linking)

VI - 13

IP - 10

DP - 2023 Oct 6

TI - Understanding the burden of mental and physical health disorders on families:

findings from the Saudi National Mental Health Survey.

PG - e072115

LID - 10.1136/bmjopen-2023-072115 [doi]

LID - e072115

AB - OBJECTIVE: To assess prevalence and correlation of factors of family burden

associated with mental and physical disorders in the general population of Saudi

Arabia. SETTING AND PARTICIPANTS: A secondary analysis of data from the Saudi

National Mental Health Survey (SNMHS). OUTCOME MEASURES: Mental and physical

health disorders of first-degree relatives and objective (time, financial) and

subjective (distress, embarrassment) family burden. RESULTS: We found significant

caregiver burden for family members with mental health disorders. Around

one-third of the sample was providing care for a family member with a health

issue. Within this group, 40% had a mental health diagnosis. 73% of the study

population reported experiencing some form of burden as a result of the care they

are obligated to provide for their family members. We found the highest burden on

male caregivers, in providing care for family members with serious memory

disorders, mental retardation, schizophrenia or psychosis, followed by, alcohol

and drug disorders, anxiety, depression or manic depression. CONCLUSION: Our

findings for family burden were statistically significant, indicating potential

negative impact on caregiver coping ability with the demands of caring for family

members with health issues. A comprehensive review of national mental health

policies is required to integrate aspects of community mental health promotion,

scale-up prevention, screening interventions and social support to protect

against the difficulties of mental illness and reduce the burden on caregivers,

the family, society, health system and the economy.

CI - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No

commercial re-use. See rights and permissions. Published by BMJ.

FAU - Zedan, Haya S

AU - Zedan HS

AUID- ORCID: 0000-0002-7246-9559

AD - Department of Public Health, College of Health Sciences, Saudi Electronic

University, Riyadh, Saudi Arabia.

FAU - Bilal, Lisa

AU - Bilal L

AUID- ORCID: 0000-0002-7574-4210

AD - King Salman Center for Disability Research, Riyadh, Saudi Arabia.

AD - Biostatistics, Epidemiology and Scientific Computing Department, King Faisal

Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

AD - SABIC Psychological Health Research & Applications Chair (SPHRAC), King Saud

University College of Medicine, Riyadh, Saudi Arabia.

FAU - Hyder, Sanaa

AU - Hyder S

AD - King Salman Center for Disability Research, Riyadh, Saudi Arabia.

AD - Biostatistics, Epidemiology and Scientific Computing Department, King Faisal

Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

AD - SABIC Psychological Health Research & Applications Chair (SPHRAC), King Saud

University College of Medicine, Riyadh, Saudi Arabia.

FAU - Naseem, Mohammad Talal

AU - Naseem MT

AUID- ORCID: 0000-0003-1949-4496

AD - King Salman Center for Disability Research, Riyadh, Saudi Arabia.

AD - Biostatistics, Epidemiology and Scientific Computing Department, King Faisal

Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

AD - SABIC Psychological Health Research & Applications Chair (SPHRAC), King Saud

University College of Medicine, Riyadh, Saudi Arabia.

FAU - Akkad, Marya

AU - Akkad M

AUID- ORCID: 0000-0001-9097-5079

AD - King Salman Center for Disability Research, Riyadh, Saudi Arabia.

AD - Biostatistics, Epidemiology and Scientific Computing Department, King Faisal

Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

AD - SABIC Psychological Health Research & Applications Chair (SPHRAC), King Saud

University College of Medicine, Riyadh, Saudi Arabia.

FAU - Al-Habeeb, Abdulhameed

AU - Al-Habeeb A

AD - National Center for Mental Health Promotion (NCMH), Saudi Arabia Ministry of

Health, Riyadh, Saudi Arabia.

FAU - Al-Subaie, Abdullah S

AU - Al-Subaie AS

AD - SABIC Psychological Health Research & Applications Chair (SPHRAC), King Saud

University College of Medicine, Riyadh, Saudi Arabia.

AD - Edrak Medical Center, Riyadh, Saudi Arabia.

FAU - Altwaijri, Yasmin

AU - Altwaijri Y

AUID- ORCID: 0000-0001-8826-3224

AD - King Salman Center for Disability Research, Riyadh, Saudi Arabia

yasmint@kfshrc.edu.sa.

AD - Biostatistics, Epidemiology and Scientific Computing Department, King Faisal

Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

AD - SABIC Psychological Health Research & Applications Chair (SPHRAC), King Saud

University College of Medicine, Riyadh, Saudi Arabia.

LA - eng

GR - R01 MH070884/MH/NIMH NIH HHS/United States

GR - R13 MH066849/MH/NIMH NIH HHS/United States

GR - R01 MH069864/MH/NIMH NIH HHS/United States

GR - R01 DA016558/DA/NIDA NIH HHS/United States

GR - R03 TW006481/TW/FIC NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20231006

PL - England

TA - BMJ Open

JT - BMJ open

JID - 101552874

SB - IM

MH - Humans

MH - Male

MH - Saudi Arabia/epidemiology

MH - *Mental Disorders/epidemiology

MH - *Psychotic Disorders

MH - *Schizophrenia

MH - Adaptation, Psychological

MH - Caregivers/psychology

MH - Family/psychology

MH - Health Surveys

PMC - PMC10565287

OTO - NOTNLM

OT - epidemiologic studies

OT - mental health

OT - primary care

OT - psychiatry

COIS- Competing interests: None declared.

EDAT- 2023/10/07 00:41

MHDA- 2023/10/10 06:42

CRDT- 2023/10/06 21:13

PHST- 2023/10/10 06:42 [medline]

PHST- 2023/10/07 00:41 [pubmed]

PHST- 2023/10/06 21:13 [entrez]

AID - bmjopen-2023-072115 [pii]

AID - 10.1136/bmjopen-2023-072115 [doi]

PST - epublish

SO - BMJ Open. 2023 Oct 6;13(10):e072115. doi: 10.1136/bmjopen-2023-072115.

PMID- 37801319

OWN - NLM

STAT- MEDLINE

DCOM- 20231009

LR - 20231011

IS - 2574-3805 (Electronic)

IS - 2574-3805 (Linking)

VI - 6

IP - 10

DP - 2023 Oct 2

TI - Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among

Hospitalized Men With Schizophrenia: A Randomized Clinical Trial.

PG - e2335518

LID - 10.1001/jamanetworkopen.2023.35518 [doi]

LID - e2335518

AB - IMPORTANCE: Limited evidence supports multigenetic pharmacogenomics-guided

treatment (MPGT) in schizophrenia. OBJECTIVE: To evaluate the clinical

effectiveness of MPGT in schizophrenia in a randomized clinical trial (RCT).

DESIGN, SETTING, AND PARTICIPANTS: This RCT was conducted from March 2020 to

March 2022. Male Chinese Han inpatients aged 18 to 60 years diagnosed with

schizophrenia with a Positive and Negative Symptom Scale (PANSS) score of 60 or

more from 2 selected study hospitals were included. Patients and raters were

masked to MPGT or treatment as usual (TAU) randomization. INTERVENTIONS:

Participants were randomly assigned in a 1:1 ratio to receive either MPGT or TAU

for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the

percentage change in PANSS total scores (range, 30 to 210) from baseline to week

6 analyzed by a modified intention-to-treat mixed model for repeated measures.

The secondary outcome included response and symptomatic remission rates. RESULTS:

A total of 210 participants (mean [SD] age, 29.2 [8.8] years) were enrolled and

analyzed, with 113 assigned to MPGT and 97 to TAU. Compared with those randomized

to TAU, participants randomized to MPGT demonstrated a significantly higher

percentage change in PANSS score (74.2% vs 64.9%; adjusted mean difference, 9.2

percentage points; 95% CI, 4.4-14.1 percentage points; P < .001) and a higher

response rate (93 of 113 [82.3%] vs 63 of 97 [64.9%]; adjusted odds ratio, 2.48;

95% CI, 1.28-4.80; P = .01) at the end of week 6. CONCLUSIONS AND RELEVANCE: In

this RCT of MPGT, MPGT was more effective than TAU in treating patients with

schizophrenia. These findings suggest that multigenetic pharmacogenomic testing

could serve as an effective tool to guide the treatment of schizophrenia. TRIAL

REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2000029671.

FAU - Kang, Zhewei

AU - Kang Z

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

FAU - Qin, Ying

AU - Qin Y

AD - The Second People's Hospital of Guizhou Province, Guiyang, China.

FAU - Sun, Yutao

AU - Sun Y

AD - Tangshan Mental Health Center, Tangshan Fifth Hospital, Tangshan, China.

FAU - Lu, Zhe

AU - Lu Z

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

FAU - Sun, Yaoyao

AU - Sun Y

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

FAU - Chen, Huan

AU - Chen H

AD - Shantou University Mental Health Center, Shantou, China.

FAU - Feng, Xiaoyang

AU - Feng X

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

FAU - Zhang, Yuyanan

AU - Zhang Y

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

FAU - Guo, Hua

AU - Guo H

AD - Zhumadian Second People's Hospital, Zhumadian, China.

FAU - Yan, Hao

AU - Yan H

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

FAU - Yue, Weihua

AU - Yue W

AD - Institute of Mental Health, Peking University Sixth Hospital, Beijing, China.

AD - National Clinical Research Center for Mental Disorders, Peking University Sixth

Hospital, Beijing, China.

AD - NHC Key Laboratory of Mental Health, Research Unit of Diagnosis and Treatment of

Mood Cognitive Disorder, Chinese Academy of Medical Sciences, Beijing, China.

AD - PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China.

AD - Chinese Institute for Brain Research, Beijing, China.

LA - eng

SI - ChiCTR/ChiCTR2000029671

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20231002

PL - United States

TA - JAMA Netw Open

JT - JAMA network open

JID - 101729235

SB - IM

MH - Male

MH - Humans

MH - Adult

MH - *Pharmacogenetics

MH - *Schizophrenia/drug therapy/genetics

MH - Treatment Outcome

PMC - PMC10559185

COIS- Conflict of Interest Disclosures: None reported.

EDAT- 2023/10/06 12:44

MHDA- 2023/10/09 06:42

CRDT- 2023/10/06 11:33

PHST- 2023/10/09 06:42 [medline]

PHST- 2023/10/06 12:44 [pubmed]

PHST- 2023/10/06 11:33 [entrez]

AID - 2810261 [pii]

AID - zoi231020 [pii]

AID - 10.1001/jamanetworkopen.2023.35518 [doi]

PST - epublish

SO - JAMA Netw Open. 2023 Oct 2;6(10):e2335518. doi:

10.1001/jamanetworkopen.2023.35518.

PMID- 37789971

OWN - NLM

STAT- MEDLINE

DCOM- 20231005

LR - 20231005

IS - 1177-8881 (Electronic)

IS - 1177-8881 (Linking)

VI - 17

DP - 2023

TI - Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in

Therapy.

PG - 3023-3031

LID - 10.2147/DDDT.S366769 [doi]

AB - This review aims to provide a comprehensive overview of the current literature on

the drug design, development, and therapy of lurasidone for the treatment of

schizophrenia. Lurasidone has antagonistic effects on the dopamine D(2),

5-hydroxytryptamine (5-HT)(2A), and 5-HT(7) receptors and a partial agonistic

effect on the 5-HT(1A) receptor with low affinities for muscarinic M(1),

histamine H(1), and a(1) adrenergic receptors. The receptor-binding profile of

lurasidone is thought to be associated with fewer side effects such as

anticholinergic effects, lipid abnormalities, hyperglycemia, and weight gain.

Behavioral pharmacological studies have demonstrated that lurasidone exerts

anxiolytic and antidepressive effects and improves cognitive function, which are

associated with the modulation of 5-HT(7) and 5-HT(1A) receptors. Literature

search using PubMed was performed to find published studies of randomized

controlled trials and recent meta-analyses regarding efficacy and safety,

particularly metabolic side effects of lurasidone in schizophrenia. In short-term

studies, the results of randomized placebo-controlled trials and meta-analyses

have suggested that lurasidone was superior to placebo in improving total

psychopathology, positive symptoms, negative symptoms, and general

psychopathology in patients with acute schizophrenia. Regarding safety,

lurasidone had minimal metabolic side effects, and was identified as one of the

drugs with the most benign profiles for metabolic side effects. Long-term trials

revealed that lurasidone had the preventive effects on relapse, with minimal

effects on weight gain and other metabolic side effects. Furthermore, lurasidone

improves cognitive and functional performance of patients with schizophrenia,

especially in long-term treatment. Patients with schizophrenia require long-term

treatment with antipsychotics for relapse prevention; thus, minimizing weight

gain and other side effects is crucial. Lurasidone is suitable as one of the

first-line antipsychotic drugs in the acute phase, and a switching strategy

should be considered during the maintenance phase, to balance efficacy and

adverse effects and achieve favorable outcomes in the long-term course of

schizophrenia.

FAU - Miura, Itaru

AU - Miura I

AUID- ORCID: 0000-0002-2133-5809

AD - Department of Neuropsychiatry, Fukushima Medical University School of Medicine,

Fukushima, Japan.

FAU - Horikoshi, Sho

AU - Horikoshi S

AD - Department of Neuropsychiatry, Fukushima Medical University School of Medicine,

Fukushima, Japan.

AD - Department of Neuropsychiatry, Horikoshi Psychosomatic Clinic, Fukushima, Japan.

FAU - Ichinose, Mizue

AU - Ichinose M

AD - Department of Neuropsychiatry, Fukushima Medical University School of Medicine,

Fukushima, Japan.

AD - Department of Neuropsychiatry, Hoshigaoka Hospital, Koriyama, Japan.

FAU - Suzuki, Yuhei

AU - Suzuki Y

AD - Department of Neuropsychiatry, Fukushima Medical University School of Medicine,

Fukushima, Japan.

FAU - Watanabe, Kenya

AU - Watanabe K

AD - Department of Pharmacy, Fukushima Medical University Hospital, Fukushima, Japan.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230928

PL - New Zealand

TA - Drug Des Devel Ther

JT - Drug design, development and therapy

JID - 101475745

RN - O0P4I5851I (Lurasidone Hydrochloride)

RN - 333DO1RDJY (Serotonin)

RN - 0 (Isoindoles)

RN - 0 (Thiazoles)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - Lurasidone Hydrochloride/adverse effects

MH - *Schizophrenia/drug therapy

MH - Serotonin

MH - Isoindoles/pharmacology

MH - Thiazoles/pharmacology

MH - *Antipsychotic Agents/adverse effects

MH - Weight Gain

PMC - PMC10544203

OTO - NOTNLM

OT - antipsychotics

OT - lurasidone

OT - schizophrenia

OT - serotonin-dopamine antagonist

COIS- Dr. Miura has received speaker’s honoraria from Sumitomo, Eisai, Janssen, Meiji

Seika Pharma, Otsuka, Takeda, Towa, Tanabe-Mitsubishi, and Yoshitomi. Dr.

Horikoshi has received honoraria for lectures from Sumitomo, Janssen, Meiji Seika

Pharma, Otsuka, Takeda, Lundbeck, and Yoshitomi. Drs. Ichinose, Suzuki, and

Watanabe declare no conflicts of interest in this work.

EDAT- 2023/10/04 06:44

MHDA- 2023/10/05 06:44

CRDT- 2023/10/04 03:57

PHST- 2023/07/07 00:00 [received]

PHST- 2023/09/15 00:00 [accepted]

PHST- 2023/10/05 06:44 [medline]

PHST- 2023/10/04 06:44 [pubmed]

PHST- 2023/10/04 03:57 [entrez]

AID - 366769 [pii]

AID - 10.2147/DDDT.S366769 [doi]

PST - epublish

SO - Drug Des Devel Ther. 2023 Sep 28;17:3023-3031. doi: 10.2147/DDDT.S366769.

eCollection 2023.

PMID- 37788803

OWN - NLM

STAT- MEDLINE

DCOM- 20231005

LR - 20231005

IS - 2155-7780 (Electronic)

IS - 2155-7780 (Linking)

VI - 25

IP - 5

DP - 2023 Sep 26

TI - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depression,

Schizophrenia, and Obsessive-Compulsive Disorder: An Umbrella Meta-Analysis.

LID - 22r03423 [pii]

LID - 10.4088/PCC.22r03423 [doi]

AB - Objective: To analyze the safety and efficacy of repetitive transcranial magnetic

stimulation (rTMS) for major depressive disorder, schizophrenia, and

obsessive-compulsive disorder (OCD) via umbrella meta-analysis. Data Sources:

Meta-analysis studies were searched in PubMed from inception to May 2021 using

the keywords anxiety, depression, ADHD, schizophrenia, mood disorder, OCD,

psychiatric disorders, GAD, bipolar disorders, ASD, PTSD, transcranial magnetic

stimulation, transcranial, magnetic, stimulation. PRISMA guidelines were

followed. Study Selection: Abstracts and full-length articles were reviewed for

meta-analysis studies with data on the safety and efficacy of rTMS and sham and

were collected for quantitative analysis. The full texts of all identified

studies were independently screened and assessed to determine eligibility. Any

disagreement was resolved through consensus. Data Extraction: The descriptive

variables extracted included the author names, study year, sample size, studies

included in the meta-analysis, study period, and type of intervention. Results:

28 meta-analyses were included; 13 were on treatment-resistant depression, 9 on

schizophrenia, and 6 on OCD. In treatment-resistant depression, the rTMS group

had higher odds of response compared to sham (odds ratio [OR] = 3.27; 95% CI,

2.76-3.87; P < .00001) and higher odds of remission (secondary outcome)

(OR = 2.83; 95% CI, 2.33-3.45; P < .00001). rTMS was superior to sham in the

reduction of negative symptoms of schizophrenia (mean difference [MD]: 0.47; 95%

CI, 0.23-0.7; P < .0001). However, no significant difference was found between

the effects of rTMS and sham on auditory hallucinations (MD: 0.24; 95% CI,

0.26-0.74; P = .35), which resulted in 94% heterogeneity. TMS was better than

sham in reducing the severity of OCD symptoms (MD: 0.81; 95% CI, 0.53-1.10;

P < .00001). Conclusions: The effectiveness of rTMS for symptom reduction in

various psychiatric disorders is associated with differences in neuropathology,

disease-specific target site, and frequency of rTMS. Prim Care Companion CNS

Disord 2023;25(5):22r03423. Author affiliations are listed at the end of this

article.

FAU - Patel, Shweta

AU - Patel S

AD - Department of Epidemiology, New York University, New York.

AD - Corresponding Author: Saral Desai, MD, Department of Psychiatry, Tower

Health/Phoenixville Hospital, 140 Nutt Rd, Phoenixville, PA 19460

(srd342@drexel.edu).

FAU - Silvi, Suraiya

AU - Silvi S

AD - Department of Psychiatry, Millwood Hospital, Arlington, Texas.

FAU - Desai, Saral

AU - Desai S

AD - Department of Psychiatry, Tower Health/Phoenixville Hospital, Phoenixville,

Pennsylvania.

FAU - Rahman, Fayaz

AU - Rahman F

AD - Karuna Medical College, Palakkad, Kerala, India.

FAU - Depa, Nishitha

AU - Depa N

AD - St. George's University School of Medicine, St. George's, Grenada, West Indies.

FAU - Hanif, Sarah

AU - Hanif S

AD - Department of Child and Adolescent Psychiatry, Tulane University School of

Medicine, New Orleans, Louisiana.

FAU - Rizvi, Syeda

AU - Rizvi S

AD - Department of Child and Adolescent Psychiatry, BronxCare Health System, New York.

FAU - Hsieh, Ya-Ching

AU - Hsieh YC

AD - Department of Public Health, Icahn School of Medicine at Mount Sinai, New York.

FAU - Malik, Preeti

AU - Malik P

AD - Department of Pathology, Montefiore Medical Center, New York.

FAU - Patel, Urvish

AU - Patel U

AD - Department of Public Health, Icahn School of Medicine at Mount Sinai, New York.

FAU - Mansuri, Zeeshan

AU - Mansuri Z

AD - Department of Psychiatry, Boston Children's Hospital/Harvard Medical School,

Massachusetts.

FAU - Mercy, Rana Prathap

AU - Mercy RP

AD - Department of Psychiatry, Indiana University Health Ball Memorial Hospital,

Muncie.

FAU - Aedma, Kapil

AU - Aedma K

AD - Department of Psychiatry, Unitypoint Health, Peoria, Illinois.

FAU - Parikh, Tapan

AU - Parikh T

AD - Department of Psychiatry, Northwestern University Feinberg School of Medicine,

Chicago, Illinois.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230926

PL - United States

TA - Prim Care Companion CNS Disord

JT - The primary care companion for CNS disorders

JID - 101547532

SB - IM

MH - Humans

MH - *Schizophrenia/therapy

MH - *Depressive Disorder, Major/therapy

MH - Transcranial Magnetic Stimulation/methods

MH - Depression

MH - *Obsessive-Compulsive Disorder/therapy

MH - Treatment Outcome

EDAT- 2023/10/04 00:42

MHDA- 2023/10/05 06:44

CRDT- 2023/10/03 19:22

PHST- 2023/10/05 06:44 [medline]

PHST- 2023/10/04 00:42 [pubmed]

PHST- 2023/10/03 19:22 [entrez]

AID - 22r03423 [pii]

AID - 10.4088/PCC.22r03423 [doi]

PST - epublish

SO - Prim Care Companion CNS Disord. 2023 Sep 26;25(5):22r03423. doi:

10.4088/PCC.22r03423.

PMID- 37773873

OWN - NLM

STAT- MEDLINE

DCOM- 20231005

LR - 20231005

IS - 1536-5964 (Electronic)

IS - 0025-7974 (Print)

IS - 0025-7974 (Linking)

VI - 102

IP - 39

DP - 2023 Sep 29

TI - The association between short-term exposure to nitrogen dioxide and hospital

admission for schizophrenia: A systematic review and meta-analysis.

PG - e35024

LID - 10.1097/MD.0000000000035024 [doi]

LID - e35024

AB - BACKGROUND: Ambient air pollution has been identified as a primary risk factor

for mental disorders. In recent years, the relationship between exposure to

ambient nitrogen dioxide (NO2) and the risk of hospital admissions (HAs) for

schizophrenia has garnered increasing scientific interest, but evidence from

epidemiological studies has been inconsistent. Therefore, a systematic review and

meta-analysis were conducted to comprehensively identify potential correlations.

METHODS: A literature search in 3 international databases was conducted before

December 31, 2022. Relative risk (RR) and corresponding 95% confidence intervals

(CI) were calculated to evaluate the strength of the associations. Summary effect

sizes were calculated using a random-effects model due to the expected

heterogeneity (I2 over 50%). RESULTS: A total of ten eligible studies were

included in the meta-analysis, including 1,412,860 participants. The pooled

analysis found that an increased risk of HAs for schizophrenia was associated

with exposure to each increase of 10 μg/m3 in NO2 (RR = 1.029, 95% CI =

1.016-1.041, P < .001). However, the heterogeneity was high for the summary

estimates, reducing the credibility of the evidence. In 2-pollutant models,

results for NO2 increased by 0.3%, 0.2% and 2.3%, respectively, after adjusting

for PM2.5, PM10 and SO2. CONCLUSIONS: This study provides evidence that NO2

exposure significantly increases the risk of hospital admission for

schizophrenia. Future studies are required to clarify the potential biological

mechanism between schizophrenia and NO2 exposure to provide a more definitive

result.

FAU - Xu, Jiating

AU - Xu J

AUID- ORCID: 0000-0003-4979-2048

AD - Department of General Psychiatry II, The Third Hospital of Quzhou, Quzhou City,

China.

FAU - Lan, Zhiyong

AU - Lan Z

AD - Department of General Psychiatry II, The Third Hospital of Quzhou, Quzhou City,

China.

FAU - Xu, Penghao

AU - Xu P

AD - Department of Geriatric Psychiatry II, The Third Hospital of Quzhou, Quzhou City,

China.

FAU - Zhang, Zhihua

AU - Zhang Z

AD - Department of Geriatric Psychiatry II, The Third Hospital of Quzhou, Quzhou City,

China.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

PL - United States

TA - Medicine (Baltimore)

JT - Medicine

JID - 2985248R

RN - S7G510RUBH (Nitrogen Dioxide)

RN - 0 (Air Pollutants)

SB - IM

MH - Humans

MH - Nitrogen Dioxide/adverse effects/analysis

MH - *Air Pollutants/adverse effects/analysis

MH - *Schizophrenia/epidemiology

MH - Environmental Exposure/adverse effects/analysis

MH - Hospitals

PMC - PMC10545286

COIS- The authors have no funding and conflicts of interest to disclose.

EDAT- 2023/09/29 18:42

MHDA- 2023/10/05 06:44

CRDT- 2023/09/29 15:44

PHST- 2023/10/05 06:44 [medline]

PHST- 2023/09/29 18:42 [pubmed]

PHST- 2023/09/29 15:44 [entrez]

AID - 00005792-202309290-00091 [pii]

AID - 10.1097/MD.0000000000035024 [doi]

PST - ppublish

SO - Medicine (Baltimore). 2023 Sep 29;102(39):e35024. doi:

10.1097/MD.0000000000035024.

PMID- 37725971

OWN - NLM

STAT- MEDLINE

DCOM- 20230921

LR - 20230925

IS - 1468-2834 (Electronic)

IS - 0002-0729 (Linking)

VI - 52

IP - 9

DP - 2023 Sep 1

TI - New horizons in schizophrenia in older people.

LID - afad161 [pii]

LID - 10.1093/ageing/afad161 [doi]

AB - People aged 65 years and older will soon constitute more than a quarter of the

total population with schizophrenia, challenging the existing systems of care.

For a long time, research into schizophrenia in later life was very limited.

However, recent years have seen an encouraging surge in novel and high-quality

studies related to this stage of life. Older people with schizophrenia consist of

those who had an early onset and aged with the disorder, and of a smaller but

sizeable group with a late onset or a very late onset. With ageing, physical

needs gain importance relative to psychiatric needs. Medical comorbidity

contributes to a markedly higher mortality compared to the general population. In

many persons, symptoms and functioning fluctuate with time, leading to

deterioration in some but improvement in others. Of note, a substantial number of

older people may experience subjective well-being in spite of ongoing symptoms

and social impairments. The majority of individuals with schizophrenia reside in

the community, but when institutionalization is required many are placed in

residential or nursing homes where staff is often ill-equipped to address their

complex needs. There is a clear need for implementation of new models of care in

which mental health and general health systems cooperate. This review provides a

state-of-the-art overview of current knowledge in late life schizophrenia and

related disorders, with a focus on themes with clinical relevance.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of the

journals.permissions@oup.com.

FAU - Meesters, Paul D

AU - Meesters PD

AD - Department of Research and Education, Friesland Mental Health Services,

Leeuwarden, The Netherlands.

LA - eng

PT - Journal Article

PT - Review

PL - England

TA - Age Ageing

JT - Age and ageing

JID - 0375655

SB - IM

MH - Humans

MH - Aged

MH - *Schizophrenia/diagnosis/therapy

MH - Aging

MH - Clinical Relevance

MH - Institutionalization

MH - Mental Health

OTO - NOTNLM

OT - ageing

OT - mental health care

OT - older people

OT - schizophrenia

EDAT- 2023/09/20 00:43

MHDA- 2023/09/21 06:42

CRDT- 2023/09/19 18:33

PHST- 2023/04/29 00:00 [received]

PHST- 2023/09/21 06:42 [medline]

PHST- 2023/09/20 00:43 [pubmed]

PHST- 2023/09/19 18:33 [entrez]

AID - 7275528 [pii]

AID - 10.1093/ageing/afad161 [doi]

PST - ppublish

SO - Age Ageing. 2023 Sep 1;52(9):afad161. doi: 10.1093/ageing/afad161.

PMID- 37716320

OWN - NLM

STAT- MEDLINE

DCOM- 20231003

LR - 20231010

IS - 1872-7123 (Electronic)

IS - 0165-1781 (Linking)

VI - 328

DP - 2023 Oct

TI - Exercise as an add-on treatment in individuals with schizophrenia: Results from a

large multicenter randomized controlled trial.

PG - 115480

LID - S0165-1781(23)00430-4 [pii]

LID - 10.1016/j.psychres.2023.115480 [doi]

AB - Current treatment methods do not achieve recovery for most individuals with

schizophrenia, and symptoms such as negative symptoms and cognitive deficits

often persist. Aerobic endurance training has been suggested as a potential

add-on treatment targeting both physical and mental health. We performed a

large-scale multicenter, rater-blind, parallel-group randomized controlled

clinical trial in individuals with stable schizophrenia. Participants underwent a

professionally supervised six-month training comprising either aerobic endurance

training (AET) or flexibility, strengthening, and balance training (FSBT, control

group), follow-up was another six months. The primary endpoint was all-cause

discontinuation (ACD); secondary endpoints included effects on psychopathology,

cognition, functioning, and cardiovascular risk. In total, 180 participants were

randomized. AET was not superior to FSBT in ACD and most secondary outcomes, with

dropout rates of 59.55% and 57.14% in the six-month active phase, respectively.

However, both groups showed significant improvements in positive, general, and

total symptoms, levels of functioning and in cognitive performance. A higher

training frequency additionally promoted further memory domains. Participants

with higher baseline cognitive abilities were more likely to respond to the

interventions. Our results support integrating exercise into schizophrenia

treatment, while future studies should aim to develop personalized training

recommendations to maximize exercise-induced benefits.

FAU - Maurus, Isabel

AU - Maurus I

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany. Electronic address: Isabel.Maurus@med.uni-muenchen.de.

FAU - Roell, Lukas

AU - Roell L

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany; Neuroimaging Core Unit Munich (NICUM), University Hospital, LMU

Munich, Munich, Germany.

FAU - Lembeck, Moritz

AU - Lembeck M

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Papazova, Irina

AU - Papazova I

AD - Department of Psychiatry, Psychotherapy and Psychosomatics of the University

Augsburg, Medical Faculty, University of Augsburg, Bezirkskrankenhaus Augsburg,

Augsburg, Germany.

FAU - Greska, David

AU - Greska D

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Muenz, Susanne

AU - Muenz S

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Wagner, Elias

AU - Wagner E

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Campana, Mattia

AU - Campana M

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Schwaiger, Rebecca

AU - Schwaiger R

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Schneider-Axmann, Thomas

AU - Schneider-Axmann T

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Rosenberger, Kerstin

AU - Rosenberger K

AD - Institute of Medical Statistics and Computational Biology, Faculty of Medicine

and University Hospital Cologne, University of Cologne, Cologne, Germany.

FAU - Hellmich, Martin

AU - Hellmich M

AD - Institute of Medical Statistics and Computational Biology, Faculty of Medicine

and University Hospital Cologne, University of Cologne, Cologne, Germany.

FAU - Sykorova, Eliska

AU - Sykorova E

AD - Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg

University, Germany.

FAU - Thieme, Cristina E

AU - Thieme CE

AD - Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg

University, Germany.

FAU - Vogel, Bob O

AU - Vogel BO

AD - Department of Psychiatry and Psychotherapy, University Hospital Charité Berlin,

Berlin, Germany.

FAU - Harder, Carolin

AU - Harder C

AD - Department of Psychiatry and Psychotherapy, University Hospital Charité Berlin,

Berlin, Germany.

FAU - Mohnke, Sebastian

AU - Mohnke S

AD - Department of Psychiatry and Psychotherapy, University Hospital Charité Berlin,

Berlin, Germany.

FAU - Huppertz, Charlotte

AU - Huppertz C

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen

University, Germany.

FAU - Roeh, Astrid

AU - Roeh A

AD - Department of Psychiatry, Psychotherapy and Psychosomatics of the University

Augsburg, Medical Faculty, University of Augsburg, Bezirkskrankenhaus Augsburg,

Augsburg, Germany.

FAU - Keller-Varady, Katriona

AU - Keller-Varady K

AD - Hannover Medical School, Institute of Sports Medicine, Hannover, Germany.

FAU - Malchow, Berend

AU - Malchow B

AD - Department of Psychiatry and Psychotherapy, University Hospital Göttingen,

Göttingen, Germany.

FAU - Walter, Henrik

AU - Walter H

AD - Department of Psychiatry and Psychotherapy, University Hospital Charité Berlin,

Berlin, Germany.

FAU - Wolfarth, Bernd

AU - Wolfarth B

AD - Department of Sports Medicine, University Hospital Charité Berlin, Berlin,

Germany.

FAU - Wölwer, Wolfgang

AU - Wölwer W

AD - Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine

University, Duesseldorf, Germany.

FAU - Henkel, Karsten

AU - Henkel K

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen

University, Germany.

FAU - Hirjak, Dusan

AU - Hirjak D

AD - Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg

University, Germany.

FAU - Schmitt, Andrea

AU - Schmitt A

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany; Laboratory of Neuroscience (LIM27), Institute of Psychiatry,

University of Sao Paulo, São Paulo, Brazil.

FAU - Hasan, Alkomiet

AU - Hasan A

AD - Department of Psychiatry, Psychotherapy and Psychosomatics of the University

Augsburg, Medical Faculty, University of Augsburg, Bezirkskrankenhaus Augsburg,

Augsburg, Germany.

FAU - Meyer-Lindenberg, Andreas

AU - Meyer-Lindenberg A

AD - Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg

University, Germany.

FAU - Falkai, Peter

AU - Falkai P

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany; Max Planck Institute of Psychiatry, Munich, Germany.

LA - eng

SI - ClinicalTrials.gov/T32MH125792

SI - DRKS/DRKS00009804

PT - Journal Article

PT - Multicenter Study

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230910

PL - Ireland

TA - Psychiatry Res

JT - Psychiatry research

JID - 7911385

SB - IM

MH - Humans

MH - *Schizophrenia/complications/therapy

MH - Exercise

MH - Exercise Therapy/methods

MH - *Cognition Disorders/complications

MH - Cognition

OTO - NOTNLM

OT - Cardiovascular risk

OT - Clinical trial

OT - Lifestyle intervention

OT - Physical activity

OT - Psychosis

COIS- Declaration of Competing Interest AS: honorary speaker for TAD Pharma and Roche,

member of Roche advisory boards. AH: editor of the German (DGPPN) schizophrenia

treatment guidelines, first author of the WFSBP schizophrenia treatment

guidelines; on advisory boards of and speaker fees from AbbVie (speaker fees

only), Advanz (speaker fees only), Janssen-Cilag, Lundbeck, Recordati, Rovi, and

Otsuka. PF: co-editor of the German (DGPPN) schizophrenia treatment guidelines,

co-author of the WFSBP schizophrenia treatment guidelines; on advisory boards and

speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. AML:

consultant fees from Boehringer Ingelheim, Elsevier, Brainsway, Lundbeck Int.

Neuroscience Foundation, Lundbeck A/S, Sumitomo Dainippon Pharma Co., Academic

Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer

Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint

Partnership, University of Cambridge, Dt. Zentrum für Neurodegenerative

Erkrankungen, Zürich University, Brain Mind Institute, L.E.K. Consulting, ICARE

Schizophrenia, Science Advances, Fondation FondaMental, v Behring Röntgen

Stiftung, The Wolfson Foundation, and Sage Therapeutics; speaker fees from

Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland,

Atheneum, Fama Public Relations, Institut d'investigacions Biomèdiques August Pi

i Sunyer (IDIBAPS), Janssen-Cilag, Hertie Stiftung, Bodelschwingh-Klinik, Pfizer,

Atheneum, University of Freiburg, Schizophrenia Academy, Hong Kong Society of

Biological Psychiatry, Fama Public Relations, Spanish Society of Psychiatry,

Italian Society of Biological Psychiatry, Reunions I Ciencia S.L., and Brain

Center Rudolf Magnus UMC Utrecht; awards from the Prix Roger de Spoelberch grant

and the CINP Lilly Neuroscience Clinical Research Award 2016. IM, LR, ML, IP, DG,

SMu, EW, MC, RS, TSA, KR, MH, ES, ET, BV, CHa, SMo, CHu, AR, KKV, BM, HW, BW, WW,

KH, and DH report no conflicts of interest.

EDAT- 2023/09/17 00:42

MHDA- 2023/10/03 06:47

CRDT- 2023/09/16 18:12

PHST- 2023/07/10 00:00 [received]

PHST- 2023/09/07 00:00 [revised]

PHST- 2023/09/09 00:00 [accepted]

PHST- 2023/10/03 06:47 [medline]

PHST- 2023/09/17 00:42 [pubmed]

PHST- 2023/09/16 18:12 [entrez]

AID - S0165-1781(23)00430-4 [pii]

AID - 10.1016/j.psychres.2023.115480 [doi]

PST - ppublish

SO - Psychiatry Res. 2023 Oct;328:115480. doi: 10.1016/j.psychres.2023.115480. Epub

2023 Sep 10.

PMID- 37672016

OWN - NLM

STAT- MEDLINE

DCOM- 20230907

LR - 20230915

IS - 1555-2101 (Electronic)

IS - 0160-6689 (Linking)

VI - 84

IP - 5

DP - 2023 Sep 4

TI - Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary

Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized,

Open-label, Parallel-Arm, Pivotal Study.

LID - 23m14873 [pii]

LID - 10.4088/JCP.23m14873 [doi]

AB - Objective: Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new

long-acting injectable antipsychotic formulation for administration every 2

months. A randomized, open-label, 32-week trial evaluated the safety,

tolerability, and pharmacokinetics of Ari 2MRTU 960 in clinically stable adults

with schizophrenia or bipolar I disorder (per DSM-5 criteria). This secondary

analysis evaluated the safety and efficacy of Ari 2MRTU 960 in the subpopulation

of patients with schizophrenia. Methods: Patients were randomized to receive Ari

2MRTU 960 every 56 ± 2 days (4 injections scheduled) or aripiprazole once-monthly

400 mg (AOM 400) every 28 ± 2 days (8 injections scheduled). Data were collected

during August 2019-July 2020 across 16 US sites. Primary endpoints included

safety and tolerability, evaluated throughout. Secondary endpoints for efficacy

in patients with schizophrenia included change from baseline at week 32 in

Positive and Negative Syndrome Scale, Clinical Global Impression - Severity, and

Subjective Well-being under Neuroleptic Treatment - Short Form scores, along with

Clinical Global Impression - Improvement at week 32. Results: Patients with

schizophrenia were randomized to Ari 2MRTU 960 (n = 92) or AOM 400 (n = 93). The

incidence of treatment-emergent adverse events (TEAEs) was similar between Ari

2MRTU 960 (66.3%) and AOM 400 (63.4%). The most frequently reported TEAE was

increased weight (Ari 2MRTU 960: 21.7%; AOM 400: 18.3%). Patients in both

treatment groups remained clinically stable throughout, with minimal change from

baseline observed in efficacy parameters at week 32. Conclusions: Ari 2MRTU 960

was well tolerated in clinically stable patients with schizophrenia, with

efficacy similar to AOM 400. Trial Registration: ClinicalTrials.gov identifier:

NCT04030143.

FAU - Citrome, Leslie

AU - Citrome L

AD - Department of Psychiatry and Behavioral Sciences, New York Medical College,

Valhalla.

FAU - Such, Pedro

AU - Such P

AD - H. Lundbeck A/S, Valby, Denmark.

FAU - Yildirim, Murat

AU - Yildirim M

AD - H. Lundbeck A/S, Valby, Denmark.

FAU - Madera-McDonough, Jessica

AU - Madera-McDonough J

AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New

Jersey.

FAU - Beckham, Clodagh

AU - Beckham C

AD - Otsuka Pharmaceutical Europe Ltd., Wexham, United Kingdom.

FAU - Zhang, Zhen

AU - Zhang Z

AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New

Jersey.

FAU - Larsen, Frank

AU - Larsen F

AD - H. Lundbeck A/S, Valby, Denmark.

FAU - Harlin, Matthew

AU - Harlin M

AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New

Jersey.

AD - Corresponding Author: Matthew Harlin, MS, Otsuka.

LA - eng

SI - ClinicalTrials.gov/NCT04030143

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230904

PL - United States

TA - J Clin Psychiatry

JT - The Journal of clinical psychiatry

JID - 7801243

RN - 82VFR53I78 (Aripiprazole)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - Adult

MH - Aripiprazole

MH - *Schizophrenia

MH - *Antipsychotic Agents

MH - *Bipolar Disorder

MH - Diagnostic and Statistical Manual of Mental Disorders

EDAT- 2023/09/06 12:42

MHDA- 2023/09/07 06:43

CRDT- 2023/09/06 10:43

PHST- 2023/09/07 06:43 [medline]

PHST- 2023/09/06 12:42 [pubmed]

PHST- 2023/09/06 10:43 [entrez]

AID - 23m14873 [pii]

AID - 10.4088/JCP.23m14873 [doi]

PST - epublish

SO - J Clin Psychiatry. 2023 Sep 4;84(5):23m14873. doi: 10.4088/JCP.23m14873.

PMID- 37655280

OWN - NLM

STAT- MEDLINE

DCOM- 20230904

LR - 20230911

IS - 2296-2565 (Electronic)

IS - 2296-2565 (Linking)

VI - 11

DP - 2023

TI - A systematic review of Clinical Practice Guidelines for the development of the

WHO's Package of Interventions for Rehabilitation: focus on schizophrenia.

PG - 1215617

LID - 10.3389/fpubh.2023.1215617 [doi]

LID - 1215617

AB - BACKGROUND: The identification of interventions for rehabilitation and related

evidence is a crucial step in the development of World Health Organization's

(WHO) Package of Interventions for Rehabilitation (PIR). Interventions for

rehabilitation may be particularly relevant in schizophrenia, as this condition

is associated with a high risk of disability, poor functioning, and lack of

autonomy. Aiming to collect evidence for the WHO PIR, we conducted a systematic

review of Clinical Practice Guidelines (CPG) on interventions for rehabilitation

of schizophrenia. METHODS: Methods for the systematic identification and critical

appraisal of CPG were developed by WHO Rehabilitation Programme and Cochrane

Rehabilitation under the guidance of WHO's guideline review committee

secretariat. The Appraisal of Guidelines for Research & Evaluation Instrument

(AGREE II) was used to evaluate the methodological quality of identified CPG.

RESULTS: After full text screening, nine CPG were identified, for a total of 130

recommendations. Three were excluded because their total AGREE-II scores were

below cut-off. Six CPG were approved by the Technical Working Group and included

for data extraction. Only one CPG with specific focus on rehabilitation of

schizophrenia was retrieved. Other CPG were general, including some

recommendations on rehabilitation. Some CPG gave no indications on the assessment

of rehabilitation needs. Discrepancies were detectable, with different CPG

emphasizing different domains. Most recommendations addressed "symptoms of

schizophrenia," while "community and social life" was targeted by few

recommendations. International CPG were often conceptualized for high-income

countries, and CPG accounting for their implementation in lower income contexts

were scarce. Quality of evidence was high/moderate for 41.54% (n = 54) of the

recommendations, and very low only in two cases (1.52%). N = 45 (34.62%) were

based on experts' opinion. CONCLUSIONS: The concepts of recovery and

rehabilitation in schizophrenia are relatively new in medical sciences and

somewhat ill-defined. An unbalanced distribution in the domains addressed by

available CPG is therefore understandable. However, the need for more focus in

some areas of rehabilitation is obvious. More clarity is also required regarding

which interventions should be prioritized and which are more feasible for global

implementation in the rehabilitation of schizophrenia.

FAU - Serra, Riccardo

AU - Serra R

AD - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

AD - Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement

Sciences, WHO Collaborating Centre for Research and Training in Mental Health and

Service Evaluation, University of Verona, Verona, Italy.

AD - Department of Neurosciences, Center for Public Health Psychiatry, KU Leuven

University, Leuven, Belgium.

FAU - Etemadi, Yasaman

AU - Etemadi Y

AD - Sensory Functions, Disability and Rehabilitation Unit, Department of

Noncommunicable Diseases, World Health Organization, Geneva, Switzerland.

FAU - van Regteren Altena, Marieke

AU - van Regteren Altena M

AD - Department of Mental Health and Substance Use, World Health Organization, Geneva,

Switzerland.

FAU - Barbui, Corrado

AU - Barbui C

AD - Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement

Sciences, WHO Collaborating Centre for Research and Training in Mental Health and

Service Evaluation, University of Verona, Verona, Italy.

FAU - Tarsitani, Lorenzo

AU - Tarsitani L

AD - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

LA - eng

PT - Journal Article

PT - Systematic Review

DEP - 20230815

PL - Switzerland

TA - Front Public Health

JT - Frontiers in public health

JID - 101616579

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Income

MH - World Health Organization

PMC - PMC10465692

OTO - NOTNLM

OT - World Health Organization (WHO)

OT - psychosis

OT - rehabilitation

OT - schizophrenia

OT - systematic review

COIS- The authors declare that the research was conducted in the absence of any

commercial or financial relationships that could be construed as a potential

conflict of interest.

EDAT- 2023/09/01 06:43

MHDA- 2023/09/04 06:43

CRDT- 2023/09/01 04:11

PHST- 2023/05/02 00:00 [received]

PHST- 2023/07/28 00:00 [accepted]

PHST- 2023/09/04 06:43 [medline]

PHST- 2023/09/01 06:43 [pubmed]

PHST- 2023/09/01 04:11 [entrez]

AID - 10.3389/fpubh.2023.1215617 [doi]

PST - epublish

SO - Front Public Health. 2023 Aug 15;11:1215617. doi: 10.3389/fpubh.2023.1215617.

eCollection 2023.

PMID- 37653768

OWN - NLM

STAT- MEDLINE

DCOM- 20230905

LR - 20230905

IS - 1536-5964 (Electronic)

IS - 0025-7974 (Print)

IS - 0025-7974 (Linking)

VI - 102

IP - 34

DP - 2023 Aug 25

TI - Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in

reduction of relapses in patients with schizophrenia: An Asian subgroup analysis

of phase 3, randomized study.

PG - e34623

LID - 10.1097/MD.0000000000034623 [doi]

LID - e34623

AB - BACKGROUND: Evaluate efficacy and safety of paliperidone palmitate 6-monthly

(PP6M) for patients with schizophrenia in the Asian subgroup of a global,

multicenter, noninferiority phase-3 study (NCT03345342). METHODS: Patients

received paliperidone palmitate 1-monthly (PP1M, 100/150 mg eq.) or paliperidone

palmitate 3-monthly (PP3M, 350/525 mg eq.) during the maintenance phase and

entered a 12-month double-blind (DB) phase, wherein they were randomized (2:1) to

PP6M (700/1000 mg. eq.) or PP3M (350/525 mg eq.). Subgroup analysis was performed

for 90 (12.7%) patients from Asia region (India, Taiwan, Malaysia, Hong Kong, and

Korea). Primary endpoint was time-to-relapse during DB phase (Kaplan-Meier

estimates). Secondary endpoints were changes from baseline in Positive and

Negative Syndrome Scale, Clinical Global Impression-Severity scale, Personal and

Social Performance (PSP) scale score. RESULTS: In Asian subgroup, 91.9% (82/90)

of patients completed DB phase (PP6M: 54/62 [87%]; PP3M: 28/28 [100%]). Median

time-to-relapse was "not-estimable" due to low relapse rates in both groups.

Estimated difference (95% confidence interval [CI]) between relapse-free patients

in PP6M and PP3M groups of Asian subgroup was -0.1% [-8.5%, 8.4%] (global study

population: -2.9% [-6.8%, 1.1%]). Mean change from baseline in secondary efficacy

parameters was comparable between both groups, similar to the global study

population. The incidence of extrapyramidal symptoms was higher in the Asian

subgroup than in the global study population. CONCLUSION: Consistent with the

global study population, PP6M was noninferior to PP3M in preventing relapse in

patients with schizophrenia from the Asia region. Findings suggest the

possibility of switching from PP1M/PP3M to twice-yearly PP6M without loss of

efficacy and with no unexpected safety concerns.

FAU - Richarz, Ute

AU - Richarz U

AUID- ORCID: 0000-0001-5928-7905

AD - Janssen Research & Development, Cilag Zug, Zug, Switzerland.

FAU - Han, John

AU - Han J

AD - Janssen Research & Development, LLC, Titusville, NJ, USA.

FAU - Bai, Ya-Mei

AU - Bai YM

AD - Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.

AD - Division of Psychiatry, School of Medicine and Institute of Brain Science,

National Yang-Ming Chiao Tung University, Taipei, Taiwan.

FAU - Yu-Hai Chen, Eric

AU - Yu-Hai Chen E

AD - School of Clinical Medicine, University of Hong Kong, Pokfulam, Hong Kong Special

Administrative Region, China.

FAU - Chung, Young Chul

AU - Chung YC

AD - Chonbuk National University Hospital, Jeonju, South Korea.

FAU - Jhanwar, Venu Gopal

AU - Jhanwar VG

AD - Deva Institute of Health Care and Research Pvt. Ltd., Varanasi, India.

FAU - Kim, Sung-Wan

AU - Kim SW

AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju,

Korea.

FAU - Sulaiman, Ahmad Hatim

AU - Sulaiman AH

AD - Department of Psychological Medicine, Faculty of Medicine, University Malaya,

Kuala Lumpur, Malaysia.

FAU - Knight, Karl

AU - Knight K

AD - Janssen Research & Development, LLC, Titusville, NJ, USA.

FAU - Gopal, Srihari

AU - Gopal S

AD - Janssen Research & Development, LLC, Titusville, NJ, USA.

LA - eng

SI - ClinicalTrials.gov/NCT03345342

PT - Clinical Trial, Phase III

PT - Equivalence Trial

PT - Journal Article

PT - Multicenter Study

PL - United States

TA - Medicine (Baltimore)

JT - Medicine

JID - 2985248R

RN - R8P8USM8FR (Paliperidone Palmitate)

SB - IM

MH - Humans

MH - Asian

MH - Hong Kong

MH - *Paliperidone Palmitate/administration & dosage/therapeutic use

MH - *Schizophrenia/drug therapy

PMC - PMC10470698

COIS- The authors have no funding and conflicts of interest to disclose.

EDAT- 2023/09/01 06:43

MHDA- 2023/09/04 06:43

CRDT- 2023/09/01 01:43

PHST- 2023/09/04 06:43 [medline]

PHST- 2023/09/01 06:43 [pubmed]

PHST- 2023/09/01 01:43 [entrez]

AID - 00005792-202308250-00040 [pii]

AID - 10.1097/MD.0000000000034623 [doi]

PST - ppublish

SO - Medicine (Baltimore). 2023 Aug 25;102(34):e34623. doi:

10.1097/MD.0000000000034623.

PMID- 37643803

OWN - NLM

STAT- MEDLINE

DCOM- 20230831

LR - 20230920

IS - 1488-2434 (Electronic)

IS - 1180-4882 (Print)

IS - 1180-4882 (Linking)

VI - 48

IP - 4

DP - 2023 Jul-Aug

TI - Clusters of psychosis: compensation as a contributor to the heterogeneity of

schizophrenia.

PG - E325-E329

LID - 10.1503/jpn.230120 [doi]

FAU - Palaniyappan, Lena

AU - Palaniyappan L

AD - From the Douglas Mental Health University Institute, Department of Psychiatry,

McGill University, Montréal, Que. and the Robarts Research Institute & Lawson

Health Research Institute, London, Ont. lena.palaniyappan@mcgill.ca.

LA - eng

PT - Editorial

PT - Research Support, Non-U.S. Gov't

DEP - 20230829

PL - Canada

TA - J Psychiatry Neurosci

JT - Journal of psychiatry & neuroscience : JPN

JID - 9107859

SB - IM

MH - Humans

MH - *Schizophrenia

MH - *Psychotic Disorders

PMC - PMC10473036

COIS- Competing interests: Lena Palaniyappan reports personal fees from Janssen Canada,

Otsuka Canada, SPMM Course Limited UK and the Canadian Psychiatric Association;

book royalties from Oxford University Press; and investigator-initiated

educational grants from Sunovion, Janssen Canada and Otsuka Canada, outside the

submitted work.

EDAT- 2023/08/30 00:41

MHDA- 2023/08/31 06:41

CRDT- 2023/08/29 20:43

PHST- 2023/08/31 06:41 [medline]

PHST- 2023/08/30 00:41 [pubmed]

PHST- 2023/08/29 20:43 [entrez]

AID - 48/4/E325 [pii]

AID - 48-4-E325 [pii]

AID - 10.1503/jpn.230120 [doi]

PST - epublish

SO - J Psychiatry Neurosci. 2023 Aug 29;48(4):E325-E329. doi: 10.1503/jpn.230120.

Print 2023 Jul-Aug.

PMID- 37643481

OWN - NLM

STAT- MEDLINE

DCOM- 20230906

LR - 20230906

IS - 1876-2026 (Electronic)

IS - 1876-2018 (Linking)

VI - 87

DP - 2023 Sep

TI - Application of computational methods to the study of schizophrenia an exciting

but treacherous frontier.

PG - 103752

LID - S1876-2018(23)00308-8 [pii]

LID - 10.1016/j.ajp.2023.103752 [doi]

FAU - Tandon, Rajiv

AU - Tandon R

AD - Department of Psychiatry, WMU Homer Stryker School of Medicine, Kalamazoo, MI,

United States. Electronic address: rajiv.tandon@med.wmich.edu.

LA - eng

PT - Editorial

DEP - 20230822

PL - Netherlands

TA - Asian J Psychiatr

JT - Asian journal of psychiatry

JID - 101517820

SB - IM

MH - Humans

MH - *Schizophrenia

MH - *Computational Biology

COIS- Declaration of Competing Interest None.

EDAT- 2023/08/29 18:42

MHDA- 2023/09/04 06:42

CRDT- 2023/08/29 18:00

PHST- 2023/09/04 06:42 [medline]

PHST- 2023/08/29 18:42 [pubmed]

PHST- 2023/08/29 18:00 [entrez]

AID - S1876-2018(23)00308-8 [pii]

AID - 10.1016/j.ajp.2023.103752 [doi]

PST - ppublish

SO - Asian J Psychiatr. 2023 Sep;87:103752. doi: 10.1016/j.ajp.2023.103752. Epub 2023

Aug 22.

PMID- 37627285

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230828

IS - 2218-273X (Electronic)

IS - 2218-273X (Linking)

VI - 13

IP - 8

DP - 2023 Aug 5

TI - The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis,

Translational Issues for Treatment-Resistant Schizophrenia.

LID - 10.3390/biom13081220 [doi]

LID - 1220

AB - Almost 25% of schizophrenia patients suffer from obsessive-compulsive symptoms

(OCS) considered a transdiagnostic clinical continuum. The presence of symptoms

pertaining to both schizophrenia and obsessive-compulsive disorder (OCD) may

complicate pharmacological treatment and could contribute to lack or poor

response to the therapy. Despite the clinical relevance, no reviews have been

recently published on the possible neurobiological underpinnings of this

comorbidity, which is still unclear. An integrative view exploring this topic

should take into account the following aspects: (i) the implication for

glutamate, dopamine, and serotonin neurotransmission as demonstrated by genetic

findings; (ii) the growing neuroimaging evidence of the common brain regions and

dysfunctional circuits involved in both diseases; (iii) the pharmacological

modulation of dopaminergic, serotoninergic, and glutamatergic systems as current

therapeutic strategies in schizophrenia OCS; (iv) the recent discovery of

midbrain dopamine neurons and dopamine D1- and D2-like receptors as orchestrating

hubs in repetitive and psychotic behaviors; (v) the contribution of

N-methyl-D-aspartate receptor subunits to both psychosis and OCD neurobiology.

Finally, we discuss the potential role of the postsynaptic density as a

structural and functional hub for multiple molecular signaling both in

schizophrenia and OCD pathophysiology.

FAU - Vellucci, Licia

AU - Vellucci L

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - Ciccarelli, Mariateresa

AU - Ciccarelli M

AUID- ORCID: 0000-0001-8944-414X

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - Buonaguro, Elisabetta Filomena

AU - Buonaguro EF

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - Fornaro, Michele

AU - Fornaro M

AUID- ORCID: 0000-0002-9647-0853

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - D'Urso, Giordano

AU - D'Urso G

AUID- ORCID: 0000-0001-5156-658X

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - De Simone, Giuseppe

AU - De Simone G

AUID- ORCID: 0000-0003-0422-3415

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - Iasevoli, Felice

AU - Iasevoli F

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - Barone, Annarita

AU - Barone A

AUID- ORCID: 0000-0002-2751-5683

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

FAU - de Bartolomeis, Andrea

AU - de Bartolomeis A

AD - Section of Psychiatry, Laboratory of Translational and Molecular Psychiatry and

Unit of Treatment-Resistant Psychosis, Department of Neuroscience, Reproductive

Sciences and Dentistry University Medical School of Naples "Federico II", Via

Pansini 5, 80131 Naples, Italy.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230805

PL - Switzerland

TA - Biomolecules

JT - Biomolecules

JID - 101596414

RN - VTD58H1Z2X (Dopamine)

RN - 3KX376GY7L (Glutamic Acid)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy

MH - Schizophrenia, Treatment-Resistant

MH - Dopamine

MH - Neurobiology

MH - *Psychotic Disorders/drug therapy

MH - Glutamic Acid

PMC - PMC10452784

OTO - NOTNLM

OT - antipsychotics

OT - clozapine

OT - obsessive-compulsive disorder

OT - postsynaptic density

OT - psychosis

OT - selective serotonin reuptake inhibitors

OT - synapsis

OT - treatment-resistant schizophrenia

COIS- A.d.B. has received unrestricted research support from Janssen, Lundbeck, and

Otsuka and lecture honoraria for educational meetings from Chiesi, Lundbeck,

Roche, Sunovion, Vitria, Recordati, Angelini and Takeda; he has served on

advisory boards for Eli Lilly, Jansen, Lundbeck, Otsuka, Roche, Vitria, Chiesi,

Recordati, Angelini, Takeda. No activity is related directly or indirectly to the

present manuscript content. MF, over the past 12 months (February 2022–February

2023), received honoraria for his speaker activity at the Fall American Society

of Clinical Psychopharmacology (ASCP) event. M.F served as a rater for Biohaven

Pharmaceuticals, Inc. (New Haven, CT, USA) (trial entitled “A Ran-domized,

Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive

Compulsive Disorder”, protocol BHV4157-302; and “A Randomized, Double-Blind,

Place-bo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive

Disorder”, protocol BHV4157-303 (“Study”)) and ACADIA Pharmaceuticals Inc.

(protocol ACP-103-064 entitled “A Phase 3, Randomized, Double-Blind,

Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as

Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2)”

(“Study”)) within the frame of the Massachusetts General Hospital (MGH) Clinical

Trials Network and Institute and its subsidiaries (Boston, MA, USA). All the

other authors declare no conflicts of interest.

EDAT- 2023/08/26 10:45

MHDA- 2023/08/28 07:16

CRDT- 2023/08/26 01:05

PHST- 2023/02/28 00:00 [received]

PHST- 2023/07/24 00:00 [revised]

PHST- 2023/07/31 00:00 [accepted]

PHST- 2023/08/28 07:16 [medline]

PHST- 2023/08/26 10:45 [pubmed]

PHST- 2023/08/26 01:05 [entrez]

AID - biom13081220 [pii]

AID - biomolecules-13-01220 [pii]

AID - 10.3390/biom13081220 [doi]

PST - epublish

SO - Biomolecules. 2023 Aug 5;13(8):1220. doi: 10.3390/biom13081220.

PMID- 37627253

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230828

IS - 2218-273X (Electronic)

IS - 2218-273X (Linking)

VI - 13

IP - 8

DP - 2023 Jul 30

TI - Counting the Toll of Inflammation on Schizophrenia-A Potential Role for Toll-like

Receptors.

LID - 10.3390/biom13081188 [doi]

LID - 1188

AB - Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs)

that are ubiquitously expressed in the human body. They protect the brain and

central nervous system from self and foreign antigens/pathogens. The immune

response elicited by these receptors culminates in the release of cytokines,

chemokines, and interferons causing an inflammatory response, which can be both

beneficial and harmful to neurodevelopment. In addition, the detrimental effects

of TLR activation have been implicated in multiple neurodegenerative diseases

such as Alzheimer's, multiple sclerosis, etc. Many studies also support the

theory that cytokine imbalance may be involved in schizophrenia, and a vast

amount of literature showcases the deleterious effects of this imbalance on

cognitive performance in the human population. In this review, we examine the

current literature on TLRs, their potential role in the pathogenesis of

schizophrenia, factors affecting TLR activity that contribute towards the risk of

schizophrenia, and lastly, the role of TLRs and their impact on cognitive

performance in schizophrenia.

FAU - Patlola, Saahithh Redddi

AU - Patlola SR

AUID- ORCID: 0000-0003-4367-1720

AD - Department of Pharmacology & Therapeutics, School of Medicine, University of

Galway, H91 TK33 Galway, Ireland.

FAU - Donohoe, Gary

AU - Donohoe G

AD - School of Psychology, University of Galway, H91 TK33 Galway, Ireland.

FAU - McKernan, Declan P

AU - McKernan DP

AUID- ORCID: 0000-0002-9691-1671

AD - Department of Pharmacology & Therapeutics, School of Medicine, University of

Galway, H91 TK33 Galway, Ireland.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230730

PL - Switzerland

TA - Biomolecules

JT - Biomolecules

JID - 101596414

RN - 0 (Toll-Like Receptors)

RN - 0 (Cytokines)

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Toll-Like Receptors

MH - Central Nervous System

MH - Inflammation

MH - Brain

MH - Cytokines

PMC - PMC10452856

OTO - NOTNLM

OT - Toll-like receptor

OT - cognition

OT - inflammation

OT - schizophrenia

COIS- The authors declare no conflict of interest.

EDAT- 2023/08/26 10:45

MHDA- 2023/08/28 07:16

CRDT- 2023/08/26 01:05

PHST- 2023/05/16 00:00 [received]

PHST- 2023/07/25 00:00 [revised]

PHST- 2023/07/25 00:00 [accepted]

PHST- 2023/08/28 07:16 [medline]

PHST- 2023/08/26 10:45 [pubmed]

PHST- 2023/08/26 01:05 [entrez]

AID - biom13081188 [pii]

AID - biomolecules-13-01188 [pii]

AID - 10.3390/biom13081188 [doi]

PST - epublish

SO - Biomolecules. 2023 Jul 30;13(8):1188. doi: 10.3390/biom13081188.

PMID- 37626909

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230829

IS - 2073-4409 (Electronic)

IS - 2073-4409 (Linking)

VI - 12

IP - 16

DP - 2023 Aug 19

TI - Microglia and Other Cellular Mediators of Immunological Dysfunction in

Schizophrenia: A Narrative Synthesis of Clinical Findings.

LID - 10.3390/cells12162099 [doi]

LID - 2099

AB - Schizophrenia is a complex psychiatric condition that may involve immune system

dysregulation. Since most putative disease mechanisms in schizophrenia have been

derived from genetic association studies and fluid-based molecular analyses, this

review aims to summarize the emerging evidence on clinical correlates to immune

system dysfunction in this psychiatric disorder. We conclude this review by

attempting to develop a unifying hypothesis regarding the relative contributions

of microglia and various immune cell populations to the development of

schizophrenia. This may provide important translational insights that can become

useful for addressing the multifaceted clinical presentation of schizophrenia.

FAU - Nguyen, Khoa D

AU - Nguyen KD

AD - Department of Microbiology and Immunology, Stanford University, Palo Alto, CA

94305, USA.

AD - Tranquis Therapeutics, Palo Alto, CA 94065, USA.

FAU - Amerio, Andrea

AU - Amerio A

AUID- ORCID: 0000-0002-3439-340X

AD - Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology,

Genetics, Maternal and Child Health, University of Genoa, 16126 Genoa, Italy.

AD - IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

FAU - Aguglia, Andrea

AU - Aguglia A

AUID- ORCID: 0000-0002-2003-2101

AD - Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology,

Genetics, Maternal and Child Health, University of Genoa, 16126 Genoa, Italy.

AD - IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

FAU - Magnani, Luca

AU - Magnani L

AUID- ORCID: 0000-0002-3620-2021

AD - Department of Psychiatry, San Maurizio Hospital of Bolzano, 39100 Bolzano, Italy.

FAU - Parise, Alberto

AU - Parise A

AD - Geriatric-Rehabilitation Department, University Hospital of Parma, 43126 Parma,

Italy.

FAU - Conio, Benedetta

AU - Conio B

AD - Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology,

Genetics, Maternal and Child Health, University of Genoa, 16126 Genoa, Italy.

AD - IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

FAU - Serafini, Gianluca

AU - Serafini G

AUID- ORCID: 0000-0002-6631-856X

AD - Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology,

Genetics, Maternal and Child Health, University of Genoa, 16126 Genoa, Italy.

AD - IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

FAU - Amore, Mario

AU - Amore M

AD - Section of Psychiatry, Department of Neuroscience, Rehabilitation, Ophthalmology,

Genetics, Maternal and Child Health, University of Genoa, 16126 Genoa, Italy.

AD - IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

FAU - Costanza, Alessandra

AU - Costanza A

AD - Department of Psychiatry, Adult Psychiatry Service, University Hospitals of

Geneva (HUG), 1207 Geneva, Switzerland.

AD - Department of Psychiatry, Faculty of Biomedical Sciences, University of Italian

Switzerland (USI), 6900 Lugano, Switzerland.

AD - Department of Psychiatry, Faculty of Medicine, University of Geneva (UNIGE), 1211

Geneva, Switzerland.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230819

PL - Switzerland

TA - Cells

JT - Cells

JID - 101600052

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Microglia

MH - Genetic Association Studies

PMC - PMC10453550

OTO - NOTNLM

OT - clinical correlates

OT - immunological dysfunction

OT - microglia

OT - neuroinflammation

OT - schizophrenia

COIS- KDN is the scientific founder of Tranquis Therapeutics, a biotechnology company

that develops novel treatments for neuroinflammatory and neurodegenerative

diseases. KDN is also a scientific advisor for Tochikunda, a biotechnology

company that develops SARS-CoV-2 diagnostic devices. All other authors declare no

conflicts of interest and that they have no commercial associations (e.g.,

consultancies, stock ownership, equity interest, patent/licensing arrangement,

etc.) that might pose a conflict of interest in connection with the submitted

article.

EDAT- 2023/08/26 10:42

MHDA- 2023/08/28 07:16

CRDT- 2023/08/26 01:02

PHST- 2023/07/11 00:00 [received]

PHST- 2023/08/13 00:00 [revised]

PHST- 2023/08/17 00:00 [accepted]

PHST- 2023/08/28 07:16 [medline]

PHST- 2023/08/26 10:42 [pubmed]

PHST- 2023/08/26 01:02 [entrez]

AID - cells12162099 [pii]

AID - cells-12-02099 [pii]

AID - 10.3390/cells12162099 [doi]

PST - epublish

SO - Cells. 2023 Aug 19;12(16):2099. doi: 10.3390/cells12162099.

PMID- 37620825

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230831

IS - 1471-244X (Electronic)

IS - 1471-244X (Linking)

VI - 23

IP - 1

DP - 2023 Aug 24

TI - Efficacy and safety of Transcranial Direct Current Stimulation (tDCS) on

cognitive function in chronic schizophrenia with Tardive Dyskinesia (TD): a

randomized, double-blind, sham-controlled, clinical trial.

PG - 623

LID - 10.1186/s12888-023-05112-0 [doi]

LID - 623

AB - OBJECTIVE: Previous studies have shown that transcranial direct current

stimulation(tDCS) led to an improvement of cognitive function in patients with

schizophrenia, but rare study has explored the effect of tDCS on long-term

hospitalized chronic schizophrenia with tardive dyskinesia (TD). The present

research explored if cognitive function in patients with long-term hospitalized

chronic schizophrenia with TD could be improved through tDCS. METHODS: This study

is a randomized, double-blind, sham-controlled clinical trial. Of the 52

patients, 14 dropped out, and 38 completed the experiment. Thirty-eight patients

on stable treatment regimens were randomly assigned to receive active

tDCS(n = 21) or sham stimulation(n = 17) on weekdays of the first, third, and

fifth weeks of treatment. Patients performed the Pattern Recognition Memory (PRM)

and the Intra/Extradimensional Set Shift (IED) from the Cambridge

Neuropsychological Test Automated Battery (CANTAB) at baseline and the end of

week 3, week 5. Clinical symptoms were also measured at the baseline and the

fifth week using the Scale for the Assessment of Negative Symptoms (SANS) and the

Positive and Negative Syndrome Scale (PANSS). Side effects of tDCS were assessed

with an experimenter-administered open-ended questionnaire during the whole

experiment. RESULTS: There were no significant differences in PRM and IED

performance metrics, SANS total score and PANSS total score between active and

sham tDCS groups at the end of week 5 (p > 0.05). Furthermore, there was a

significant difference in the adverse effects of the tingling sensation between

the two groups (p < 0.05), but there was no significant difference in other side

effects (p > 0.05). CONCLUSION: According to these findings, no evidence supports

using anodal stimulation over the left dorsolateral prefrontal cortex to improve

cognitive function in patients with long-term hospitalized chronic schizophrenia

with TD.

FAU - Zhou, Yue

AU - Zhou Y

AD - Xuzhou Medical University, Xuzhou, China.

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

FAU - Xia, Xingzhi

AU - Xia X

AD - Xuzhou Medical University, Xuzhou, China.

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

FAU - Zhao, Xueli

AU - Zhao X

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

FAU - Yang, Ruchang

AU - Yang R

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

AD - Medical College of Soochow University, Suzhou, China.

FAU - Wu, Yuxuan

AU - Wu Y

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

AD - Medical College of Soochow University, Suzhou, China.

FAU - Liu, Junjun

AU - Liu J

AD - Nanjing Meishan Hospital, Nanjing, China.

FAU - Lyu, Xiaoli

AU - Lyu X

AD - Affiliated WuTaiShan Hospital of Medical College of Yangzhou University,

Yangzhou, China.

FAU - Li, Zhe

AU - Li Z

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

FAU - Zhang, Guangya

AU - Zhang G

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China.

FAU - Du, Xiangdong

AU - Du X

AD - Xuzhou Medical University, Xuzhou, China. xiangdong-du@163.com.

AD - Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University,

Suzhou, China. xiangdong-du@163.com.

LA - eng

SI - ClinicalTrials.gov/NCT03497013

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230824

PL - England

TA - BMC Psychiatry

JT - BMC psychiatry

JID - 100968559

SB - IM

MH - Humans

MH - *Tardive Dyskinesia/therapy

MH - *Transcranial Direct Current Stimulation/adverse effects

MH - *Schizophrenia/complications/therapy

MH - *Drug-Related Side Effects and Adverse Reactions

MH - Cognition

PMC - PMC10464035

OTO - NOTNLM

OT - Chronic Schizophrenia

OT - Intra/Extradimensional Set Shift

OT - Pattern Recognition Memory

OT - Randomized Controlled Trial

OT - Tardive Dyskinesia

OT - tDCS

COIS- The authors declare no competing interests.

EDAT- 2023/08/25 00:42

MHDA- 2023/08/28 06:42

CRDT- 2023/08/24 23:48

PHST- 2023/02/21 00:00 [received]

PHST- 2023/08/14 00:00 [accepted]

PHST- 2023/08/28 06:42 [medline]

PHST- 2023/08/25 00:42 [pubmed]

PHST- 2023/08/24 23:48 [entrez]

AID - 10.1186/s12888-023-05112-0 [pii]

AID - 5112 [pii]

AID - 10.1186/s12888-023-05112-0 [doi]

PST - epublish

SO - BMC Psychiatry. 2023 Aug 24;23(1):623. doi: 10.1186/s12888-023-05112-0.

PMID- 37611908

OWN - NLM

STAT- MEDLINE

DCOM- 20230921

LR - 20230921

IS - 1460-9568 (Electronic)

IS - 0953-816X (Linking)

VI - 58

IP - 6

DP - 2023 Sep

TI - Cannabinoid receptor gene CNR1 is downregulated in subcortical brain samples and

upregulated in blood samples of individuals with schizophrenia: A participant

data systematic meta-analysis.

PG - 3540-3554

LID - 10.1111/ejn.16122 [doi]

AB - Cannabis use leads to symptom exacerbation in schizophrenia patients, and

endocannabinoid ligands have been studied as tentative schizophrenia

therapeutics. Here, we aimed to characterise the connection between schizophrenia

and the cannabinoid receptor 1 gene (CNR1) and explore possible mechanisms

affecting its expression in schizophrenia. We performed a participant data

systematic meta-analysis of CNR1 gene expression and additional endocannabinoid

system genes in both brain (subcortical areas) and blood samples. We integrated

eight brain sample datasets (overall 316 samples; 149 schizophrenia and 167

controls) and two blood sample datasets (overall 90 samples; 53 schizophrenia and

37 controls) while following the PRISMA meta-analysis guidelines. CNR1 was

downregulated in subcortical regions and upregulated in blood samples of patients

with schizophrenia. CNR2 and genes encoding endocannabinoids synthesis and

degradation did not show differential expression in the brain or blood, except

fatty acid amide hydrolase (FAAH), which showed a downregulation trend in blood.

In addition, the brain expression levels of CNR1 and three GABA receptor genes,

GABRA1, GABRA6 and GABRG2, were positively correlated (R = .57, .36, .54;

p = 2.7 × 10(-14) , 6.9 × 10(-6) and 1.1 × 10(-12) , respectively). Brain CNR1

downregulation and the positive correlation with three GABA receptor genes

suggest an association with GABA neurotransmission and possible effects on

negative schizophrenia symptoms. Further studies are required for clarifying the

opposite CNR1 dysregulation in the brain and blood of schizophrenia patients and

the potential of endocannabinoid ligands as schizophrenia therapeutics.

European Neuroscience Societies and John Wiley & Sons Ltd.

FAU - Bloch Priel, Stav

AU - Bloch Priel S

AUID- ORCID: 0000-0001-8099-2297

AD - Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

FAU - Yitzhaky, Assif

AU - Yitzhaky A

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

FAU - Gurwitz, David

AU - Gurwitz D

AD - Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel

Aviv University, Tel Aviv, Israel.

AD - Sagol School for Neuroscience, Tel Aviv University, Tel Aviv, Israel.

FAU - Hertzberg, Libi

AU - Hertzberg L

AUID- ORCID: 0000-0002-7895-8089

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

AD - Shalvata Mental Health Center, affiliated with the Faculty of Medicine, Tel-Aviv

University, Tel Aviv, Israel.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

DEP - 20230823

PL - France

TA - Eur J Neurosci

JT - The European journal of neuroscience

JID - 8918110

RN - 0 (CNR1 protein, human)

RN - 0 (Endocannabinoids)

RN - 0 (Ligands)

RN - 0 (Receptor, Cannabinoid, CB1)

RN - 0 (Receptors, Cannabinoid)

SB - IM

MH - Humans

MH - Brain

MH - Endocannabinoids

MH - Ligands

MH - *Receptor, Cannabinoid, CB1/genetics

MH - Receptors, Cannabinoid

MH - *Schizophrenia/genetics

OTO - NOTNLM

OT - CNR1

OT - gene expression

OT - participant data meta-analysis

OT - schizophrenia

EDAT- 2023/08/24 00:42

MHDA- 2023/09/20 06:42

CRDT- 2023/08/23 19:33

PHST- 2023/04/01 00:00 [revised]

PHST- 2022/12/09 00:00 [received]

PHST- 2023/07/31 00:00 [accepted]

PHST- 2023/09/20 06:42 [medline]

PHST- 2023/08/24 00:42 [pubmed]

PHST- 2023/08/23 19:33 [entrez]

AID - 10.1111/ejn.16122 [doi]

PST - ppublish

SO - Eur J Neurosci. 2023 Sep;58(6):3540-3554. doi: 10.1111/ejn.16122. Epub 2023 Aug

23.

PMID- 37598366

OWN - NLM

STAT- MEDLINE

DCOM- 20230822

LR - 20230822

IS - 1788-6120 (Electronic)

IS - 0030-6002 (Linking)

VI - 164

IP - 33

DP - 2023 Aug 20

TI - [Psychiatric disorders are associated with high mortality rates: somatic

comorbidity and mortality in autism spectrum disorder and schizophrenia].

PG - 1287-1293

LID - 10.1556/650.2023.32843 [doi]

AB - A significant proportion of the high mortality associated with psychiatric

illness is due to premature death in comorbidity with somatic illness, and to a

lesser extent suicide and accidents. In our literature review, we demonstrate

that the risk of mortality for individuals diagnosed with autism spectrum

disorder and schizophrenia is more than twice of that of controls. With respect

to schizophrenia diagnosis, national data from Hungary are available, and

consistent with the international data show an increased risk of mortality. In

Hungary, the mortality risk of persons with a diagnosis of schizophrenia is about

2.4 times higher than that of controls matched by age, sex and postcode. In

particular, the risk of dying from schizophrenia is increased among young people

(7-10 times) and we highlight that although the risk of death in schizophrenia is

higher for men than for women, the risk of dying from schizophrenia for women

diagnosed with schizophrenia is higher than for men compared to the female

control group (relative risk). Considering the high prevalence of psychiatric

disorders, an important prerequisite for improving the national mortality rates

recorded for somatic illnesses is the early diagnosis and treatment of

psychiatric illnesses comorbid with somatic illnesses. The data presented here

can help to support the reforms needed in medical education and training and in

the organization of health care to reduce mortality. Orv Hetil. 2023; 164(33):

1287-1293.

FAU - Bitter, István

AU - Bitter I

AD - 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Pszichiátriai és

Pszichoterápiás Klinika Budapest, Balassa u. 6., 1083 Magyarország.

FAU - Czobor, Pál

AU - Czobor P

AD - 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Pszichiátriai és

Pszichoterápiás Klinika Budapest, Balassa u. 6., 1083 Magyarország.

FAU - Kakuszi, Brigitta

AU - Kakuszi B

AD - 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Pszichiátriai és

Pszichoterápiás Klinika Budapest, Balassa u. 6., 1083 Magyarország.

FAU - Réthelyi, János

AU - Réthelyi J

AD - 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Pszichiátriai és

Pszichoterápiás Klinika Budapest, Balassa u. 6., 1083 Magyarország.

LA - hun

PT - English Abstract

PT - Journal Article

PT - Review

TT - A pszichiátriai betegségekre jelentős korai halálozási arányszámok jellemzők:

szomatikus komorbiditás és mortalitás autizmusspektrum-zavarban és

szkizofréniában.

DEP - 20230820

PL - Hungary

TA - Orv Hetil

JT - Orvosi hetilap

JID - 0376412

SB - IM

MH - Male

MH - Female

MH - Humans

MH - Adolescent

MH - *Schizophrenia/epidemiology

MH - *Autism Spectrum Disorder/epidemiology

MH - *Mental Disorders/epidemiology

MH - Comorbidity

MH - Mortality, Premature

OTO - NOTNLM

OT - autism spectrum disorder

OT - autizmusspektrum-zavar

OT - comorbidity

OT - komorbiditás

OT - mortality

OT - mortalitás

OT - schizophrenia

OT - szkizofrénia

EDAT- 2023/08/20 18:41

MHDA- 2023/08/22 06:42

CRDT- 2023/08/20 15:03

PHST- 2023/04/27 00:00 [received]

PHST- 2023/05/24 00:00 [accepted]

PHST- 2023/08/22 06:42 [medline]

PHST- 2023/08/20 18:41 [pubmed]

PHST- 2023/08/20 15:03 [entrez]

AID - 10.1556/650.2023.32843 [doi]

PST - epublish

SO - Orv Hetil. 2023 Aug 20;164(33):1287-1293. doi: 10.1556/650.2023.32843. Print 2023

Aug 20.

PMID- 37593363

OWN - NLM

STAT- MEDLINE

DCOM- 20230821

LR - 20230901

IS - 2046-1402 (Electronic)

IS - 2046-1402 (Linking)

VI - 12

DP - 2023

TI - Dance/movement therapy as a holistic approach to diminish health discrepancies

and promote wellness for people with schizophrenia: a review of the literature.

PG - 33

LID - 10.12688/f1000research.127377.2 [doi]

LID - 33

AB - Individuals with a diagnosis of schizophrenia face a myriad of obstacles to

wellness, beginning with diagnostic discrepancies including over- and

misdiagnoses on the schizophrenia spectrum. People with schizophrenia experience

profound amounts of stigmatization from the general population, their healthcare

providers, and even themselves. Such stigmatization creates a barrier for

wellness, poorer prognoses, and often limits adherence to physical and mental

healthcare. Moreover, it can exacerbate the already stifling symptomatology of

their diagnoses, including specific bodily-related symptomatology. Oftentimes, a

diagnosis of schizophrenia disrupts one's relationship with their body including

a diminished mind-body connection, decreased interoceptive awareness, and thus

unsuccessful intra- and interpersonal relationships. Some recent research

suggests the use of mind-body therapies, however, if these practices are

internalizing, they may not be appropriate for people with schizophrenia

experiencing more acute symptomatology excluding them from treatment.

Dance/movement therapy (DMT) is an embodied psychotherapeutic treatment option

that can support participants in improving mind-body connection, social

relationships, and self-regulatory skill development. Research on DMT has shown

promising results for people with schizophrenia, however such research is limited

and would benefit from increased studies that particularly measure the effects of

DMT on mind-body connection and increased interoception for people with

schizophrenia. Moreover, integrative and collaborative treatment models that

couple DMT and biofeedback may further our understanding of the physiological and

neurological effects of DMT interventions for people with schizophrenia and

beyond. This review will examine the recent literature on health inequities for

people with schizophrenia, their specific body-based disruptions and needs, and

DMT as a promising treatment model, particularly when coupled with biofeedback.

FAU - Biondo, Jacelyn

AU - Biondo J

AUID- ORCID: 0000-0002-8925-5135

AD - Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA,

19107, USA.

LA - eng

PT - Journal Article

PT - Research Support, U.S. Gov't, P.H.S.

PT - Review

DEP - 20230801

PL - England

TA - F1000Res

JT - F1000Research

JID - 101594320

SB - IM

MH - Humans

MH - *Dance Therapy

MH - *Schizophrenia/therapy

MH - Physical Therapy Modalities

MH - Movement

MH - Health Facilities

PMC - PMC10429376

OTO - NOTNLM

OT - dance/movement therapy

OT - embodiment

OT - healthcare disparities

OT - interoception

OT - mind-body connection

OT - neurobiology

OT - schizophrenia

COIS- No competing interests were disclosed.

EDAT- 2023/08/18 06:42

MHDA- 2023/08/21 06:42

CRDT- 2023/08/18 03:52

PHST- 2023/07/28 00:00 [accepted]

PHST- 2023/08/21 06:42 [medline]

PHST- 2023/08/18 06:42 [pubmed]

PHST- 2023/08/18 03:52 [entrez]

AID - 10.12688/f1000research.127377.2 [doi]

PST - epublish

SO - F1000Res. 2023 Aug 1;12:33. doi: 10.12688/f1000research.127377.2. eCollection

2023.

PMID- 37565853

OWN - NLM

STAT- MEDLINE

DCOM- 20230814

LR - 20230814

IS - 1536-5964 (Electronic)

IS - 0025-7974 (Print)

IS - 0025-7974 (Linking)

VI - 102

IP - 32

DP - 2023 Aug 11

TI - The application of cognitive behavioral therapy in patients with schizophrenia: A

review.

PG - e34827

LID - 10.1097/MD.0000000000034827 [doi]

LID - e34827

AB - The aim of this review is to explore the clinical nursing application of

cognitive behavioral therapy (CBT) in patients with schizophrenia. A literature

search was conducted using the CINAHL and MEDLINE databases. The database search

occurred during the month of December 2022. This article comprehensively

summarizes the theoretical basis of CBT in improving schizophrenia in clinical

nursing, its application in managing symptoms and improving social function, as

well as research progress in this field. There are still inconsistencies in the

research results on CBT, but overall, psychological intervention combined with

drug treatment is more effective than conventional treatment alone. If social

function training can be added at the same time, it is believed that it will have

better effects on clinical treatment and can maintain long-lasting effectiveness.

Only in this way can patients truly understand and recognize the disease, improve

treatment compliance, and ultimately achieve the goal of improving prognosis and

quality of life.

FAU - Xu, Feifei

AU - Xu F

AUID- ORCID: 0000-0002-6425-243

AD - School of Psychology, Zhejiang Normal University, Jin Hua, China.

FAU - Zhang, Hang

AU - Zhang H

AD - School of Humanities and International Education Exchange, Anhui University of

Chinese Medicine, HeFei, China.

LA - eng

PT - Journal Article

PT - Review

PL - United States

TA - Medicine (Baltimore)

JT - Medicine

JID - 2985248R

SB - IM

MH - Humans

MH - Quality of Life

MH - *Cognitive Behavioral Therapy/methods

MH - *Schizophrenia/therapy

MH - Patient Compliance

PMC - PMC10419479

COIS- The authors have no funding and conflicts of interest to disclose.

EDAT- 2023/08/11 12:42

MHDA- 2023/08/14 06:42

CRDT- 2023/08/11 10:13

PHST- 2023/08/14 06:42 [medline]

PHST- 2023/08/11 12:42 [pubmed]

PHST- 2023/08/11 10:13 [entrez]

AID - 00005792-202308110-00012 [pii]

AID - 10.1097/MD.0000000000034827 [doi]

PST - ppublish

SO - Medicine (Baltimore). 2023 Aug 11;102(32):e34827. doi:

10.1097/MD.0000000000034827.

PMID- 37565416

OWN - NLM

STAT- MEDLINE

DCOM- 20230814

LR - 20230814

IS - 1802-9973 (Electronic)

IS - 0862-8408 (Linking)

VI - 72

IP - Suppl 2

DP - 2023 Jul 31

TI - Exploring the Association between Schizophrenia and Cardiovascular Diseases:

Insights into the Role of Sigma 1 Receptor.

PG - S113-S126

AB - Contemporary society is characterized by rapid changes. Various epidemiological,

political and economic crises represent a burden to mental health of nowadays

population, which may at least partially explain the increasing incidence of

mental disorders, including schizophrenia. Schizophrenia is associated with

premature mortality by at least 13-15 years. The leading cause of premature

mortality in schizophrenia patients is high incidence of cardiovascular diseases.

The specific-cause mortality risk for cardiovascular diseases in schizophrenia

patients is more than twice higher as compared to the general population. Several

factors are discussed as the factor of cardiovascular diseases development.

Intensive efforts to identify possible link between schizophrenia and

cardiovascular diseases are made. It seems that sigma 1 receptor may represent

such link. By modulation of the activity of several neurotransmitter systems,

including dopamine, glutamate, and GABA, sigma 1 receptor might play a role in

pathophysiology of schizophrenia. Moreover, significant roles of sigma 1 receptor

in cardiovascular system have been repeatedly reported. The detailed role of

sigma 1 receptor in both schizophrenia and cardiovascular disorders development

however remains unclear. The article presents an overview of current knowledge

about the association between schizophrenia and cardiovascular diseases and

proposes possible explanations with special emphasis on the role of the sigma 1

receptor.

FAU - Rafcikova, J

AU - Rafcikova J

AD - Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech

Republic. stracina@med.muni.cz.

FAU - Novakova, M

AU - Novakova M

FAU - Stracina, T

AU - Stracina T

LA - eng

PT - Journal Article

PT - Review

PL - Czech Republic

TA - Physiol Res

JT - Physiological research

JID - 9112413

SB - IM

MH - Humans

MH - *Cardiovascular Diseases/diagnosis/epidemiology

MH - *Cardiovascular System

MH - *Schizophrenia/diagnosis/epidemiology

EDAT- 2023/08/11 06:43

MHDA- 2023/08/14 06:42

CRDT- 2023/08/11 05:34

PHST- 2023/08/14 06:42 [medline]

PHST- 2023/08/11 06:43 [pubmed]

PHST- 2023/08/11 05:34 [entrez]

AID - 935099 [pii]

PST - ppublish

SO - Physiol Res. 2023 Jul 31;72(Suppl 2):S113-S126.

PMID- 37561694

OWN - NLM

STAT- MEDLINE

DCOM- 20230814

LR - 20230814

IS - 1932-6203 (Electronic)

IS - 1932-6203 (Linking)

VI - 18

IP - 8

DP - 2023

TI - The effects of assessing character strengths vs. psychopathology on mood, hope,

perceived stigma and cognitive performance in individuals with psychosis.

PG - e0289872

LID - 10.1371/journal.pone.0289872 [doi]

LID - e0289872

AB - OBJECTIVES: The main objective of the present study was to investigate whether

assessments of psychopathology vs. character strengths were associated with

systematic differences concerning transient psychological states (i.e., cognitive

performance, state mood, optimism, therapy motivation, perceived stigma) in

individuals with psychotic disorders. An additional goal was to evaluate the

acceptance and appraisal of a subsequent online character-strength intervention,

consisting of top-two strengths feedback, and to explore associations between

character strengths and psychotic symptoms. The study thus aimed to contribute to

the discussion on the extension of current treatment approaches for schizophrenia

through positive psychological interventions. METHODS: The study was implemented

online applying a randomized within-subject cross-over design in N = 39 patients

with self-reported psychosis. After a baseline assessment, briefly capturing

psychological states (including cognition: TMT A/B, positive and negative affect,

motivation for change/ therapy, optimism, and self-stigma) participants were

randomly assigned to a first questionnaire block, which addressed either

individual character strengths (VIA-IS) or psychopathology (CAPE & BSI). This was

followed by a second, brief assessment of transient psychological states,

whereafter the second questionnaire block was conducted, this time with the

respective opposite (strengths or psychopathology) assessment. A final

psychological states assessment was conducted. Afterwards, participants received

feedback on their top-two strengths and a brief psycho-education, followed by a

qualitative assessment. RESULTS: Contrary to expectations, there were no

differences between the psychological states after the pathology vs. character

strengths assessment blocks. Character strengths mainly correlated negatively

with negative symptoms, with medium to large effect sizes. Participants were

generally satisfied with the intervention and rated a focus on personal strengths

in psychotherapy as highly important. CONCLUSION: Our main hypothesis stating

that the assessment of character strengths (vs. psychopathology) is associated

with differences in subsequent psychological states could not be confirmed.

Qualitative findings indicate that the emphasis on individual character strengths

interventions is well accepted and viewed as important. The associations of

character strengths with negative symptoms are important from the background of

the cognitive model or defeatist beliefs (e.g., amotivation due to perceiving the

self as 'incapable'), which could be addressed in experimental or intervention

studies targeting character strengths.

under the terms of the Creative Commons Attribution License, which permits

unrestricted use, distribution, and reproduction in any medium, provided the

original author and source are credited.

FAU - Randhawa, Aman

AU - Randhawa A

AUID- ORCID: 0000-0001-5837-6711

AD - Universitätsklinikum Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and

Psychotherapy, Hamburg, Germany.

FAU - Kühn, Simone

AU - Kühn S

AD - Universitätsklinikum Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and

Psychotherapy, Hamburg, Germany.

AD - Lise-Meitner Group for Environmental Neuroscience, Max Planck Institute for Human

Development, Berlin, Germany.

FAU - Schöttle, Daniel

AU - Schöttle D

AD - Universitätsklinikum Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and

Psychotherapy, Hamburg, Germany.

FAU - Moritz, Steffen

AU - Moritz S

AD - Universitätsklinikum Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and

Psychotherapy, Hamburg, Germany.

FAU - Gallinat, Jürgen

AU - Gallinat J

AD - Universitätsklinikum Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and

Psychotherapy, Hamburg, Germany.

FAU - Ascone, Leonie

AU - Ascone L

AD - Universitätsklinikum Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and

Psychotherapy, Hamburg, Germany.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230810

PL - United States

TA - PLoS One

JT - PloS one

JID - 101285081

SB - IM

MH - Humans

MH - *Psychotic Disorders/therapy/psychology

MH - *Schizophrenia/therapy

MH - Character

MH - Affect

MH - Cognition

PMC - PMC10414607

COIS- The authors have declared that no competing interests exist.

EDAT- 2023/08/10 18:42

MHDA- 2023/08/14 06:41

CRDT- 2023/08/10 13:33

PHST- 2022/09/24 00:00 [received]

PHST- 2023/07/27 00:00 [accepted]

PHST- 2023/08/14 06:41 [medline]

PHST- 2023/08/10 18:42 [pubmed]

PHST- 2023/08/10 13:33 [entrez]

AID - PONE-D-22-26122 [pii]

AID - 10.1371/journal.pone.0289872 [doi]

PST - epublish

SO - PLoS One. 2023 Aug 10;18(8):e0289872. doi: 10.1371/journal.pone.0289872.

eCollection 2023.

PMID- 37553268

OWN - NLM

STAT- MEDLINE

DCOM- 20230918

LR - 20231003

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Linking)

VI - 259

DP - 2023 Sep

TI - Exploring language and cognition in schizophrenia: Insights from computational

analysis.

PG - 1-3

LID - S0920-9964(23)00256-6 [pii]

LID - 10.1016/j.schres.2023.07.030 [doi]

FAU - Cecchi, Guillermo A

AU - Cecchi GA

AD - IBM TJ Watson Research Center, Yorktown Heights, NY, USA.

FAU - Corcoran, Cheryl M

AU - Corcoran CM

AD - Icahn School of Medicine at Mount Sinai, New York, NY, USA; James J. Peters

Veterans Administration, Bronx, NY, USA. Electronic address:

Cheryl.Corcoran@mssm.edu.

LA - eng

PT - Editorial

DEP - 20230806

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

SB - IM

MH - Humans

MH - *Schizophrenia/complications

MH - Cognition

MH - Language

MH - Problem Solving

MH - Semantics

OTO - NOTNLM

OT - Coherence

OT - Disorganization

OT - Emotion

OT - Mentalizing

OT - Natural language processing (NLP)

OT - Philosophy

OT - Semantic

OT - Syntactic

COIS- Declaration of competing interest The authors have no conflicts of interest to

declare.

EDAT- 2023/08/09 01:05

MHDA- 2023/09/18 12:43

CRDT- 2023/08/08 21:51

PHST- 2023/07/23 00:00 [received]

PHST- 2023/07/24 00:00 [accepted]

PHST- 2023/09/18 12:43 [medline]

PHST- 2023/08/09 01:05 [pubmed]

PHST- 2023/08/08 21:51 [entrez]

AID - S0920-9964(23)00256-6 [pii]

AID - 10.1016/j.schres.2023.07.030 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Sep;259:1-3. doi: 10.1016/j.schres.2023.07.030. Epub 2023 Aug

PMID- 37552680

OWN - NLM

STAT- MEDLINE

DCOM- 20230810

LR - 20230810

IS - 1932-6203 (Electronic)

IS - 1932-6203 (Linking)

VI - 18

IP - 8

DP - 2023

TI - Relationship between Toxoplasma gondii infection and psychiatric disorders in

Iran: A systematic review with meta-analysis.

PG - e0284954

LID - 10.1371/journal.pone.0284954 [doi]

LID - e0284954

AB - BACKGROUND: Toxoplasma gondii, a ubiquitous parasitic protozoan, may be an

important cause of neurological and psychiatric diseases. The present systematic

review and meta-analysis, therefore, was conducted to investigate the scientific

evidence regarding the potential association between T. gondii infection and

psychiatric disorders in Iran. METHODS: We systematically reviewed articles from

world-wide databases, including PubMed, Scopus, Science Direct, Web of Science,

Google Scholar, and Iranian national databases up to July 30th, 2021. The

Newcastle Ottawa Scale (NOS) was used to assess the quality of included studies.

The common odds ratio (OR) was estimated using inverse variance and a

random-effects model. Heterogeneity was assessed using the χ2-based Cochrane test

(Q) and the I2 index. Also, sensitivity analyses and publication bias were

calculated. Moreover, subgroup analysis was performed based on the type of

disorder and quality score of different eligible studies. RESULTS: 16 studies

were included in this meta-analysis. Our meta-analyses found that the OR of the

risk of anti- T. gondii IgG and IgM in psychiatric patients compared to the

control group was 1.56 (95% CI; 1.23-1.99) and 1.76 (95% CI: 1.19-2.61),

respectively. Subgroup analysis based on the type of disorder showed that the OR

of the risk of anti- T. gondii IgG in Iranian schizophrenia patients and other

psychiatric disorders compared to the control group were 1.50 (95% CI; 1.09-2.07)

and 2.03 (95% CI: 1.14-3.60), respectively, which are statistically significant.

Also, the OR of the risk of anti- T. gondii IgM in Iranian schizophrenia and

depression patients compared to the control group was 1.54 (95% CI; 0.9-2.64) and

1.03 (95% CI: 0.2-5.24), respectively, which are not statistically significant.

Additionally, subgroup analysis based on quality scores showed no significant

influence on the results according to the moderate quality studies. However, this

association was significant according to the high quality studies. The obtained

results of Egger's test were 1.5 (95% CI; -0.62-3.73, P = 0.15) and 0.47 (95% CI;

-0.82-1.76, P = 0.45), respectively, indicating publication bias. The significant

results of the heterogeneity analysis confirmed a high level of heterogeneity in

the IgG test (P = 0.000, I2 = 66.6%). However, no significant results from the

test of heterogeneity were detected in the IgM test (P = 0.15, I2 = 27.5%). The

results of the sensitivity analysis showed that the impact of each study on the

meta-analysis was not significant on overall estimates. CONCLUSIONS: Despite the

limited number of studies, these outcomes supported a possible link between T.

gondii infection and psychiatric disorders in Iran. However, more high-quality

investigations are needed in the future.

under the terms of the Creative Commons Attribution License, which permits

unrestricted use, distribution, and reproduction in any medium, provided the

original author and source are credited.

FAU - Montazeri, Mahbobeh

AU - Montazeri M

AD - Toxoplasmosis Research Center, Communicable Diseases Institute, Mazandaran

University of Medical Sciences, Sari, Iran.

FAU - Moradi, Elahe

AU - Moradi E

AD - Toxoplasmosis Research Center, Communicable Diseases Institute, Mazandaran

University of Medical Sciences, Sari, Iran.

AD - Student Research Committee, Mazandaran University of Medical Sciences, Sari,

Iran.

FAU - Moosazadeh, Mahmood

AU - Moosazadeh M

AD - Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute,

Mazandaran University of Medical Sciences, Sari, Iran.

FAU - Hosseini, Seyed Hamzeh

AU - Hosseini SH

AD - Toxoplasmosis Research Center, Communicable Diseases Institute, Mazandaran

University of Medical Sciences, Sari, Iran.

AD - Psychiatry and Behavioral Sciences Research Center, Mazandaran University of

Medical Sciences, Sari, Iran.

FAU - Fakhar, Mahdi

AU - Fakhar M

AUID- ORCID: 0000-0002-4690-6938

AD - Iranian National Registry Center for Toxoplasmosis (INRCT), Imam Khomeini

Hospital, Mazandaran University of Medical Sciences, Sari, Iran.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

DEP - 20230808

PL - United States

TA - PLoS One

JT - PloS one

JID - 101285081

RN - 0 (Immunoglobulin G)

RN - 0 (Immunoglobulin M)

SB - IM

MH - Humans

MH - Iran/epidemiology

MH - *Toxoplasmosis/complications/epidemiology/parasitology

MH - *Toxoplasma

MH - *Schizophrenia/epidemiology

MH - Immunoglobulin G

MH - Immunoglobulin M

MH - Seroepidemiologic Studies

PMC - PMC10409283

COIS- The authors of this manuscript have no competing interests.

EDAT- 2023/08/08 18:42

MHDA- 2023/08/10 06:43

CRDT- 2023/08/08 13:34

PHST- 2023/08/10 06:43 [medline]

PHST- 2023/08/08 18:42 [pubmed]

PHST- 2023/08/08 13:34 [entrez]

AID - PONE-D-22-03968 [pii]

AID - 10.1371/journal.pone.0284954 [doi]

PST - epublish

SO - PLoS One. 2023 Aug 8;18(8):e0284954. doi: 10.1371/journal.pone.0284954.

eCollection 2023.

PMID- 37545122

OWN - NLM

STAT- MEDLINE

DCOM- 20231012

LR - 20231013

IS - 1541-3527 (Electronic)

IS - 0091-2174 (Linking)

VI - 58

IP - 6

DP - 2023 Nov

TI - A randomized controlled trial of Vitamin D supplementation in Iranian patients

with schizophrenia: Effects on serum levels of glycogen synthase kinase-3β and

symptom severity.

PG - 559-575

LID - 10.1177/00912174231193303 [doi]

AB - BACKGROUND: Growing evidence has shown that hypovitaminosis D is a risk factor

for developing schizophrenia and comorbid conditions. Therefore, this study aimed

to examine the effect of vitamin D supplementation on serum levels of vitamin D,

metabolic factors related to insulin resistance (IR) and the severity of the

disorder in patients with schizophrenia. METHODS: Forty-eight chronic male

patients with schizophrenia with vitamin D deficiency (≤20 ng/mL= (≤50 nmol/l)

were selected and randomly assigned to vitamin D treatment and placebo groups.

Subjects were supplemented for 8 weeks with vitamin D (2000 IU/day) or placebo.

RESULTS: Within-group comparison revealed that the vitamin D group had a

significant reduction in waist circumference, Positive and Negative Syndrome

Scale - total score (PANSS-TS), and glycogen synthase kinase 3 beta (GSK-3β)

levels (P = .022, P = <.001 and P = .013, respectively). On the other hand, the

placebo group showed a significant increase in the level of fasting serum insulin

and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (P = .003 and P

= .003). The between-group comparison showed a significant difference in terms of

PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P

= .013 and P = .014 respectively). CONCLUSIONS: Among vitamin D deficient

patients with schizophrenia, vitamin D supplementation may affect GSK-3 β, an

important biomarker in schizophrenia and insulin resistance. In addition, vitamin

D supplementation in such patients may reduce the disorder's symptom severity.

FAU - Kalejahi, Parinaz

AU - Kalejahi P

AUID- ORCID: 0000-0002-5473-171X

AD - Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz

University of Medical Sciences, Tabriz, Iran.

FAU - Kheirouri, Sorayya

AU - Kheirouri S

AD - Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz

University of Medical Sciences, Tabriz, Iran.

FAU - Noorazar, Seyed Gholamreza

AU - Noorazar SG

AD - Research Center of Psychiatry and Behavioral Sciences, Tabriz University of

Medical Sciences, Tabriz, Iran.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230806

PL - United States

TA - Int J Psychiatry Med

JT - International journal of psychiatry in medicine

JID - 0365646

RN - 0 (Blood Glucose)

RN - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)

RN - 0 (Insulin)

RN - 1406-16-2 (Vitamin D)

RN - 0 (Vitamins)

SB - IM

MH - Humans

MH - Male

MH - Blood Glucose

MH - Dietary Supplements

MH - Glycogen Synthase Kinase 3 beta/blood

MH - Insulin/blood

MH - *Insulin Resistance

MH - Iran

MH - *Schizophrenia/drug therapy

MH - Vitamin D/therapeutic use

MH - *Vitamin D Deficiency/complications/drug therapy

MH - Vitamins

OTO - NOTNLM

OT - GSK-3β

OT - insulin resistance

OT - schizophrenia

OT - severity

OT - vitamin D supplementation

COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts

of interest with respect to the research, authorship, and/or publication of this

article.

EDAT- 2023/08/07 06:41

MHDA- 2023/10/12 06:43

CRDT- 2023/08/07 01:44

PHST- 2023/10/12 06:43 [medline]

PHST- 2023/08/07 06:41 [pubmed]

PHST- 2023/08/07 01:44 [entrez]

AID - 10.1177/00912174231193303 [doi]

PST - ppublish

SO - Int J Psychiatry Med. 2023 Nov;58(6):559-575. doi: 10.1177/00912174231193303.

Epub 2023 Aug 6.

PMID- 37544705

OWN - NLM

STAT- MEDLINE

DCOM- 20230808

LR - 20230808

IS - 1532-8228 (Electronic)

IS - 0883-9417 (Linking)

VI - 45

DP - 2023 Aug

TI - The effect of interpersonal relations theory-based motivational interviews on

functional remission and insight levels of patients with schizophrenia: A

randomized controlled trial.

PG - 72-79

LID - S0883-9417(23)00055-9 [pii]

LID - 10.1016/j.apnu.2023.04.018 [doi]

AB - BACKGROUND: Using therapeutic techniques and conducting motivational interviews

in communication with patients with schizophrenia increases individuals'

functional remission, insight, and motivation levels. AIM: This single-blind,

randomized controlled study examines the effect of Interpersonal Relations

Theory-Based motivational interviews on functional remission and insight levels

in patients with schizophrenia. METHODS: The participants of this study were 40

patients with schizophrenia randomly assigned to either the experimental or

control groups (20 in each group). The researchers carried out a 6-session

Interpersonal Relations Theory-based motivational interview with the participants

in the experimental group. Study data were collected using a demographic

questionnaire, the Functional Remission of General Schizophrenia Scale (FROGS),

and the Scale for Assessing the Three Components of Insight (SAI). RESULTS:

Social Functioning, Health and Treatment, Daily Living Skills, and SAI scores of

the individuals in the intervention group were statistically higher than those in

the control group (p < 0.05) in the post-intervention and follow-up measures.

There was a positive and significant correlation between the post-intervention

Social Functioning, Health and Treatment, Daily Life Skills, and total FROGS

scores and the SAI score of the individuals in the intervention group (p < 0.05).

CONCLUSIONS: It was concluded that motivational interviews based on Interpersonal

Relations Theory were effective in increasing the insights and functionality of

patients with schizophrenia. Psychiatric nurses' practice of motivational

interviews based on the therapeutic relationship is considered to increase the

quality of care and satisfaction of patients with schizophrenia. It is

recommended that this practice be used extensively in clinical practice.

FAU - Köktaş, Nesrin Çunkuş

AU - Köktaş NÇ

AD - Department of Psychiatric Nursing, Faculty of Health Science, Pamukkale

University, Denizli, Turkey. Electronic address: ncunkus@pau.edu.tr.

FAU - Yiğitoğlu, Gülay Taşdemir

AU - Yiğitoğlu GT

AD - Department of Psychiatric Nursing, Faculty of Health Science, Pamukkale

University, Denizli, Turkey.

FAU - Kenar, Ayşe Nur İnci

AU - Kenar ANİ

AD - Department of Psychiatric, Faculty of Medicine, Pamukkale University, Denizli,

Turkey.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230509

PL - United States

TA - Arch Psychiatr Nurs

JT - Archives of psychiatric nursing

JID - 8708534

SB - IM

MH - Humans

MH - *Schizophrenia/therapy

MH - Single-Blind Method

MH - Interpersonal Relations

MH - *Motivational Interviewing

MH - Social Adjustment

OTO - NOTNLM

OT - Functional remission

OT - Insight

OT - Interpersonal relations theory

OT - Motivational interviews

OT - Schizophrenia

COIS- Declaration of competing interest The authors declare no conflict of interest.

The funders had no role in the design of the study; in the collection, analyses,

or interpretation of data; in the writing of the manuscript, or in the decision

to publish the results.

EDAT- 2023/08/07 00:42

MHDA- 2023/08/08 06:42

CRDT- 2023/08/06 20:56

PHST- 2022/03/19 00:00 [received]

PHST- 2022/12/31 00:00 [revised]

PHST- 2023/04/30 00:00 [accepted]

PHST- 2023/08/08 06:42 [medline]

PHST- 2023/08/07 00:42 [pubmed]

PHST- 2023/08/06 20:56 [entrez]

AID - S0883-9417(23)00055-9 [pii]

AID - 10.1016/j.apnu.2023.04.018 [doi]

PST - ppublish

SO - Arch Psychiatr Nurs. 2023 Aug;45:72-79. doi: 10.1016/j.apnu.2023.04.018. Epub

2023 May 9.

PMID- 37542559

OWN - NLM

STAT- MEDLINE

DCOM- 20230825

LR - 20231013

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Print)

IS - 0940-1334 (Linking)

VI - 273

IP - 6

DP - 2023 Sep

TI - Cellular pathology in the limbic system in schizophrenia.

PG - 1207-1208

LID - 10.1007/s00406-023-01659-x [doi]

FAU - Schmitt, Andrea

AU - Schmitt A

AD - Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich,

Munich, Germany. Andrea.Schmitt@med.uni-muenchen.de.

AD - Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of Sao

Paulo, São Paulo, SP, Brazil. Andrea.Schmitt@med.uni-muenchen.de.

FAU - Falkai, Peter

AU - Falkai P

AD - Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich,

Munich, Germany.

AD - Max Planck Institute of Psychiatry, Munich, Germany.

LA - eng

PT - Comment

PT - Editorial

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

SB - IM

CON - Eur Arch Psychiatry Clin Neurosci. 2023 Sep;273(6):1209-1223. PMID: 36350376

MH - Humans

MH - *Schizophrenia/pathology

MH - Limbic System

MH - Brain/pathology

PMC - PMC10449720

EDAT- 2023/08/06 05:41

MHDA- 2023/08/25 06:42

CRDT- 2023/08/05 11:04

PHST- 2023/08/25 06:42 [medline]

PHST- 2023/08/06 05:41 [pubmed]

PHST- 2023/08/05 11:04 [entrez]

AID - 10.1007/s00406-023-01659-x [pii]

AID - 1659 [pii]

AID - 10.1007/s00406-023-01659-x [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Sep;273(6):1207-1208. doi:

10.1007/s00406-023-01659-x.

PMID- 37536144

OWN - NLM

STAT- MEDLINE

DCOM- 20230906

LR - 20231010

IS - 1872-7123 (Electronic)

IS - 0165-1781 (Linking)

VI - 327

DP - 2023 Sep

TI - The emerging role of exosomes in Schizophrenia.

PG - 115394

LID - S0165-1781(23)00344-X [pii]

LID - 10.1016/j.psychres.2023.115394 [doi]

AB - Schizophrenia (SCZ), a serious mental disorder, is one of the leading causes of

disease burden worldwide. Exosomes, as a natural nanocarrier, are able to cross

the blood-brain barrier (BBB) and play a key bridging role in central nervous

system (CNS) communication, participating in important physiological processes

such as neural regeneration, prominent plasticity, axonal support, and

neuroinflammation. In recent years, exosomes have received widespread attention

in the field of neurodegenerative diseases and mental disorders, especially

Alzheimer's disease. However, there are few reviews on exosomes and SCZ.

Therefore, we conducted a literature search in PubMed and Web of Science using

the following search terms: "schizophrenia", "mental disorder", "central system",

"exosome", "extracellular vesicles" to identify publications from January 2010 to

December 2022. Our review summarized exosomes secreted by different cell types in

the CNS and the double-edged role of exosomes in the development of SCZ, and

discussed their future potential as biomarkers and therapeutic targets. In

conclusion, this article provides an up-to-date overview of the current research

on the involvement of exosomes in SCZ, while also highlighting the challenges

that are currently faced in this field.

FAU - Dai, Jie

AU - Dai J

AD - School of Public Health, Wuhan University, Wuhan, China.

FAU - Zhang, Min-Zhe

AU - Zhang MZ

AD - School of Public Health, Wuhan University, Wuhan, China.

FAU - He, Qi-Qiang

AU - He QQ

AD - School of Public Health, Wuhan University, Wuhan, China; Hubei Biomass-Resource

Chemistry and Environmental Biotechnology Key Laboratory, Wuhan University,

Wuhan, China.

FAU - Chen, Rui

AU - Chen R

AD - School of Public Health, Wuhan University, Wuhan, China. Electronic address:

chenrui2020@whu.edu.cn.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230730

PL - Ireland

TA - Psychiatry Res

JT - Psychiatry research

JID - 7911385

SB - IM

MH - Humans

MH - *Schizophrenia/metabolism

MH - *Exosomes/metabolism

MH - *Alzheimer Disease

MH - Blood-Brain Barrier/metabolism

MH - *Psychotic Disorders/metabolism

OTO - NOTNLM

OT - Blood-brain barrier

OT - Exosomes

OT - Schizophrenia

COIS- Declaration of Competing Interest The authors declared no potential conflicts of

interest with respect to the research, authorship, and/or publication of this

article.

EDAT- 2023/08/04 01:08

MHDA- 2023/09/06 06:42

CRDT- 2023/08/03 18:07

PHST- 2023/03/10 00:00 [received]

PHST- 2023/07/25 00:00 [revised]

PHST- 2023/07/29 00:00 [accepted]

PHST- 2023/09/06 06:42 [medline]

PHST- 2023/08/04 01:08 [pubmed]

PHST- 2023/08/03 18:07 [entrez]

AID - S0165-1781(23)00344-X [pii]

AID - 10.1016/j.psychres.2023.115394 [doi]

PST - ppublish

SO - Psychiatry Res. 2023 Sep;327:115394. doi: 10.1016/j.psychres.2023.115394. Epub

2023 Jul 30.

PMID- 37532985

OWN - NLM

STAT- MEDLINE

DCOM- 20230807

LR - 20230807

IS - 1471-244X (Electronic)

IS - 1471-244X (Linking)

VI - 23

IP - 1

DP - 2023 Aug 2

TI - Decrease in cognitive performance and increase of the neutrophil-to-lymphocyte

and platelet-to-lymphocyte ratios with higher doses of antipsychotics in women

with schizophrenia: a cross-sectional study.

PG - 558

LID - 10.1186/s12888-023-05050-x [doi]

LID - 558

AB - BACKGROUND: We explored the relationship between symptoms, cognitive performance,

neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and

platelet-to-lymphocyte ratio (PLR) (three markers of inflammation), and

antipsychotic dose (in chlorpromazine units) in male and female patients with

schizophrenia. METHODS: We conducted a cross-sectional analysis in patients with

schizophrenia of the complete blood count and the results of neuropsychological

testing, using the Welch t-test to compare groups and the Pearson test for

correlations. RESULTS: We found that the NLR and the PLR are higher among women

with schizophrenia when compared with men. In women, the NLR and the PLR

correlate positively with antipsychotic drug dose and inversely with a working

memory test (Direct Digit Span). Higher doses of antipsychotics are associated

with worse working and semantic memory and mental flexibility in the women in our

sample. CONCLUSION: Higher doses of antipsychotics were associated with worse

working and semantic memory and mental flexibility in women with schizophrenia.

No such correlations were present in men, suggesting that, in female patients,

cognitive performance deteriorates as the antipsychotic dose is increased, a

finding that could be mediated by inflammatory mechanisms, given the demonstrated

relationship to biomarkers of inflammation - e.g., the NLR and the PLR. TRIAL

REGISTRATION: NCT03788759 (ClinicalTrials.gov).

FAU - Frota, Ilgner Justa

AU - Frota IJ

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil. ilgner0@gmail.com.

FAU - de Oliveira, Alissandra Lima Barbosa

AU - de Oliveira ALB

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - De Lima, David Nunes Jr

AU - De Lima DN Jr

AD - Department of Clinical Medicine, Faculty of Medicine, Federal University of

Ceará, Fortaleza, Brazil.

FAU - Costa Filho, Carlos Winston Luz

AU - Costa Filho CWL

AD - Department of Medical Education, Faculdade Paraíso, Araripina, Brazil.

FAU - Menezes, Carlos Eduardo de Souza

AU - Menezes CES

AD - Department of Psychology, Christus University Center, Fortaleza, Brazil.

FAU - Soares, Michelle Verde Ramo

AU - Soares MVR

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - Chaves Filho, Adriano José Maia

AU - Chaves Filho AJM

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - Lós, Deniele Bezerra

AU - Lós DB

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - Moreira, Roberta Tavares de Araújo

AU - Moreira RTA

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - Viana, Glautemberg de Almeida

AU - Viana GA

AD - Laboratory of Clinical and Toxicological Analysis, Department of Pharmacy,

Federal University of Ceará, Fortaleza, Brazil.

FAU - Campos, Eugênio de Moura

AU - Campos EM

AD - Department of Clinical Medicine, Faculty of Medicine, Federal University of

Ceará, Fortaleza, Brazil.

FAU - Vasconcelos, Silvânia Maria Mendes

AU - Vasconcelos SMM

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - Seeman, Mary V

AU - Seeman MV

AD - Department of Psychiatry, University of Toronto, Toronto, Canada.

FAU - Macêdo, Danielle S

AU - Macêdo DS

AD - Neuropsychopharmacology and Translational Psychiatry Laboratory, Drug Research

and Development Center, Faculty of Medicine, Federal University of Ceará, Rua

Coronel Nunes de Melo, 1000 - Rodolfo Teófilo, Fortaleza, CE, Postal Code

60430-275, Brazil.

FAU - Sanders, Lia Lira Olivier

AU - Sanders LLO

AD - Department of Clinical Medicine, Faculty of Medicine, Federal University of

Ceará, Fortaleza, Brazil.

LA - eng

SI - ClinicalTrials.gov/NCT03788759

PT - Clinical Trial

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

DEP - 20230802

PL - England

TA - BMC Psychiatry

JT - BMC psychiatry

JID - 100968559

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Female

MH - Humans

MH - Male

MH - *Antipsychotic Agents/therapeutic use

MH - Cognition

MH - Cross-Sectional Studies

MH - Inflammation

MH - Lymphocytes

MH - Neutrophils

MH - *Schizophrenia/drug therapy

PMC - PMC10394759

OTO - NOTNLM

OT - Antipsychotics

OT - Executive function

OT - Inflammation

OT - Neuropsychological tests

OT - Neutrophil-to-lymphocyte ratio

OT - Schizophrenia

COIS- The authors declare no competing interests.

EDAT- 2023/08/03 01:06

MHDA- 2023/08/04 06:43

CRDT- 2023/08/02 23:33

PHST- 2023/04/26 00:00 [received]

PHST- 2023/07/24 00:00 [accepted]

PHST- 2023/08/04 06:43 [medline]

PHST- 2023/08/03 01:06 [pubmed]

PHST- 2023/08/02 23:33 [entrez]

AID - 10.1186/s12888-023-05050-x [pii]

AID - 5050 [pii]

AID - 10.1186/s12888-023-05050-x [doi]

PST - epublish

SO - BMC Psychiatry. 2023 Aug 2;23(1):558. doi: 10.1186/s12888-023-05050-x.

PMID- 37527479

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230911

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 5

DP - 2023 Sep 7

TI - Predictors of Mortality Following a Schizophrenia Spectrum Diagnosis: Evidence

From the 20-Year Follow-up of the OPUS Randomized Controlled Trial.

PG - 1256-1268

LID - 10.1093/schbul/sbad111 [doi]

AB - BACKGROUND AND HYPOTHESIS: The life expectancy of patients diagnosed with

schizophrenia is 10-12 years lower than in the general population and the

mortality gap seems to be worsening. Many of these deaths might be avoidable. We

aimed to determine mortality rates and causes of death after a first-episode

psychosis, and to examine if clinical characteristics at baseline or during

illness could predict mortality. STUDY DESIGN: The OPUS study was a randomized

controlled trial of 578 patients first diagnosed with schizophrenia spectrum

disorders. Patients were clinically assessed after 2, 5, 10, and 20 years.

Information about time and cause of death was obtained from the Danish Cause of

Death Register. Hazard ratios were used to assess predictors of death. STUDY

RESULTS: In total, 82 (14.4%) participants died during 20 years of follow-up. The

most common cause of death was suicide (27%). At baseline employment (HR 0.47

P = .049), psychotic disorder other than schizophrenia (HR 0.36, P = .017), and

longer duration of untreated psychosis (HR 0.57 P = .042) predicted lower

mortality while substance use predicted higher mortality (HR 2.56, P < .001).

During follow-up, symptom remission without antipsychotic medication and recovery

predicted lower mortality (HR 0.08 P = .013 and HR 0.21, P = .028) while

substance use (HR 3.64 P < .001), and all chronic illnesses predicted increased

risk. CONCLUSIONS: There is an increased risk of early mortality in schizophrenia

compared to the background population, and there is an urgent need for new

efforts to improve the disparities in health that lead to this increased

mortality.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of the

please email: journals.permissions@oup.com.

FAU - Starzer, Marie Stefanie Kejser

AU - Starzer MSK

AD - Copenhagen Research Center for Mental Health - CORE, Mental Health Center

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

FAU - Hansen, Helene Gjervig

AU - Hansen HG

AD - Copenhagen Research Center for Mental Health - CORE, Mental Health Center

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

FAU - Hjorthøj, Carsten

AU - Hjorthøj C

AUID- ORCID: 0000-0002-6943-4785

AD - Copenhagen Research Center for Mental Health - CORE, Mental Health Center

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Department of Public Health, Section of Epidemiology, University of Copenhagen,

Copenhagen, Denmark.

FAU - Speyer, Helene

AU - Speyer H

AD - Copenhagen Research Center for Mental Health - CORE, Mental Health Center

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

FAU - Albert, Nikolai

AU - Albert N

AUID- ORCID: 0000-0002-0685-9647

AD - Copenhagen Research Center for Mental Health - CORE, Mental Health Center

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Mental Health Centre Amager, University Hospital of Copenhagen, Denmark.

FAU - Nordentoft, Merete

AU - Nordentoft M

AD - Copenhagen Research Center for Mental Health - CORE, Mental Health Center

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

LA - eng

SI - ClinicalTrials.gov/NCT00157313

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

MH - Humans

MH - *Schizophrenia/epidemiology

MH - Follow-Up Studies

MH - *Psychotic Disorders

MH - *Suicide

MH - Cause of Death

PMC - PMC10483333

OTO - NOTNLM

OT - Schizophrenia spectrum

OT - cause of death

OT - longitudinal study

OT - mortality

OT - predictors

OT - risk factors

COIS- We declare no competing interests.

EDAT- 2023/08/01 19:12

MHDA- 2023/09/08 06:43

PMCR- 2024/08/01

CRDT- 2023/08/01 16:04

PHST- 2024/08/01 00:00 [pmc-release]

PHST- 2023/09/08 06:43 [medline]

PHST- 2023/08/01 19:12 [pubmed]

PHST- 2023/08/01 16:04 [entrez]

AID - 7234858 [pii]

AID - sbad111 [pii]

AID - 10.1093/schbul/sbad111 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Sep 7;49(5):1256-1268. doi: 10.1093/schbul/sbad111.

PMID- 37526007

OWN - NLM

STAT- MEDLINE

DCOM- 20230809

LR - 20231004

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Print)

IS - 0007-1250 (Linking)

VI - 223

IP - 2

DP - 2023 Aug

TI - Cost-effectiveness analysis of physical activity interventions for people with

schizophrenia or bipolar disorder: systematic review.

PG - 362-376

LID - 10.1192/bjp.2023.52 [doi]

AB - BACKGROUND: Clinical guidelines recommend providing physical activity

interventions (PAIs) to people with schizophrenia or bipolar disorder for weight

management. However, the cost-effectiveness of PAIs is unknown. AIMS: To evaluate

the availability and methodological quality of economic evaluations of PAIs for

people with schizophrenia or bipolar disorder. METHOD: Four databases (MEDLINE,

Embase, PsycInfo and Scopus) were searched on 5 July 2022. Based on the retrieved

studies, forward and backward citation searches were conducted. Two reviewers

independently selected studies for inclusion. Study quality was assessed using

the Drummond checklist. Review results were presented using narrative synthesis.

RESULTS: Fourteen articles reporting nine studies were included. All included

studies assessed PAIs within a multicomponent lifestyle intervention. Mixed

findings were reported on the cost-effectiveness of multicomponent lifestyle

intervention: three studies reported it as cost-effective; four studies reported

it as not cost-effective; and two studies did not conclude whether it was

cost-effective or not. Very limited evidence suggests that certain patient

subgroups might be more likely to benefit from multicomponent lifestyle

interventions with a PAI component: men; individuals with comorbid type 2

diabetes; and individuals who have been psychiatric hospital in-patients for ≥1

year. The quality of included studies ranged from moderate to high. CONCLUSIONS:

The current economic evidence suggests that not all modalities of multicomponent

lifestyle intervention including a PAI component are cost-effective for people

with schizophrenia or bipolar disorder; and not all people with schizophrenia or

bipolar disorder would benefit equally from the intervention. Future research is

urgently needed to identify the cost-effective modality of PAI for different

patient subgroups.

FAU - Jin, Huajie

AU - Jin H

AUID- ORCID: 0000-0002-3872-3998

AD - King's Health Economics (KHE), Health Service and Population Research Department,

Institute of Psychiatry, Psychology & Neuroscience, King's College London,

London, UK.

FAU - Kolawole, Oluwafunso

AU - Kolawole O

AUID- ORCID: 0000-0001-6303-3991

AD - King's Health Economics (KHE), Health Service and Population Research Department,

Institute of Psychiatry, Psychology & Neuroscience, King's College London,

London, UK.

FAU - Wang, Zhengwei

AU - Wang Z

AUID- ORCID: 0000-0003-0836-5349

AD - King's Health Economics (KHE), Health Service and Population Research Department,

Institute of Psychiatry, Psychology & Neuroscience, King's College London,

London, UK.

LA - eng

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20230801

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

MH - Male

MH - Humans

MH - *Bipolar Disorder/therapy

MH - *Schizophrenia/therapy

MH - Cost-Effectiveness Analysis

MH - *Diabetes Mellitus, Type 2

MH - Exercise

MH - Cost-Benefit Analysis

PMC - PMC10405045

OTO - NOTNLM

OT - Physical activity

OT - bipolar affective disorders

OT - cost-effectiveness

OT - schizophrenia

OT - systematic review

COIS- None.

EDAT- 2023/08/01 06:44

MHDA- 2023/08/09 06:43

CRDT- 2023/08/01 04:43

PHST- 2023/08/09 06:43 [medline]

PHST- 2023/08/01 06:44 [pubmed]

PHST- 2023/08/01 04:43 [entrez]

AID - S0007125023000521 [pii]

AID - 10.1192/bjp.2023.52 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Aug;223(2):362-376. doi: 10.1192/bjp.2023.52. Epub 2023 Aug

PMID- 37517367

OWN - NLM

STAT- MEDLINE

DCOM- 20230821

LR - 20230821

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Linking)

VI - 258

DP - 2023 Aug

TI - Impaired calcium channel function and pronounced hippocampal atrophy in a

schizophrenia patient with cognitive impairment carrying Presenilin-2 Ser130Leu

mutation: A case report and literature review.

PG - 78-80

LID - S0920-9964(23)00251-7 [pii]

LID - 10.1016/j.schres.2023.07.024 [doi]

FAU - Zhang, Ziyi

AU - Zhang Z

AD - Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue

Xiang, Chengdu 610041, Sichuan Province, PR China.

FAU - Lin, Hua

AU - Lin H

AD - Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37

Guo Xue Xiang, Chengdu 610041, Sichuan Province, PR China.

FAU - Feng, Zijuan

AU - Feng Z

AD - Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue

Xiang, Chengdu 610041, Sichuan Province, PR China.

FAU - Xie, Hongsheng

AU - Xie H

AD - Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37

Guo Xue Xiang, Chengdu 610041, Sichuan Province, PR China.

FAU - Liu, Peng

AU - Liu P

AD - Department of Emergency, West China Hospital of Sichuan University, No. 37 Guo

Xue Xiang, Chengdu 610041, Sichuan Province, PR China.

FAU - Shu, Yang

AU - Shu Y

AD - State Key Laboratory of Biotherapy, West China Hospital, Sichuan University,

Chengdu, Sichuan, PR China.

FAU - Jia, Zhiyun

AU - Jia Z

AD - Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37

Guo Xue Xiang, Chengdu 610041, Sichuan Province, PR China. Electronic address:

zhiyunjia@hotmail.com.

FAU - Zhang, Shuting

AU - Zhang S

AD - Department of Neurology, West China Hospital, Sichuan University, No. 37 Guo Xue

Xiang, Chengdu 610041, Sichuan Province, PR China. Electronic address:

shutingzhang@scu.edu.cn.

LA - eng

PT - Case Reports

PT - Letter

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230728

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

RN - 0 (Calcium Channels)

RN - 0 (Presenilin-2)

RN - 0 (Presenilin-1)

SB - IM

MH - Humans

MH - Calcium Channels

MH - *Schizophrenia/complications/diagnostic imaging/genetics

MH - Presenilin-2/genetics/metabolism

MH - Mutation/genetics

MH - *Cognitive Dysfunction/genetics

MH - Hippocampus/diagnostic imaging/metabolism

MH - Atrophy

MH - Presenilin-1/genetics/metabolism

MH - Magnetic Resonance Imaging

COIS- Declaration of competing interest ZZ, HL, ZF, HX, PL, YS, ZJ and SZ have no

potential conflict of interests to declare.

EDAT- 2023/07/31 00:41

MHDA- 2023/08/21 06:42

CRDT- 2023/07/30 18:10

PHST- 2023/05/16 00:00 [received]

PHST- 2023/07/12 00:00 [revised]

PHST- 2023/07/23 00:00 [accepted]

PHST- 2023/08/21 06:42 [medline]

PHST- 2023/07/31 00:41 [pubmed]

PHST- 2023/07/30 18:10 [entrez]

AID - S0920-9964(23)00251-7 [pii]

AID - 10.1016/j.schres.2023.07.024 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Aug;258:78-80. doi: 10.1016/j.schres.2023.07.024. Epub 2023

Jul 28.

PMID- 37517366

OWN - NLM

STAT- MEDLINE

DCOM- 20230821

LR - 20230821

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Linking)

VI - 258

DP - 2023 Aug

TI - Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and

treatments.

PG - 71-77

LID - S0920-9964(23)00235-9 [pii]

LID - 10.1016/j.schres.2023.07.010 [doi]

AB - The negative symptoms of schizophrenia, which often appear earlier than any other

symptom, are prominent and clinically relevant in the majority of patients. As a

result, interest in their treatment has increased. Patients who exhibit

significant negative symptoms have worse functional outcomes than those without,

resulting in impairments in occupational, household, and recreational

functioning, as well as difficulties in relationships. Yet treatment with

currently available medications does not lead to any significant improvements in

this core component of schizophrenia. An increased understanding of the

pathophysiology underlying negative symptoms and the discovery of novel

treatments that do not directly target dopamine offer the potential to develop

therapies that may reduce negative symptoms and increase quality of life for

patients. The current article will discuss the impact of negative symptoms,

outline current measurement tools for the assessment of negative symptoms, and

examine how these measures may be improved. Insights into the neural circuitry

underlying negative symptoms will be discussed, and promising targets for the

development of effective treatments for these symptoms will be identified. As

more prospective, large-scale, randomized studies focus on the effects of

treatments on negative symptoms, progress in this area is foreseeable. However,

improvements in clinical assessment instruments, a better understanding of the

underlying neural mechanisms, development of novel treatments with varied

targets, and a greater focus on personalized treatment are all important to

produce significant benefits for patients with negative symptoms of

schizophrenia.

FAU - Marder, Stephen R

AU - Marder SR

AD - Semel Institute for Neuroscience and Human Behavior, University of California,

Los Angeles, Los Angeles, CA, United States of America; Veterans Affairs Desert

Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA,

United States of America. Electronic address: SMarder@mednet.ucla.edu.

FAU - Umbricht, Daniel

AU - Umbricht D

AD - Xperimed LLC, Basel, Switzerland; University of Zurich, Zurich, Switzerland.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230728

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

SB - IM

MH - Humans

MH - *Schizophrenia/diagnosis/drug therapy

MH - Quality of Life

MH - Prospective Studies

MH - Treatment Outcome

OTO - NOTNLM

OT - Negative symptoms

OT - Neural circuitry

OT - Novel treatments

OT - Schizophrenia

OT - TAAR1

COIS- Declaration of competing interest SRM: Dr. Marder has served on advisory boards

for Roche, Boehringer-Ingelheim, Merck, Sunovion, Otsuka, Neurocrine, Sunovion,

Newron, and Biogen. DU: Dr. Umbricht has served as consultant to Biogen,

Heptares, Shionogi, Roche and ERG and as contractor to Autifony Therapeutics and

Gilgamesh Pharmaceuticals.

EDAT- 2023/07/31 00:41

MHDA- 2023/08/21 06:42

CRDT- 2023/07/30 18:10

PHST- 2023/01/04 00:00 [received]

PHST- 2023/04/20 00:00 [revised]

PHST- 2023/07/10 00:00 [accepted]

PHST- 2023/08/21 06:42 [medline]

PHST- 2023/07/31 00:41 [pubmed]

PHST- 2023/07/30 18:10 [entrez]

AID - S0920-9964(23)00235-9 [pii]

AID - 10.1016/j.schres.2023.07.010 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Aug;258:71-77. doi: 10.1016/j.schres.2023.07.010. Epub 2023

Jul 28.

PMID- 37515924

OWN - NLM

STAT- MEDLINE

DCOM- 20230911

LR - 20231003

IS - 1873-6882 (Electronic)

IS - 0959-4388 (Print)

IS - 0959-4388 (Linking)

VI - 82

DP - 2023 Oct

TI - Mechanisms of copy number variants in neuropsychiatric disorders: From genes to

therapeutics.

PG - 102750

LID - S0959-4388(23)00075-2 [pii]

LID - 10.1016/j.conb.2023.102750 [doi]

AB - Copy number variants (CNVs) are genomic imbalances strongly linked to the

aetiology of neuropsychiatric disorders such as schizophrenia and autism. By

virtue of their large size, CNVs often contain many genes, providing a

multi-genic view of disease processes that can be dissected in model systems.

Thus, CNV research provides an important stepping stone towards understanding

polygenic disease mechanisms, positioned between monogenic and polygenic risk

models. In this review, we will outline hypothetical models for gene interactions

occurring within CNVs and discuss different approaches used to study rodent and

stem cell disease models. We highlight recent work showing that genetic and

pharmacological strategies can be used to rescue important aspects of

CNV-mediated pathophysiology, which often converges onto synaptic pathways. We

propose that using a rescue approach in complete CNV models provides a new path

forward for precise mechanistic understanding of complex disorders and a tangible

route towards therapeutic development.

FAU - Forrest, Marc P

AU - Forrest MP

AD - Department of Neuroscience, Northwestern University Feinberg School of Medicine,

Chicago, IL 60611, USA; Center for Autism and Neurodevelopment, Northwestern

University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic

address: marc.forrest@northwestern.edu.

FAU - Penzes, Peter

AU - Penzes P

AD - Department of Neuroscience, Northwestern University Feinberg School of Medicine,

Chicago, IL 60611, USA; Center for Autism and Neurodevelopment, Northwestern

University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic

address: p-penzes@northwestern.edu.

LA - eng

GR - R01 NS114977/NS/NINDS NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Review

DEP - 20230727

PL - England

TA - Curr Opin Neurobiol

JT - Current opinion in neurobiology

JID - 9111376

SB - IM

MH - Humans

MH - DNA Copy Number Variations/genetics

MH - Genetic Predisposition to Disease

MH - *Schizophrenia/drug therapy/genetics

MH - *Autistic Disorder/genetics/therapy

MH - Genomics

PMC - PMC10529795

MID - NIHMS1922710

COIS- Declaration of competing interest The authors declare that they have no known

competing financial interests or personal relationships that could have appeared

to influence the work reported in this paper.

EDAT- 2023/07/30 01:06

MHDA- 2023/09/11 06:42

PMCR- 2024/10/01

CRDT- 2023/07/29 18:05

PHST- 2023/03/12 00:00 [received]

PHST- 2023/06/01 00:00 [revised]

PHST- 2023/06/27 00:00 [accepted]

PHST- 2024/10/01 00:00 [pmc-release]

PHST- 2023/09/11 06:42 [medline]

PHST- 2023/07/30 01:06 [pubmed]

PHST- 2023/07/29 18:05 [entrez]

AID - S0959-4388(23)00075-2 [pii]

AID - 10.1016/j.conb.2023.102750 [doi]

PST - ppublish

SO - Curr Opin Neurobiol. 2023 Oct;82:102750. doi: 10.1016/j.conb.2023.102750. Epub

2023 Jul 27.

PMID- 37511595

OWN - NLM

STAT- MEDLINE

DCOM- 20230803

LR - 20230803

IS - 1422-0067 (Electronic)

IS - 1422-0067 (Linking)

VI - 24

IP - 14

DP - 2023 Jul 23

TI - Potential Roles for the GluN2D NMDA Receptor Subunit in Schizophrenia.

LID - 10.3390/ijms241411835 [doi]

LID - 11835

AB - Glutamate N-methyl-D-aspartate receptor (NMDAR) hypofunction has been proposed to

underlie schizophrenia symptoms. This theory arose from the observation that

administration of NMDAR antagonists, which are compounds that inhibit NMDAR

activity, reproduces behavioural and molecular schizophrenia-like phenotypes,

including hallucinations, delusions and cognitive impairments in healthy humans

and animal models. However, the role of specific NMDAR subunits in these

schizophrenia-relevant phenotypes is largely unknown. Mounting evidence

implicates the GluN2D subunit of NMDAR in some of these symptoms and pathology.

Firstly, genetic and post-mortem studies show changes in the GluN2D subunit in

people with schizophrenia. Secondly, the psychosis-inducing effects of NMDAR

antagonists are blunted in GluN2D-knockout mice, suggesting that the GluN2D

subunit mediates NMDAR-antagonist-induced psychotomimetic effects. Thirdly, in

the mature brain, the GluN2D subunit is relatively enriched in parvalbumin

(PV)-containing interneurons, a cell type hypothesized to underlie the cognitive

symptoms of schizophrenia. Lastly, the GluN2D subunit is widely and abundantly

expressed early in development, which could be of importance considering

schizophrenia is a disorder that has its origins in early neurodevelopment. The

limitations of currently available therapies warrant further research into novel

therapeutic targets such as the GluN2D subunit, which may help us better

understand underlying disease mechanisms and develop novel and more effective

treatment options.

FAU - Vinnakota, Chitra

AU - Vinnakota C

AD - Department of Psychiatry, School of Clinical Sciences, Faculty of Medical,

Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.

FAU - Hudson, Matthew R

AU - Hudson MR

AD - Department of Neuroscience, Faculty of Medical, Nursing and Health Sciences,

Monash University, Melbourne, VIC 3004, Australia.

FAU - Jones, Nigel C

AU - Jones NC

AUID- ORCID: 0000-0002-1080-8439

AD - Department of Neuroscience, Faculty of Medical, Nursing and Health Sciences,

Monash University, Melbourne, VIC 3004, Australia.

FAU - Sundram, Suresh

AU - Sundram S

AUID- ORCID: 0000-0002-9674-0227

AD - Department of Psychiatry, School of Clinical Sciences, Faculty of Medical,

Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.

AD - Mental Health Program, Monash Health, Clayton, VIC 3168, Australia.

FAU - Hill, Rachel A

AU - Hill RA

AD - Department of Psychiatry, School of Clinical Sciences, Faculty of Medical,

Nursing and Health Sciences, Monash University, Clayton, VIC 3168, Australia.

LA - eng

GR - 2000893/National Health and Medical Research Council/

PT - Journal Article

PT - Review

DEP - 20230723

PL - Switzerland

TA - Int J Mol Sci

JT - International journal of molecular sciences

JID - 101092791

RN - 0 (NR2D NMDA receptor)

RN - 0 (Receptors, N-Methyl-D-Aspartate)

RN - 0 (Grin2d protein, mouse)

SB - IM

MH - Animals

MH - Humans

MH - Mice

MH - Brain/metabolism

MH - Interneurons/metabolism

MH - Mice, Knockout

MH - Receptors, N-Methyl-D-Aspartate/metabolism

MH - *Schizophrenia/metabolism

PMC - PMC10380280

OTO - NOTNLM

OT - GluN2D

OT - NMDA receptor

OT - NMDAR antagonists

OT - schizophrenia

COIS- The authors declare no conflict of interest.

EDAT- 2023/07/29 11:50

MHDA- 2023/07/31 06:42

CRDT- 2023/07/29 01:25

PHST- 2023/05/12 00:00 [received]

PHST- 2023/07/19 00:00 [revised]

PHST- 2023/07/22 00:00 [accepted]

PHST- 2023/07/31 06:42 [medline]

PHST- 2023/07/29 11:50 [pubmed]

PHST- 2023/07/29 01:25 [entrez]

AID - ijms241411835 [pii]

AID - ijms-24-11835 [pii]

AID - 10.3390/ijms241411835 [doi]

PST - epublish

SO - Int J Mol Sci. 2023 Jul 23;24(14):11835. doi: 10.3390/ijms241411835.

PMID- 37510364

OWN - NLM

STAT- MEDLINE

DCOM- 20230731

LR - 20230801

IS - 2073-4425 (Electronic)

IS - 2073-4425 (Linking)

VI - 14

IP - 7

DP - 2023 Jul 17

TI - Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression,

Schizophrenia and Bipolar Disorder.

LID - 10.3390/genes14071460 [doi]

LID - 1460

AB - Immune gene variants are known to be associated with the risk of psychiatric

disorders, their clinical manifestations, and their response to therapy. This

narrative review summarizes the current literature over the past decade on the

association of polymorphic variants of cytokine genes with risk, severity, and

response to treatment for severe mental disorders such as bipolar disorder,

depression, and schizophrenia. A search of literature in databases was carried

out using keywords related to depressive disorder, bipolar disorder,

schizophrenia, inflammation, and cytokines. Gene lists were extracted from

publications to identify common genes and pathways for these mental disorders.

Associations between polymorphic variants of the IL1B, IL6, and TNFA genes were

the most replicated and relevant in depression. Polymorphic variants of the IL1B,

IL6, IL6R, IL10, IL17A, and TNFA genes have been associated with schizophrenia.

Bipolar disorder has mainly been associated with polymorphic variants of the IL1B

gene. Interestingly, the IL6R gene polymorphism (rs2228145) was associated with

all three diseases. Some cytokine genes have also been associated with clinical

presentation and response to pharmacotherapy. There is also evidence that some

specific polymorphic variants may affect the expression of cytokine genes. Thus,

the data from this review indicate a link between neuroinflammation and severe

mental disorders.

FAU - Mikhalitskaya, Ekaterina V

AU - Mikhalitskaya EV

AUID- ORCID: 0000-0001-7085-2741

AD - Mental Health Research Institute, Tomsk National Research Medical Center of the

Russian Academy of Sciences, 634014 Tomsk, Russia.

FAU - Vyalova, Natalya M

AU - Vyalova NM

AD - Mental Health Research Institute, Tomsk National Research Medical Center of the

Russian Academy of Sciences, 634014 Tomsk, Russia.

FAU - Ermakov, Evgeny A

AU - Ermakov EA

AUID- ORCID: 0000-0002-1084-6419

AD - Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the

Russian Academy of Sciences, 630090 Novosibirsk, Russia.

FAU - Levchuk, Lyudmila A

AU - Levchuk LA

AD - Mental Health Research Institute, Tomsk National Research Medical Center of the

Russian Academy of Sciences, 634014 Tomsk, Russia.

FAU - Simutkin, German G

AU - Simutkin GG

AUID- ORCID: 0000-0002-9813-3789

AD - Mental Health Research Institute, Tomsk National Research Medical Center of the

Russian Academy of Sciences, 634014 Tomsk, Russia.

FAU - Bokhan, Nikolay A

AU - Bokhan NA

AD - Mental Health Research Institute, Tomsk National Research Medical Center of the

Russian Academy of Sciences, 634014 Tomsk, Russia.

FAU - Ivanova, Svetlana A

AU - Ivanova SA

AUID- ORCID: 0000-0001-7078-323X

AD - Mental Health Research Institute, Tomsk National Research Medical Center of the

Russian Academy of Sciences, 634014 Tomsk, Russia.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230717

PL - Switzerland

TA - Genes (Basel)

JT - Genes

JID - 101551097

RN - 0 (Interleukin-6)

RN - 0 (Cytokines)

SB - IM

MH - Humans

MH - Polymorphism, Single Nucleotide/genetics

MH - *Bipolar Disorder/genetics

MH - Interleukin-6/genetics

MH - Genetic Predisposition to Disease

MH - *Schizophrenia/genetics

MH - Depression/genetics

MH - Cytokines/genetics

PMC - PMC10379485

OTO - NOTNLM

OT - SNP

OT - bipolar disorder

OT - cytokines

OT - depressive disorder

OT - genetic association

OT - genetic markers

OT - schizophrenia

OT - single nucleotide polymorphisms

COIS- The authors declare no conflict of interest. The funders had no role in the

design of the study; in the collection, analyses, or interpretation of data; in

the writing of the manuscript; or in the decision to publish the results.

EDAT- 2023/07/29 11:45

MHDA- 2023/07/31 11:42

CRDT- 2023/07/29 01:17

PHST- 2023/06/06 00:00 [received]

PHST- 2023/07/07 00:00 [revised]

PHST- 2023/07/14 00:00 [accepted]

PHST- 2023/07/31 11:42 [medline]

PHST- 2023/07/29 11:45 [pubmed]

PHST- 2023/07/29 01:17 [entrez]

AID - genes14071460 [pii]

AID - genes-14-01460 [pii]

AID - 10.3390/genes14071460 [doi]

PST - epublish

SO - Genes (Basel). 2023 Jul 17;14(7):1460. doi: 10.3390/genes14071460.

PMID- 37506738

OWN - NLM

STAT- MEDLINE

DCOM- 20230911

LR - 20230911

IS - 1439-0795 (Electronic)

IS - 0176-3679 (Print)

IS - 0176-3679 (Linking)

VI - 56

IP - 5

DP - 2023 Sep

TI - Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia

(The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial.

PG - 169-181

LID - 10.1055/a-2110-4259 [doi]

AB - BACKGROUND: Quick symptomatic remission after the onset of psychotic symptoms is

critical in schizophrenia treatment, determining the subsequent disease course

and recovery. In this context, only every second patient with acute schizophrenia

achieves symptomatic remission within three months of initiating antipsychotic

treatment. The potential indication extension of clozapine-the most effective

antipsychotic-to be introduced at an earlier stage (before treatment-resistance)

is supported by several lines of evidence, but respective clinical trials are

lacking. METHODS: Two hundred-twenty patients with acute non-treatment-resistant

schizophrenia will be randomized in this double-blind, 8-week parallel-group

multicentric trial to either clozapine or olanzapine. The primary endpoint is the

number of patients in symptomatic remission at the end of week 8 according to

international consensus criteria ('Andreasen criteria'). Secondary endpoints and

other assessments comprise a comprehensive safety assessment (i. e., myocarditis

screening), changes in psychopathology, global functioning, cognition, affective

symptoms and quality of life, and patients' and relatives' views on treatment.

DISCUSSION: This multicentre trial aims to examine whether clozapine is more

effective than a highly effective second-generation antipsychotics (SGAs),

olanzapine, in acute schizophrenia patients who do not meet the criteria for

treatment-naïve or treatment-resistant schizophrenia. Increasing the likelihood

to achieve symptomatic remission in acute schizophrenia can improve the overall

outcome, reduce disease-associated burden and potentially prevent mid- and

long-term disease chronicity.

CI - The Author(s). This is an open access article published by Thieme under the terms

of the Creative Commons Attribution-NonDerivative-NonCommercial-License,

permitting copying and reproduction so long as the original work is given

appropriate credit. Contents may not be used for commercial purposes, or adapted,

remixed, transformed or built upon.

(https://creativecommons.org/licenses/by-nc-nd/4.0/).

FAU - Wagner, Elias

AU - Wagner E

AD - Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich,

Munich, Germany.

FAU - Strube, Wolfgang

AU - Strube W

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Augsburg, Germany.

FAU - Görlitz, Thomas

AU - Görlitz T

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Augsburg, Germany.

FAU - Aksar, Aslihan

AU - Aksar A

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Augsburg, Germany.

FAU - Bauer, Ingrid

AU - Bauer I

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Augsburg, Germany.

FAU - Campana, Mattia

AU - Campana M

AD - Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich,

Munich, Germany.

FAU - Moussiopoulou, Joanna

AU - Moussiopoulou J

AD - Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich,

Munich, Germany.

FAU - Hapfelmeier, Alexander

AU - Hapfelmeier A

AD - Institute of AI and Informatics in Medicine, School of Medicine, Technical

University of Munich, Munich, Germany.

AD - Institute of General Practice and Health Services Research, School of Medicine,

Technical University of Munich, Munich, Germany.

FAU - Wagner, Petra

AU - Wagner P

AD - Münchner Studienzentrum, Technical University of Munich, School of Medicine,

Munich, Germany.

FAU - Egert-Schwender, Silvia

AU - Egert-Schwender S

AD - Münchner Studienzentrum, Technical University of Munich, School of Medicine,

Munich, Germany.

FAU - Bittner, Robert

AU - Bittner R

AD - Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University

Hospital Frankfurt, Frankfurt, Germany.

FAU - Eckstein, Kathrin

AU - Eckstein K

AD - Clinic for Psychiatry and Psychotherapy, University of Tübingen, Tübingen,

Germany.

FAU - Nenadić, Igor

AU - Nenadić I

AD - Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg,

Germany.

FAU - Kircher, Tilo

AU - Kircher T

AD - Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg,

Germany.

FAU - Langguth, Berthold

AU - Langguth B

AD - Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg,

Germany.

FAU - Meisenzahl, Eva

AU - Meisenzahl E

AD - Department of Psychiatry and Psychotherapy, LVR-Klinikum Düsseldorf, Kliniken der

Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.

FAU - Lambert, Martin

AU - Lambert M

AD - Department of Psychiatry and Psychotherapy, Centre for Psychosocial Medicine,

University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.

FAU - Neff, Sigrid

AU - Neff S

AD - Department of Psychiatry and Psychotherapy 1 und 2, Rheinhessen-Fachklinik Alzey,

Academic Hospital of the University of Mainz, Alzey, Germany.

FAU - Malchow, Berend

AU - Malchow B

AD - Department of Psychiatry and Psychotherapy, University Medical Center Göttingen,

Göttingen, Germany.

FAU - Falkai, Peter

AU - Falkai P

AD - Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich,

Munich, Germany.

FAU - Hirjak, Dusan

AU - Hirjak D

AD - Department of Psychiatry and Psychotherapy, Central Institute of Mental Health,

Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

FAU - Böttcher, Kent-Tjorben

AU - Böttcher KT

AD - Department of Psychiatry and Psychotherapy, Central Institute of Mental Health,

Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

FAU - Meyer-Lindenberg, Andreas

AU - Meyer-Lindenberg A

AD - Department of Psychiatry and Psychotherapy, Central Institute of Mental Health,

Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

FAU - Blankenstein, Christiane

AU - Blankenstein C

AD - Münchner Studienzentrum, Technical University of Munich, School of Medicine,

Munich, Germany.

FAU - Leucht, Stefan

AU - Leucht S

AD - Department of Psychiatry and Psychotherapy, Technical University of Munich,

School of Medicine, Munich, Germany.

FAU - Hasan, Alkomiet

AU - Hasan A

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Augsburg, Germany.

LA - eng

PT - Clinical Trial

PT - Clinical Trial Protocol

DEP - 20230728

PL - Germany

TA - Pharmacopsychiatry

JT - Pharmacopsychiatry

JID - 8402938

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

RN - N7U69T4SZR (Olanzapine)

SB - IM

MH - Humans

MH - *Clozapine/therapeutic use

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/therapeutic use

MH - Olanzapine/therapeutic use

MH - Quality of Life

MH - Treatment Outcome

MH - Randomized Controlled Trials as Topic

MH - Multicenter Studies as Topic

PMC - PMC10484642

COIS- E. Wagner has been invited to advisory boards from Recordati. W. Strube has

received a speaker’s honorarium from Mag&More GmbH and neurocare and was a member

of the advisory board of Recordati. A. Hasan has received speakership fees from

Lundbeck, Otsuka, Janssen, Rovi, AbbVie and Recordati. He was member of advisory

boards of Boehringer Ingelheim, Lundbeck, Otsuka, Janssen, Rovi, and Recordati.

M. Lambert has received honoraria for consultancy and speakers’ fees from

AstraZeneca, Bristol-Myers Squibb, Lilly Deutschland GmbH, Janssen Cilag GmbH,

Lundbeck GmbH, Otsuka Pharma GmbH, Roche Deutschland Holding GmbH, Sanovi

Aventis, Trommsdorff GmbH & Co. KG, Takeda Pharma Vertrieb GmbH, and is founder

of MiNDNET e-Health-Solutions GmbH. P. Falkai is on the advisory boards and

receives speaker fees from Janssen, Lundbeck, Otsuka, Servier and Richter B.

Langguth has received honoraria for consultancy and speakers’ fees from ANM,

AstraZeneca, Autifony Therapeutics, Decibel Therapeutics, Desyncra, Gerson

Lehmanns Group, Lundbeck, Merz, MagVenture, Medical Tribune, Neurolite, Neuromod,

Novartis, Pfizer, Rovi, Schwabe, Sea Pharma, Servier, Sonova and Sound

Therapeutics; All other co-authors report no conflict of interest.

EDAT- 2023/07/29 06:41

MHDA- 2023/09/11 06:42

CRDT- 2023/07/28 18:53

PHST- 2023/09/11 06:42 [medline]

PHST- 2023/07/29 06:41 [pubmed]

PHST- 2023/07/28 18:53 [entrez]

AID - phpsy2023-04-1174 [pii]

AID - 10.1055/a-2110-4259 [doi]

PST - ppublish

SO - Pharmacopsychiatry. 2023 Sep;56(5):169-181. doi: 10.1055/a-2110-4259. Epub 2023

Jul 28.

PMID- 37500245

OWN - NLM

STAT- MEDLINE

DCOM- 20230731

LR - 20230802

IS - 1558-3147 (Electronic)

IS - 0193-953X (Linking)

VI - 46

IP - 3

DP - 2023 Sep

TI - Schizophrenia in Women: Clinical Considerations.

PG - 475-486

LID - S0193-953X(23)00054-0 [pii]

LID - 10.1016/j.psc.2023.04.005 [doi]

AB - Men and women, for biologic and sociocultural reasons, differ in the nature of

their risks for schizophrenia and also in their care needs. Women with

schizophrenia have several reproduction-associated risks and care needs that

require special clinical consideration. They also have several specific risks

related to antipsychotics and gender-associated needs not necessarily related to

biology. These require clinicians' diagnostic acumen, treatment skills, cultural

sensitivity, and advocacy know-how. Although this does not pertain to everyone,

awareness on the part of clinicians is essential. This article addresses the

current evidence for difference.

FAU - Seeman, Mary V

AU - Seeman MV

AD - Department of Psychiatry, University of Toronto, Toronto, Ontario M5P3L6, Canada.

Electronic address: mary.seeman@utoronto.ca.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230527

PL - United States

TA - Psychiatr Clin North Am

JT - The Psychiatric clinics of North America

JID - 7708110

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Male

MH - Humans

MH - Female

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/therapeutic use

OTO - NOTNLM

OT - Antipsychotics adverse effects

OT - Reproductive needs

OT - Risks

OT - Schizophrenia

OT - Sex/gender

OT - Violence

EDAT- 2023/07/28 01:08

MHDA- 2023/07/31 06:43

CRDT- 2023/07/27 20:57

PHST- 2023/07/31 06:43 [medline]

PHST- 2023/07/28 01:08 [pubmed]

PHST- 2023/07/27 20:57 [entrez]

AID - S0193-953X(23)00054-0 [pii]

AID - 10.1016/j.psc.2023.04.005 [doi]

PST - ppublish

SO - Psychiatr Clin North Am. 2023 Sep;46(3):475-486. doi: 10.1016/j.psc.2023.04.005.

Epub 2023 May 27.

PMID- 37490701

OWN - NLM

STAT- MEDLINE

DCOM- 20230727

LR - 20230902

IS - 1469-493X (Electronic)

IS - 1361-6137 (Linking)

VI - 7

IP - 7

DP - 2023 Jul 25

TI - Cognitive behavioural therapy plus standard care versus standard care for

persistent aggressive behaviour or agitation in people with schizophrenia.

PG - CD013511

LID - 10.1002/14651858.CD013511.pub2 [doi]

LID - CD013511

AB - BACKGROUND: Schizophrenia and other psychoses are thought to be associated with a

substantial increase in aggressive behaviour, violence and violent offending.

However, acts of aggression or violence committed by people with severe mental

illness are rare and circumscribed to a small minority of individuals. We know

little about the frequency and variability of violent episodes for people with

schizophrenia who present chronic or recurrent aggressive episodes, and of

available interventions to reduce such problems. A psychological intervention,

cognitive behavioural therapy (CBT), aims to challenge dysfunctional thoughts and

has been used since the mid-1970s to improve mental health and emotional

disorders. CBT includes different interventional procedures, such as cognitive

therapy, elements of behavioural therapy, problem-solving interventions, and

coping skills training, among others. Although CBT presents much diversity,

interventions are characteristically problem-focused, goal-directed,

future-oriented, time-limited (about 12 to 20 sessions over four to six months),

and empirically based. CBT has shown clinically beneficial effects in persistent

positive and negative symptoms of schizophrenia and its use as an add-on therapy

to medication in the treatment of schizophrenia is supported by treatment

guidelines. However, several Cochrane Reviews recently concluded that, due to the

low quality of evidence available, no firm conclusions can currently be made

regarding the effectiveness of adding CBT to standard care for people with

schizophrenia, or about CBT compared to other psychosocial treatments for people

with schizophrenia. Whereas CBT is not an emergency or crisis intervention that

acts immediately on the known or unknown triggers underlying aggressive

behaviour, might be a timely treatment used to manage persistent aggression or

repeated aggressive episodes in people with schizophrenia. OBJECTIVES: To assess

the efficacy and safety of (cognitive behavioural therapy ()CBT) plus standard

care versus standard care alone for people with schizophrenia and persistent

aggression. SEARCH METHODS: On 18 January 2023, we searched the Cochrane

Schizophrenia Group's Study-Based Register of Trials which is based on CENTRAL,

CINAHL, ClinicalTrials.Gov, Embase, ISRCTN, MEDLINE, PsycINFO, PubMed, and WHO

ICTRP. We also inspected references of all identified studies for more studies.

SELECTION CRITERIA: All randomised controlled trials comparing CBT plus standard

care with standard care alone for people with schizophrenia and persistent

aggression. DATA COLLECTION AND ANALYSIS: We independently inspected citations,

selected studies, extracted data and appraised study quality. For binary

outcomes, we calculated risk ratios (RR) and their 95% confidence intervals

(CIs). For continuous outcomes we calculated mean differences (MD) and their

95%CIs for outcomes reported with the same measurement scale. Post hoc, for

counts over person-time outcomes, we calculated incidence rate ratios (IRRs) and

their 95%CIs. If feasible, we combined study outcomes with the random-effects

model. We assessed the risk of bias for included studies and created a summary of

findings table using the GRADE approach. MAIN RESULTS: We included two studies

with 184 participants with psychotic disorder (mainly schizophrenia) and

violence. The studies were run in forensic units and prison. Both studies were at

high risk of bias on blinding (performance and detection bias). CBT plus standard

care as compared with standard care may result in little to no difference in the

frequency of physical violence at end of trial (IRR 0.52; 95% CI 0.23 to 1.18)

and follow-up (IRR 0.86; 95% CI 0.44 to 1.68). The confidence interval did not

exclude the null effect, and the certainty of the evidence is very low due to

lack of blinding and to the small sample size. One study reported no deaths in

both arms and zero serious and other adverse events. The other study did not

report any figure for deaths or adverse events. CBT plus standard care as

compared with standard care may result in little to no difference in leaving the

study early for any reason (RR 1.04; 95% CI 0.53 to 2.00). Confidence interval

did not exclude the null effect and the certainty of the evidence is low due to

lack of blinding and the small sample size. AUTHORS' CONCLUSIONS: Whereas the

evidence from only two studies with 184 participants suggests the use of CBT plus

standard care may reduce some aggressive behaviours in patients with

schizophrenia, the grading of the certainty of the evidence is very low. It

implies that there is not yet reliable evidence to guide clinical decisions and

therefore more evidence is needed to get a more precise estimate of the effect of

the intervention. Currently, we have very little confidence in the effect

estimate, and the true effect could be substantially different from its estimate.

FAU - Ballesteros, Javier

AU - Ballesteros J

AD - Department of Neuroscience, University of the Basque Country, CIBER Salud Mental

(CIBERSAM), Leioa, Spain.

FAU - Moreno-Calvete, Maria Concepcion

AU - Moreno-Calvete MC

AD - Department of Mental Health, Biocruces Bizkaia Health Research Institute, Bizkaia

Mental Health Network, Basque Health Service, Bilbao, Spain.

FAU - Santos-Zorrozúa, Borja

AU - Santos-Zorrozúa B

AD - Scientific coordination Unit, Biocruces Health Research Institute, Cruces

University Hospital, Barakaldo, Spain.

FAU - González-Fraile, Eduardo

AU - González-Fraile E

AD - Centro de Investigación, Transferencia e Innovación (CITEI), Universidad

Internacional de la Rioja, Logroño, Spain.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

PT - Systematic Review

DEP - 20230725

PL - England

TA - Cochrane Database Syst Rev

JT - The Cochrane database of systematic reviews

JID - 100909747

SB - IM

UOF - doi: 10.1002/14651858.CD013511

MH - Humans

MH - *Schizophrenia/complications/therapy

MH - *Psychotic Disorders

MH - *Cognitive Behavioral Therapy/methods

MH - Aggression

MH - Anxiety

PMC - PMC10368081

COIS- Javier Ballesteros: none known María Concepción Moreno‐Calvete: none known

Eduardo González‐Fraile: none known Borja Santos: none known

EDAT- 2023/07/25 19:15

MHDA- 2023/07/27 06:42

PMCR- 2024/07/25

CRDT- 2023/07/25 16:33

PHST- 2024/07/25 00:00 [pmc-release]

PHST- 2023/07/27 06:42 [medline]

PHST- 2023/07/25 19:15 [pubmed]

PHST- 2023/07/25 16:33 [entrez]

AID - CD013511.pub2 [pii]

AID - 10.1002/14651858.CD013511.pub2 [doi]

PST - epublish

SO - Cochrane Database Syst Rev. 2023 Jul 25;7(7):CD013511. doi:

10.1002/14651858.CD013511.pub2.

PMID- 37490267

OWN - NLM

STAT- MEDLINE

DCOM- 20230821

LR - 20230921

IS - 1179-1934 (Electronic)

IS - 1172-7047 (Print)

IS - 1172-7047 (Linking)

VI - 37

IP - 8

DP - 2023 Aug

TI - Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly

Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic

Review and Meta-Analysis.

PG - 695-713

LID - 10.1007/s40263-023-01028-1 [doi]

AB - BACKGROUND: Considering the improvement in adherence and convenience,

once-monthly paliperidone palmitate (PP1M) has been increasingly used in the

treatment of schizophrenia. However, the outcomes for patients who switch from

oral antipsychotics (OAPs) to PP1M have not been reliably assessed. The objective

of this systematic review and meta-analysis was to investigate the efficacy and

safety of PP1M in the management of patients with schizophrenia with a prior

history of OAP use. METHODS: We conducted a systematic search in PubMed, EMBASE,

and the Cochrane Library on 19 July 2022 to identify eligible studies. All

studies that examined the effectiveness and safety of switching from OAPs to PP1M

in patients with schizophrenia were included. The primary outcomes were relapse

rate, hospitalisation rate, and the change from baseline in the Positive and

Negative Syndrome Scale (PANSS) total score. The secondary outcomes included the

changed number of inpatient visits, changed length of stay hospitalisation,

change from baseline in the Clinical Global Impressions-Severity (CGI-S) score

and the personal and social performance (PSP) total score, response rate,

proportion of treatment discontinuation, and adverse events. We included

randomised-controlled trials (RCTs), single-arm studies, and observational

studies. Case reports, case series, and reviews were excluded. The quality

assessment of included studies was performed using the Revised Cochrane

risk-of-bias tool for randomised trials (RoB2), the 9-point Newcastle-Ottawa

Scale (NOS) instrument for non-randomised studies and cohort studies, and the

12-item National Institutes of Health (NIH) quality assessment tool for

before-after (Pre-Post) study without control group. Follow-up times were

reported as short- (≤ 13 weeks), medium- (14-26 weeks), and long term (≥ 27

weeks). Data were pooled using meta-analysis. RESULTS: Fifteen studies with a

total of 4740 patients were included. The long-term relapse rates and

hospitalisation rates were 12% (95% CI 0.07-0.18) and 18% (95% CI 0.15-0.20),

respectively. The short-, medium-, and long-term change in PANSS total score was

- 21.69 (95% CI - 30.02 to -13.36), - 14.98 (95% CI - 21.45 to - 8.51) and -

17.88 (95% CI - 31.94 to -3.82), respectively. Approximately 50% of patients

reported at least a 30% reduction in the PANSS score at the short-term follow-up.

Improvements in CGI-S and PSP score were observed during various periods. There

was a reduction in the length of stay hospitalisation and the number of inpatient

visits at the medium- and long-term follow-ups. Low discontinuation and adverse

event rates were reported. CONCLUSION: Based on our findings, this study may

support the efficacy and safety of switching from OAPs to PP1M for the treatment

of patients with schizophrenia. Future large-scale studies are warranted to

confirm our findings.

FAU - Li, Qian

AU - Li Q

AUID- ORCID: 0000-0002-7919-3057

AD - Peking University Sixth Hospital, Peking University Institute of Mental Health,

NHC Key Laboratory of Mental Health (Peking University), National Clinical

Research Centre for Mental Disorders (Peking University Sixth Hospital), Beijing,

China.

FAU - Li, Xin

AU - Li X

AUID- ORCID: 0000-0002-0404-5500

AD - Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China.

FAU - Ye, Chong

AU - Ye C

AUID- ORCID: 0000-0001-7111-8514

AD - Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China.

FAU - Jia, Miaomiao

AU - Jia M

AD - Xi'an Janssen Pharmaceutical Ltd., Chaoyang District, Beijing, China.

FAU - Si, Tianmei

AU - Si T

AUID- ORCID: 0000-0001-9823-2720

AD - Peking University Sixth Hospital, Peking University Institute of Mental Health,

NHC Key Laboratory of Mental Health (Peking University), National Clinical

Research Centre for Mental Disorders (Peking University Sixth Hospital), Beijing,

China. si.tian-mei@163.com.

LA - eng

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Systematic Review

DEP - 20230725

PL - New Zealand

TA - CNS Drugs

JT - CNS drugs

JID - 9431220

RN - 0 (Antipsychotic Agents)

RN - R8P8USM8FR (Paliperidone Palmitate)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - Paliperidone Palmitate/adverse effects

MH - *Schizophrenia/drug therapy

MH - Administration, Oral

MH - Recurrence

MH - Chronic Disease

PMC - PMC10439041

COIS- Qian Li and Tianmei Si declare that they have no conflict of interest. Xin Li,

Chong Ye, and Miaomiao Jia are employees of Xi’an Janssen Pharmaceutical Ltd.

EDAT- 2023/07/25 13:08

MHDA- 2023/08/21 06:43

CRDT- 2023/07/25 11:11

PHST- 2023/07/12 00:00 [accepted]

PHST- 2023/08/21 06:43 [medline]

PHST- 2023/07/25 13:08 [pubmed]

PHST- 2023/07/25 11:11 [entrez]

AID - 10.1007/s40263-023-01028-1 [pii]

AID - 1028 [pii]

AID - 10.1007/s40263-023-01028-1 [doi]

PST - ppublish

SO - CNS Drugs. 2023 Aug;37(8):695-713. doi: 10.1007/s40263-023-01028-1. Epub 2023 Jul

25.

PMID- 37486369

OWN - NLM

STAT- MEDLINE

DCOM- 20230726

LR - 20230726

IS - 1980-220X (Electronic)

IS - 0080-6234 (Print)

IS - 0080-6234 (Linking)

VI - 57

DP - 2023

TI - Membranophone percussion instruments in music therapy with adult patients in the

health context: a scope review.

PG - e20220263

LID - S0080-62342023000100802 [pii]

LID - 10.1590/1980-220X-REEUSP-2022-0263en [doi]

LID - e20220263

AB - OBJECTIVE: To map scientific knowledge about the use of percussion instruments in

music therapy in individuals over 18 years of age in the health context. METHOD:

Scope review with search strategy implemented in September 2021, in 13 databases,

using indexed descriptors and keywords. Studies on the use of membranophones for

care of people over 18 years of age were included. Studies with the participation

of pregnant women, psychiatric patients (schizophrenia, psychosis, addiction), or

people with hearing impairment, and journal editorials were excluded. The

selection process was carried out by two independent researchers. RESULTS:

Thirteen studies were included and the results showed that the membranophones

have a positive impact on the physical, psychological, and social health of

people in different care environments, and allow them to repeat rhythmic patterns

and play music. Active music therapy was the strategy predominantly used in

interventions, and the most used membranophone was the djembe. CONCLUSION: The

results suggest that music therapy with membranophones proved to be a viable

intervention with beneficial results in improving physical, psychological, and

social health of people over 18 years of age.

FAU - Tamiasso, Renata Souza Souto

AU - Tamiasso RSS

AUID- ORCID: 0000-0001-5569-1214

AD - Universidade de São Paulo, Escola de Enfermagem, Departamento de Enfermagem

Médico-Cirúrgica, São Paulo, SP, Brazil.

FAU - Silva, Vladimir Araujo da

AU - Silva VAD

AUID- ORCID: 0000-0001-9241-6350

AD - Universidade Federal de Santa Catarina - Campus de Curitibanos, Coordenadoria

Especial de Biociências e Saúde Única, Curitibanos, SC, Brazil.

FAU - Turrini, Ruth Natalia Teresa

AU - Turrini RNT

AUID- ORCID: 0000-0002-4910-7672

AD - Escola de Enfermagem - Programa de Pós-graduação Enfermagem na Saúde do Adulto,

Universidade de São Paulo, São Paulo, SP, Brazil.

LA - eng

LA - por

PT - Journal Article

PT - Review

DEP - 20230721

PL - Brazil

TA - Rev Esc Enferm USP

JT - Revista da Escola de Enfermagem da U S P

JID - 0242726

MH - Adult

MH - Humans

MH - *Music Therapy/methods

MH - Percussion

MH - *Schizophrenia

PMC - PMC10364967

EDAT- 2023/07/24 13:07

MHDA- 2023/07/26 06:43

CRDT- 2023/07/24 11:05

PHST- 2022/07/27 00:00 [received]

PHST- 2023/04/14 00:00 [accepted]

PHST- 2023/07/26 06:43 [medline]

PHST- 2023/07/24 13:07 [pubmed]

PHST- 2023/07/24 11:05 [entrez]

AID - S0080-62342023000100802 [pii]

AID - 10.1590/1980-220X-REEUSP-2022-0263en [doi]

PST - epublish

SO - Rev Esc Enferm USP. 2023 Jul 21;57:e20220263. doi:

10.1590/1980-220X-REEUSP-2022-0263en. eCollection 2023.

PMID- 37482283

OWN - NLM

STAT- MEDLINE

DCOM- 20230907

LR - 20230929

IS - 1878-4216 (Electronic)

IS - 0278-5846 (Linking)

VI - 127

DP - 2023 Dec 20

TI - The relationship between negative symptoms and MATRICS neurocognitive domains: A

meta-analysis and systematic review.

PG - 110833

LID - S0278-5846(23)00119-7 [pii]

LID - 10.1016/j.pnpbp.2023.110833 [doi]

AB - BACKGROUND: Negative symptoms (NS) are a core symptom domain in schizophrenia

spectrum disorders and are associated with poorer social and vocational

functioning, and with increased likelihood and durations of hospital admission.

NS are not well understood, limiting available interventions. However, numerous

studies have reported associations between neurocognitive domains and NS

severity. Thus, one promising area in understanding NS is in relation to

neurocognition. Currently, the specificity of the relationship between NS and

neurocognition is unknown, meaning that there is no consensus regarding which

neurocognitive domain is most strongly associated with NS. There is a need to

systematically examine the relationship between NS and various neurocognitive

domains within study samples. METHODS: A systematic search of Ovid PsycINFO, Ovid

MEDLINE and Web of Science was performed for articles published since 2004 (year

of MATRICS Consensus publication). Inclusion criteria were: 1) individuals with

schizophrenia spectrum disorders, first episode psychosis or clinical high risk

2) assessed all six MATRICS neurocognitive domains (processing speed, attention,

working memory, verbal learning & memory, visual learning & memory, reasoning &

problem solving), 3) reported correlations between all six MATRICS neurocognitive

domains and global NS. A three-level random effects hierarchical meta-analysis

was performed to assess the relationship between NS (global, expressive, and

experiential dimensions) and the six MATRICS neurocognitive domains. RESULTS: 21

studies were included in the review (n = 3619). All MATRICS neurocognitive

domains had small significant correlations with global NS (r = -0.16 to -0.20,

p < 0.0001). This relationship was significantly moderated by diagnosis and the

moderating effect of sex/ gender trended on significance. Analysis of a subset of

the studies revealed that MATRICS neurocognitive domains also had small

significant correlations with the two NS dimensions, expressive and experiential.

Correlations were stronger with the expressive NS dimension. CONCLUSIONS: This

review is novel in assessing the relationship between multiple neurocognitive

domains and NS within the same sample, by synthesizing close to two decades of

research. Our results suggest that there is a non-specific relationship between

neurocognition and NS, and that expressive NS may have a stronger relationship

with neurocognitive functioning-based on the MATRICS classification of

neurocognition and the neurocognitive assessments used in the included studies.

This has implications on our understanding of NS and neurocognition, as well as

their treatments. As we gain better understanding of the directionality of the

NS-cognition relationship, it could suggest that NS, particularly in the

expressive domain, could be improved by targeting cognition globally or that

neurocognitive treatments could be more effective if NS are addressed first.

Further implications of these results are discussed.

FAU - Au-Yeung, Christy

AU - Au-Yeung C

AD - Department of Psychology, McGill University, Montreal, Quebec, Canada; Douglas

Research Centre, Montréal, Québec, Canada.

FAU - Penney, Danielle

AU - Penney D

AD - Douglas Research Centre, Montréal, Québec, Canada; Department of Psychology,

Université du Québec à Montréal, Montréal, Québec, Canada.

FAU - Rae, Jesse

AU - Rae J

AD - Douglas Research Centre, Montréal, Québec, Canada.

FAU - Carling, Hannah

AU - Carling H

AD - Department of Psychology, McGill University, Montreal, Quebec, Canada; Douglas

Research Centre, Montréal, Québec, Canada.

FAU - Lassman, Libby

AU - Lassman L

AD - Douglas Research Centre, Montréal, Québec, Canada; Department of Psychiatry,

McGill University, Montreal, Quebec, Canada.

FAU - Lepage, Martin

AU - Lepage M

AD - Douglas Research Centre, Montréal, Québec, Canada; Department of Psychiatry,

McGill University, Montreal, Quebec, Canada. Electronic address:

martin.lepage@mcgill.ca.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Systematic Review

DEP - 20230722

PL - England

TA - Prog Neuropsychopharmacol Biol Psychiatry

JT - Progress in neuro-psychopharmacology & biological psychiatry

JID - 8211617

SB - IM

MH - Humans

MH - *Schizophrenia/diagnosis

MH - *Psychotic Disorders/psychology

MH - *Cognition Disorders/complications

MH - Learning

MH - Memory, Short-Term

MH - Neuropsychological Tests

OTO - NOTNLM

OT - Negative symptoms

OT - Neurocognition

OT - Psychosis

OT - Schizophrenia

COIS- Declaration of Competing Interest ML reports grants from Otsuka Lundbeck

Alliance, Roche, and diaMentis personal fees from Otsuka Canada, personal fees

from Lundbeck Canada, grants and personal fees from Janssen, and personal fees

from Boehringer-Ingelheim, outside the submitted work. Salary awards include

Canadian Institutes for Health Research, Fonds de la Recherche en Santé du Québec

(ML, DP, LL), James McGill Professorship (ML). Ethical Statement is not

applicable as this is a review paper.

EDAT- 2023/07/24 00:41

MHDA- 2023/09/07 06:42

CRDT- 2023/07/23 19:27

PHST- 2023/04/28 00:00 [received]

PHST- 2023/07/11 00:00 [revised]

PHST- 2023/07/16 00:00 [accepted]

PHST- 2023/09/07 06:42 [medline]

PHST- 2023/07/24 00:41 [pubmed]

PHST- 2023/07/23 19:27 [entrez]

AID - S0278-5846(23)00119-7 [pii]

AID - 10.1016/j.pnpbp.2023.110833 [doi]

PST - ppublish

SO - Prog Neuropsychopharmacol Biol Psychiatry. 2023 Dec 20;127:110833. doi:

10.1016/j.pnpbp.2023.110833. Epub 2023 Jul 22.

PMID- 37480362

OWN - NLM

STAT- MEDLINE

DCOM- 20230831

LR - 20230905

IS - 1469-5111 (Electronic)

IS - 1461-1457 (Print)

IS - 1461-1457 (Linking)

VI - 26

IP - 8

DP - 2023 Aug 29

TI - Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label

2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With

Schizophrenia.

PG - 537-544

LID - 10.1093/ijnp/pyad028 [doi]

AB - BACKGROUND: Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to

paliperidone palmitate 3-month in preventing relapse in patients with

schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report

long-term efficacy and safety results from a 2-year single-arm, open-label

extension (OLE; NCT04072575) of this DB study. METHODS: Participants who

completed the DB study without relapse were enrolled and followed-up every 3

months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000

mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints

included assessment of relapse, Positive and Negative Syndrome Scale total score,

Personal and Social Performance score, and Clinical Global Impression-Severity

scale change from baseline. Safety was assessed by treatment-emergent adverse

events (TEAEs), physical examinations, and laboratory tests. RESULTS: Of 178

participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men:

70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178

(3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD)

changes from baseline to endpoint were as follows: Positive and Negative Syndrome

Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51);

and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178

participants (62.4%) reported ≥1 TEAE; most common (>5%) TEAEs were headache

(13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%)

participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew

due to TEAEs. No deaths were reported. CONCLUSIONS: The relapse rate observed

with PP6M during the 2-year OLE was low (3.9%). Clinical and functional

improvements demonstrated in the DB study were maintained during OLE, and no new

safety concerns were identified. TRIAL REGISTRATION: ClinicalTrials.gov

Identifier: NCT04072575; EudraCT number: 2018-004532-30.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of CINP.

FAU - Najarian, Dean

AU - Najarian D

AD - Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.

FAU - Turkoz, Ibrahim

AU - Turkoz I

AD - Janssen Research & Development, LLC, Titusville, New Jersey, USA.

FAU - Knight, R Karl

AU - Knight RK

AD - Janssen Research & Development, LLC, Titusville, New Jersey, USA.

FAU - Galderisi, Silvana

AU - Galderisi S

AD - University of Campania "Luigi Vanvitelli," Naples, Italy.

FAU - Lamaison, Hector F

AU - Lamaison HF

AD - Department of Psychiatry, National University of La Plata (UNLP), Buenos Aires,

Argentina.

FAU - Zalitacz, Piotr

AU - Zalitacz P

AD - Head of Psychiatric Unit, Gorlice Specialist Hospital, Gorlice, Poland.

FAU - Aravind, Suresh

AU - Aravind S

AD - Janssen Research & Development, LLC, Titusville, New Jersey, USA.

AD - Dural Consulting LLC, St Petersburg, Florida, USA (Dr Aravind).

FAU - Richarz, Ute

AU - Richarz U

AD - Janssen Research & Development, Cilag Int., Gubelstrasse, Zug, Switzerland.

LA - eng

SI - ClinicalTrials.gov/NCT04072575

SI - ClinicalTrials.gov/NCT03345342

SI - EudraCT/2018-004532-30

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

PL - England

TA - Int J Neuropsychopharmacol

JT - The international journal of neuropsychopharmacology

JID - 9815893

RN - R8P8USM8FR (Paliperidone Palmitate)

SB - IM

MH - Male

MH - Humans

MH - Adult

MH - *Paliperidone Palmitate/adverse effects

MH - *Schizophrenia/drug therapy

MH - Double-Blind Method

PMC - PMC10464922

OTO - NOTNLM

OT - Long-term efficacy

OT - long-acting injectable

OT - open-label extension

OT - paliperidone palmitate 6-month

OT - schizophrenia

EDAT- 2023/07/22 21:06

MHDA- 2023/08/31 06:41

CRDT- 2023/07/22 10:12

PHST- 2023/03/09 00:00 [received]

PHST- 2023/07/03 00:00 [accepted]

PHST- 2023/08/31 06:41 [medline]

PHST- 2023/07/22 21:06 [pubmed]

PHST- 2023/07/22 10:12 [entrez]

AID - 7227994 [pii]

AID - pyad028 [pii]

AID - 10.1093/ijnp/pyad028 [doi]

PST - ppublish

SO - Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028.

PMID- 37480304

OWN - NLM

STAT- MEDLINE

DCOM- 20230724

LR - 20230724

IS - 0353-5053 (Print)

IS - 0353-5053 (Linking)

VI - 35

IP - 2

DP - 2023 Summer

TI - PAIN THRESHOLD PARADOX IN SCHIZOPHRENIA: A NARRATIVE REVIEW BASED ON THE LASTEST

NEUROSCIENCE.

PG - 174-179

LID - 10.24869/psyd.2023.174 [doi]

AB - INTRODUCTION: Pain is one of the basic defense responses of living organisms.

Although the threshold for pain perception varies from person to person, there is

no doubt that pain reduces a person's quality of life. Assessing the subjective

experience of pain is especially important in the treatment of patients with

schizophrenia. In light of recent advances in neuroscience, we discuss pain

thresholds in patients with schizophrenia. METHODS: A narrative review of pain

thresholds in patients with schizophrenia was conducted. We electronically

searched the PubMed and Google Scholar databases for articles in English with

"pain," "schizophrenia," "neural circuits," and "neurotransmitters" in the title

or abstract, for the period January 2000 through June 2022. RESULTS: A seemingly

contradictory phenomenon has been noted with regard to pain thresholds in

patients with schizophrenia. One phenomenon is a high pain threshold for

nociceptive stimuli, and the other is a low pain threshold in chronic pain. As a

result, a pain threshold paradox has been observed. CONCLUSIONS: Many

schizophrenia patients appear to have an excess of dopamine in the mesolimbic

system, which stimulates both the descending pain inhibitory pathway and the

salience network. As a result, a pain threshold paradox has been observed, in

which the threshold for acute nociceptive pain is high and the threshold for

chronic pain is low.

FAU - Nagamine, Takahiko

AU - Nagamine T

AD - Sunlight Brain Research Center, Hofu, Yamaguchi, Japan.

AD - Department of Psychosomatic Dentistry, Tokyo Medical and Dental University,

Tokyo, Japan.

LA - eng

PT - Journal Article

PT - Review

PL - Croatia

TA - Psychiatr Danub

JT - Psychiatria Danubina

JID - 9424753

SB - IM

MH - Humans

MH - Pain Threshold

MH - *Chronic Pain

MH - Quality of Life

MH - *Schizophrenia

MH - Pain Perception

OTO - NOTNLM

OT - default mode network

OT - descending pain inhibitory pathway

OT - mesolimbic dopamine

OT - pain threshold paradox

OT - salience network

OT - schizophrenia

EDAT- 2023/07/22 21:06

MHDA- 2023/07/24 06:42

CRDT- 2023/07/22 07:32

PHST- 2023/07/24 06:42 [medline]

PHST- 2023/07/22 21:06 [pubmed]

PHST- 2023/07/22 07:32 [entrez]

AID - 10.24869/psyd.2023.174 [doi]

PST - ppublish

SO - Psychiatr Danub. 2023 Summer;35(2):174-179. doi: 10.24869/psyd.2023.174.

PMID- 37478950

OWN - NLM

STAT- MEDLINE

DCOM- 20230920

LR - 20230920

IS - 1879-1026 (Electronic)

IS - 0048-9697 (Linking)

VI - 899

DP - 2023 Nov 15

TI - Seasonal peak and the role of local weather in schizophrenia occurrence: A global

analysis of epidemiological evidence.

PG - 165658

LID - S0048-9697(23)04281-X [pii]

LID - 10.1016/j.scitotenv.2023.165658 [doi]

AB - BACKGROUND: Many studies have shown that the onset of schizophrenia peaked in

certain months within a year and the local weather conditions could affect the

morbidity risk of schizophrenia. This study aimed to conduct a systematic

analysis of schizophrenia seasonality in different countries of the world and to

explore the effects of weather factors globally. METHODS: We searched three

databases (PubMed, Web of Science, and China National Knowledge Infrastructure)

for eligible studies published up to September 2022. Schizophrenia seasonality

was compared between hemispheres and within China. A meta-analysis was conducted

to pool excess risk (ER, absolute percentage increase in risk) of the onset of

schizophrenia associated with various weather factors including temperature (an

increase or decrease of temperature as a reflection of high or low temperature;

heatwave; temperature variation), precipitation, etc. RESULTS: We identified 84

relevant articles from 22 countries, mainly in China. The seasonality analysis

found that the onset of schizophrenia mostly peaked in the cold season in the

southern hemisphere but in the warm season in the northern hemisphere.

Interestingly in China, schizophrenia seasonality presented two peaks,

respectively in the late cold and warm seasons. The meta-analysis further

revealed an increased risk of schizophrenia after short-term exposure to high

temperature [ER%: 0.45 % (95 % confidence interval (CI): 0.14 % to 0.76 %)], low

temperature [ER%: 0.52 % (95%CI: 0.29 % to 0.75 %)], heatwave [ER%: 7.26 %

(95%CI: 4.45 % to 10.14 %)], temperature variation [ER%: 1.02 % (95%CI: 0.55 % to

1.50 %)], extreme precipitation [ER%: 3.96 % (95%CI: 2.29 % to 5.67 %)]. The

effect of other weather factors such as sunlight on schizophrenia was scarcely

investigated with inconsistent findings. CONCLUSION: This study provided evidence

of intra- and inter-country variations in schizophrenia seasonality, especially

the double-peak seasons in China. Exposure to local weather conditions mainly

temperature changes and precipitation could affect the onset risk of

schizophrenia.

FAU - Hu, Jihong

AU - Hu J

AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui

Medical University, Hefei, China; Anhui Province Key Laboratory of Major

Autoimmune Disease, Hefei, China.

FAU - Feng, Yufan

AU - Feng Y

AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui

Medical University, Hefei, China; Anhui Province Key Laboratory of Major

Autoimmune Disease, Hefei, China.

FAU - Su, Hong

AU - Su H

AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui

Medical University, Hefei, China; Anhui Province Key Laboratory of Major

Autoimmune Disease, Hefei, China.

FAU - Xu, Zhiwei

AU - Xu Z

AD - School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland,

Australia.

FAU - Ho, Hung Chak

AU - Ho HC

AD - Department of Public and International Affairs, City University of Hong Kong,

Hong Kong, China.

FAU - Zheng, Hao

AU - Zheng H

AD - Department of Environmental Health, Jiangsu Provincial Center for Disease Control

and Prevention, Nanjing, China.

FAU - Zhang, Wenyi

AU - Zhang W

AD - Chinese PLA Center for Disease Control and Prevention, Beijing, China.

FAU - Tao, Junwen

AU - Tao J

AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui

Medical University, Hefei, China; Anhui Province Key Laboratory of Major

Autoimmune Disease, Hefei, China.

FAU - Wu, Keyu

AU - Wu K

AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui

Medical University, Hefei, China; Anhui Province Key Laboratory of Major

Autoimmune Disease, Hefei, China.

FAU - Hossain, Mohammad Zahid

AU - Hossain MZ

AD - International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b),

Dhaka, Bangladesh.

FAU - Zhang, Yunquan

AU - Zhang Y

AD - Department of Epidemiology and Biostatistics, School of Public Health, Wuhan

University of Science and Technology, Wuhan, China.

FAU - Hu, Kejia

AU - Hu K

AD - Department of Big Data in Health Science, School of Public Health, Zhejiang

University, Hangzhou, China.

FAU - Huang, Cunrui

AU - Huang C

AD - Vanke School of Public Health, Tsinghua University, Beijing, China. Electronic

address: huangcunrui@tsinghua.edu.cn.

FAU - Cheng, Jian

AU - Cheng J

AD - Department of Epidemiology and Biostatistics, School of Public Health, Anhui

Medical University, Hefei, China; Anhui Province Key Laboratory of Major

Autoimmune Disease, Hefei, China. Electronic address: jiancheng_cchh@163.com.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Review

DEP - 20230720

PL - Netherlands

TA - Sci Total Environ

JT - The Science of the total environment

JID - 0330500

SB - IM

MH - Humans

MH - Seasons

MH - *Schizophrenia/epidemiology

MH - Weather

MH - Temperature

MH - Cold Temperature

OTO - NOTNLM

OT - Globally

OT - Meteorological factors

OT - Schizophrenia

OT - Seasonality

COIS- Declaration of competing interest The authors declare that they have no known

competing financial interests or personal relationships that could have appeared

to influence the work reported in this paper.

EDAT- 2023/07/22 10:41

MHDA- 2023/09/20 06:42

CRDT- 2023/07/21 19:22

PHST- 2023/04/25 00:00 [received]

PHST- 2023/07/07 00:00 [revised]

PHST- 2023/07/17 00:00 [accepted]

PHST- 2023/09/20 06:42 [medline]

PHST- 2023/07/22 10:41 [pubmed]

PHST- 2023/07/21 19:22 [entrez]

AID - S0048-9697(23)04281-X [pii]

AID - 10.1016/j.scitotenv.2023.165658 [doi]

PST - ppublish

SO - Sci Total Environ. 2023 Nov 15;899:165658. doi: 10.1016/j.scitotenv.2023.165658.

Epub 2023 Jul 20.

PMID- 37478889

OWN - NLM

STAT- MEDLINE

DCOM- 20230925

LR - 20230926

IS - 2215-0374 (Electronic)

IS - 2215-0366 (Linking)

VI - 10

IP - 10

DP - 2023 Oct

TI - The interpersonal computational psychiatry of social coordination in

schizophrenia.

PG - 801-808

LID - S2215-0366(23)00146-3 [pii]

LID - 10.1016/S2215-0366(23)00146-3 [doi]

AB - Impairments in social coordination form a core dimension of various psychiatric

disorders, including schizophrenia. Advances in interpersonal and computational

psychiatry support a major change in studying social coordination in

schizophrenia. Although these developments provided novel perspectives to study

how interpersonal activities shape coordination and to examine computational

mechanisms, direct attempts to integrate the two methodologies have been sparse.

Here, we propose an interpersonal computational framework that (1) leverages the

active inference framework to model aberrant social coordination processes in

schizophrenia and (2) incorporates dynamical system models to dissect

intrapersonal and interpersonal synchronisation to inform a statistical model

based on active inference. We discuss how this interpersonal computational

psychiatry framework can elucidate the aberrant processes leading to

psychopathology, with schizophrenia as an example, and highlight how it might aid

clinical intervention and practice. Finally, we discuss challenges and

opportunities for using the framework in studying social coordination

impairments.

FAU - Pan, Yafeng

AU - Pan Y

AD - Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou,

China.

FAU - Wen, Yalan

AU - Wen Y

AD - Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou,

China.

FAU - Jin, Jingwen

AU - Jin J

AD - Department of Psychology, The University of Hong Kong, Hong Kong Special

Administrative Region, China; State Key Laboratory of Brain and Cognitive

Sciences, The University of Hong Kong, Hong Kong Special Administrative Region,

China.

FAU - Chen, Ji

AU - Chen J

AD - Department of Psychology and Behavioral Sciences, Zhejiang University, Hangzhou,

China; Department of Psychiatry, The Fourth Affiliated Hospital, Zhejiang

University School of Medicine, Yiwu, Zhejiang, China. Electronic address:

jichen.allen@hotmail.com.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230718

PL - England

TA - Lancet Psychiatry

JT - The lancet. Psychiatry

JID - 101638123

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Psychopathology

MH - *Psychiatry

MH - Interpersonal Relations

COIS- Declaration of interests We declare no competing interests.

EDAT- 2023/07/22 10:41

MHDA- 2023/09/25 06:42

CRDT- 2023/07/21 18:53

PHST- 2023/02/09 00:00 [received]

PHST- 2023/04/13 00:00 [revised]

PHST- 2023/04/13 00:00 [accepted]

PHST- 2023/09/25 06:42 [medline]

PHST- 2023/07/22 10:41 [pubmed]

PHST- 2023/07/21 18:53 [entrez]

AID - S2215-0366(23)00146-3 [pii]

AID - 10.1016/S2215-0366(23)00146-3 [doi]

PST - ppublish

SO - Lancet Psychiatry. 2023 Oct;10(10):801-808. doi: 10.1016/S2215-0366(23)00146-3.

Epub 2023 Jul 18.

PMID- 37476977

OWN - NLM

STAT- MEDLINE

DCOM- 20230808

LR - 20230911

IS - 1778-3585 (Electronic)

IS - 0924-9338 (Print)

IS - 0924-9338 (Linking)

VI - 66

IP - 1

DP - 2023 Jul 21

TI - The future of diagnosis in clinical neurosciences: Comparing multiple sclerosis

and schizophrenia.

PG - e58

LID - 10.1192/j.eurpsy.2023.2432 [doi]

LID - e58

AB - The ongoing developments of psychiatric classification systems have largely

improved reliability of diagnosis, including that of schizophrenia. However, with

an unknown pathophysiology and lacking biomarkers, its validity still remains

low, requiring further advancements. Research has helped establish multiple

sclerosis (MS) as the central nervous system (CNS) disorder with an established

pathophysiology, defined biomarkers and therefore good validity and significantly

improved treatment options. Before proposing next steps in research that aim to

improve the diagnostic process of schizophrenia, it is imperative to recognize

its clinical heterogeneity. Indeed, individuals with schizophrenia show high

interindividual variability in terms of symptomatic manifestation, response to

treatment, course of illness and functional outcomes. There is also a

multiplicity of risk factors that contribute to the development of schizophrenia.

Moreover, accumulating evidence indicates that several dimensions of

psychopathology and risk factors cross current diagnostic categorizations.

Schizophrenia shares a number of similarities with MS, which is a demyelinating

disease of the CNS. These similarities appear in the context of age of onset,

geographical distribution, involvement of immune-inflammatory processes,

neurocognitive impairment and various trajectories of illness course. This

article provides a critical appraisal of diagnostic process in schizophrenia,

taking into consideration advancements that have been made in the diagnosis and

management of MS. Based on the comparison between the two disorders, key

directions for studies that aim to improve diagnostic process in schizophrenia

are formulated. All of them converge on the necessity to deconstruct the

psychosis spectrum and adopt dimensional approaches with deep phenotyping to

refine current diagnostic boundaries.

FAU - Misiak, Błażej

AU - Misiak B

AD - Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland.

FAU - Samochowiec, Jerzy

AU - Samochowiec J

AUID- ORCID: 0000-0003-1438-583X

AD - Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland.

FAU - Kowalski, Krzysztof

AU - Kowalski K

AUID- ORCID: 0000-0002-7145-8284

AD - Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland.

FAU - Gaebel, Wolfgang

AU - Gaebel W

AD - Department of Psychiatry and Psychotherapy, LVR-Klinikum Düsseldorf, Medical

Faculty, Heinrich-Heine-University, Düsseldorf, Germany.

AD - WHO Collaborating Centre on Quality Assurance and Empowerment in Mental Health,

DEU-131, Düsseldorf, Germany.

FAU - Bassetti, Claudio L A

AU - Bassetti CLA

AUID- ORCID: 0000-0002-4535-0245

AD - Department of Neurology, Inselspital, Bern University Hospital, University Bern,

Switzerland.

AD - Interdisciplinary Sleep-Wake-Epilepsy-Center, Inselspital, Bern University

Hospital, University Bern, Bern, Switzerland.

FAU - Chan, Andrew

AU - Chan A

AD - Department of Neurology, Inselspital, Bern University Hospital, University Bern,

Switzerland.

FAU - Gorwood, Philip

AU - Gorwood P

AUID- ORCID: 0000-0003-1845-3676

AD - Université Paris Cité, INSERM, U1266 (Institute of Psychiatry and Neuroscience of

Paris), Paris, France.

AD - CMME, GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, Paris, France.

FAU - Papiol, Sergi

AU - Papiol S

AUID- ORCID: 0000-0001-9366-8728

AD - Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid,

Spain.

AD - Department of Psychiatry, Institute of Psychiatric Phenomics and Genomics,

University Hospital, Ludwig Maximilian University, Munich, Germany.

FAU - Dom, Geert

AU - Dom G

AUID- ORCID: 0000-0001-6492-0429

AD - Collaborative Antwerp Psychiatric Research Institute, University of Antwerp,

B-2610Antwerp, Belgium.

AD - Multiversum Psychiatric Hospital, B-2530Boechout, Belgium.

FAU - Volpe, Umberto

AU - Volpe U

AD - Unit of Clinical Psychiatry, Department of Clinical Neurosciences/DIMSC,

Polytechnic University of Marche, 60126Ancona, Italy.

FAU - Szulc, Agata

AU - Szulc A

AD - Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland.

FAU - Kurimay, Tamas

AU - Kurimay T

AUID- ORCID: 0000-0002-5996-8417

AD - Department of Psychiatry, St. Janos Hospital, Budapest, Hungary.

FAU - Kärkkäinen, Hilkka

AU - Kärkkäinen H

AUID- ORCID: 0009-0001-4630-3117

AD - President of GAMIAN-Europe, Ixelles, Belgium.

FAU - Decraene, Andre

AU - Decraene A

AD - European Federation of Associations of Families of People with Mental Illness

(EUFAMI), Leuven, Belgium.

FAU - Wisse, Jan

AU - Wisse J

AD - Century House, Wargrave Road, Henley-on-Thames, OxfordshireRG9 2LT, UK.

FAU - Fiorillo, Andrea

AU - Fiorillo A

AUID- ORCID: 0000-0002-6926-0762

AD - Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples,

Italy.

FAU - Falkai, Peter

AU - Falkai P

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Nussbaumstraße 7, 80336Munich, Germany.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230721

PL - England

TA - Eur Psychiatry

JT - European psychiatry : the journal of the Association of European Psychiatrists

JID - 9111820

RN - 0 (Biomarkers)

SB - IM

MH - Humans

MH - *Schizophrenia/diagnosis

MH - *Multiple Sclerosis/diagnosis

MH - Reproducibility of Results

MH - *Psychotic Disorders/psychology

MH - *Neurosciences

MH - Biomarkers

PMC - PMC10486256

OTO - NOTNLM

OT - diagnosis

OT - dimension

OT - multiple sclerosis

OT - neurology

OT - psychiatry

OT - psychopathology

OT - reliability

OT - schizophrenia

OT - validity

COIS- Concerning the topic of the paper, none of the authors have a conflict of

interest.

EDAT- 2023/07/21 06:44

MHDA- 2023/08/08 06:42

CRDT- 2023/07/21 05:26

PHST- 2023/08/08 06:42 [medline]

PHST- 2023/07/21 06:44 [pubmed]

PHST- 2023/07/21 05:26 [entrez]

AID - S092493382302432X [pii]

AID - 10.1192/j.eurpsy.2023.2432 [doi]

PST - epublish

SO - Eur Psychiatry. 2023 Jul 21;66(1):e58. doi: 10.1192/j.eurpsy.2023.2432.

PMID- 37473954

OWN - NLM

STAT- MEDLINE

DCOM- 20230907

LR - 20230929

IS - 1878-4216 (Electronic)

IS - 0278-5846 (Linking)

VI - 127

DP - 2023 Dec 20

TI - Dynamic functional connectivity in schizophrenia and bipolar disorder: A review

of the evidence and associations with psychopathological features.

PG - 110827

LID - S0278-5846(23)00113-6 [pii]

LID - 10.1016/j.pnpbp.2023.110827 [doi]

AB - Alterations of functional network connectivity have been implicated in the

pathophysiology of schizophrenia (SCZ) and bipolar disorder (BD). Recent studies

also suggest that the temporal dynamics of functional connectivity (dFC) can be

altered in these disorders. Here, we summarized the existing literature on dFC in

SCZ and BD, and their association with psychopathological and cognitive features.

We systematically searched PubMed, Web of Science, and Scopus for studies

investigating dFC in SCZ and BD and identified 77 studies. Our findings support a

general model of dysconnectivity of dFC in SCZ, whereas a heterogeneous picture

arose in BD. Although dFC alterations are more severe and widespread in SCZ

compared to BD, dysfunctions of a triple network system underlying goal-directed

behavior and sensory-motor networks were present in both disorders. Furthermore,

in SCZ, positive and negative symptoms were associated with abnormal dFC.

Implications for understanding the pathophysiology of disorders, the role of

neurotransmitters, and treatments on dFC are discussed. The lack of standards for

dFC metrics, replication studies, and the use of small samples represent major

limitations for the field.

FAU - Cattarinussi, Giulia

AU - Cattarinussi G

AD - Department of Neuroscience (DNS), University of Padova, Italy; Padova

Neuroscience Center, University of Padova, Italy.

FAU - Di Giorgio, Annabella

AU - Di Giorgio A

AD - Department of Mental Health and Addictions, ASST Papa Giovanni XXIII, Bergamo,

Italy.

FAU - Moretti, Federica

AU - Moretti F

AD - Department of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.

FAU - Bondi, Emi

AU - Bondi E

AD - Department of Mental Health and Addictions, ASST Papa Giovanni XXIII, Bergamo,

Italy.

FAU - Sambataro, Fabio

AU - Sambataro F

AD - Department of Neuroscience (DNS), University of Padova, Italy; Padova

Neuroscience Center, University of Padova, Italy. Electronic address:

fabio.sambataro@unipd.it.

LA - eng

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20230718

PL - England

TA - Prog Neuropsychopharmacol Biol Psychiatry

JT - Progress in neuro-psychopharmacology & biological psychiatry

JID - 8211617

SB - IM

MH - Humans

MH - *Schizophrenia

MH - *Bipolar Disorder

MH - Magnetic Resonance Imaging

OTO - NOTNLM

OT - Bipolar disorder

OT - Dynamic fluidity

OT - Dynamic functional connectivity

OT - ICA

OT - Psychopathology

OT - Psychosis

OT - Schizophrenia

COIS- Declaration of Competing Interest The authors declare that they have no known

competing financial interests or personal relationships that could have appeared

to influence the work reported in this paper.

EDAT- 2023/07/21 01:11

MHDA- 2023/09/07 06:42

CRDT- 2023/07/20 19:26

PHST- 2023/01/10 00:00 [received]

PHST- 2023/06/05 00:00 [revised]

PHST- 2023/07/10 00:00 [accepted]

PHST- 2023/09/07 06:42 [medline]

PHST- 2023/07/21 01:11 [pubmed]

PHST- 2023/07/20 19:26 [entrez]

AID - S0278-5846(23)00113-6 [pii]

AID - 10.1016/j.pnpbp.2023.110827 [doi]

PST - ppublish

SO - Prog Neuropsychopharmacol Biol Psychiatry. 2023 Dec 20;127:110827. doi:

10.1016/j.pnpbp.2023.110827. Epub 2023 Jul 18.

PMID- 37471567

OWN - NLM

STAT- MEDLINE

DCOM- 20230724

LR - 20230724

IS - 1555-2101 (Electronic)

IS - 0160-6689 (Linking)

VI - 84

IP - 5

DP - 2023 Jul 19

TI - Therapeutic Reference Range for Olanzapine in Schizophrenia: Systematic Review on

Blood Concentrations, Clinical Effects, and Dopamine Receptor Occupancy.

LID - 22r14626 [pii]

LID - 10.4088/JCP.22r14626 [doi]

AB - Objective: Aiming at revising the therapeutic reference range for olanzapine, the

present study highlights the association between blood olanzapine levels,

clinical effects, and dopamine D(2)-receptor occupancy for oral and long-acting

injectable (LAI) formulations. Data Sources: Databases were systematically

searched for randomized controlled trials (RCTs) and uncontrolled trials

concerning blood olanzapine levels in relation to clinical outcomes or

D(2)-receptor occupancy using MEDLINE (PubMed), Web of Science, PsycINFO, and

Cochrane Library (March 2021, updated in December 2021). We excluded articles not

written in English or German and non-human data. Search terms included

olanzapine, blood level, drug monitoring, PET, and SPECT. Study Selection: The

process of study selection followed a previously published protocol and PRISMA

guidelines. A total of 2,824 articles were identified through database search and

1 article via reference list check. Thirty-four studies were suitable for

qualitative synthesis, and 13 studies were included in the quantitative analysis.

Data Extraction: Reviewers performed data extraction and quality assessment of

the included studies independently following the review protocol. Results:

Evidence for a relationship between blood olanzapine level and efficacy/side

effects (constipation) is considered low (Level C). In total, 3 studies of

moderate quality consistently showed therapeutic thresholds of around 20 ng/mL

for olanzapine 12 hours post-dose. This threshold is in line with findings from

positron emission tomography (PET) studies that suggest optimal drug efficacy

(65%-80% D(2)-receptor occupancy) between 17 and 44 ng/mL. Conclusions: We

suggest a therapeutic reference range of 20-40 ng/mL for olanzapine oral and LAI

formulations. In this range, optimal treatment response is expected in patients

with schizophrenia and schizophrenia spectrum disorders. Side effects, especially

weight gain, may already occur at therapeutic levels. However, higher plasma

concentrations are in general well tolerated and should not necessarily require a

dose reduction in case of good response and tolerance.

FAU - Wesner, Katja

AU - Wesner K

AD - Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical

Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

FAU - Hiemke, Christoph

AU - Hiemke C

AD - Department of Psychiatry and Psychotherapy, Institute of Clinical Chemistry and

Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Bergemann, Niels

AU - Bergemann N

AD - Department of General Psychiatry, University of Heidelberg, Heidelberg, Germany.

AD - Department of Biological and Clinical Psychology, University of Trier, Trier,

Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Egberts, Karin M

AU - Egberts KM

AD - ); Department of Child and Adolescent Psychiatry, Psychosomatics and

Psychotherapy, University Hospital Würzburg, Würzburg, Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Fekete, Stefanie

AU - Fekete S

AD - ); Department of Child and Adolescent Psychiatry, Psychosomatics and

Psychotherapy, University Hospital Würzburg, Würzburg, Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Gerlach, Manfred

AU - Gerlach M

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Havemann-Reinecke, Ursula

AU - Havemann-Reinecke U

AD - Department of Psychiatry and Psychosomatics, University of Göttingen, Göttingen,

Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Lense, Xenija M

AU - Lense XM

AD - Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical

Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

FAU - Riemer, Thomas G

AU - Riemer TG

AD - Charité-Medical University of Berlin, corporate member of Freie Universität

Berlin and Humboldt- Universität zu Berlin, Institute of Clinical Pharmacology

and Toxicology, Berlin, Germany.

FAU - Schoretsanitis, Georgios

AU - Schoretsanitis G

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of

Psychiatry, University of Zurich, Zurich, Switzerland.

AD - Behavioral Health Pavilion, Department of Psychiatry, Northwell Health, The

Zucker Hillside Hospital, Glen Oaks, and Department of Psychiatry, Zucker School

of Medicine at Northwell/Hofstra, Hempstead, New York.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Uhr, Manfred

AU - Uhr M

AD - Clinical Laboratory, Max Planck Institute of Psychiatry, Munich, Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Zernig, Gerald

AU - Zernig G

AD - Department of Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.

AD - Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol,

Austria.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Gründer, Gerhard

AU - Gründer G

AD - Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical

Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

FAU - Hart, Xenia M

AU - Hart XM

AD - Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical

Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

AD - Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP),

Task Force "Therapeutic Drug Monitoring".

AD - Corresponding Author: Xenia M. Hart, Central Institute of Mental Health Mannheim;

J5, 68159 Mannheim (xenia.hart@zi-mannheim.de).

LA - eng

PT - Journal Article

PT - Systematic Review

DEP - 20230719

PL - United States

TA - J Clin Psychiatry

JT - The Journal of clinical psychiatry

JID - 7801243

RN - N7U69T4SZR (Olanzapine)

RN - 0 (Antipsychotic Agents)

RN - 0 (Receptors, Dopamine D2)

RN - 12794-10-4 (Benzodiazepines)

SB - IM

MH - Humans

MH - Olanzapine/therapeutic use

MH - *Antipsychotic Agents/adverse effects

MH - Reference Values

MH - *Schizophrenia/drug therapy/chemically induced

MH - Receptors, Dopamine D2

MH - Benzodiazepines/adverse effects

EDAT- 2023/07/20 19:14

MHDA- 2023/07/24 06:42

CRDT- 2023/07/20 14:34

PHST- 2023/07/24 06:42 [medline]

PHST- 2023/07/20 19:14 [pubmed]

PHST- 2023/07/20 14:34 [entrez]

AID - 22r14626 [pii]

AID - 10.4088/JCP.22r14626 [doi]

PST - epublish

SO - J Clin Psychiatry. 2023 Jul 19;84(5):22r14626. doi: 10.4088/JCP.22r14626.

PMID- 37470979

OWN - NLM

STAT- MEDLINE

DCOM- 20230728

LR - 20230901

IS - 1179-1934 (Electronic)

IS - 1172-7047 (Print)

IS - 1172-7047 (Linking)

VI - 37

IP - 7

DP - 2023 Jul

TI - Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in

Schizophrenia.

PG - 545-570

LID - 10.1007/s40263-023-01022-7 [doi]

AB - Patients with schizophrenia experience a broad range of detrimental health

outcomes resulting from illness severity, heterogeneity of disease, lifestyle

behaviors, and adverse effects of antipsychotics. Because of these various

factors, patients with schizophrenia have a much higher risk of cardiometabolic

abnormalities than people without psychiatric illness. Although exposure to many

antipsychotics increases cardiometabolic risk factors, mortality is higher in

patients who are not treated versus those who are treated with antipsychotics.

This indicates both direct and indirect benefits of adequately treated illness,

as well as the need for beneficial medications that result in fewer

cardiometabolic risk factors and comorbidities. The aim of the current narrative

review was to outline the association between cardiometabolic dysfunction and

schizophrenia, as well as discuss the confluence of factors that increase

cardiometabolic risk in this patient population. An increased understanding of

the pathophysiology of schizophrenia has guided discovery of novel treatments

that do not directly target dopamine and that not only do not add, but may

potentially minimize relevant cardiometabolic burden for these patients. Key

discoveries that have advanced the understanding of the neural circuitry and

pathophysiology of schizophrenia now provide possible pathways toward the

development of new and effective treatments that may mitigate the risk of

metabolic dysfunction in these patients. Novel targets and preclinical and

clinical data on emerging treatments, such as glycine transport inhibitors,

nicotinic and muscarinic receptor agonists, and trace amine-associated receptor-1

agonists, offer promise toward relevant therapeutic advancements. Numerous areas

of investigation currently exist with the potential to considerably progress our

knowledge and treatment of schizophrenia.

FAU - Meyer, Jonathan M

AU - Meyer JM

AUID- ORCID: 0000-0001-7294-4834

AD - Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.

jmmeyer@health.ucsd.edu.

FAU - Correll, Christoph U

AU - Correll CU

AUID- ORCID: 0000-0002-7254-5646

AD - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

AD - Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School

of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

AD - Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin,

Berlin, Germany.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230720

PL - New Zealand

TA - CNS Drugs

JT - CNS drugs

JID - 9431220

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy/epidemiology

MH - *Antipsychotic Agents/adverse effects

MH - Comorbidity

MH - *Cardiovascular Diseases/chemically induced

PMC - PMC10374807

COIS- Dr. Meyer has been a consultant and/or advisor to or has received honoraria from

Acadia, Alkermes, AbbVie, Cerevel, Intra-Cellular, Karuna, Neurocrine, Noven,

Otsuka, Relmada, Sunovion, and Teva. Dr. Correll has been a consultant and/or

advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan,

Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX

Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk,

Intra-Cellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck,

MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan,

Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada,

Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda,

Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served

on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus,

and Teva. He has received grant support from Janssen and Takeda. He is a stock

option holder of Cardio Diagnostics, Mindpax, LB Pharma, and Quantic. He received

support for travel, manuscript preparation or other reason from Angelini, Gedeon

Richter, Janssen/J&J, Karuna, Lundbeck, Mylan, Otsuka, Recordati, Sunovion, Teva,

and Viatris. He has received payment for lectures including service on speakers

bureaus from AbbVie, Angelini, Aristo, Damitsa, Gedeon Richter, Hikma,

Intra-Cellular Therapies, Janssen/J&J, Lundbeck, Mitsubishi Tanabe Pharma, Mylan,

Otsuka, Recordati, Seqirus, Sunovion, Takeda, and Viatris.

EDAT- 2023/07/20 13:06

MHDA- 2023/07/28 06:43

CRDT- 2023/07/20 11:16

PHST- 2023/06/21 00:00 [accepted]

PHST- 2023/07/28 06:43 [medline]

PHST- 2023/07/20 13:06 [pubmed]

PHST- 2023/07/20 11:16 [entrez]

AID - 10.1007/s40263-023-01022-7 [pii]

AID - 1022 [pii]

AID - 10.1007/s40263-023-01022-7 [doi]

PST - ppublish

SO - CNS Drugs. 2023 Jul;37(7):545-570. doi: 10.1007/s40263-023-01022-7. Epub 2023 Jul

20.

PMID- 37468932

OWN - NLM

STAT- MEDLINE

DCOM- 20230721

LR - 20230722

IS - 1741-7015 (Electronic)

IS - 1741-7015 (Linking)

VI - 21

IP - 1

DP - 2023 Jul 19

TI - Early non-response as a predictor of later non-response to antipsychotics in

schizophrenia: a randomized trial.

PG - 263

LID - 10.1186/s12916-023-02968-7 [doi]

LID - 263

AB - BACKGROUND: It remains a challenge to predict the long-term response to

antipsychotics in patients with schizophrenia who do not respond at an early

stage. This study aimed to investigate the optimal predictive cut-off value for

early non-response that would better predict later non-response to antipsychotics

in patients with schizophrenia. METHODS: This multicenter, 8-week, open-label,

randomized trial was conducted at 19 psychiatric centers throughout China. All

enrolled participants were assigned to olanzapine, risperidone, amisulpride, or

aripiprazole monotherapy for 8 weeks. The positive and negative syndrome scale

(PANSS) was evaluated at baseline, week 2, week 4, and week 8. The main outcome

was the prediction of nonresponse. Nonresponse is defined as a < 20% reduction in

the total scores of PANSS from baseline to endpoint. Severity ratings of mild,

moderate, and severe illness corresponded to baseline PANSS total scores of 58,

75, and 95, respectively. RESULTS: At week 2, a reduction of < 5% in the PANSS

total score showed the highest total accuracy in the severe and mild

schizophrenia patients (total accuracy, 75.0% and 80.8%, respectively), and

patients who were treated with the risperidone and amisulpride groups (total

accuracy, 82.4%, and 78.2%, respectively). A 10% decrease exhibited the best

overall accuracy in the moderate schizophrenia patients (total accuracy, 84.0%),

olanzapine (total accuracy, 79.2%), and aripiprazole group (total accuracy,

77.4%). At week 4, the best predictive cut-off value was < 20%, regardless of the

antipsychotic or severity of illness (total accuracy ranging from 89.8 to 92.1%).

CONCLUSIONS: Symptom reduction at week 2 has acceptable discrimination in

predicting later non-response to antipsychotics in schizophrenia, and a more

accurate predictive cut-off value should be determined according to the

medication regimen and baseline illness severity. The response to treatment

during the next 2 weeks after week 2 could be further assessed to determine

whether there is a need to change antipsychotic medication during the first four

weeks. TRIAL REGISTRATION: This study was registered on Clinicaltrials.gov

(NCT03451734).

FAU - Long, Yujun

AU - Long Y

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

FAU - Wu, Qiongqiong

AU - Wu Q

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

FAU - Yang, Ye

AU - Yang Y

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

FAU - Cai, Jingda

AU - Cai J

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

FAU - Xiao, Jingmei

AU - Xiao J

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

FAU - Liu, Zhaoqian

AU - Liu Z

AD - Department of Clinical Pharmacology, Xiangya Hospital, Central South University,

Changsha, Hunan, China.

FAU - Xu, Yifeng

AU - Xu Y

AD - Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong

University School of Medicine, Shanghai, China.

FAU - Chen, Ying

AU - Chen Y

AD - Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of

Sichuan University, Chengdu, Sichuan, China.

FAU - Huang, Manli

AU - Huang M

AD - Department of Psychiatry, The First Affiliated Hospital, Zhejiang University

School of Medicine, Hangzhou, Zhejiang, China.

FAU - Zhang, Ruiguo

AU - Zhang R

AD - Department of Psychiatry, Xijing Hospital, Air Force Military Medical University,

Xi'an, Shaanxi, China.

FAU - Xu, Xijia

AU - Xu X

AD - Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical

University, Nanjing Brain Hospital, Nanjing, Jiangsu, China.

FAU - Hu, Jian

AU - Hu J

AD - Department of Psychiatry, The First Affiliated Hospital of Harbin Medical

University, Harbin, Heilongjiang, China.

FAU - Liu, Zhifen

AU - Liu Z

AD - Department of Psychiatry, The First Hospital of Shanxi Medical University,

Taiyuan, Shanxi, China.

FAU - Liu, Fang

AU - Liu F

AD - Department of Psychiatry, The First Affiliated Hospital of Kunming Medical

University, Kunming, Yunnan, China.

FAU - Zheng, Yingjun

AU - Zheng Y

AD - Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical

University, Guangzhou, Guangdong, China.

FAU - Meng, Huaqing

AU - Meng H

AD - Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical

University, Chongqing, China.

FAU - Wang, Zhimin

AU - Wang Z

AD - The National Clinical Research Center for Mental Disorders, Beijing Anding

Hospital, Capital Medical University, Beijing, China.

FAU - Tang, Yanqing

AU - Tang Y

AD - Department of Psychiatry, the First Hospital of China Medical University,

Shenyang, Liaoning, China.

FAU - Song, Xueqin

AU - Song X

AD - Department of Psychiatry, The First Affiliated Hospital of Zhengzhou University,

Zhengzhou, Henan, China.

FAU - Chen, Yunchun

AU - Chen Y

AD - Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong

University, Xi'an, Shaanxi, China.

FAU - Wang, Xueyi

AU - Wang X

AD - Department of Psychiatry, First Hospital of Hebei Medical University,

Shijiazhuang, Hebei, China.

FAU - Liu, Tiebang

AU - Liu T

AD - Department of Psychiatry, Shenzhen Kangning Hospital, Shenzhen, Guangdong, China.

FAU - Wu, Xiaoli

AU - Wu X

AD - Department of Psychiatry, The Third Affiliated Hospital, Sun Yat-Sen University,

Guangzhou, Guangdong, China.

FAU - Fang, Maosheng

AU - Fang M

AD - Wuhan Mental Health Center, Wuhan, Hubei, China.

FAU - Wan, Chunling

AU - Wan C

AD - Bio-X Institutes, Key Laboratory for the Genetics of Developmental and

Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University,

Shanghai, China.

FAU - Zhao, Jingping

AU - Zhao J

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

FAU - Wu, Renrong

AU - Wu R

AD - Department of Psychiatry, National Clinical Research Center for Mental Disorders,

and National Center for Mental Disorders, The Second Xiangya Hospital of Central

South University, 139# Renmin Middle RD, Changsha, 410011, Hunan, China.

wurenrong@csu.edu.cn.

LA - eng

SI - ClinicalTrials.gov/NCT03451734

PT - Journal Article

PT - Multicenter Study

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230719

PL - England

TA - BMC Med

JT - BMC medicine

JID - 101190723

RN - 0 (Antipsychotic Agents)

RN - N7U69T4SZR (Olanzapine)

RN - L6UH7ZF8HC (Risperidone)

RN - 82VFR53I78 (Aripiprazole)

RN - 8110R61I4U (Amisulpride)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/therapeutic use

MH - *Schizophrenia/drug therapy

MH - Olanzapine/therapeutic use

MH - Risperidone/therapeutic use

MH - Aripiprazole/therapeutic use

MH - Amisulpride/therapeutic use

MH - Treatment Outcome

PMC - PMC10354903

OTO - NOTNLM

OT - Atypical antipsychotic

OT - Early response

OT - Prediction

OT - Schizophrenia

COIS- The authors declare that they have no competing interests.

EDAT- 2023/07/20 01:06

MHDA- 2023/07/21 06:42

CRDT- 2023/07/19 23:46

PHST- 2023/03/25 00:00 [received]

PHST- 2023/06/30 00:00 [accepted]

PHST- 2023/07/21 06:42 [medline]

PHST- 2023/07/20 01:06 [pubmed]

PHST- 2023/07/19 23:46 [entrez]

AID - 10.1186/s12916-023-02968-7 [pii]

AID - 2968 [pii]

AID - 10.1186/s12916-023-02968-7 [doi]

PST - epublish

SO - BMC Med. 2023 Jul 19;21(1):263. doi: 10.1186/s12916-023-02968-7.

PMID- 37464177

OWN - NLM

STAT- MEDLINE

DCOM- 20230721

LR - 20230829

IS - 2158-3188 (Electronic)

IS - 2158-3188 (Linking)

VI - 13

IP - 1

DP - 2023 Jul 18

TI - The role of Extracellular Genomic Materials (EGMs) in psychiatric disorders.

PG - 262

LID - 10.1038/s41398-023-02549-5 [doi]

LID - 262

AB - Extracellular Genomic Materials (EGMs) are the nucleic acids secreted or released

from all types of cells by endogenous or exogenous stimuli through varying

mechanisms into the extracellular region and inevitably to all biological fluids.

EGMs could be found as free, protein-bound, and/ or with vesicles. EGMs can

potentially have immunophenotypic and/or genotypic characteristics of a cell of

origin, travel to distant organs, and interact with the new microenvironment. To

achieve all, EGMs might bi-directionally transit through varying membranes,

including the blood-brain barrier. Such ability provides the transfer of any

information related to the pathophysiological changes in psychiatric disorders in

the brain to the other distant organ systems or vice versa. In this article, many

aspects of EGMs have been elegantly reviewed, including their potential in

diagnosis as biomarkers, application in treatment modalities, and functional

effects in the pathophysiology of psychiatric disorders. The psychiatric

disorders were studied under subgroups of Schizophrenia spectrum disorders,

bipolar disorder, depressive disorders, and an autism spectrum disorders. EGMs

provide a robust and promising tool in clinics for prognosis and diagnosis. The

successful application of EGMs into treatment modalities might further provide

encouraging outcomes for researchers and clinicians in psychiatric disorders.

FAU - Kurtulmuş, Ayşe

AU - Kurtulmuş A

AD - Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul

University, Istanbul, Turkey.

AD - Institute of Health Sciences, Istanbul University, Istanbul, Turkey.

AD - Istanbul Göztepe Prof.Dr.Süleyman Yalçın City Hospital, Department of Psychiatry,

Istanbul, Turkey.

FAU - Koçana, Cemal Çağıl

AU - Koçana CÇ

AD - Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul

University, Istanbul, Turkey.

AD - Institute of Health Sciences, Istanbul University, Istanbul, Turkey.

FAU - Toprak, Selin Fulya

AU - Toprak SF

AD - Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul

University, Istanbul, Turkey.

AD - Institute of Health Sciences, Istanbul University, Istanbul, Turkey.

FAU - Sözer, Selçuk

AU - Sözer S

AUID- ORCID: 0000-0002-5035-4048

AD - Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul

University, Istanbul, Turkey. ssozer@istanbul.edu.tr.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230718

PL - United States

TA - Transl Psychiatry

JT - Translational psychiatry

JID - 101562664

RN - 0 (Biomarkers)

SB - IM

EIN - Transl Psychiatry. 2023 Aug 28;13(1):287. PMID: 37640710

MH - Humans

MH - *Mental Disorders/diagnosis/genetics

MH - *Bipolar Disorder/genetics

MH - *Schizophrenia/diagnosis/genetics

MH - Genomics

MH - Biomarkers

PMC - PMC10354097

COIS- The authors declare no competing interests.

EDAT- 2023/07/19 01:06

MHDA- 2023/07/21 06:43

CRDT- 2023/07/18 23:32

PHST- 2022/10/04 00:00 [received]

PHST- 2023/06/27 00:00 [accepted]

PHST- 2023/06/26 00:00 [revised]

PHST- 2023/07/21 06:43 [medline]

PHST- 2023/07/19 01:06 [pubmed]

PHST- 2023/07/18 23:32 [entrez]

AID - 10.1038/s41398-023-02549-5 [pii]

AID - 2549 [pii]

AID - 10.1038/s41398-023-02549-5 [doi]

PST - epublish

SO - Transl Psychiatry. 2023 Jul 18;13(1):262. doi: 10.1038/s41398-023-02549-5.

PMID- 37464041

OWN - NLM

STAT- MEDLINE

DCOM- 20230721

LR - 20230812

IS - 1546-170X (Electronic)

IS - 1078-8956 (Linking)

VI - 29

IP - 7

DP - 2023 Jul

TI - Depression pathophysiology, risk prediction of recurrence and comorbid

psychiatric disorders using genome-wide analyses.

PG - 1832-1844

LID - 10.1038/s41591-023-02352-1 [doi]

AB - Depression is a common psychiatric disorder and a leading cause of disability

worldwide. Here we conducted a genome-wide association study meta-analysis of six

datasets, including >1.3 million individuals (371,184 with depression) and

identified 243 risk loci. Overall, 64 loci were new, including genes encoding

glutamate and GABA receptors, which are targets for antidepressant drugs.

Intersection with functional genomics data prioritized likely causal genes and

revealed new enrichment of prenatal GABAergic neurons, astrocytes and

oligodendrocyte lineages. We found depression to be highly polygenic, with

~11,700 variants explaining 90% of the single-nucleotide polymorphism

heritability, estimating that >95% of risk variants for other psychiatric

disorders (anxiety, schizophrenia, bipolar disorder and attention deficit

hyperactivity disorder) were influencing depression risk when both concordant and

discordant variants were considered, and nearly all depression risk variants

influenced educational attainment. Additionally, depression genetic risk was

associated with impaired complex cognition domains. We dissected the genetic and

clinical heterogeneity, revealing distinct polygenic architectures across

subgroups of depression and demonstrating significantly increased absolute risks

for recurrence and psychiatric comorbidity among cases of depression with the

highest polygenic burden, with considerable sex differences. The risks were up to

5- and 32-fold higher than cases with the lowest polygenic burden and the

background population, respectively. These results deepen the understanding of

the biology underlying depression, its disease progression and inform precision

medicine approaches to treatment.

FAU - Als, Thomas D

AU - Als TD

AUID- ORCID: 0000-0002-2963-1928

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark. tda@biomed.au.dk.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark. tda@biomed.au.dk.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark. tda@biomed.au.dk.

FAU - Kurki, Mitja I

AU - Kurki MI

AD - Institute for Molecular Medicine Finland, University of Helsinki, Helsinki,

Finland.

AD - Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts

General Hospital and Harvard Medical School, Boston, MA, USA.

AD - Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,

Cambridge, MA, USA.

FAU - Grove, Jakob

AU - Grove J

AUID- ORCID: 0000-0003-2284-5744

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

AD - Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.

FAU - Voloudakis, Georgios

AU - Voloudakis G

AUID- ORCID: 0000-0002-5729-632X

AD - Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New

York, NY, USA.

AD - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount

Sinai, New York, NY, USA.

AD - Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine

at Mount Sinai, New York, NY, USA.

AD - Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Mental Illness Research, Education, and Clinical Center (VISN 2 South), James J

Peters VA Medical Center, Bronx, NY, USA.

FAU - Therrien, Karen

AU - Therrien K

AUID- ORCID: 0000-0003-3351-7260

AD - Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New

York, NY, USA.

AD - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount

Sinai, New York, NY, USA.

AD - Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine

at Mount Sinai, New York, NY, USA.

AD - Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Mental Illness Research, Education, and Clinical Center (VISN 2 South), James J

Peters VA Medical Center, Bronx, NY, USA.

AD - Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai,

New York, NY, USA.

FAU - Tasanko, Elisa

AU - Tasanko E

AD - Department of Psychology and Logopedics, SleepWell Research Program, University

of Helsinki, Helsinki, Finland.

FAU - Nielsen, Trine Tollerup

AU - Nielsen TT

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

FAU - Naamanka, Joonas

AU - Naamanka J

AUID- ORCID: 0000-0003-3092-7416

AD - Department of Psychology and Logopedics, SleepWell Research Program, University

of Helsinki, Helsinki, Finland.

FAU - Veerapen, Kumar

AU - Veerapen K

AD - Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts

General Hospital and Harvard Medical School, Boston, MA, USA.

AD - Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,

Cambridge, MA, USA.

AD - Department of Medicine, Harvard Medical School, Boston, MA, USA.

FAU - Levey, Daniel F

AU - Levey DF

AUID- ORCID: 0000-0001-8431-9569

AD - Division of Human Genetics, Department of Psychiatry, Yale University School of

Medicine, New Haven, CT, USA.

AD - Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West

Haven, CT, USA.

FAU - Bendl, Jaroslav

AU - Bendl J

AUID- ORCID: 0000-0001-9989-2720

AD - Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New

York, NY, USA.

AD - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount

Sinai, New York, NY, USA.

AD - Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine

at Mount Sinai, New York, NY, USA.

AD - Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

FAU - Bybjerg-Grauholm, Jonas

AU - Bybjerg-Grauholm J

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum

Institut, Copenhagen, Denmark.

FAU - Zeng, Biao

AU - Zeng B

AD - Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New

York, NY, USA.

AD - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount

Sinai, New York, NY, USA.

AD - Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine

at Mount Sinai, New York, NY, USA.

AD - Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

FAU - Demontis, Ditte

AU - Demontis D

AUID- ORCID: 0000-0001-9124-2766

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

FAU - Rosengren, Anders

AU - Rosengren A

AUID- ORCID: 0000-0002-6682-1288

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Mental Health Centre Sct. Hans, Capital Region of Denmark, Institute of

Biological Psychiatry, Copenhagen University Hospital, Copenhagen, Denmark.

FAU - Athanasiadis, Georgios

AU - Athanasiadis G

AUID- ORCID: 0000-0002-2927-4035

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Mental Health Centre Sct. Hans, Capital Region of Denmark, Institute of

Biological Psychiatry, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Department of Evolutionary Biology, Ecology and Environmental Sciences,

University of Barcelona, Barcelona, Spain.

FAU - Bækved-Hansen, Marie

AU - Bækved-Hansen M

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum

Institut, Copenhagen, Denmark.

FAU - Qvist, Per

AU - Qvist P

AUID- ORCID: 0000-0002-0750-0089

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

FAU - Bragi Walters, G

AU - Bragi Walters G

AUID- ORCID: 0000-0002-5415-6487

AD - deCODE Genetics/Amgen, Reykjavik, Iceland.

FAU - Thorgeirsson, Thorgeir

AU - Thorgeirsson T

AUID- ORCID: 0000-0002-5149-7040

AD - deCODE Genetics/Amgen, Reykjavik, Iceland.

FAU - Stefánsson, Hreinn

AU - Stefánsson H

AD - deCODE Genetics/Amgen, Reykjavik, Iceland.

FAU - Musliner, Katherine L

AU - Musliner KL

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - National Centre for Register-Based Research (NCRR), Business and Social Sciences,

Aarhus University, Aarhus, Denmark.

AD - Department of Affective Disorders, Aarhus University Hospital-Psychiatry, Aarhus,

Denmark.

AD - The Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

FAU - Rajagopal, Veera M

AU - Rajagopal VM

AUID- ORCID: 0000-0002-5236-168X

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

FAU - Farajzadeh, Leila

AU - Farajzadeh L

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

FAU - Thirstrup, Janne

AU - Thirstrup J

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

FAU - Vilhjálmsson, Bjarni J

AU - Vilhjálmsson BJ

AUID- ORCID: 0000-0003-2277-9249

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.

AD - National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.

FAU - McGrath, John J

AU - McGrath JJ

AD - National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.

AD - Queensland Centre for Mental Health Research, The Park Centre for Mental Health,

Brisbane, Queensland, Australia.

AD - Queensland Brain Institute, University of Queensland, Brisbane, Queensland,

Australia.

FAU - Mattheisen, Manuel

AU - Mattheisen M

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU

Munich, Munich, Germany.

AD - Department of Community Health and Epidemiology, Dalhousie University, Halifax,

Nova Scotia, Canada.

AD - Faculty of Computer Science, Dalhousie University, Halifax, Nova Scotia, Canada.

FAU - Meier, Sandra

AU - Meier S

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Department of Community Health and Epidemiology, Dalhousie University, Halifax,

Nova Scotia, Canada.

AD - Faculty of Computer Science, Dalhousie University, Halifax, Nova Scotia, Canada.

AD - Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.

FAU - Agerbo, Esben

AU - Agerbo E

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - National Centre for Register-Based Research (NCRR), Business and Social Sciences,

Aarhus University, Aarhus, Denmark.

AD - Centre for Integrated Register-based Research, CIRRAU, Aarhus University, Aarhus,

Denmark.

FAU - Stefánsson, Kári

AU - Stefánsson K

AD - deCODE Genetics/Amgen, Reykjavik, Iceland.

FAU - Nordentoft, Merete

AU - Nordentoft M

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Mental Health Centre Copenhagen, Capital Region of Denmark, Copenhagen University

Hospital, Copenhagen, Denmark.

FAU - Werge, Thomas

AU - Werge T

AUID- ORCID: 0000-0003-1829-0766

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Mental Health Centre Sct. Hans, Capital Region of Denmark, Institute of

Biological Psychiatry, Copenhagen University Hospital, Copenhagen, Denmark.

AD - Institute of Clinical Sciences and GLOBE Institute, LF Center for GeoGenetics,

University of Copenhagen, Copenhagen, Denmark.

FAU - Hougaard, David M

AU - Hougaard DM

AUID- ORCID: 0000-0001-5928-3517

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum

Institut, Copenhagen, Denmark.

FAU - Mortensen, Preben B

AU - Mortensen PB

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - National Centre for Register-Based Research (NCRR), Business and Social Sciences,

Aarhus University, Aarhus, Denmark.

AD - Centre for Integrated Register-based Research, CIRRAU, Aarhus University, Aarhus,

Denmark.

FAU - Stein, Murray B

AU - Stein MB

AUID- ORCID: 0000-0001-9564-2871

AD - Psychiatry Service, VA San Diego Healthcare System, San Diego, CA, USA.

AD - Departments of Psychiatry and Herbert Wertheim School of Public Health,

University of California, San Diego, La Jolla, CA, USA.

FAU - Gelernter, Joel

AU - Gelernter J

AUID- ORCID: 0000-0002-4067-1859

AD - Division of Human Genetics, Department of Psychiatry, Yale University School of

Medicine, New Haven, CT, USA.

AD - Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West

Haven, CT, USA.

FAU - Hovatta, Iiris

AU - Hovatta I

AUID- ORCID: 0000-0002-5990-7892

AD - Department of Psychology and Logopedics, SleepWell Research Program, University

of Helsinki, Helsinki, Finland.

FAU - Roussos, Panos

AU - Roussos P

AD - Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New

York, NY, USA.

AD - Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount

Sinai, New York, NY, USA.

AD - Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine

at Mount Sinai, New York, NY, USA.

AD - Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY,

USA.

AD - Mental Illness Research, Education, and Clinical Center (VISN 2 South), James J

Peters VA Medical Center, Bronx, NY, USA.

AD - Center for Dementia Research, Nathan Kline Institute for Psychiatric Research,

Orangeburg, NY, USA.

FAU - Daly, Mark J

AU - Daly MJ

AD - Institute for Molecular Medicine Finland, University of Helsinki, Helsinki,

Finland.

AD - Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts

General Hospital and Harvard Medical School, Boston, MA, USA.

AD - Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,

Cambridge, MA, USA.

AD - Department of Medicine, Harvard Medical School, Boston, MA, USA.

FAU - Mors, Ole

AU - Mors O

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark.

AD - Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.

FAU - Palotie, Aarno

AU - Palotie A

AUID- ORCID: 0000-0002-2527-5874

AD - Institute for Molecular Medicine Finland, University of Helsinki, Helsinki,

Finland.

FAU - Børglum, Anders D

AU - Børglum AD

AUID- ORCID: 0000-0001-8627-7219

AD - Department of Biomedicine, Aarhus University, Aarhus, Denmark.

anders@biomed.au.dk.

AD - The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH,

Aarhus, Denmark. anders@biomed.au.dk.

AD - Center for Genomics and Personalized Medicine, Aarhus, Denmark.

anders@biomed.au.dk.

LA - eng

SI - figshare/10.6084/m9.figshare.22139849

GR - U01 MH109514/MH/NIMH NIH HHS/United States

GR - R01 MH124851/MH/NIMH NIH HHS/United States

GR - K08 MH122911/MH/NIMH NIH HHS/United States

GR - T32 MH087004/MH/NIMH NIH HHS/United States

GR - R01 DK125246/DK/NIDDK NIH HHS/United States

GR - R01 AG067025/AG/NIA NIH HHS/United States

GR - R01 AI116442/AI/NIAID NIH HHS/United States

GR - R01 DK109677/DK/NIDDK NIH HHS/United States

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, N.I.H., Extramural

PT - Research Support, U.S. Gov't, Non-P.H.S.

DEP - 20230718

PL - United States

TA - Nat Med

JT - Nature medicine

JID - 9502015

SB - IM

CIN - Nat Genet. 2023 Aug;55(8):1253. PMID: 37558886

MH - Male

MH - Female

MH - Humans

MH - Genome-Wide Association Study

MH - Depression

MH - *Bipolar Disorder/epidemiology/genetics

MH - *Schizophrenia/epidemiology/genetics

MH - *Attention Deficit Disorder with Hyperactivity/epidemiology/genetics

MH - Polymorphism, Single Nucleotide/genetics

MH - Genetic Predisposition to Disease

EDAT- 2023/07/19 01:06

MHDA- 2023/07/21 06:44

CRDT- 2023/07/18 23:27

PHST- 2022/06/30 00:00 [received]

PHST- 2023/04/17 00:00 [accepted]

PHST- 2023/07/21 06:44 [medline]

PHST- 2023/07/19 01:06 [pubmed]

PHST- 2023/07/18 23:27 [entrez]

AID - 10.1038/s41591-023-02352-1 [pii]

AID - 10.1038/s41591-023-02352-1 [doi]

PST - ppublish

SO - Nat Med. 2023 Jul;29(7):1832-1844. doi: 10.1038/s41591-023-02352-1. Epub 2023 Jul

18.

PMID- 37462253

OWN - NLM

STAT- MEDLINE

DCOM- 20230803

LR - 20230804

IS - 1541-3527 (Electronic)

IS - 0091-2174 (Print)

IS - 0091-2174 (Linking)

VI - 58

IP - 5

DP - 2023 Sep

TI - Genetic origins of schizophrenia, child maltreatment in Kurdistan (Iran), coping

strategies in psoriasis patients, problematic benzodiazepine use, and COVID-19

pandemic effects on pregnant women, older adults with psychiatric illness, and

physician training.

PG - 423-425

LID - 10.1177/00912174231191051 [doi]

LID - 00912174231191051

FAU - Koenig, Harold G

AU - Koenig HG

AD - Professor of Psychiatry & Behavioral Sciences.

AD - Associate Professor of Medicine.

AD - Duke University Medical Center, Durham, North Carolina.

AD - Adjunct Professor, Department of Medicine, King Abdulaziz University, Jeddah,

Saudi Arabia.

AD - Visiting Professor, Department of Psychiatry, Shiraz University of Medical

Sciences, Iran.

AD - Editor-in-Chief, International Journal of Psychiatry in Medicine.

LA - eng

PT - Editorial

DEP - 20230718

PL - United States

TA - Int J Psychiatry Med

JT - International journal of psychiatry in medicine

JID - 0365646

RN - 12794-10-4 (Benzodiazepines)

SB - IM

MH - Child

MH - Humans

MH - Female

MH - Pregnancy

MH - Aged

MH - Pregnant Women

MH - *COVID-19

MH - Iran

MH - *Schizophrenia/drug therapy

MH - Benzodiazepines

MH - Pandemics

MH - Adaptation, Psychological

MH - *Mental Disorders

MH - *Child Abuse/psychology

MH - *Psoriasis

PMC - PMC10354540

EDAT- 2023/07/18 13:07

MHDA- 2023/08/03 06:42

CRDT- 2023/07/18 07:33

PHST- 2023/08/03 06:42 [medline]

PHST- 2023/07/18 13:07 [pubmed]

PHST- 2023/07/18 07:33 [entrez]

AID - 10.1177_00912174231191051 [pii]

AID - 10.1177/00912174231191051 [doi]

PST - ppublish

SO - Int J Psychiatry Med. 2023 Sep;58(5):423-425. doi: 10.1177/00912174231191051.

Epub 2023 Jul 18.

PMID- 37453406

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230829

IS - 1873-7943 (Electronic)

IS - 0005-7916 (Linking)

VI - 81

DP - 2023 Dec

TI - Metacognitive monitoring in schizotypy: Systematic literature review and new

empirical data.

PG - 101891

LID - S0005-7916(23)00058-7 [pii]

LID - 10.1016/j.jbtep.2023.101891 [doi]

AB - BACKGROUND AND OBJECTIVES: Deficits in metacognition, the ability to monitor

one's own mental states, are key elements of the functional pathology of

schizophrenia spectrum disorders. Little is known, however, about the integrity

of metacognitive processes in subclinical schizotypy. The purpose of the present

investigation was two-fold: First, we conducted a preregistered, systematic

literature review to synthesize previous research efforts on the role of

metacognition in schizotypy. Second, we investigated the relationship between

self-reported dimensions of schizotypy and psychometric as well as behavioral

measures of metacognition in a preregistered online study. METHODS: A large

sample (N = 330) completed a questionnaire battery and an episodic memory

experiment; task-based metacognition was tapped via trial-by-trial confidence

ratings. RESULTS: In keeping with findings from our literature review, higher

schizotypy was associated with diminished introspective insight and an overly

self-referential and maladaptive metacognitive style in metacognition

questionnaires. Importantly, low task-based metacognitive efficiency was

predictive of high levels of cognitive disorganization, whereas task-related

overconfidence (i.e., increased metacognitive bias) was linked with positive

schizotypy. LIMITATIONS: Due to the comparatively small number of k = 20 studies

meeting our inclusion criteria, the systematic literature review provides only

preliminary indications for potential conclusions. Furthermore, control over

potential disturbing influences in the experimental study was limited due to its

online format. CONCLUSIONS: Overall, we provide evidence for specific

metacognitive deficits in schizotypy and discuss a potential continuity of

preserved and impaired aspects of metacognitive monitoring along the psychosis

continuum.

FAU - Lehmann, Mirko

AU - Lehmann M

AD - Department of Psychology, University of Bonn, Kaiser-Karl-Ring 9, 53111, Bonn,

NRW, Germany. Electronic address: mirko_lehmann@uni-bonn.de.

FAU - Ettinger, Ulrich

AU - Ettinger U

AD - Department of Psychology, University of Bonn, Kaiser-Karl-Ring 9, 53111, Bonn,

NRW, Germany. Electronic address: ulrich.ettinger@uni-bonn.de.

LA - eng

PT - Journal Article

PT - Systematic Review

DEP - 20230708

PL - Netherlands

TA - J Behav Ther Exp Psychiatry

JT - Journal of behavior therapy and experimental psychiatry

JID - 0245075

SB - IM

MH - Humans

MH - *Metacognition

MH - *Schizotypal Personality Disorder

MH - *Psychotic Disorders/psychology

MH - *Schizophrenia

OTO - NOTNLM

OT - Confidence

OT - Metacognition

OT - Psychopathology

OT - Psychosis

OT - Schizophrenia

OT - Self-monitoring

COIS- Declaration of competing interest None.

EDAT- 2023/07/16 01:06

MHDA- 2023/08/28 06:42

CRDT- 2023/07/15 18:10

PHST- 2022/11/14 00:00 [received]

PHST- 2023/06/21 00:00 [revised]

PHST- 2023/06/25 00:00 [accepted]

PHST- 2023/08/28 06:42 [medline]

PHST- 2023/07/16 01:06 [pubmed]

PHST- 2023/07/15 18:10 [entrez]

AID - S0005-7916(23)00058-7 [pii]

AID - 10.1016/j.jbtep.2023.101891 [doi]

PST - ppublish

SO - J Behav Ther Exp Psychiatry. 2023 Dec;81:101891. doi:

10.1016/j.jbtep.2023.101891. Epub 2023 Jul 8.

PMID- 37451595

OWN - NLM

STAT- MEDLINE

DCOM- 20230907

LR - 20230929

IS - 1878-4216 (Electronic)

IS - 0278-5846 (Linking)

VI - 127

DP - 2023 Dec 20

TI - The mitochondria in schizophrenia with 22q11.2 deletion syndrome: From

pathogenesis to therapeutic promise of targeted natural drugs.

PG - 110831

LID - S0278-5846(23)00117-3 [pii]

LID - 10.1016/j.pnpbp.2023.110831 [doi]

AB - Schizophrenia is a complex multi-factor neurological disorder that caused an

array of severe indelible consequences to the individuals and society.

Additionally, anti-schizophrenic drugs are unsuitable for treating negative

symptoms and have more significant side effects and drug resistance. For better

treatment and prevention, we consider exploring the pathogenesis of schizophrenia

from other perspectives. A growing body of evidence of 22q11.2 deletion syndrome

(22q11DS) suggested that the occurrence and progression of schizophrenia are

related to mitochondrial dysfunction. So combing through the literature of

22q11DS published from 2000 to 2023, this paper reviews the mechanism of

schizophrenia based on mitochondrial dysfunction, and it focuses on the natural

drugs targeting mitochondria to enhance mitochondrial function, which are

potential to improve the current treatment of schizophrenia.

FAU - Xiong, Zongxiang

AU - Xiong Z

AD - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

FAU - Wang, Heting

AU - Wang H

AD - Department of Traditional Chinese Medicine, Sichuan Provincial People's Hospital,

University of Electronic Science and Technology of China, Chengdu, China.

FAU - Qu, Yutian

AU - Qu Y

AD - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,

Chengdu, China.

FAU - Peng, Sihan

AU - Peng S

AD - Hospital of Chengdu University of Traditional Chinese Medicine, TCM Regulating

Metabolic Diseases Key Laboratory of Sichuan Province, Chengdu, China.

FAU - He, Yuchi

AU - He Y

AD - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,

Chengdu, China.

FAU - Yang, Qingyan

AU - Yang Q

AD - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,

Chengdu, China.

FAU - Xu, Xinyue

AU - Xu X

AD - School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,

Chengdu, China.

FAU - Lv, De

AU - Lv D

AD - Hospital of Chengdu University of Traditional Chinese Medicine, TCM Regulating

Metabolic Diseases Key Laboratory of Sichuan Province, Chengdu, China.

FAU - Liu, Ya

AU - Liu Y

AD - Hospital of Chengdu University of Traditional Chinese Medicine, TCM Regulating

Metabolic Diseases Key Laboratory of Sichuan Province, Chengdu, China.

FAU - Xie, Chunguang

AU - Xie C

AD - Hospital of Chengdu University of Traditional Chinese Medicine, TCM Regulating

Metabolic Diseases Key Laboratory of Sichuan Province, Chengdu, China.

FAU - Zhang, Xiyu

AU - Zhang X

AD - Hospital of Chengdu University of Traditional Chinese Medicine, TCM Regulating

Metabolic Diseases Key Laboratory of Sichuan Province, Chengdu, China. Electronic

address: zhangxiyutcm@163.com.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230713

PL - England

TA - Prog Neuropsychopharmacol Biol Psychiatry

JT - Progress in neuro-psychopharmacology & biological psychiatry

JID - 8211617

SB - IM

MH - Humans

MH - *Schizophrenia

MH - *DiGeorge Syndrome/pathology

MH - Mitochondria/pathology

OTO - NOTNLM

OT - 22q11DS

OT - Mitochondria

OT - Schizophrenia

OT - Targeted natural drugs

COIS- Declaration of Competing Interest The authors declare that the research was

conducted in the absence of any commercial or financial relationships that could

be construed as a potential conflict of interest.

EDAT- 2023/07/15 10:42

MHDA- 2023/09/07 06:42

CRDT- 2023/07/14 19:28

PHST- 2023/03/02 00:00 [received]

PHST- 2023/05/30 00:00 [revised]

PHST- 2023/07/11 00:00 [accepted]

PHST- 2023/09/07 06:42 [medline]

PHST- 2023/07/15 10:42 [pubmed]

PHST- 2023/07/14 19:28 [entrez]

AID - S0278-5846(23)00117-3 [pii]

AID - 10.1016/j.pnpbp.2023.110831 [doi]

PST - ppublish

SO - Prog Neuropsychopharmacol Biol Psychiatry. 2023 Dec 20;127:110831. doi:

10.1016/j.pnpbp.2023.110831. Epub 2023 Jul 13.

PMID- 37442999

OWN - NLM

STAT- MEDLINE

DCOM- 20230717

LR - 20230718

IS - 1471-244X (Electronic)

IS - 1471-244X (Linking)

VI - 23

IP - 1

DP - 2023 Jul 13

TI - Hopefulness among individuals living with schizophrenia and their caregivers in

Tanzania: an actor-partner interdependence model.

PG - 508

LID - 10.1186/s12888-023-04990-8 [doi]

LID - 508

AB - BACKGROUND: Hopefulness is a positive orientation or state of mind that can aid

in the recovery and treatment of mental illness, as it can have significant

impacts on clinical and psychosocial outcomes. As resource-constrained settings

work to implement recovery-oriented care, there is a need to better understand

hopefulness among people living with schizophrenia (PLWS) and caregivers in their

extended family networks. This study seeks to examine the dyadic relationship of

hopefulness and its associated correlates among PLWS attending outpatient

psychiatric clinics and their caregivers in Tanzania. METHODS: This study

utilized baseline and immediate post-intervention data collected as part of a

randomized controlled trial testing a culturally tailored model of Family

Psychoeducation, KUPAA, in Tanzania. The Herth Hope Index was used to measure

hopefulness among PLWS (n = 33) and their caregivers (n = 33) at baseline and

immediate post-intervention. Univariable and multivariable regression models were

conducted to determine correlates of hopefulness at baseline, while the

Actor-Partner Interdependence Model (APIM) was employed to examine the

longitudinal, dyadic relationship of hopefulness among and between PLWS and their

caregivers. RESULTS: Better family functioning was associated with higher levels

of hopefulness in PLWS and their caregivers. Lower levels of stigma, lower

symptom severity, and lower disability were associated with higher levels of

hopefulness in PLWS. For PLWS and their caregivers, actor effects from the APIM

model were less than one (PLWS, [Formula: see text]; caregivers, [Formula: see

text]), indicating stability (within each person) in hopefulness over time.

Regarding partner effects, a caregiver's baseline hopefulness had a positive

effect on the hopefulness of their PLWS at follow-up ([Formula: see text]). This

indicates that higher caregiver hope at time 0 is associated with higher levels

of hope in PLWS at time 1. Baseline hopefulness levels for PLWS had a negative

effect on caregivers' hopefulness at follow-up ([Formula: see text]). This

suggests that higher hopefulness among PLWS at baseline is associated with lower

levels of hope in caregivers at follow-up. CONCLUSION: Hopefulness is important

to consider in family or caregiver-based treatments for PLWS because caregiver

hopefulness may influence improvements in hopefulness among PLWS over time.

Future studies should further explore the longitudinal dyadic relationship of

hopefulness for these populations, as hope is a non-pharmacological and

modifiable mechanism of change that is underutilized in care and treatment plans

for PLWS globally. TRIAL REGISTRATION: Clinical Trials #NCT04013932, July 10,

2019.

FAU - Martinez, Alyssa

AU - Martinez A

AD - Harvard Medical School, Department of Global Health & Social Medicine, Boston,

MA, USA.

FAU - Baumgartner, Joy Noel

AU - Baumgartner JN

AD - Duke Global Health Institute, Duke University, Durham, NC, USA.

AD - School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill,

NC, USA.

FAU - Kaaya, Sylvia

AU - Kaaya S

AD - School of Medicine, Muhimbili University of Health and Allied Sciences, Dar Es

Salaam, Tanzania.

FAU - Swai, Praxeda

AU - Swai P

AD - School of Medicine, Muhimbili University of Health and Allied Sciences, Dar Es

Salaam, Tanzania.

FAU - Lawala, Paul S

AU - Lawala PS

AD - Mirembe National Mental Health Hospital, Dodoma, Tanzania.

FAU - Thedai, Beatrice

AU - Thedai B

AD - Mbeya Zonal Referral Hospital, Mbeya, Tanzania.

FAU - Minja, Anna

AU - Minja A

AD - School of Medicine, Muhimbili University of Health and Allied Sciences, Dar Es

Salaam, Tanzania.

FAU - Headley, Jennifer

AU - Headley J

AD - Duke Global Health Institute, Duke University, Durham, NC, USA.

FAU - Egger, Joseph R

AU - Egger JR

AD - Duke Global Health Institute, Duke University, Durham, NC, USA.

joseph.egger@duke.edu.

LA - eng

SI - ClinicalTrials.gov/NCT04013932

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230713

PL - England

TA - BMC Psychiatry

JT - BMC psychiatry

JID - 100968559

SB - IM

MH - Humans

MH - *Caregivers/psychology

MH - *Schizophrenia/therapy

MH - Tanzania

MH - Surveys and Questionnaires

MH - Quality of Life/psychology

PMC - PMC10339619

OTO - NOTNLM

OT - Actor-partner interdependence model (APIM)

OT - Caregiving

OT - Hopefulness

OT - Psychotic disorders

OT - Schizophrenia

COIS- None.

EDAT- 2023/07/14 13:06

MHDA- 2023/07/17 06:42

CRDT- 2023/07/13 23:26

PHST- 2022/10/25 00:00 [received]

PHST- 2023/06/30 00:00 [accepted]

PHST- 2023/07/17 06:42 [medline]

PHST- 2023/07/14 13:06 [pubmed]

PHST- 2023/07/13 23:26 [entrez]

AID - 10.1186/s12888-023-04990-8 [pii]

AID - 4990 [pii]

AID - 10.1186/s12888-023-04990-8 [doi]

PST - epublish

SO - BMC Psychiatry. 2023 Jul 13;23(1):508. doi: 10.1186/s12888-023-04990-8.

PMID- 37433247

OWN - NLM

STAT- MEDLINE

DCOM- 20230719

LR - 20230720

IS - 1879-1379 (Electronic)

IS - 0022-3956 (Linking)

VI - 164

DP - 2023 Aug

TI - Aberrant brain structure in patients with schizophrenia and violence: A

meta-analysis.

PG - 447-453

LID - S0022-3956(23)00335-7 [pii]

LID - 10.1016/j.jpsychires.2023.06.036 [doi]

AB - Previous studies have indicated that schizophrenia is associated with an

increased risk of violence, which may constitute a public health concern, leading

to poor treatment outcomes and stigmatization of patients. Investigating brain

structural features of violence in schizophrenia could help us understand its

specific pathogenesis and find effective biomarkers. Our study aimed at

identifying reliable brain structural changes associated with violence in

patients with schizophrenia by conducting a meta-analysis and meta-regression of

magnetic resonance imaging studies. Specific brain changes in patients with

schizophrenia and violence (VSZ) were studied, compared with patients with

schizophrenia and violence (VSZ), patients with non-violent schizophrenia (NVSZ),

and individuals with a history of violence only and health controls. Primary

outcomes revealed that there was no significant difference of gray matter volume

between patients with VSZ and patient with NVSZ. Compared with controls, patients

with VSZ exhibited decreased gray matter volume in the insula, the superior

temporal gyrus (STG), the left inferior frontal gyrus, the left parahippocampus,

and the right putamen. Compared with individuals with a history of violence only,

patients with VSZ exhibited decreased volume in the right insula and the right

STG. Meta-regression analysis revealed a negative correlation between the

duration of schizophrenia and the volume of the right insula in patients with

VSZ. These findings may suggest a shared neurobiological basis for both violence

and psychiatric symptoms. The impaired frontotemporal-limbic network may serve as

a neurobiological basis for higher prevalence of violent behaviour in patients

with schizophrenia. However, it is important to note that these changes are not

unique to patients with VSZ. Further investigation is needed to explore the

neural mechanism that drive the interaction between violent behaviour and

specific aggression-related dimensions of schizophrenia.

FAU - Wang, Yong-Ming

AU - Wang YM

AD - School of Biology & Basic Medical Sciences, Medical College of Soochow

University, Suzhou, 215123, China.

FAU - Wang, Ying

AU - Wang Y

AD - School of Biology & Basic Medical Sciences, Medical College of Soochow

University, Suzhou, 215123, China.

FAU - Cao, Qun

AU - Cao Q

AD - Department of Bioengineering, University of Pittsburgh, 3700 O'Hara Street,

Pittsburgh, PA, 15261, USA.

FAU - Zhang, Meng

AU - Zhang M

AD - Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical

School, Beijing, 100096, China. Electronic address: me.zhang@pku.edu.cn.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

DEP - 20230706

PL - England

TA - J Psychiatr Res

JT - Journal of psychiatric research

JID - 0376331

SB - IM

MH - Humans

MH - *Schizophrenia/pathology

MH - Brain/diagnostic imaging/pathology

MH - Gray Matter/diagnostic imaging/pathology

MH - Cerebral Cortex/pathology

MH - Violence/psychology

MH - Magnetic Resonance Imaging/methods

OTO - NOTNLM

OT - Aggression

OT - Brain structure

OT - Gray matter volume

OT - Schizophrenia

OT - Violence

COIS- Declaration of competing interest Dr. YM Wang, Dr. Y Wang, Dr. Q Cao, Dr. M Zhang

have nothing to disclose relevant conflict of interest to the present work.

EDAT- 2023/07/11 19:12

MHDA- 2023/07/19 06:43

CRDT- 2023/07/11 18:00

PHST- 2022/12/20 00:00 [received]

PHST- 2023/05/16 00:00 [revised]

PHST- 2023/06/27 00:00 [accepted]

PHST- 2023/07/19 06:43 [medline]

PHST- 2023/07/11 19:12 [pubmed]

PHST- 2023/07/11 18:00 [entrez]

AID - S0022-3956(23)00335-7 [pii]

AID - 10.1016/j.jpsychires.2023.06.036 [doi]

PST - ppublish

SO - J Psychiatr Res. 2023 Aug;164:447-453. doi: 10.1016/j.jpsychires.2023.06.036.

Epub 2023 Jul 6.

PMID- 37431924

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230911

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 5

DP - 2023 Sep 7

TI - Pleiotropic CACNA1C Variants and Neuronal Function in Psychosis.

PG - 1095-1096

LID - 10.1093/schbul/sbad104 [doi]

FAU - Docherty, Anna R

AU - Docherty AR

AUID- ORCID: 0000-0001-7139-7007

AD - Department of Psychiatry, University of Utah School of Medicine, Salt Lake City,

UT, USA.

AD - Huntsman Mental Health Institute, Salt Lake City, UT, USA.

AD - Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral

Genetics, Virginia Commonwealth University, Richmond, VA, USA.

LA - eng

PT - Editorial

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

RN - 0 (Calcium Channels, L-Type)

RN - 0 (CACNA1C protein, human)

SB - IM

MH - Humans

MH - *Psychotic Disorders/genetics

MH - *Schizophrenia/genetics

MH - Calcium Channels, L-Type/genetics

MH - Polymorphism, Single Nucleotide

PMC - PMC10483443

EDAT- 2023/07/11 13:10

MHDA- 2023/09/08 06:42

PMCR- 2024/07/11

CRDT- 2023/07/11 08:03

PHST- 2024/07/11 00:00 [pmc-release]

PHST- 2023/09/08 06:42 [medline]

PHST- 2023/07/11 13:10 [pubmed]

PHST- 2023/07/11 08:03 [entrez]

AID - 7222584 [pii]

AID - sbad104 [pii]

AID - 10.1093/schbul/sbad104 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Sep 7;49(5):1095-1096. doi: 10.1093/schbul/sbad104.

PMID- 37429186

OWN - NLM

STAT- MEDLINE

DCOM- 20230719

LR - 20230720

IS - 1879-1379 (Electronic)

IS - 0022-3956 (Linking)

VI - 164

DP - 2023 Aug

TI - Short- and long-term changes in symptom dimensions among patients with

schizophrenia spectrum disorders and different durations of illness: A

meta-analysis.

PG - 416-439

LID - S0022-3956(23)00328-X [pii]

LID - 10.1016/j.jpsychires.2023.06.031 [doi]

AB - In schizophrenia spectrum disorders, improvement in symptoms varies between

patients with short and long durations of illness. In this meta-analysis we

provided an overview of both short- and long-term symptomatic improvement for

patients with schizophrenia spectrum disorders with distinct durations of

illness. We included 82 longitudinal studies assessing the course of positive,

negative, depressive and disorganization symptoms. We analyzed effect sizes of

change in four subgroups based on durations of illness at baseline: <2 years, 2-5

years, 5-10 years, >10 years. Potential moderators were explored using

meta-regression and sensitivity analyses. Overall, we found large improvements of

positive symptoms and small improvements of negative, depressive, and

disorganization symptoms. Positive and disorganization symptoms improved

relatively stronger for patients earlier in the course of illness, whereas

negative and depressive symptoms showed modest improvement regardless of duration

of illness. Improvement of symptoms was associated with higher baseline severity

of positive symptoms, a younger age, a smaller subsample with schizophrenia, and,

specifically for negative symptoms, higher baseline severity of depressive

symptoms. Future research should focus on exploring ways to optimize improvement

in negative and depressive symptoms for patients with schizophrenia spectrum

disorders.

FAU - de Winter, Lars

AU - de Winter L

AD - Phrenos Center of Expertise, Utrecht, the Netherlands; Department of Psychiatry,

Amsterdam UMC Location AMC, Amsterdam, the Netherlands. Electronic address:

Lwinter@kcphrenos.nl.

FAU - Vermeulen, Jentien M

AU - Vermeulen JM

AD - Department of Psychiatry, Amsterdam UMC Location AMC, Amsterdam, the Netherlands.

FAU - Couwenbergh, Chrisje

AU - Couwenbergh C

AD - Phrenos Center of Expertise, Utrecht, the Netherlands.

FAU - van Weeghel, Jaap

AU - van Weeghel J

AD - Phrenos Center of Expertise, Utrecht, the Netherlands; Tranzo, Tilburg

University, Tilburg, the Netherlands.

FAU - Hasson-Ohayon, Ilanit

AU - Hasson-Ohayon I

AD - Department of Psychology, Bar-Ilan University, Ramat-Gan, Israel.

FAU - Mulder, Cornelis L

AU - Mulder CL

AD - Epidemiological and Social Psychiatric Research Institute, Erasmus MC, Rotterdam,

the Netherlands; Parnassia Psychiatric Institute, the Netherlands.

FAU - Boonstra, Nynke

AU - Boonstra N

AD - NHL Stenden University of Applied Science, Leeuwarden, the Netherlands; Utrecht

University Medical Center, Utrecht, the Netherlands.

FAU - Veling, Wim

AU - Veling W

AD - University of Groningen, University Medical Center Groningen, Groningen, the

Netherlands.

FAU - de Haan, Lieuwe

AU - de Haan L

AD - Department of Psychiatry, Amsterdam UMC Location AMC, Amsterdam, the Netherlands.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Review

DEP - 20230704

PL - England

TA - J Psychiatr Res

JT - Journal of psychiatric research

JID - 0376331

SB - IM

MH - Humans

MH - *Schizophrenia/complications/diagnosis

MH - Longitudinal Studies

MH - *Psychotic Disorders/diagnosis

OTO - NOTNLM

OT - Course

OT - Epidemiology

OT - Longitudinal

OT - Meta-analysis

OT - Psychosis

OT - Schizophrenia spectrum disorders

OT - Symptoms

COIS- Declaration of competing interest All authors declare no financial relationships

with commercial interest

EDAT- 2023/07/11 01:08

MHDA- 2023/07/19 06:43

CRDT- 2023/07/10 18:07

PHST- 2022/12/06 00:00 [received]

PHST- 2023/05/29 00:00 [revised]

PHST- 2023/06/23 00:00 [accepted]

PHST- 2023/07/19 06:43 [medline]

PHST- 2023/07/11 01:08 [pubmed]

PHST- 2023/07/10 18:07 [entrez]

AID - S0022-3956(23)00328-X [pii]

AID - 10.1016/j.jpsychires.2023.06.031 [doi]

PST - ppublish

SO - J Psychiatr Res. 2023 Aug;164:416-439. doi: 10.1016/j.jpsychires.2023.06.031.

Epub 2023 Jul 4.

PMID- 37428030

OWN - NLM

STAT- MEDLINE

DCOM- 20230712

LR - 20230930

IS - 1555-2101 (Electronic)

IS - 0160-6689 (Linking)

VI - 84

IP - 4

DP - 2023 Jul 5

TI - Differential Effects of an Intervention to Reduce Cardiovascular Risk for

Patients With Bipolar Disorder, Schizoaffective Disorder, or Schizophrenia: A

Randomized Clinical Trial.

LID - 22m14710 [pii]

LID - 10.4088/JCP.22m14710 [doi]

AB - Objective: To measure the impact of a clinical decision support (CDS) tool on

total modifiable cardiovascular risk at 12 months separately for outpatients with

3 subtypes of serious mental illness (SMI) identified via ICD-9 and ICD-10 codes:

bipolar disorder, schizoaffective disorder, and schizophrenia. Methods: This

cluster-randomized pragmatic clinical trial was active from March 2016 to

September 2018; data were analyzed from April 2021 to September 2022. Clinicians

and patients from 78 primary care clinics participated. All 8,922 adult patients

aged 18-75 years with diagnosed SMI, at least 1 cardiovascular risk factor not at

goal, and an index and follow-up visit during the study period were included. The

CDS tool provided a summary of modifiable cardiovascular risk and personalized

treatment recommendations. Results: Intervention patients had 4% relative

reduction in total modifiable cardiovascular risk at 12 months compared to

controls (relative risk ratio = 0.96; 95% CI, 0.94 to 0.98), with similar

intervention benefits for all 3 SMI subtypes. At index, 10-year cardiovascular

risk was higher for patients with schizophrenia (mean [SD] = 11.3% [9.2%]) than

for patients with bipolar disorder (8.5% [8.9%]) or schizoaffective disorder

(9.4% [8.1%]), while 30-year cardiovascular risk was highest for patients with

schizoaffective disorder (44% with 2 or more major cardiovascular risk factors,

compared to 40% for patients with schizophrenia and 37% for patients with bipolar

disorder). Smoking was highly prevalent (47%), and mean (SD) BMI was 32.7 (7.9).

Conclusions: This CDS intervention produced a clinically and statistically

significant 4% relative reduction in total modifiable cardiovascular risk for

intervention patients versus controls at 12 months, an effect observed across all

3 SMI subtypes and attributable to the aggregate impact of small changes in

multiple cardiovascular risk factors. Trial Registration: ClinicalTrials.gov

Identifier: NCT02451670.

FAU - Rossom, Rebecca C

AU - Rossom RC

AD - HealthPartners Institute, Minneapolis, Minnesota (Rossom, Crain, Sperl-Hillen,

Hooker, Miley, O'Connor).

FAU - Crain, A Lauren

AU - Crain AL

AD - HealthPartners Institute, Minneapolis, Minnesota (Rossom, Crain, Sperl-Hillen,

Hooker, Miley, O'Connor).

FAU - Waring, Stephen

AU - Waring S

AD - Essentia Health, Duluth, Minnesota (Waring).

FAU - Sperl-Hillen, JoAnn M

AU - Sperl-Hillen JM

AD - HealthPartners Institute, Minneapolis, Minnesota (Rossom, Crain, Sperl-Hillen,

Hooker, Miley, O'Connor).

FAU - Hooker, Stephanie A

AU - Hooker SA

AD - HealthPartners Institute, Minneapolis, Minnesota (Rossom, Crain, Sperl-Hillen,

Hooker, Miley, O'Connor).

FAU - Miley, Kathleen

AU - Miley K

AD - HealthPartners Institute, Minneapolis, Minnesota (Rossom, Crain, Sperl-Hillen,

Hooker, Miley, O'Connor).

FAU - O'Connor, Patrick J

AU - O'Connor PJ

AD - HealthPartners Institute, Minneapolis, Minnesota (Rossom, Crain, Sperl-Hillen,

Hooker, Miley, O'Connor).

LA - eng

SI - ClinicalTrials.gov/NCT02451670

GR - U19 MH092201/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

DEP - 20230705

PL - United States

TA - J Clin Psychiatry

JT - The Journal of clinical psychiatry

JID - 7801243

SB - IM

MH - Adult

MH - Humans

MH - *Schizophrenia/drug therapy

MH - *Bipolar Disorder/psychology

MH - *Cardiovascular Diseases/epidemiology/prevention & control

MH - Risk Factors

MH - *Psychotic Disorders/drug therapy

MH - Heart Disease Risk Factors

EDAT- 2023/07/10 13:06

MHDA- 2023/07/12 06:42

CRDT- 2023/07/10 10:04

PHST- 2023/07/12 06:42 [medline]

PHST- 2023/07/10 13:06 [pubmed]

PHST- 2023/07/10 10:04 [entrez]

AID - 22m14710 [pii]

AID - 10.4088/JCP.22m14710 [doi]

PST - epublish

SO - J Clin Psychiatry. 2023 Jul 5;84(4):22m14710. doi: 10.4088/JCP.22m14710.

PMID- 37424202

OWN - NLM

STAT- MEDLINE

DCOM- 20230711

LR - 20230718

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Linking)

VI - 223

IP - 1

DP - 2023 Jul

TI - A new era for the negative symptoms of schizophrenia.

PG - 269-270

LID - 10.1192/bjp.2023.69 [doi]

AB - Negative symptoms remain one of the major unmet needs for people with

schizophrenia, and the past decade has witnessed a surge in interest in negative

symptoms. In this themed issue, we present new concepts of negative symptoms and

recent findings on their epidemiology and pathophysiology and on therapeutic

options for their management.

FAU - Fernandez-Egea, Emilio

AU - Fernandez-Egea E

AUID- ORCID: 0000-0003-4128-8955

AD - Cambridgeshire and Peterborough NHS Foundation Trust, Fulbourn Hospital,

Cambridge, UK; and Department of Psychiatry, University of Cambridge, Cambridge,

UK.

FAU - Mucci, Armida

AU - Mucci A

AD - Department of Mental and Physical Health and Preventative Medicine, University of

Campania Luigi Vanvitelli, Caserta, Italy.

FAU - Lee, Jimmy

AU - Lee J

AUID- ORCID: 0000-0002-7724-7445

AD - Department of Psychosis, Institute of Mental Health, Singapore; and Lee Kong

Chian School of Medicine, Nanyang Technological University, Singapore.

FAU - Kirkpatrick, Brian

AU - Kirkpatrick B

AUID- ORCID: 0009-0006-8657-8330

AD - Psychiatric Research Institute, University of Arkansas for Medical Sciences,

Little Rock, Arizona, USA.

LA - eng

GR - MR/W029987/1/MRC_/Medical Research Council/United Kingdom

GR - BRC-1215-20014/DH_/Department of Health/United Kingdom

PT - Editorial

PT - Research Support, Non-U.S. Gov't

DEP - 20230710

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

MH - Humans

MH - *Schizophrenia/diagnosis/epidemiology/therapy

MH - Anhedonia/physiology

MH - Schizophrenic Psychology

OTO - NOTNLM

OT - Motivation

OT - alogia

OT - anhedonia

OT - emotion

EDAT- 2023/07/10 06:42

MHDA- 2023/07/11 06:42

CRDT- 2023/07/10 02:13

PHST- 2023/07/11 06:42 [medline]

PHST- 2023/07/10 06:42 [pubmed]

PHST- 2023/07/10 02:13 [entrez]

AID - S0007125023000697 [pii]

AID - 10.1192/bjp.2023.69 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jul;223(1):269-270. doi: 10.1192/bjp.2023.69. Epub 2023 Jul

10.

PMID- 37424200

OWN - NLM

STAT- MEDLINE

DCOM- 20230711

LR - 20230718

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Print)

IS - 0007-1250 (Linking)

VI - 223

IP - 1

DP - 2023 Jul

TI - Negative symptoms in the clinic: we treat what we can describe.

PG - 271-272

LID - 10.1192/bjp.2023.68 [doi]

AB - Recent research has led to important changes in the concepts and assessment of

negative symptoms in schizophrenia. We review current negative symptom concepts

and their clinical implications, as well as new methods of assessing these

symptoms. These changes hold promise for improving our understanding and

treatment of negative symptoms.

FAU - Kirkpatrick, Brian

AU - Kirkpatrick B

AUID- ORCID: 0009-0006-8657-8330

AD - Psychiatric Research Institute, University of Arkansas for Medical Sciences,

Little Rock, Arizona, USA.

FAU - Luther, Lauren

AU - Luther L

AD - Department of Psychology, University of Georgia, Athens, Georgia, USA.

FAU - Strauss, Gregory P

AU - Strauss GP

AUID- ORCID: 0000-0002-7218-5169

AD - Department of Psychology, University of Georgia, Athens, Georgia, USA.

LA - eng

GR - R21 MH122863/MH/NIMH NIH HHS/United States

GR - R61 MH121560/MH/NIMH NIH HHS/United States

GR - R21 MH112925/MH/NIMH NIH HHS/United States

GR - R01 MH120092/MH/NIMH NIH HHS/United States

GR - R01 MH116039/MH/NIMH NIH HHS/United States

PT - Comment

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Review

DEP - 20230710

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

CON - Br J Psychiatry. 2023 Jul;223(1):273-279. PMID: 36601754

MH - Humans

MH - Psychiatric Status Rating Scales

MH - *Schizophrenic Psychology

MH - *Schizophrenia/diagnosis/therapy

MH - Psychometrics

PMC - PMC10348465

MID - NIHMS1900671

OTO - NOTNLM

OT - Negative symptoms

OT - assessment

OT - factor analysis

OT - psychometrics

OT - schizophrenia

COIS- G.P.S. and B.K. are original developers of the Brief Negative Symptom Scale

(BNSS) and receive royalties and consultation fees from Medavante-ProPhase in

connection with commercial use of the BNSS and other professional activities;

these fees are donated to the Brain and Behavior Research Foundation. G.P.S. and

B.K. are also part owners and co-founders of Quantic Innovations, which provides

digital phenotyping data collection, analysis, and interpretation and has

contracts with Karuna and Sunovion. B.K. has received honoraria and travel

support from ProPhase LLC for training pharmaceutical company raters on the BNSS,

consulting fees and travel support from Genentech/Roche, Minerva Neurosciences,

Lundbeck, Acadia, Karuna, Otsuka and Medavante-ProPhase, consulting fees from

anonymized pharmaceutical companies and investors through Decision Resources,

Inc., and Guideposts, and from Wockhardt Bio AG for consulting on a legal issue.

G.P.S. has consulted for Minerva Neurosciences, Acadia, Otsuka, Sunovion,

Boeringher-Ingelheim, Karuna, and Lundbeck. L.L. has no conflicts to report.

EDAT- 2023/07/10 06:42

MHDA- 2023/07/11 06:41

PMCR- 2024/01/10

CRDT- 2023/07/10 02:13

PHST- 2024/01/10 00:00 [pmc-release]

PHST- 2023/07/11 06:41 [medline]

PHST- 2023/07/10 06:42 [pubmed]

PHST- 2023/07/10 02:13 [entrez]

AID - S0007125023000685 [pii]

AID - 10.1192/bjp.2023.68 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jul;223(1):271-272. doi: 10.1192/bjp.2023.68. Epub 2023 Jul

10.

PMID- 37413782

OWN - NLM

STAT- MEDLINE

DCOM- 20230719

LR - 20230720

IS - 1879-1379 (Electronic)

IS - 0022-3956 (Linking)

VI - 164

DP - 2023 Aug

TI - Ribosome subunits are upregulated in brain samples of a subgroup of individuals

with schizophrenia: A systematic gene expression meta-analysis.

PG - 372-381

LID - S0022-3956(23)00311-4 [pii]

LID - 10.1016/j.jpsychires.2023.06.013 [doi]

AB - One of the new theories accounting for the underlying pathophysiology of

schizophrenia is excitation/inhibition imbalance. Interestingly, perturbation in

protein synthesis machinery as well as oxidative stress can lead to

excitation/inhibition imbalance. We thus performed a systematic meta-analysis of

the expression of 79 ribosome subunit genes and two oxidative-stress related

genes, HIF1A and NQO1, in brain samples of individuals with schizophrenia vs.

healthy controls. We integrated 12 gene expression datasets, following the PRISMA

guidelines (overall 511 samples, 253 schizophrenia and 258 controls). Five

ribosome subunit genes were significantly upregulated in a subgroup of the

patients with schizophrenia, while 24 (30%) showed a tendency for upregulation.

HIF1A and NQO1 were also found to be significantly upregulated. Moreover, HIF1A

and NQO1 showed positive correlation with the expression of the upregulated

ribosome subunit genes. Our results, together with previous findings, suggest a

possible role for altered mRNA translation in the pathogenesis of schizophrenia,

in association with markers of increased oxidative stress in a subgroup of

patients. Further studies should define whether the upregulation of ribosome

subunits result in altered mRNA translation, which proteins are modulated and how

it characterizes a subgroup of the patients with schizophrenia.

FAU - Mekiten, Ori

AU - Mekiten O

AD - Faculty of Medicine, Tel-Aviv University, Israel.

FAU - Yitzhaky, Assif

AU - Yitzhaky A

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

FAU - Gould, Nathaniel

AU - Gould N

AD - Sagol Department of Neurobiology, University of Haifa, Haifa, Israel.

FAU - Rosenblum, Kobi

AU - Rosenblum K

AD - Sagol Department of Neurobiology, University of Haifa, Haifa, Israel; Center for

Gene Manipulation in the Brain, University of Haifa, Haifa, Israel.

FAU - Hertzberg, Libi

AU - Hertzberg L

AD - Faculty of Medicine, Tel-Aviv University, Israel; Department of Physics of

Complex Systems, Weizmann Institute of Science, Rehovot, Israel; Shalvata Mental

Health Center, Israel. Electronic address: libi.hertzberg@gmail.com.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230630

PL - England

TA - J Psychiatr Res

JT - Journal of psychiatric research

JID - 0376331

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Brain/metabolism

MH - Gene Expression Profiling

MH - Ribosome Subunits/metabolism

MH - Gene Expression

OTO - NOTNLM

OT - Excitation/inhibition imbalance

OT - Gene expression

OT - Oxidative-stress

OT - RPL

OT - RPS

OT - Schizophrenia

COIS- Declaration of competing interest The authors certify that they have no

affiliations with or involvement in any organization or entity with any financial

interest or non-financial interest in the subject matter or materials discussed

in this manuscript

EDAT- 2023/07/07 01:05

MHDA- 2023/07/19 06:43

CRDT- 2023/07/06 18:03

PHST- 2023/01/13 00:00 [received]

PHST- 2023/06/05 00:00 [revised]

PHST- 2023/06/15 00:00 [accepted]

PHST- 2023/07/19 06:43 [medline]

PHST- 2023/07/07 01:05 [pubmed]

PHST- 2023/07/06 18:03 [entrez]

AID - S0022-3956(23)00311-4 [pii]

AID - 10.1016/j.jpsychires.2023.06.013 [doi]

PST - ppublish

SO - J Psychiatr Res. 2023 Aug;164:372-381. doi: 10.1016/j.jpsychires.2023.06.013.

Epub 2023 Jun 30.

PMID- 37403159

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1479-5876 (Electronic)

IS - 1479-5876 (Linking)

VI - 21

IP - 1

DP - 2023 Jul 4

TI - Efficacy of low-dose risperidone in combination with sertraline in first-episode

drug-naïve patients with schizophrenia: a randomized controlled open-label study.

PG - 432

LID - 10.1186/s12967-023-04272-7 [doi]

LID - 432

AB - OBJECTIVE: Despite advances in pharmacology, the treatment of schizophrenia (SZ)

remains a challenge due to relapse after antipsychotic discontinuation and

multiple adverse effects of antipsychotics. We hypothesized that a low dose of

risperidone in combination with sertraline would reduce serious adverse effects

without decreasing treatment response. This study aimed to examine the efficacy,

safety, and tolerability of low-dose risperidone combined with sertraline to

reduce risperidone dose and serious adverse effects in first-episode and

medication-naive (FEMN) SZ patients. METHODS: A total of 230 patients with FEMN

SZ were randomly assigned to receive low-dose risperidone in combination with

sertraline (RS group) or regular-dose risperidone (control group). The Positive

and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale (HAMD), and

Personal and Social Performance Scale (PSP) were assessed at baseline and the end

of the first, second, third, and sixth months. In addition, serum prolactin

levels and extrapyramidal symptoms were measured at baseline and follow-up.

RESULTS: Repeated measures ANCOVA showed significant interaction effects of

treatment by time on psychotic symptoms, as well as HAMD, PSP scores, prolactin

levels, and extrapyramidal symptoms (all p < 0.05). Compared with the control

group, the RS group had greater decreases in PANSS total score and its subscores

and HAMD score (all p < 0.01) and a greater increase in PSP total score

(p < 0.01). Notably, side effects were lower in the RS group relative to the

control group. Improvements in HAMD and PANSS total scores, changes in prolactin

levels and gender predicted improvements in PSP from baseline to month 6.

CONCLUSIONS: Our study suggests that low-dose risperidone in combination with

sertraline was more effective for psychotic symptoms and psychosocial

functioning, with significantly fewer adverse effects in patients with FEMN SZ.

TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT04076371.

FAU - Lang, Xiaoe

AU - Lang X

AD - Department of Psychiatry, First Hospital of Shanxi Medical University, Taiyuan,

China.

FAU - Xue, Mei

AU - Xue M

AD - Qingdao Mental Health Center, Qingdao, China.

FAU - Zang, Xiaocui

AU - Zang X

AD - Qingdao Mental Health Center, Qingdao, China.

FAU - Wu, Fengchun

AU - Wu F

AD - Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical

University, Guangzhou, China. 13580380071@163.com.

AD - Guangdong Engineering Technology Research Center for Translational Medicine of

Mental Disorders, Guangzhou, China. 13580380071@163.com.

FAU - Xiu, Meihong

AU - Xiu M

AD - Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan

Hospital, Beijing, China. xiumeihong97@163.com.

FAU - Zhang, Xiangyang

AU - Zhang X

AD - CAS Key Laboratory of Mental Health, Institute of Psychology, Beijing, China.

zhangxy@psych.ac.cn.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China. zhangxy@psych.ac.cn.

LA - eng

SI - ClinicalTrials.gov/NCT04076371

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230704

PL - England

TA - J Transl Med

JT - Journal of translational medicine

JID - 101190741

RN - L6UH7ZF8HC (Risperidone)

RN - QUC7NX6WMB (Sertraline)

RN - 9002-62-4 (Prolactin)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - Risperidone/therapeutic use

MH - *Schizophrenia/drug therapy/chemically induced

MH - Sertraline/therapeutic use

MH - Prolactin/therapeutic use

MH - *Antipsychotic Agents/adverse effects

MH - *Drug-Related Side Effects and Adverse Reactions

MH - Treatment Outcome

PMC - PMC10318661

OTO - NOTNLM

OT - Efficacy

OT - First-episode

OT - Risperidone

OT - Schizophrenia

OT - Sertraline

COIS- No competing interests was disclosed for each author.

EDAT- 2023/07/05 01:06

MHDA- 2023/07/06 06:42

CRDT- 2023/07/04 23:44

PHST- 2023/02/26 00:00 [received]

PHST- 2023/06/13 00:00 [accepted]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/07/05 01:06 [pubmed]

PHST- 2023/07/04 23:44 [entrez]

AID - 10.1186/s12967-023-04272-7 [pii]

AID - 4272 [pii]

AID - 10.1186/s12967-023-04272-7 [doi]

PST - epublish

SO - J Transl Med. 2023 Jul 4;21(1):432. doi: 10.1186/s12967-023-04272-7.

PMID- 37400227

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230706

IS - 2224-7041 (Electronic)

IS - 2078-9947 (Linking)

VI - 33

IP - 2

DP - 2023 Jun

TI - Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review.

PG - 44-64

LID - 10.12809/eaap2261 [doi]

AB - OBJECTIVE: Clozapine is a potent antipsychotic medication with a complex receptor

profile. It is reserved for treatment-resistant schizophrenia. We systematically

reviewed studies of non-psychosis symptoms of clozapine withdrawal. METHODS:

CINAHL, Medline, PsycINFO, PubMed, and the Cochrane Database of Systematic

Reviews were searched using the keywords 'clozapine,' and 'withdrawal,' or

'supersensitivity,' 'cessation,' 'rebound,' or 'discontinuation'. Studies related

to non-psychosis symptoms after clozapine withdrawal were included. RESULTS: Five

original studies and 63 case reports / series were included in analysis. In 195

patients included in the five original studies, approximately 20% experienced

non-psychosis symptoms following discontinuation of clozapine. In 89 patients in

four of the studies, 27 experienced cholinergic rebound, 13 exhibited

extrapyramidal symptoms (including tardive dyskinesia), and three had catatonia.

In 63 case reports / series included, 72 patients with non-psychosis symptoms

were reported, which were catatonia (n=30), dystonia or dyskinesia (n=17),

cholinergic rebound (n=11), serotonin syndrome (n=4), mania (n=3), insomnia

(n=3), neuroleptic malignant syndrome (NMS) [n=3, one of them had both catatonia

and NMS], and de novo obsessive compulsive symptoms (n=2). Restarting clozapine

appeared to be the most effective treatment. CONCLUSIONS: Non-psychosis symptoms

following clozapine withdrawal have important clinical implications. Clinicians

should be aware of the possible presentations of symptoms to ensure early

recognition and management. Further research is warranted to better characterise

the prevalence, risk factors, prognosis, and optimal drug dosing for each

withdrawal symptom.

FAU - Yee, B

AU - Yee B

AD - Department of Medicine, College of Medicine and Public Health, Flinders

University, Adelaide, South Australia, Australia.

FAU - Looi, J C L

AU - Looi JCL

AD - Academic Unit of Psychiatry and Addiction Medicine, The Australian National

University School of Medicine and Psychology, Canberra Hospital, Canberra,

Australian Capital Territory, Australia.

FAU - Agaciak, M

AU - Agaciak M

AD - Department of Medicine, College of Medicine and Public Health, Flinders

University, Adelaide, South Australia, Australia.

FAU - Allison, S

AU - Allison S

AD - Department of Medicine, College of Medicine and Public Health, Flinders

University, Adelaide, South Australia, Australia.

FAU - Chan, S K W

AU - Chan SKW

AD - Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong

Kong, Hong Kong SAR, China.

FAU - Bastiampillai, T

AU - Bastiampillai T

AD - Department of Medicine, College of Medicine and Public Health, Flinders

University, Adelaide, South Australia, Australia.

AD - Department of Psychiatry, Monash University, Melbourne, Victoria, Australia.

LA - eng

PT - Journal Article

PT - Systematic Review

PL - China

TA - East Asian Arch Psychiatry

JT - East Asian archives of psychiatry : official journal of the Hong Kong College of

Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan

qi kan

JID - 101536416

RN - 0 (Antipsychotic Agents)

RN - 0 (Cholinergic Agents)

RN - J60AR2IKIC (Clozapine)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - *Catatonia/chemically induced/complications/drug therapy

MH - Cholinergic Agents/therapeutic use

MH - *Clozapine/adverse effects

MH - *Schizophrenia/drug therapy/complications

MH - *Substance Withdrawal Syndrome/etiology/diagnosis

OTO - NOTNLM

OT - Catatonia

OT - Clozapine

OT - Dyskinesias

OT - Dystonia

OT - Serotonin syndrome

OT - Substance withdrawal syndrome

COIS- As an editor of the journal, SKW Chan was not involved in the peer review

process. Other authors have disclosed no conflicts of interest.

EDAT- 2023/07/04 01:05

MHDA- 2023/07/05 06:42

CRDT- 2023/07/03 21:02

PHST- 2023/07/05 06:42 [medline]

PHST- 2023/07/04 01:05 [pubmed]

PHST- 2023/07/03 21:02 [entrez]

AID - 10.12809/eaap2261 [doi]

PST - ppublish

SO - East Asian Arch Psychiatry. 2023 Jun;33(2):44-64. doi: 10.12809/eaap2261.

PMID- 37399490

OWN - NLM

STAT- MEDLINE

DCOM- 20230915

LR - 20230920

IS - 2473-9537 (Electronic)

IS - 2473-9529 (Print)

IS - 2473-9529 (Linking)

VI - 7

IP - 18

DP - 2023 Sep 26

TI - Polygenic risk of major depressive disorder as a risk factor for venous

thromboembolism.

PG - 5341-5350

LID - 10.1182/bloodadvances.2023010562 [doi]

AB - Major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SCZ)

are associated with an increased risk of cardiovascular diseases, including

venous thromboembolism (VTE). The reasons for this are complex and include

obesity, smoking, and use of hormones and psychotropic medications. Genetic

studies have increasingly provided evidence of the shared genetic risk of

psychiatric and cardiometabolic illnesses. This study aimed to determine whether

a genetic predisposition to MDD, BD, or SCZ is associated with an increased risk

of VTE. Genetic correlations using the largest genome-wide genetic meta-analyses

summary statistics for MDD, BD, and SCZ (Psychiatric Genetics Consortium) and a

recent genome-wide genetic meta-analysis of VTE (INVENT Consortium) demonstrated

a positive association between VTE and MDD but not BD or SCZ. The same summary

statistics were used to construct polygenic risk scores for MDD, BD, and SCZ in

UK Biobank participants of self-reported White British ancestry. These were

assessed for impact on self-reported VTE risk (10 786 cases, 285 124 controls),

using logistic regression, in sex-specific and sex-combined analyses. We

identified significant positive associations between polygenic risk for MDD and

the risk of VTE in men, women, and sex-combined analyses, independent of the

known risk factors. Secondary analyses demonstrated that this association was not

driven by those with lifetime experience of mental illness. Meta-analyses of

individual data from 6 additional independent cohorts replicated the sex-combined

association. This report provides evidence for shared biological mechanisms

leading to MDD and VTE and suggests that, in the absence of genetic data, a

family history of MDD might be considered when assessing the risk of VTE.

under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

FAU - Ward, Joey

AU - Ward J

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

FAU - Le, Ngoc-Quynh

AU - Le NQ

AD - Genomics of Complex Disease Unit, Institut d'Investigació Biomèdica Sant Pau,

Barcelona, Spain.

FAU - Suryakant, Suryakant

AU - Suryakant S

AD - University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR

1219, Bordeaux, France.

FAU - Brody, Jennifer A

AU - Brody JA

AUID- ORCID: 0000-0001-8509-148X

AD - Cardiovascular Health Research Unit, Department of Medicine, University of

Washington, Seattle, WA.

FAU - Amouyel, Philippe

AU - Amouyel P

AUID- ORCID: 0000-0001-9088-234X

AD - University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille,

U1167-RID-AGE-Facteurs de Risque et Déterminants Moléculaires des Maladies Liées

au Vieillissement, Lille, France.

FAU - Boland, Anne

AU - Boland A

AUID- ORCID: 0000-0001-8789-5676

AD - Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine,

Evry, France.

AD - Laboratory of Excellence in Medical Genomics, GENMED, Evry, France.

FAU - Bown, Rosemary

AU - Bown R

AUID- ORCID: 0000-0002-1719-2761

AD - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow,

United Kingdom.

FAU - Cullen, Breda

AU - Cullen B

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

FAU - Debette, Stéphanie

AU - Debette S

AD - University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR

1219, Bordeaux, France.

FAU - Deleuze, Jean-François

AU - Deleuze JF

AD - Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine,

Evry, France.

AD - Laboratory of Excellence in Medical Genomics, GENMED, Evry, France.

AD - Centre d'Etude du Polymorphisme Humain, Fondation Jean Dausset, Paris, France.

FAU - Emmerich, Joseph

AU - Emmerich J

AD - Department of Vascular Medicine, Paris Saint-Joseph Hospital Group, University of

Paris, Paris, France.

AD - UMR1153, INSERM CRESS, Paris, France.

FAU - Graham, Nicholas

AU - Graham N

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

FAU - Germain, Marine

AU - Germain M

AD - University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR

1219, Bordeaux, France.

FAU - Anderson, Jana J

AU - Anderson JJ

AUID- ORCID: 0000-0001-7290-6635

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

FAU - Pell, Jill P

AU - Pell JP

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

FAU - Lyall, Donald M

AU - Lyall DM

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

FAU - Lyall, Laura M

AU - Lyall LM

AUID- ORCID: 0000-0001-7216-1434

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

AD - Laboratory of Excellence in Medical Genomics, GENMED, Evry, France.

FAU - Smith, Daniel J

AU - Smith DJ

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

AD - Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United

Kingdom.

FAU - Wiggins, Kerri L

AU - Wiggins KL

AUID- ORCID: 0000-0003-2749-1279

AD - Cardiovascular Health Research Unit, Department of Medicine, University of

Washington, Seattle, WA.

FAU - Soria, José Manuel

AU - Soria JM

AD - Genomics of Complex Disease Unit, Institut d'Investigació Biomèdica Sant Pau,

Barcelona, Spain.

FAU - Souto, Juan Carlos

AU - Souto JC

AD - Unitat d'Hemostàsia i Trombosi, Institut d'Investigació Biomèdica Sant Pau,

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

FAU - Morange, Pierre-Emmanuel

AU - Morange PE

AD - Aix-Marseille University, INSERM, INRAE, Centre de Recherche en CardioVasculaire

et Nutrition, Laboratory of Haematology, CRB Assistance Publique - Hôpitaux de

Marseille, HemoVasc, Marseille, France.

FAU - Smith, Nicholas L

AU - Smith NL

AD - Department of Epidemiology, University of Washington, Seattle, WA.

AD - Kaiser Permanente Washington Health Research Institute, Kaiser Permanente

Washington, Seattle, WA.

AD - Department of Veterans Affairs Office of Research and Development, Seattle

Epidemiologic Research and Information Center, Seattle, WA.

FAU - Trégouët, David-Alexandre

AU - Trégouët DA

AUID- ORCID: 0000-0001-9084-7800

AD - University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR

1219, Bordeaux, France.

FAU - Sabater-Lleal, Maria

AU - Sabater-Lleal M

AUID- ORCID: 0000-0002-0128-379X

AD - Genomics of Complex Disease Unit, Institut d'Investigació Biomèdica Sant Pau,

Barcelona, Spain.

AD - Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institute,

Stockholm, Sweden.

FAU - Strawbridge, Rona J

AU - Strawbridge RJ

AUID- ORCID: 0000-0001-8506-3585

AD - School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.

AD - Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institute,

Stockholm, Sweden.

AD - Health Data Research UK, Glasgow, United Kingdom.

LA - eng

GR - BHF_/British Heart Foundation/United Kingdom

GR - MC_PC_17217/MRC_/Medical Research Council/United Kingdom

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PL - United States

TA - Blood Adv

JT - Blood advances

JID - 101698425

SB - IM

MH - Male

MH - Humans

MH - Female

MH - *Depressive Disorder, Major/epidemiology/genetics/psychology

MH - *Venous Thromboembolism/etiology/genetics

MH - *Bipolar Disorder/genetics

MH - *Schizophrenia/genetics

MH - Risk Factors

PMC - PMC10506044

COIS- Conflict-of-interest disclosure: The authors declare no competing financial

interests.

EDAT- 2023/07/03 19:07

MHDA- 2023/09/15 06:42

CRDT- 2023/07/03 15:32

PHST- 2023/06/16 00:00 [accepted]

PHST- 2023/04/26 00:00 [received]

PHST- 2023/09/15 06:42 [medline]

PHST- 2023/07/03 19:07 [pubmed]

PHST- 2023/07/03 15:32 [entrez]

AID - 496693 [pii]

AID - 10.1182/bloodadvances.2023010562 [doi]

PST - ppublish

SO - Blood Adv. 2023 Sep 26;7(18):5341-5350. doi: 10.1182/bloodadvances.2023010562.

PMID- 37389803

OWN - NLM

STAT- MEDLINE

DCOM- 20230911

LR - 20230922

IS - 2194-1327 (Electronic)

IS - 0948-6259 (Print)

IS - 0948-6259 (Linking)

VI - 37

IP - 3

DP - 2023 Sep

TI - [Safety aspects during treatment with clozapine. : Monitoring and rechallenge - a

narrative review].

PG - 130-135

LID - 10.1007/s40211-023-00473-0 [doi]

AB - BACKGROUND: Due to its unique efficacy in treatment-resistant schizophrenia,

discontinuation of treatment with clozapine is frequently associated with

a significant worsening of symptoms, but also with an increased risk of suicide.

Based on the literature, this review aims at summarizing different monitoring

recommendations in order to be able to continue this therapy despite the

occurrence of side effects. In addition, we provide recommendations when

rechallenge of a previously stopped treatment with clozapine can be considered

and when a definite discontinuation must take place. MATERIAL AND METHODS:

Medline, the Guideline for the use of clozapine 2013 of the Netherlands Clozapine

Collaboration Group, and the S3 Guideline for Schizophrenia of the German

Association of Psychiatry, Psychotherapy and Psychosomatics were searched for

relevant literature, the last query dating from April 28th, 2023. RESULTS: If

agranulocytosis or cardiomyopathy develops, treatment with clozapine must be

discontinued and should not be resumed thereafter. In contrast, treatment with

clozapine which had to be discontinued due to myocarditis or prolongation of the

QTc interval may be continued if left ventricular function is normal or after

normalization of the QTc interval. Other side effects are usually not absolute

contraindications for rechallenge but often require the adjunctive use of

additional pharmacologic and non-pharmacologic measures. CONCLUSION: Taking into

consideration various monitoring recommendations, cessation of treatment with

clozapine can often be prevented or treatment with clozapine that has been

discontinued due to side effects can be resumed.

FAU - Berger, Stefan J

AU - Berger SJ

AD - Department für Psychiatrie, Psychotherapie, Psychosomatik und Medizinische

Psychologie, Univ.-Klinik für Psychiatrie I, Medizinische Universität Innsbruck,

Anichstr. 35, 6020, Innsbruck, Österreich.

FAU - Hofer, Alex

AU - Hofer A

AUID- ORCID: 0000-0002-5834-4258

AD - Department für Psychiatrie, Psychotherapie, Psychosomatik und Medizinische

Psychologie, Univ.-Klinik für Psychiatrie I, Medizinische Universität Innsbruck,

Anichstr. 35, 6020, Innsbruck, Österreich. a.hofer@i-med.ac.at.

LA - ger

PT - English Abstract

PT - Journal Article

PT - Review

TT - Sicherheitsaspekte bei der Behandlung mit Clozapin : Monitoring und Rechallenge –

eine narrative Übersicht.

DEP - 20230630

PL - Germany

TA - Neuropsychiatr

JT - Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der

Gesellschaft Osterreichischer Nervenarzte und Psychiater

JID - 9440588

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Clozapine/adverse effects

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - *Myocarditis/chemically induced/drug therapy/epidemiology

MH - Psychotherapy

PMC - PMC10491511

OTO - NOTNLM

OT - Clozapine

OT - Monitoring

OT - Rechallenge

EDAT- 2023/06/30 13:11

MHDA- 2023/09/11 06:42

CRDT- 2023/06/30 11:13

PHST- 2022/10/11 00:00 [received]

PHST- 2023/05/19 00:00 [accepted]

PHST- 2023/09/11 06:42 [medline]

PHST- 2023/06/30 13:11 [pubmed]

PHST- 2023/06/30 11:13 [entrez]

AID - 10.1007/s40211-023-00473-0 [pii]

AID - 473 [pii]

AID - 10.1007/s40211-023-00473-0 [doi]

PST - ppublish

SO - Neuropsychiatr. 2023 Sep;37(3):130-135. doi: 10.1007/s40211-023-00473-0. Epub

2023 Jun 30.

PMID- 37386572

OWN - NLM

STAT- MEDLINE

DCOM- 20230703

LR - 20230715

IS - 1472-6963 (Electronic)

IS - 1472-6963 (Linking)

VI - 23

IP - 1

DP - 2023 Jun 29

TI - Impact of Watson's human caring-based health promotion program on caregivers of

individuals with schizophrenia.

PG - 711

LID - 10.1186/s12913-023-09725-9 [doi]

LID - 711

AB - BACKGROUND: Caring for people with schizophrenia is accompanied by challenges

that impact caregiver health. We conducted this study to explore the effect of a

Caring Science-Based health promotion program on the sense of coherence and

well-being among caregivers of persons with schizophrenia. METHODS: This

randomized clinical trial with the Solomon four-group design was conducted on 72

caregivers randomly allocated into two intervention and two control groups. A

health promotion program based on Watson's theory was performed individually

through five face-to-face sessions and a four-week follow-up. Settings were the

psychiatric centers of the three educational, specialty, and subspecialty

Ibn-e-Sina, Moharary, and Hafez hospitals affiliated with Shiraz University of

Medical Sciences (SUMS), south of Iran. The data were collected using a

demographic information form, the Sense of Coherence Scale, and the Caregiver

Well-Being Scale. One-way ANOVA, chi-square, Kruskal-Wallis, and independent

t-test were used to determine the homogeneity at baseline. In the post-test,

multiple between-groups and pairwise comparisons were assessed by One-way ANOVA

and Tukey's post-hoc. Within-group comparisons were evaluated using paired

t-tests. All tests were two-tailed, and the statistical level was considered

0.05. RESULTS: Data analysis showed that the mean scores of caregiver sense of

coherence and well-being from pre-intervention to post-intervention were

significantly increased in the intervention groups (p < 0.001). At the same time,

there were no significant differences in the control groups. CONCLUSION: The

health promotion program based on Watson's human caring theory facilitated

ongoing intrapersonal, and holistic caring and improved the sense of coherence

and well-being in caregivers of persons with schizophrenia. Hence, this

intervention is recommended for developing healing care programs. TRIAL

REGISTRATION: https://www.irct.ir/trial/55040 : IRCT20111105008011N2

(11/04/2021).

FAU - Bagheri, Shahpar

AU - Bagheri S

AUID- ORCID: 0000-0003-4100-9901

AD - Student Research Committee, Community Based Psychiatric Care Research Center,

Department of Nursing, School of Nursing and Midwifery, Shiraz University of

Medical Sciences, Shiraz, Iran.

FAU - Zarshenas, Ladan

AU - Zarshenas L

AUID- ORCID: 0000-0002-8122-5126

AD - Department of Nursing, School of Nursing and Midwifery, Shiraz University of

Medical Sciences, Shiraz, Iran. zarshenas@sums.ac.ir.

FAU - Rakhshan, Mahnaz

AU - Rakhshan M

AUID- ORCID: 0000-0003-1687-5154

AD - Department of Nursing, School of Nursing and Midwifery, Shiraz University of

Medical Sciences, Shiraz, Iran.

FAU - Sharif, Farkhondeh

AU - Sharif F

AUID- ORCID: 0000-0003-0710-8770

AD - Department of Nursing, School of Nursing and Midwifery, Shiraz University of

Medical Sciences, Shiraz, Iran.

FAU - Sarani, Ebrahim Moghimi

AU - Sarani EM

AUID- ORCID: 0000-0003-0790-8022

AD - Department of Psychiatry, School of Medicine, Research Center for Psychiatry and

Behavior Science, Ibn-E-Sina Hospital, Shiraz University of Medical Sciences,

Shiraz, Iran.

FAU - Shirazi, Zahra Hadian

AU - Shirazi ZH

AUID- ORCID: 0000-0002-6432-8641

AD - Department of Nursing, School of Nursing and Midwifery, Shiraz University of

Medical Sciences, Shiraz, Iran.

FAU - Sitzman, Kathleen

AU - Sitzman K

AD - Distinguished Watson Caring Science Scholar, East Carolina University, College of

Nursing, Greenville, NC, USA.

LA - eng

GR - 18819/Research Vice-Chancellor of Shiraz University of Medical Sciences/

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230629

PL - England

TA - BMC Health Serv Res

JT - BMC health services research

JID - 101088677

SB - IM

EIN - BMC Health Serv Res. 2023 Jul 13;23(1):748. PMID: 37442978

MH - Humans

MH - *Schizophrenia/therapy

MH - Caregivers

MH - Health Promotion

MH - Analysis of Variance

MH - Control Groups

PMC - PMC10311737

OTO - NOTNLM

OT - Caregivers

OT - Health promotion

OT - Schizophrenia

OT - Sense of coherence

OT - Watson’s Human Caring Theory

OT - Well-being

COIS- The authors declare they have no competing interests.

EDAT- 2023/06/30 01:06

MHDA- 2023/07/03 06:41

CRDT- 2023/06/29 23:47

PHST- 2023/02/16 00:00 [received]

PHST- 2023/06/21 00:00 [accepted]

PHST- 2023/07/03 06:41 [medline]

PHST- 2023/06/30 01:06 [pubmed]

PHST- 2023/06/29 23:47 [entrez]

AID - 10.1186/s12913-023-09725-9 [pii]

AID - 9725 [pii]

AID - 10.1186/s12913-023-09725-9 [doi]

PST - epublish

SO - BMC Health Serv Res. 2023 Jun 29;23(1):711. doi: 10.1186/s12913-023-09725-9.

PMID- 37386462

OWN - NLM

STAT- MEDLINE

DCOM- 20230703

LR - 20230704

IS - 1471-244X (Electronic)

IS - 1471-244X (Linking)

VI - 23

IP - 1

DP - 2023 Jun 29

TI - Clinical insight among persons with schizophrenia spectrum disorders treated with

amisulpride, aripiprazole or olanzapine: a semi-randomised trial.

PG - 482

LID - 10.1186/s12888-023-04981-9 [doi]

LID - 482

AB - BACKGROUND: Antipsychotic treatment may improve clinical insight. However,

previous studies have reported inconclusive findings on whether antipsychotics

improve insight over and above the reduction in symptoms of psychosis. These

studies assessed homogeneous samples in terms of stage of illness. Randomised

studies investigating a mixed population of first- and multiepisode schizophrenia

spectrum disorders might clarify this disagreement. METHODS: Our data were

derived from a pragmatic, rater-blinded, semi-randomised trial that compared the

effectiveness of amisulpride, aripiprazole and olanzapine. A sample of 144

patients with first- or multiepisode schizophrenia spectrum disorders underwent

eight assessments during a 1-year follow-up. Clinical insight was assessed by

item General 12 from the Positive and Negative Syndrome Scale (PANSS). We

analysed latent growth curve models to test if the medications had a direct

effect on insight that was over and above the reduction in total psychosis

symptoms. Furthermore, we investigated whether there were differences between the

study drugs in terms of insight. RESULTS: Based on allocation analysis, all three

drugs were associated with a reduction in total psychosis symptoms in the initial

phase (weeks 0-6). Amisulpride and olanzapine were associated with improved

insight over and above what was related to the reduction in total psychosis

symptoms in the long-term phase (weeks 6-52). However, these differential effects

were lost when only including the participants that chose the first drug in the

randomisation sequence. We found no differential effect on insight among those

who were antipsychotic-naïve and those who were previously medicated with

antipsychotics. CONCLUSIONS: Our results suggest that antipsychotic treatment

improves insight, but whether the effect on insight surpasses the effect of

reduced total psychosis symptoms is more uncertain. TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT01446328, 05.10.2011.

FAU - Stabell, L A

AU - Stabell LA

AD - Division of Psychiatry and NORMENT Centre of Excellence, Haukeland University

Hospital, Bergen, Norway. lena.antonsen.stabell@helse-bergen.no.

AD - Department of Clinical Medicine, University of Bergen, Bergen, Norway.

lena.antonsen.stabell@helse-bergen.no.

AD - Research Department, Sandviken sykehus, Haukeland University Hospital, P. Box

1400, Bergen, 5021, Norway. lena.antonsen.stabell@helse-bergen.no.

FAU - Johnsen, E

AU - Johnsen E

AD - Division of Psychiatry and NORMENT Centre of Excellence, Haukeland University

Hospital, Bergen, Norway.

AD - Department of Clinical Medicine, University of Bergen, Bergen, Norway.

FAU - Kroken, R A

AU - Kroken RA

AD - Division of Psychiatry and NORMENT Centre of Excellence, Haukeland University

Hospital, Bergen, Norway.

AD - Department of Clinical Medicine, University of Bergen, Bergen, Norway.

FAU - Løberg, E M

AU - Løberg EM

AD - Division of Psychiatry and NORMENT Centre of Excellence, Haukeland University

Hospital, Bergen, Norway.

AD - Faculty of Psychology, Department of Clinical Psychology, University of Bergen,

Bergen, Norway.

FAU - Blindheim, A

AU - Blindheim A

AD - Division of Psychiatry and NORMENT Centre of Excellence, Haukeland University

Hospital, Bergen, Norway.

FAU - Joa, I

AU - Joa I

AD - Network for Clinical Research in psychosis, TIPS, Stavanger University Hospital,

Stavanger, Norway.

AD - Faculty of Health, Network for Medical Sciences, University of Stavanger,

Stavanger, Norway.

FAU - Reitan, S K

AU - Reitan SK

AD - Department of Mental Health, St. Olav University Hospital, Trondheim, Norway.

AD - Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian

University of Science and Technology, Trondheim, Norway.

FAU - Rettenbacher, M

AU - Rettenbacher M

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of

Innsbruck, Innrain 52, Innsbruck, Austria.

FAU - Munk-Jørgensen, P

AU - Munk-Jørgensen P

AD - Department of Psychiatry, University of Southern Denmark, Odense, Denmark.

FAU - Gjestad, R

AU - Gjestad R

AD - Division of Psychiatry and NORMENT Centre of Excellence, Haukeland University

Hospital, Bergen, Norway.

AD - Centre for Research and Education in Forensic psychiatry, Haukeland University

Hospital, Bergen, Norway.

LA - eng

SI - ClinicalTrials.gov/NCT01446328

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230629

PL - England

TA - BMC Psychiatry

JT - BMC psychiatry

JID - 100968559

RN - N7U69T4SZR (Olanzapine)

RN - 82VFR53I78 (Aripiprazole)

RN - 0 (Antipsychotic Agents)

RN - 8110R61I4U (Amisulpride)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy

MH - Olanzapine/therapeutic use

MH - Aripiprazole/therapeutic use

MH - *Antipsychotic Agents/therapeutic use

MH - Amisulpride/therapeutic use

PMC - PMC10311854

OTO - NOTNLM

OT - Antipsychotic-naïve

OT - Antipsychotics

OT - Effectiveness

OT - Insight

OT - Longitudinal

COIS- The authors declare no competing interests.

EDAT- 2023/06/30 01:06

MHDA- 2023/07/03 06:42

CRDT- 2023/06/29 23:41

PHST- 2023/01/17 00:00 [received]

PHST- 2023/06/22 00:00 [accepted]

PHST- 2023/07/03 06:42 [medline]

PHST- 2023/06/30 01:06 [pubmed]

PHST- 2023/06/29 23:41 [entrez]

AID - 10.1186/s12888-023-04981-9 [pii]

AID - 4981 [pii]

AID - 10.1186/s12888-023-04981-9 [doi]

PST - epublish

SO - BMC Psychiatry. 2023 Jun 29;23(1):482. doi: 10.1186/s12888-023-04981-9.

PMID- 37376644

OWN - NLM

STAT- MEDLINE

DCOM- 20230629

LR - 20230701

IS - 1999-4915 (Electronic)

IS - 1999-4915 (Linking)

VI - 15

IP - 6

DP - 2023 Jun 9

TI - Viral Infections and Schizophrenia: A Comprehensive Review.

LID - 10.3390/v15061345 [doi]

LID - 1345

AB - Schizophrenia is a complex mental disorder with multiple genetic and

environmental factors contributing to its pathogenesis. Viral infections have

been suggested to be one of the environmental factors associated with the

development of this disorder. We comprehensively review all relevant published

literature focusing on the relationship between schizophrenia and various viral

infections, such as influenza virus, herpes virus 1 and 2 (HSV-1 and HSV-2),

cytomegalovirus (CMV), Epstein-Barr virus (EBV), retrovirus, coronavirus, and

Borna virus. These viruses may interfere with the normal maturation of the brain

directly or through immune-induced mediators, such as cytokines, leading to the

onset of schizophrenia. Changes in the expression of critical genes and elevated

levels of inflammatory cytokines have been linked to virally-induced infections

and relevant immune activities in schizophrenia. Future research is necessary to

understand this relationship better and provide insight into the molecular

mechanisms underlying the pathophysiology of schizophrenia.

FAU - Kotsiri, Ioanna

AU - Kotsiri I

AD - Department of Internal Medicine, Asklipeion General Hospital, Voulas, 16673

Athens, Greece.

FAU - Resta, Panagiota

AU - Resta P

AD - Department of Biomedical Sciences, University of West Attica, 12243 Athens,

Greece.

AD - National AIDS Reference Centre of Southern Greece, Department of Public Health

Policy, University of West Attica, 11521 Athens, Greece.

FAU - Spyrantis, Alexandros

AU - Spyrantis A

AD - Department of Internal Medicine, Asklipeion General Hospital, Voulas, 16673

Athens, Greece.

FAU - Panotopoulos, Charalampos

AU - Panotopoulos C

AD - Department of Clinical Cardiology, General Hospital of Kalamata, 24100 Kalamata,

Greece.

FAU - Chaniotis, Dimitrios

AU - Chaniotis D

AUID- ORCID: 0000-0003-2313-1305

AD - Department of Biomedical Sciences, University of West Attica, 12243 Athens,

Greece.

FAU - Beloukas, Apostolos

AU - Beloukas A

AUID- ORCID: 0000-0001-5639-0528

AD - Department of Biomedical Sciences, University of West Attica, 12243 Athens,

Greece.

AD - National AIDS Reference Centre of Southern Greece, Department of Public Health

Policy, University of West Attica, 11521 Athens, Greece.

FAU - Magiorkinis, Emmanouil

AU - Magiorkinis E

AUID- ORCID: 0000-0001-8883-7275

AD - Department of Laboratory Medicine, Sotiria General Hospital for Chest Diseases,

11527 Athens, Greece.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230609

PL - Switzerland

TA - Viruses

JT - Viruses

JID - 101509722

SB - IM

MH - Humans

MH - *Schizophrenia/genetics

MH - *Epstein-Barr Virus Infections

MH - Herpesvirus 4, Human/genetics

MH - *Virus Diseases/complications

MH - Cytomegalovirus/genetics

MH - Herpesvirus 2, Human

PMC - PMC10302918

OTO - NOTNLM

OT - congenital infections

OT - pregnancy and viral infections

OT - prenatal viral infections

OT - schizophrenia

COIS- The authors declare no conflict of interest relevant to this review.

EDAT- 2023/06/28 06:42

MHDA- 2023/06/29 06:42

CRDT- 2023/06/28 01:40

PHST- 2023/05/06 00:00 [received]

PHST- 2023/06/02 00:00 [revised]

PHST- 2023/06/08 00:00 [accepted]

PHST- 2023/06/29 06:42 [medline]

PHST- 2023/06/28 06:42 [pubmed]

PHST- 2023/06/28 01:40 [entrez]

AID - v15061345 [pii]

AID - viruses-15-01345 [pii]

AID - 10.3390/v15061345 [doi]

PST - epublish

SO - Viruses. 2023 Jun 9;15(6):1345. doi: 10.3390/v15061345.

PMID- 37365521

OWN - NLM

STAT- MEDLINE

DCOM- 20230628

LR - 20230701

IS - 1471-2288 (Electronic)

IS - 1471-2288 (Linking)

VI - 23

IP - 1

DP - 2023 Jun 26

TI - Calibrated meta-analysis to estimate the efficacy of mental health treatments in

target populations: an application to paliperidone trials for treatment of

schizophrenia.

PG - 150

LID - 10.1186/s12874-023-01958-w [doi]

LID - 150

AB - BACKGROUNDS: Meta-analyses can be a powerful tool but need to calibrate potential

unrepresentativeness of the included trials to a target population. Estimating

target population average treatment effects (TATE) in meta-analyses is important

to understand how treatments perform in well-defined target populations. This

study estimated TATE of paliperidone palmitate in patients with schizophrenia

using meta-analysis with individual patient trial data and target population

data. METHODS: We conducted a meta-analysis with data from four randomized

clinical trials and target population data from the Clinical Antipsychotic Trials

of Intervention Effectiveness (CATIE) study. Efficacy was measured using the

Positive and Negative Syndrome Scale (PANSS). Weights to equate the trial

participants and target population were calculated by comparing baseline

characteristics between the trials and CATIE. A calibrated weighted meta-analysis

with random effects was performed to estimate the TATE of paliperidone compared

to placebo. RESULTS: A total of 1,738 patients were included in the meta-analysis

along with 1,458 patients in CATIE. After weighting, the covariate distributions

of the trial participants and target population were similar. Compared to

placebo, paliperidone palmitate was associated with a significant reduction of

the PANSS total score under both unweighted (mean difference 9.07 [4.43, 13.71])

and calibrated weighted (mean difference 6.15 [2.22, 10.08]) meta-analysis.

CONCLUSIONS: The effect of paliperidone palmitate compared with placebo is

slightly smaller in the target population than that estimated directly from the

unweighted meta-analysis. Representativeness of samples of trials included in a

meta-analysis to a target population should be assessed and incorporated properly

to obtain the most reliable evidence of treatment effects in target populations.

FAU - Hong, Hwanhee

AU - Hong H

AD - Department of Biostatistics and Bioinformatics, School of Medicine, Duke

University, 2424 Erwin Road, Ste 1105, Durham, NC, 27705, USA.

hwanhee.hong@duke.edu.

FAU - Liu, Lu

AU - Liu L

AD - Department of Biostatistics and Bioinformatics, School of Medicine, Duke

University, 2424 Erwin Road, Ste 1105, Durham, NC, 27705, USA.

FAU - Mojtabai, Ramin

AU - Mojtabai R

AD - Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins

University, 615 N. Wolfe Street, Baltimore, MD, 21205, USA.

FAU - Stuart, Elizabeth A

AU - Stuart EA

AD - Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins

University, 615 N. Wolfe Street, Baltimore, MD, 21205, USA.

LA - eng

GR - R00MH111807/MH/NIMH NIH HHS/United States

GR - R01MH126856/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, N.I.H., Intramural

DEP - 20230626

PL - England

TA - BMC Med Res Methodol

JT - BMC medical research methodology

JID - 100968545

RN - R8P8USM8FR (Paliperidone Palmitate)

RN - 0 (Isoxazoles)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - Paliperidone Palmitate/therapeutic use

MH - *Schizophrenia/drug therapy

MH - Mental Health

MH - Isoxazoles/therapeutic use

MH - *Antipsychotic Agents/therapeutic use

MH - Randomized Controlled Trials as Topic

PMC - PMC10294408

OTO - NOTNLM

OT - Generalizability

OT - Individual-Level Data

OT - Meta-Analysis

OT - Paliperidone Palmitate

OT - Randomized trials

OT - Schizophrenia

OT - Target Population

COIS- None.

EDAT- 2023/06/27 01:06

MHDA- 2023/06/28 06:42

CRDT- 2023/06/26 23:35

PHST- 2022/09/05 00:00 [received]

PHST- 2023/05/25 00:00 [accepted]

PHST- 2023/06/28 06:42 [medline]

PHST- 2023/06/27 01:06 [pubmed]

PHST- 2023/06/26 23:35 [entrez]

AID - 10.1186/s12874-023-01958-w [pii]

AID - 1958 [pii]

AID - 10.1186/s12874-023-01958-w [doi]

PST - epublish

SO - BMC Med Res Methodol. 2023 Jun 26;23(1):150. doi: 10.1186/s12874-023-01958-w.

PMID- 37358825

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230911

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 5

DP - 2023 Sep 7

TI - Social Psychopharmacology: Novel Approaches to Treat Deficits in Social

Motivation in Schizophrenia.

PG - 1161-1173

LID - 10.1093/schbul/sbad094 [doi]

AB - BACKGROUND AND HYPOTHESIS: Diminished social motivation is a negative symptom of

schizophrenia and leads to severe functional consequences for many patients

suffering from the illness. However, there are no effective medications available

to treat this symptom. Despite the lack of approved treatments for patients,

there is a growing body of literature on the effects of several classes of drugs

on social motivation in healthy volunteers that may be relevant to patients. The

aim of this review is to synthesize these results in an effort to identify novel

directions for the development of medications to treat reduced social motivation

in schizophrenia. STUDY DESIGN: In this article, we review pharmacologic

challenge studies addressing the acute effects of psychoactive drugs on social

motivation in healthy volunteers and consider how these findings may be applied

to deficits in social motivation in schizophrenia. We include studies testing

amphetamines and 3,4-methylenedioxymethamphetamine (MDMA), opioids, cannabis,

serotonergic psychedelics, antidepressants, benzodiazepines, and neuropeptides.

STUDY RESULTS: We report that amphetamines, MDMA, and some opioid medications

enhance social motivation in healthy adults and may represent promising avenues

of investigation in schizophrenia. CONCLUSIONS: Given the acute effects of these

drugs on behavioral and performance-based measures of social motivation in

healthy volunteers, they may be particularly beneficial as an adjunct to

psychosocial training programs in patient populations. It remains to be

determined how these medications affect patients with deficits in social

motivation, and in which contexts they may be most effectively administered.

CI - Published by Oxford University Press on behalf of the Maryland Psychiatric

Research Center 2023.

FAU - Bershad, Anya K

AU - Bershad AK

AUID- ORCID: 0000-0002-3011-3730

AD - Department of Psychiatry and Biobehavioral Sciences, University of California,

Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles,

CAUSA.

FAU - de Wit, Harriet

AU - de Wit H

AUID- ORCID: 0000-0002-7211-8994

AD - Department of Psychiatry and Behavioral Neuroscience, University of Chicago,

Chicago, ILUSA.

LA - eng

GR - R01 DA002812/DA/NIDA NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Review

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)

SB - IM

MH - Adult

MH - Humans

MH - *Schizophrenia

MH - Motivation

MH - *Psychopharmacology

MH - *N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use

MH - *Apathy

PMC - PMC10483474

OTO - NOTNLM

OT - Amotivation

OT - approach and avoidance

OT - human behavioral pharmacology

COIS- HdW is on the Board of Directors of PharmAla Biotech and consultant to Awakn Life

Sciences and Gilgamesh Pharmaceuticals. These are unrelated to this manuscript.

EDAT- 2023/06/26 13:07

MHDA- 2023/09/08 06:43

PMCR- 2024/06/26

CRDT- 2023/06/26 11:22

PHST- 2024/06/26 00:00 [pmc-release]

PHST- 2023/09/08 06:43 [medline]

PHST- 2023/06/26 13:07 [pubmed]

PHST- 2023/06/26 11:22 [entrez]

AID - 7207745 [pii]

AID - sbad094 [pii]

AID - 10.1093/schbul/sbad094 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Sep 7;49(5):1161-1173. doi: 10.1093/schbul/sbad094.

PMID- 37354079

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230911

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 5

DP - 2023 Sep 7

TI - Social Motivation in Schizophrenia: What's Effort Got to Do With It?

PG - 1127-1137

LID - 10.1093/schbul/sbad090 [doi]

AB - BACKGROUND AND HYPOTHESIS: Social motivation, defined as the fundamental human

desire to seek out, engage in, and maintain interpersonal bonds, has become a

growing area of research in schizophrenia. The major focus has been on

understanding the impact of social reward-related processes. An obvious but

rarely acknowledged fact is that social interactions, much like other

goal-directed acts, require the exertion of effort. In this Review Article, we

argue that social motivation in schizophrenia can be conceptualized through the

lens of an established framework: effort-based decision-making (EBDM). STUDY

DESIGN: We conducted a literature review on social reward processing in

schizophrenia, then extended these findings by applying concepts and insights

from the literature on EBDM to the study of social motivation. STUDY RESULTS:

Within the EBDM framework, decisions about whether or not to pursue social

interactions are bound by cost/benefit calculations. That is, people do not

pursue social behaviors when the estimated "cost" of the required effort

outweighs the anticipated "benefit" or reward. We propose that people with

schizophrenia are less likely to engage in social interaction compared with

healthy samples because they: (1) underestimate the benefits of relationships

(based on expectations of reward/punishment), (2) overestimate the effort costs

associated with social interaction, and/or (3) fail to integrate cost-benefit

information in an optimal manner. CONCLUSIONS: EBDM is an especially promising

framework of social motivation that goes beyond the current focus on social

reward processing to include a focus on effort.

CI - Published by Oxford University Press on behalf of the Maryland Psychiatric

Research Center 2023.

FAU - Catalano, Lauren T

AU - Catalano LT

AD - Desert Pacific Mental Illness Research, Education and Clinical Center, Veterans

Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of

Medicine at University of California Los Angeles, Los Angeles, CA, USA.

FAU - Green, Michael F

AU - Green MF

AD - Desert Pacific Mental Illness Research, Education and Clinical Center, Veterans

Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of

Medicine at University of California Los Angeles, Los Angeles, CA, USA.

LA - eng

GR - IK2 CX002202/CX/CSRD VA/United States

PT - Journal Article

PT - Research Support, U.S. Gov't, Non-P.H.S.

PT - Review

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

MH - Humans

MH - *Schizophrenia/complications

MH - Motivation

MH - Decision Making

MH - Social Behavior

MH - Reward

PMC - PMC10483329

OTO - NOTNLM

OT - Schizophrenia

OT - effort-based decision-making

OT - social cognition

OT - social effort

OT - social motivation

OT - social reward

EDAT- 2023/06/24 21:03

MHDA- 2023/09/08 06:43

PMCR- 2024/06/24

CRDT- 2023/06/24 08:13

PHST- 2024/06/24 00:00 [pmc-release]

PHST- 2023/09/08 06:43 [medline]

PHST- 2023/06/24 21:03 [pubmed]

PHST- 2023/06/24 08:13 [entrez]

AID - 7206753 [pii]

AID - sbad090 [pii]

AID - 10.1093/schbul/sbad090 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Sep 7;49(5):1127-1137. doi: 10.1093/schbul/sbad090.

PMID- 37349671

OWN - NLM

STAT- MEDLINE

DCOM- 20230911

LR - 20230922

IS - 2194-1327 (Electronic)

IS - 0948-6259 (Print)

IS - 0948-6259 (Linking)

VI - 37

IP - 3

DP - 2023 Sep

TI - [Safety aspects during treatment with clozapine: : Adverse effects, titration,

and therapeutic drug monitoring - a narrative review].

PG - 122-129

LID - 10.1007/s40211-023-00474-z [doi]

AB - BACKGROUND: According to current guidelines, clozapine should be used as a third

step in treatment resistant schizophrenia (TRS). In everyday clinical practice,

however, it is frequently used at a much later stage, which leads to

a significant deterioration of prognosis. The first part of this narrative

overview focuses on the most frequent side effects of clozapine, on the relevance

of slow titration, and on specific aspects of therapeutic drug monitoring (TDM).

MATERIAL AND METHODS: Medline, the Guideline for the use of clozapine 2013 of the

Netherlands Clozapine Collaboration Group, and the S3 Guideline for Schizophrenia

of the German Association for Psychiatry, Psychotherapy and Psychosomatics were

searched for relevant literature, the last query dating from April 28th, 2023.

RESULTS: Despite its unique efficacy clozapine is underused in clinical practice

and prescription varies between and within countries. Next to hematological,

metabolic, and vegetative side effects, clozapine induced inflammation

manifesting in the form of pneumonia or myocarditis, which is mainly associated

with rapid titration, represents a major clinical challenge with CRP monitoring

being of particular relevance. In this context, it also has to be noted that sex,

smoking behavior, and ethnic origin impact clozapine metabolism, thus requiring

personalized dosing. CONCLUSION: Slow titration when possible, TDM, and CYP

diagnostics when appropriate increase patient safety during treatment with

clozapine and thus the likelihood of early prescription of this compound in TRS.

FAU - Berger, Stefan J

AU - Berger SJ

AD - Department für Psychiatrie, Psychotherapie, Psychosomatik und Medizinische

Psychologie, Univ.-Klinik für Psychiatrie I, Medizinische Universität Innsbruck,

Anichstr. 35, 6020, Innsbruck, Österreich.

FAU - Hofer, Alex

AU - Hofer A

AUID- ORCID: 0000-0002-5834-4258

AD - Department für Psychiatrie, Psychotherapie, Psychosomatik und Medizinische

Psychologie, Univ.-Klinik für Psychiatrie I, Medizinische Universität Innsbruck,

Anichstr. 35, 6020, Innsbruck, Österreich. a.hofer@i-med.ac.at.

LA - ger

PT - English Abstract

PT - Journal Article

PT - Review

TT - Sicherheitsaspekte bei der Behandlung mit Clozapin: : Unerwünschte

Arzneimittelwirkungen, Titration und Therapeutisches Drug Monitoring – eine

narrative Übersicht.

DEP - 20230622

PL - Germany

TA - Neuropsychiatr

JT - Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der

Gesellschaft Osterreichischer Nervenarzte und Psychiater

JID - 9440588

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Clozapine/adverse effects

MH - *Antipsychotic Agents/adverse effects

MH - Drug Monitoring

MH - *Schizophrenia/drug therapy

MH - *Psychiatry

PMC - PMC10491532

OTO - NOTNLM

OT - Clozapine

OT - Side Effects

OT - Therapeutic Drug Monitoring

OT - Titration

EDAT- 2023/06/23 01:10

MHDA- 2023/09/11 06:43

CRDT- 2023/06/22 23:34

PHST- 2022/10/11 00:00 [received]

PHST- 2023/05/19 00:00 [accepted]

PHST- 2023/09/11 06:43 [medline]

PHST- 2023/06/23 01:10 [pubmed]

PHST- 2023/06/22 23:34 [entrez]

AID - 10.1007/s40211-023-00474-z [pii]

AID - 474 [pii]

AID - 10.1007/s40211-023-00474-z [doi]

PST - ppublish

SO - Neuropsychiatr. 2023 Sep;37(3):122-129. doi: 10.1007/s40211-023-00474-z. Epub

2023 Jun 22.

PMID- 37349110

OWN - NLM

STAT- MEDLINE

DCOM- 20230831

LR - 20230905

IS - 1469-5111 (Electronic)

IS - 1461-1457 (Print)

IS - 1461-1457 (Linking)

VI - 26

IP - 8

DP - 2023 Aug 29

TI - Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release,

Is Associated With Clinically Important Long-Term Efficacy When Added to an

Antipsychotic in Patients With Treatment-Resistant Schizophrenia.

PG - 523-528

LID - 10.1093/ijnp/pyad035 [doi]

AB - Results from a pilot, 6-week, randomized, open-label, rater-blinded study, with

46-week extension, indicate very good tolerability with exceptional, clinically

important, increasing efficacy of evenamide (7.5, 15, and 30 mg bid), a glutamate

modulator, as add-on treatment to antipsychotics in 161 treatment-resistant,

schizophrenia patients. Ninety-five percent of patients completed 6 weeks (1

discontinued for adverse event), and 89% continued in the extension. Results from

the first 100 patients enrolled showed very low attrition over 1 year (77

completers); data pooled from all dose groups showed the Positive and Negative

Syndrome Scale total score improved significantly (P < .001; paired t test; last

observation carried forward [LOCF]) from baseline at 6 weeks (-9.4), 6 months

(-12.7), and 1 year (-14.7); similarly, the proportion of responders (≥20%

improvement) increased over time from 6 weeks (16.5%) to 6 months (39%) to 1 year

(47.4%). Noteworthy improvement was also observed at each timepoint on the

Clinical Global Impression - Severity scale and Clinical Global Impression of

Change, indicating progressively increasing efficacy of evenamide up to 1 year.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of CINP.

FAU - Anand, Ravi

AU - Anand R

AD - APC, St. Moritz, Switzerland.

FAU - Turolla, Alessio

AU - Turolla A

AD - Newron Pharmaceuticals SpA, Bresso, Italy.

FAU - Chinellato, Giovanni

AU - Chinellato G

AUID- ORCID: 0009-0001-7091-8672

AD - Newron Pharmaceuticals SpA, Bresso, Italy.

FAU - Roy, Arjun

AU - Roy A

AD - CliniRx Research Pvt Ltd, New Delhi, India.

FAU - Hartman, Richard D

AU - Hartman RD

AD - NeurWrite LLC, Morristown, NJ, USA.

LA - eng

PT - Clinical Trial, Phase II

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

PL - England

TA - Int J Neuropsychopharmacol

JT - The international journal of neuropsychopharmacology

JID - 9815893

RN - 0 (Antipsychotic Agents)

RN - 3KX376GY7L (Glutamic Acid)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/chemically induced

MH - Glutamic Acid

MH - Schizophrenia, Treatment-Resistant

PMC - PMC10464926

OTO - NOTNLM

OT - Treatment-resistant schizophrenia

OT - add-on

OT - evenamide

OT - glutamate

OT - long-term

EDAT- 2023/06/23 01:10

MHDA- 2023/08/31 06:41

CRDT- 2023/06/22 21:12

PHST- 2023/03/24 00:00 [received]

PHST- 2023/06/21 00:00 [accepted]

PHST- 2023/08/31 06:41 [medline]

PHST- 2023/06/23 01:10 [pubmed]

PHST- 2023/06/22 21:12 [entrez]

AID - 7205455 [pii]

AID - pyad035 [pii]

AID - 10.1093/ijnp/pyad035 [doi]

PST - ppublish

SO - Int J Neuropsychopharmacol. 2023 Aug 29;26(8):523-528. doi: 10.1093/ijnp/pyad035.

PMID- 37347965

OWN - NLM

STAT- MEDLINE

DCOM- 20230824

LR - 20230929

IS - 1557-8518 (Electronic)

IS - 1540-4196 (Linking)

VI - 21

IP - 6

DP - 2023 Aug

TI - Antipsychotic-Induced Metabolic Syndrome: A Review.

PG - 294-305

LID - 10.1089/met.2023.0003 [doi]

AB - Schizophrenia, a serious psychiatric disorder, is among the top 10 global causes

of disability and affects nearly 1% of the world population. Antipsychotics

constitute the best treatment for patients with schizophrenia, however, this

treatment class carries a high risk of metabolic syndrome, including lipid

abnormalities. Indeed, the risk of metabolic syndrome would be increased in the

population with schizophrenia compared to the general population. The objective

is to summarize the prevalence, the mechanisms, and the potential treatments of

antipsychotic-induced metabolic syndrome. This is a narrative review of the

literature. We searched the electronic database Medline, accessed through PubMed,

to find studies that investigated the prevalence and treatments of metabolic

syndrome in the adult population using antipsychotics. The prevalence of

metabolic syndrome in patients treated with antipsychotics ranges from 37% to

63%. Antipsychotic iatrogenic effects include weight gain/increased waist

circumference, dyslipidemia, insulin resistance/type 2 diabetes, and

hypertension. Clozapine and olanzapine are reported to precipitate the onset of

metabolic syndrome features. In patients with metabolic syndrome, an

antipsychotic with less metabolic side effects such as lurasidone, lumateperone,

ziprasidone, and aripiprazole should be prioritized. Unlike medications, aerobic

exercise and dietetic counseling were found to be efficient as the

nonpharmacologic treatment of antipsychotic-induced metabolic syndrome. Few

pharmacological treatments were proven effective against weight gain in this

patient population. The risk of metabolic syndrome induced by antipsychotics

should be early recognized and closely monitored. Primary and secondary

prevention of metabolic syndrome or onset of its feature might help reduce the

risk of death for patients using antipsychotics.

FAU - Akinola, Pelumi Samuel

AU - Akinola PS

AUID- ORCID: 0000-0001-5326-7057

AD - College of Pharmacy, Rady Faculty of Health sciences, University of Manitoba,

Winnipeg, Canada.

FAU - Tardif, Isabelle

AU - Tardif I

AD - Faculté de Médecine, Université Laval, Québec, Canada.

FAU - Leclerc, Jacinthe

AU - Leclerc J

AD - Faculté de Pharmacie, Université Laval, Québec, Canada.

AD - Centre de Recherche, Institut Universitaire de Cardiologie de Pneumologie de

Québec-Université Laval, Québec, Canada.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230622

PL - United States

TA - Metab Syndr Relat Disord

JT - Metabolic syndrome and related disorders

JID - 101150318

RN - 0 (Antipsychotic Agents)

RN - N7U69T4SZR (Olanzapine)

RN - J60AR2IKIC (Clozapine)

SB - IM

MH - Humans

MH - Adult

MH - *Antipsychotic Agents/adverse effects

MH - *Metabolic Syndrome/chemically induced

MH - *Schizophrenia/drug therapy

MH - *Olanzapine/adverse effects

MH - *Clozapine/adverse effects

MH - Weight Gain

MH - Dyslipidemias/chemically induced

MH - Diabetes Mellitus, Type 2/chemically induced

MH - Hypertension/chemically induced

OTO - NOTNLM

OT - adverse drug reaction

OT - adverse events

OT - antipsychotics

OT - metabolic syndrome

OT - schizophrenia

EDAT- 2023/06/22 19:15

MHDA- 2023/08/21 06:42

CRDT- 2023/06/22 14:53

PHST- 2023/08/21 06:42 [medline]

PHST- 2023/06/22 19:15 [pubmed]

PHST- 2023/06/22 14:53 [entrez]

AID - 10.1089/met.2023.0003 [doi]

PST - ppublish

SO - Metab Syndr Relat Disord. 2023 Aug;21(6):294-305. doi: 10.1089/met.2023.0003.

Epub 2023 Jun 22.

PMID- 37344763

OWN - NLM

STAT- MEDLINE

DCOM- 20230623

LR - 20230701

IS - 1471-244X (Electronic)

IS - 1471-244X (Linking)

VI - 23

IP - 1

DP - 2023 Jun 21

TI - Delphi panel to obtain clinical consensus about using long-acting injectable

antipsychotics to treat first-episode and early-phase schizophrenia: treatment

goals and approaches to functional recovery.

PG - 453

LID - 10.1186/s12888-023-04928-0 [doi]

LID - 453

AB - BACKGROUND: Schizophrenia is mostly a chronic disorder whose symptoms include

psychosis, negative symptoms and cognitive dysfunction. Poor adherence is common

and related relapse can impair outcomes. Long-acting injectable antipsychotics

(LAIs) may promote treatment adherence and decrease the likelihood of relapse and

rehospitalization. Using LAIs in first-episode psychosis (FEP) and early-phase

(EP) schizophrenia patients could benefit them, yet LAIs have traditionally been

reserved for chronic patients. METHODS: A three-step modified Delphi panel

process was used to obtain expert consensus on using LAIs with FEP and EP

schizophrenia patients. A literature review and input from a steering committee

of five experts in psychiatry were used to develop statements about patient

population, adverse event management, and functional recovery. Recruited Delphi

process psychiatrists rated the extent of their agreement with the statements

over three rounds (Round 1: paper survey, 1:1 interview; Rounds 2-3: email

survey). Analysis rules determined whether a statement progressed to the next

round and the level of agreement deemed consensus. Measures of central tendency

(mode, mean) and variability (interquartile range) were reported back to help

panelists assess their previous responses in the context of those of the overall

group. RESULTS: The Delphi panelists were 17 psychiatrists experienced in

treating schizophrenia with LAIs, practicing in seven countries (France, Italy,

US, Germany, Spain, Denmark, UK). Panelists were presented with 73 statements

spanning three categories: patient population; medication dosage, management, and

adverse events; and functional recovery domains and assessment. Fifty-five

statements achieved ≥ 80% agreement (considered consensus). Statements with low

agreement (40-79%) or very low agreement (< 39%) concerned initiating dosage in

FEP and EP patients, and managing loss of efficacy and breakthrough episodes,

reflecting current evidence gaps. The panel emphasized benefits of LAIs in FEP

and EP patients, with consensus that LAIs can decrease the risk of relapse,

rehospitalization, and functional dysfunction. The panel supported links between

these benefits and multidimensional longer-term functional recovery beyond

symptomatic remission. CONCLUSIONS: Findings from this Delphi panel support the

use of LAIs in FEP and EP schizophrenia patients regardless of disease severity,

number of relapses, or social support status. Gaps in clinician knowledge make

generating evidence on using LAIs in FEP and EP patients critical.

FAU - Arango, Celso

AU - Arango C

AD - Child and Adolescent Department of Psychiatry, Institute of Psychiatry and Mental

Health, IiSGM, CIBERSAM, School of Medicine, Hospital General Universitario

Gregorio Marañón, Universidad Complutense, Madrid, Spain.

FAU - Fagiolini, Andrea

AU - Fagiolini A

AD - Department of Molecular and Developmental Medicine, Division of Psychiatry,

Universita di Siena, Siena, Italy.

FAU - Gorwood, Philip

AU - Gorwood P

AD - Université Paris Cité, INSERM U1266, GHU Paris Psychiatrie et Neurosciences

(CMME), Paris, France.

FAU - Kane, John M

AU - Kane JM

AD - Institute of Behavioral Science, Feinstein Institutes for Medical

Research-Northwell Health, New York, NY, USA.

AD - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

AD - Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School

of Medicine at Hofstra/Northwell-Hempstead, New York, NY, USA.

FAU - Diaz-Mendoza, Sergio

AU - Diaz-Mendoza S

AD - OPEN Health, Patient-Centered Outcomes, Marlow, UK.

FAU - Sahota, Navdeep

AU - Sahota N

AD - OPEN Health, Patient-Centered Outcomes, London, UK.

FAU - Correll, Christoph U

AU - Correll CU

AD - Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA. ccorrell@northwell.edu.

AD - Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School

of Medicine at Hofstra/Northwell-Hempstead, New York, NY, USA.

ccorrell@northwell.edu.

AD - Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin

Berlin, Berlin, Germany. ccorrell@northwell.edu.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230621

PL - England

TA - BMC Psychiatry

JT - BMC psychiatry

JID - 100968559

RN - 0 (Antipsychotic Agents)

RN - 0 (Delayed-Action Preparations)

SB - IM

UOF - Res Sq. 2023 Mar 08;:. PMID: 36945577

MH - Humans

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/therapeutic use

MH - Consensus

MH - Goals

MH - Delayed-Action Preparations/therapeutic use

MH - Recurrence

PMC - PMC10286361

OTO - NOTNLM

OT - Antipsychotics

OT - Clinical consensus

OT - Delphi process

OT - Early-phase schizophrenia

OT - First episode psychosis

OT - Functional recovery

OT - Long-acting injectable

OT - Recommendations

OT - Schizophrenia

COIS- While the authors do not have any competing interests as defined by BMC, the

following are the author disclosures: Celso Arango has received support by the

Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III

(ISCIII), co-financed by the European Union, ERDF Funds from the European

Commission, “A way of making Europe”, financed by the European Union -

NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government

(B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union

Seventh Framework Program, European Union H2020 Program under the Innovative

Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement

No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe,

the National Institute of Mental Health of the National Institutes of Health

under Award Number 1U01MH124639-01 (Project ProNET) and Award Number

5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación

Alicia Koplowitz. Dr. Arango has been a consultant to or has received honoraria

or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen

Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage,

Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and

Takeda.Philip Gorwood received during the last 5 years fees for presentations at

congresses or participation in scientific boards from Angelini, EISI, Janssen,

Lundbeck, Otsuka, Richter, Merk and Viatris.John M. Kane has been a consultant

for or received honoraria from Alkermes, Allergan, Boehringer-Ingelheim, Cerevel,

Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS, Indivior, Intracellular

Therapies, Janssen Pharmaceutical, Johnson & Johnson, LB Pharmaceuticals, Merck,

Minerva, Neurocrine, Newron, Novartis, Otsuka, Roche, Saladax, Sunovion, and

Teva. Dr. Kane has received grant support from Otsuka, Lundbeck, Sunovion and

Janssen. Dr. Kane is a Shareholder in Vanguard Research Group, North Shore

Therapeutics, Health Rhythms, MedinCell, and LB Pharmaceuticals, Inc.Andrea

Fagiolini is /has been a consultant and/or a speaker and/or has received research

grants from Angelini, Apsen, Boheringer Ingelheim, Daiichi Sankyo, Glaxo Smith

Kline, Italfarmaco, Lundbeck, Janssen, Mylan, Otsuka, Pfizer, Recordati, Sanofi

Aventis, Sunovion, Viatris, ViforChristoph U Correll has been a consultant and/or

advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan,

Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX

Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk,

IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck,

MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan,

Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada,

Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda,

Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served

on a Data Safety Monitoring Board for Compass, Lundbeck, Relmada, Reviva, Rovi,

Supernus, and Teva. He has received grant support from Janssen and Takeda. He

received royalties from UpToDate and is also a stock option holder of Cardio

Diagnostics, Mindpax, LB Pharma and Quantic.

EDAT- 2023/06/22 01:07

MHDA- 2023/06/23 06:42

CRDT- 2023/06/21 23:33

PHST- 2023/02/16 00:00 [received]

PHST- 2023/06/06 00:00 [accepted]

PHST- 2023/06/23 06:42 [medline]

PHST- 2023/06/22 01:07 [pubmed]

PHST- 2023/06/21 23:33 [entrez]

AID - 10.1186/s12888-023-04928-0 [pii]

AID - 4928 [pii]

AID - 10.1186/s12888-023-04928-0 [doi]

PST - epublish

SO - BMC Psychiatry. 2023 Jun 21;23(1):453. doi: 10.1186/s12888-023-04928-0.

PMID- 37340095

OWN - NLM

STAT- MEDLINE

DCOM- 20230726

LR - 20230726

IS - 1447-073X (Electronic)

IS - 1447-073X (Linking)

VI - 98

IP - 4

DP - 2023 Sep

TI - Clinical anatomy of the precuneus and pathogenesis of the schizophrenia.

PG - 473-481

LID - 10.1007/s12565-023-00730-w [doi]

AB - Recent evidence has shown that the precuneus plays a role in the pathogenesis of

schizophrenia. The precuneus is a structure of the parietal lobe's medial and

posterior cortex, representing a central hub involved in multimodal integration

processes. Although neglected for several years, the precuneus is highly complex

and crucial for multimodal integration. It has extensive connections with

different cerebral areas and is an interface between external stimuli and

internal representations. In human evolution, the precuneus has increased in size

and complexity, allowing the development of higher cognitive functions, such as

visual-spatial ability, mental imagery, episodic memory, and other tasks involved

in emotional processing and mentalization. This paper reviews the functions of

the precuneus and discusses them concerning the psychopathological aspects of

schizophrenia. The different neuronal circuits, such as the default mode network

(DMN), in which the precuneus is involved and its alterations in the structure

(grey matter) and the disconnection of pathways (white matter) are described.

Anatomists.

FAU - Messina, Antonino

AU - Messina A

AUID- ORCID: 0000-0002-3594-8542

AD - Department of Clinical and Experimental Medicine, Psychiatry Unit, University of

Catania, Catania, Italy. thomessina@gmail.com.

FAU - Cuccì, Giuseppe

AU - Cuccì G

AD - Mental Health Department, Enna, Italy.

FAU - Crescimanno, Caterina

AU - Crescimanno C

AD - Faculty of Medicine and Surgery, "Kore" University, Enna, Italy.

FAU - Signorelli, Maria Salvina

AU - Signorelli MS

AD - Department of Clinical and Experimental Medicine, Psychiatry Unit, University of

Catania, Catania, Italy.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230620

PL - Japan

TA - Anat Sci Int

JT - Anatomical science international

JID - 101154140

SB - IM

MH - Humans

MH - *Magnetic Resonance Imaging

MH - Brain Mapping

MH - *Schizophrenia/pathology

MH - Parietal Lobe/pathology/physiology

MH - Cerebral Cortex

MH - Neural Pathways/physiology

OTO - NOTNLM

OT - Default mode network

OT - Multimodal integration

OT - Parietal lobe

OT - Precuneus

OT - Schizophrenia

EDAT- 2023/06/21 01:07

MHDA- 2023/07/26 06:43

CRDT- 2023/06/20 23:25

PHST- 2023/01/13 00:00 [received]

PHST- 2023/05/12 00:00 [accepted]

PHST- 2023/07/26 06:43 [medline]

PHST- 2023/06/21 01:07 [pubmed]

PHST- 2023/06/20 23:25 [entrez]

AID - 10.1007/s12565-023-00730-w [pii]

AID - 10.1007/s12565-023-00730-w [doi]

PST - ppublish

SO - Anat Sci Int. 2023 Sep;98(4):473-481. doi: 10.1007/s12565-023-00730-w. Epub 2023

Jun 20.

PMID- 37331479

OWN - NLM

STAT- MEDLINE

DCOM- 20230710

LR - 20230718

IS - 1872-9649 (Electronic)

IS - 1568-1637 (Linking)

VI - 89

DP - 2023 Aug

TI - BACE1-dependent metabolism of neuregulin 1: Bridging the gap in explaining the

occurrence of schizophrenia-like symptoms in Alzheimer's disease with psychosis?

PG - 101988

LID - S1568-1637(23)00147-2 [pii]

LID - 10.1016/j.arr.2023.101988 [doi]

AB - Alzheimer's disease is a neurodegenerative disease mainly characterized by

cortico-neuronal atrophy, impaired memory and other cognitive declines. On the

other hand, schizophrenia is a neuro-developmental disorder with an overtly

active central nervous system pruning system resulting into abrupt connections

with common symptoms including disorganised thoughts, hallucination and delusion.

Nevertheless, the fronto-temporal anomaly presents itself as a common denominator

for the two pathologies. There is even a strong presumption of increased risk of

developing co-morbid dementia for schizophrenic individuals and psychosis for

Alzheimer's disease patients, overall leading to a further deteriorated quality

of life. However, convincing proofs of how these two disorders, although very

distant from each other when considering their aetiology, develop coexisting

symptoms is yet to be resolved. At the molecular level, the two primarily

neuronal proteins β-amyloid precursor protein and neuregulin 1 have been

considered in this relevant context, although the conclusions are for the moment

only hypotheses. In order to propose a model for explaining the psychotic

schizophrenia-like symptoms that sometimes accompany AD-associated dementia, this

review projects out on the similar sensitivity shared by these two proteins

regarding their metabolism by the β-site APP cleaving enzyme 1.

FAU - Vincent, Bruno

AU - Vincent B

AD - Institute of Molecular and Cellular Pharmacology, Laboratory of Excellence

DistALZ, Université Côte d'Azur, INSERM, CNRS, Sophia-Antipolis, 06560 Valbonne,

France. Electronic address: vincent@ipmc.cnrs.fr.

FAU - Maitra, Subhamita

AU - Maitra S

AD - Department of Molecular Biology, Umeå University, Umeå 90736, Sweden.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230617

PL - England

TA - Ageing Res Rev

JT - Ageing research reviews

JID - 101128963

RN - EC 3.4.- (Amyloid Precursor Protein Secretases)

RN - EC 3.4.23.- (Aspartic Acid Endopeptidases)

RN - 0 (Neuregulin-1)

RN - 0 (Amyloid beta-Protein Precursor)

RN - 0 (Amyloid beta-Peptides)

RN - EC 3.4.23.46 (BACE1 protein, human)

SB - IM

MH - Humans

MH - *Alzheimer Disease/metabolism

MH - Amyloid Precursor Protein Secretases/metabolism

MH - *Schizophrenia

MH - Aspartic Acid Endopeptidases/metabolism

MH - *Neurodegenerative Diseases

MH - Neuregulin-1/metabolism

MH - Quality of Life

MH - *Psychotic Disorders

MH - Amyloid beta-Protein Precursor/metabolism

MH - Amyloid beta-Peptides/metabolism

OTO - NOTNLM

OT - Alzheimer

OT - BACE1

OT - Neuregulin 1

OT - Psychosis

OT - Schizophrenia

OT - βAPP

COIS- Declaration of Competing Interest None.

EDAT- 2023/06/19 00:42

MHDA- 2023/07/10 06:42

CRDT- 2023/06/18 19:14

PHST- 2023/03/08 00:00 [received]

PHST- 2023/06/14 00:00 [revised]

PHST- 2023/06/15 00:00 [accepted]

PHST- 2023/07/10 06:42 [medline]

PHST- 2023/06/19 00:42 [pubmed]

PHST- 2023/06/18 19:14 [entrez]

AID - S1568-1637(23)00147-2 [pii]

AID - 10.1016/j.arr.2023.101988 [doi]

PST - ppublish

SO - Ageing Res Rev. 2023 Aug;89:101988. doi: 10.1016/j.arr.2023.101988. Epub 2023 Jun

17.

PMID- 37329895

OWN - NLM

STAT- MEDLINE

DCOM- 20230724

LR - 20230724

IS - 2215-0374 (Electronic)

IS - 2215-0366 (Linking)

VI - 10

IP - 8

DP - 2023 Aug

TI - An international research agenda for clozapine-resistant schizophrenia.

PG - 644-652

LID - S2215-0366(23)00109-8 [pii]

LID - 10.1016/S2215-0366(23)00109-8 [doi]

AB - Treatment-resistant symptoms occur in about a third of patients with

schizophrenia and are associated with a substantial reduction in their quality of

life. The development of new treatment options for clozapine-resistant

schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an

overview of past and possible future research avenues to optimise the early

detection, diagnosis, and management of clozapine-resistant schizophrenia is

unavailable. In this Health Policy, we discuss the ongoing challenges associated

with clozapine-resistant schizophrenia faced by patients and health-care

providers worldwide to improve the understanding of this condition. We then

revisit several clozapine guidelines, the diagnostic tests and treatment options

for clozapine-resistant schizophrenia, and currently applied research approaches

in clozapine-resistant schizophrenia. We also suggest methodologies and targets

for future research, divided into innovative nosology-oriented field trials (eg,

examining dimensional symptom staging), translational approaches (eg, genetics),

epidemiological research (eg, real-world studies), and interventional studies

(eg, non-traditional trial designs incorporating lived experiences and

caregivers' perspectives). Finally, we note that low-income and middle-income

countries are under-represented in studies on clozapine-resistant schizophrenia

and propose an agenda to guide multinational research on the cause and treatment

of clozapine-resistant schizophrenia. We hope that this research agenda will

empower better global representation of patients living with clozapine-resistant

schizophrenia and ultimately improve their functional outcomes and quality of

life.

FAU - Luykx, Jurjen J

AU - Luykx JJ

AD - Department of Psychiatry and Neuropsychology, School for Mental Health and

Neuroscience, Maastricht University Medical Centre, Maastricht, Netherlands;

Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center

Utrecht, Utrecht University, Utrecht, Netherlands; GGNet Mental Health,

Warnsveld, Netherlands. Electronic address: j.luykx@maastrichtuniversity.nl.

FAU - Gonzalez-Diaz, Jairo M

AU - Gonzalez-Diaz JM

AD - Barcelona Clínic Schizophrenia Unit, Neurosciences Institute, Hospital Clinic,

Universitat de Barcelona, Barcelona, Spain; UR Center for Mental Health, School

of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia;

Clínica Nuestra Señora de la Paz, Orden Hospitalaria de San Juan de Dios, Bogotá,

Colombia.

FAU - Guu, Ta-Wei

AU - Guu TW

AD - Department of Old Age Psychiatry, Institute of Psychiatry Psychology and

Neuroscience, King's College London, London, UK; Division of Psychiatry,

Department of Internal Medicine, China Medical University Beigang Hospital,

Yunlin, Taiwan.

FAU - van der Horst, Marte Z

AU - van der Horst MZ

AD - Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center

Utrecht, Utrecht University, Utrecht, Netherlands; GGNet Mental Health,

Warnsveld, Netherlands.

FAU - van Dellen, Edwin

AU - van Dellen E

AD - Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center

Utrecht, Utrecht University, Utrecht, Netherlands; Department of Intensive Care

Medicine, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht

University, Utrecht, Netherlands; Department of Neurology, UZ Brussel and Vrije

Universiteit Brussel, Jette, Belgium.

FAU - Boks, Marco P

AU - Boks MP

AD - Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center

Utrecht, Utrecht University, Utrecht, Netherlands.

FAU - Guloksuz, Sinan

AU - Guloksuz S

AD - Department of Psychiatry and Neuropsychology, School for Mental Health and

Neuroscience, Maastricht University Medical Centre, Maastricht, Netherlands;

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

FAU - DeLisi, Lynn E

AU - DeLisi LE

AD - Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School,

Cambridge, MA, USA.

FAU - Sommer, Iris E

AU - Sommer IE

AD - Department of Biomedical Sciences of Cells and Systems, University of Groningen,

University Medical Center Groningen, Groningen, Netherlands.

FAU - Cummins, Russel

AU - Cummins R

AD - Utrecht, Netherlands.

FAU - Shiers, David

AU - Shiers D

AD - Psychosis Research Unit, Greater Manchester Mental Health NHS Trust, Manchester,

UK.

FAU - Lee, Jimmy

AU - Lee J

AD - Department of Psychosis, Institute of Mental Health, Singapore; Neuroscience and

Mental Health, Lee Kong Chian School of Medicine, Nanyang Technological

University, Singapore.

FAU - Every-Palmer, Susanna

AU - Every-Palmer S

AD - Department of Psychological Medicine, University of Otago Wellington, Wellington,

New Zealand.

FAU - Mhalla, Ahmed

AU - Mhalla A

AD - Department of Psychiatry, Fattouma Bourguiba Hospital, Faculty of Medicine of

Monastir, University of Monastir, Monastir, Tunisia.

FAU - Chadly, Zohra

AU - Chadly Z

AD - Department of Pharmacology, Fattouma Bourguiba Hospital, Faculty of Medicine of

Monastir, University of Monastir, Monastir, Tunisia.

FAU - Chan, Sherry K W

AU - Chan SKW

AD - Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine,

The University of Hong Kong, Hong Kong Special Administrative Region, China;

State Key Laboratory of Brain and Cognitive Sciences, The University of Hong

Kong, Hong Kong Special Administrative Region, China.

FAU - Cotes, Robert O

AU - Cotes RO

AD - Department of Psychiatry and Behavioral Sciences, Emory University School of

Medicine, Atlanta, GA, USA.

FAU - Takahashi, Shun

AU - Takahashi S

AD - Department of Psychiatry, Osaka University Graduate School of Medicine, Suita,

Japan; Graduate School of Rehabilitation Science, Osaka Metropolitan University,

Habikino, Japan; Clinical Research and Education Center, Asakayama General

Hospital, Sakai, Japan; Department of Neuropsychiatry, Wakayama Medical

University, Wakayama, Japan.

FAU - Benros, Michael E

AU - Benros ME

AD - Biological and Precision Psychiatry, Copenhagen Research Center for Mental

Health, Mental Health Center Copenhagen, Copenhagen University Hospital,

Copenhagen, Denmark; Department of Immunology and Microbiology, Faculty of Health

and Medical Science, University of Copenhagen, Copenhagen, Denmark.

FAU - Wagner, Elias

AU - Wagner E

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Correll, Christoph U

AU - Correll CU

AD - Department of Child and Adolescent Psychiatry, Charité Universitaetsmedizin

Berlin, Berlin, Germany; Department of Psychiatry and Molecular Medicine, Donald

and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA;

Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

FAU - Hasan, Alkomiet

AU - Hasan A

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, University of

Augsburg, Medical Faculty, Augsburg, Germany.

FAU - Siskind, Dan

AU - Siskind D

AD - Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia; Metro

South Addiction and Mental Health Service, Brisbane, QLD, Australia.

FAU - Endres, Dominique

AU - Endres D

AD - Department of Psychiatry and Psychotherapy, Medical Center - University of

Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

FAU - MacCabe, James

AU - MacCabe J

AD - Department of Psychosis Studies, Institute of Psychiatry Psychology and

Neuroscience, King's College London, London, UK.

FAU - Tiihonen, Jari

AU - Tiihonen J

AD - Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi

Hospital, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska

Institutet, and Center for Psychiatry Research, Stockholm City Council,

Stockholm, Sweden.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230614

PL - England

TA - Lancet Psychiatry

JT - The lancet. Psychiatry

JID - 101638123

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Clozapine/therapeutic use

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/therapeutic use

MH - Quality of Life

COIS- Declaration of interests JL has received honoraria from Otsuka, Janssen,

Lundbeck, and Sumitomo Pharmaceuticals. CUC has been a consultant or advisor to,

or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini,

Aristo, Boehringer Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics,

Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular

Therapies, Janssen (Johnson & Johnson), Karuna, LB Pharma, Lundbeck,

MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan,

Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada,

Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda,

Teva, and Viatris. He has provided expert testimony for Janssen and Otsuka. He

has served on a data safety monitoring board for Lundbeck, Relmada, Reviva, Rovi,

Supernus, and Teva. He has received grant support from Janssen and Takeda. He has

received royalties from UpToDate and is also a stock option holder of Cardio

Diagnostics, Mindpax, LB Pharma, and Quantic. ROC has received research funding

(awarded to his institution) from Roche and Alkermes, is a consultant to Saladax

Biomedical, and is a speaker for Clinical Care Options. ST has received speaker

honoraria from Otsuka, Mochida, Takeda, Meiji, Eisai, Sumitomo, Viatris, and

Teijin. JT has participated in research projects funded by grants from

Janssen-Cilag and Eli Lilly awarded to his institution. He also reports personal

fees from Eli Lilly, Evidera, Janssen-Cilag, Lundbeck, Mediuutiset, Otsuka,

Sidera, and Suvovion; and he is a consultant to HLS Therapeutics, Orion, and

WebMed Global. AH is co-editor of the German Association for Psychiatry,

Psychotherapy and Psychosomatics schizophrenia treatment guidelines and first

author of the World Federation of Societies of Biological Psychiatry

schizophrenia treatment guidelines. He has been on the advisory boards and has

received speaker fees from Janssen, Lundbeck, and Otsuka. EW has been on the

advisory boards of Recordati. JMG-D is funded by a grant from Ministerio de

Ciencia y Tecnología (Colombia), and has been a consultant for, received

honoraria from, or been on the speakers or advisory boards of Janssen, Eurofarma,

Servier, Sanofi, Lilly, and Pfizer. DSh is an expert advisor to the National

Institute for Health and Care Excellence (NICE) centre for guidelines; the views

expressed in this Health Policy are the authors' and not those of NICE. All other

authors declare no competing interests.

EDAT- 2023/06/18 01:07

MHDA- 2023/07/24 06:42

CRDT- 2023/06/17 18:52

PHST- 2022/12/20 00:00 [received]

PHST- 2023/02/24 00:00 [revised]

PHST- 2023/03/17 00:00 [accepted]

PHST- 2023/07/24 06:42 [medline]

PHST- 2023/06/18 01:07 [pubmed]

PHST- 2023/06/17 18:52 [entrez]

AID - S2215-0366(23)00109-8 [pii]

AID - 10.1016/S2215-0366(23)00109-8 [doi]

PST - ppublish

SO - Lancet Psychiatry. 2023 Aug;10(8):644-652. doi: 10.1016/S2215-0366(23)00109-8.

Epub 2023 Jun 14.

PMID- 37328766

OWN - NLM

STAT- MEDLINE

DCOM- 20230619

LR - 20230619

IS - 1866-1955 (Electronic)

IS - 1866-1947 (Print)

IS - 1866-1947 (Linking)

VI - 15

IP - 1

DP - 2023 Jun 16

TI - Event-related potential (ERP) markers of 22q11.2 deletion syndrome and associated

psychosis.

PG - 19

LID - 10.1186/s11689-023-09487-9 [doi]

LID - 19

AB - 22q11.2 deletion syndrome (22q11.2DS) is a multisystemic disorder characterized

by a wide range of clinical features, ranging from life-threatening to less

severe conditions. One-third of individuals with the deletion live with mild to

moderate intellectual disability; approximately 60% meet criteria for at least

one psychiatric condition.22q11.2DS has become an important model for several

medical, developmental, and psychiatric disorders. We have been particularly

interested in understanding the risk for psychosis in this population:

Approximately 30% of the individuals with the deletion go on to develop

schizophrenia. The characterization of cognitive and neural differences between

those individuals who develop schizophrenia and those who do not, despite being

at genetic risk, holds important promise in what pertains to the clarification of

paths to disease and to the development of tools for early identification and

intervention.Here, we review our previous event-related potential (ERP) findings

as potential markers for 22q11.2DS and the associated risk for psychosis, while

discussing others' work. We focus on auditory processing (auditory-evoked

potentials, auditory adaptation, and auditory sensory memory), visual processing

(visual-evoked potentials and visual adaptation), and inhibition and error

monitoring.The findings discussed suggest basic mechanistic and disease process

effects on neural processing in 22q11.2DS that are present in both early sensory

and later cognitive processing, with possible implications for phenotype. In

early sensory processes, both during auditory and visual processing, two

mechanisms that impact neural responses in opposite ways seem to coexist-one

related to the deletion, which increases brain responses; another linked to

psychosis, decreasing neural activity. Later, higher-order cognitive processes

may be equally relevant as markers for psychosis. More specifically, we argue

that components related to error monitoring may hold particular promise in the

study of risk for schizophrenia in the general population.

FAU - Francisco, Ana A

AU - Francisco AA

AUID- ORCID: 0000-0003-4030-0297

AD - Department of Pediatrics, The Cognitive Neurophysiology Laboratory, Albert

Einstein College of Medicine, Bronx, NY, USA. claraafrancisco@gmail.com.

FAU - Foxe, John J

AU - Foxe JJ

AD - Department of Pediatrics, The Cognitive Neurophysiology Laboratory, Albert

Einstein College of Medicine, Bronx, NY, USA.

AD - Department of Neuroscience, Rose F. Kennedy Center, Albert Einstein College of

Medicine, Bronx, NY, USA.

AD - Department of Neuroscience, The Frederick J. and Marion A, Schindler Cognitive

Neurophysiology Laboratory, The Ernest J. Del Monde Institute for Neuroscience,

University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.

FAU - Molholm, Sophie

AU - Molholm S

AD - Department of Pediatrics, The Cognitive Neurophysiology Laboratory, Albert

Einstein College of Medicine, Bronx, NY, USA. sophie.molholm@einsteinmed.edu.

AD - Department of Neuroscience, Rose F. Kennedy Center, Albert Einstein College of

Medicine, Bronx, NY, USA. sophie.molholm@einsteinmed.edu.

AD - Department of Neuroscience, The Frederick J. and Marion A, Schindler Cognitive

Neurophysiology Laboratory, The Ernest J. Del Monde Institute for Neuroscience,

University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.

sophie.molholm@einsteinmed.edu.

LA - eng

GR - U54 HD090260/HD/NICHD NIH HHS/United States

GR - P50 HD105352/HD/NICHD NIH HHS/United States

PT - Journal Article

PT - Review

DEP - 20230616

PL - England

TA - J Neurodev Disord

JT - Journal of neurodevelopmental disorders

JID - 101483832

SB - IM

MH - Humans

MH - *DiGeorge Syndrome/psychology

MH - *Psychotic Disorders/complications

MH - *Schizophrenia/complications/genetics

MH - Evoked Potentials

MH - Brain

PMC - PMC10273715

OTO - NOTNLM

OT - DiGeorge syndrome

OT - EEG

OT - Error monitoring

OT - Response inhibition

OT - Schizophrenia

OT - Sensory processing

OT - Velo-cardio-facial syndrome

COIS- The authors declare that they have no competing interests.

EDAT- 2023/06/17 05:11

MHDA- 2023/06/19 13:08

CRDT- 2023/06/16 23:34

PHST- 2022/11/08 00:00 [received]

PHST- 2023/06/07 00:00 [accepted]

PHST- 2023/06/19 13:08 [medline]

PHST- 2023/06/17 05:11 [pubmed]

PHST- 2023/06/16 23:34 [entrez]

AID - 10.1186/s11689-023-09487-9 [pii]

AID - 9487 [pii]

AID - 10.1186/s11689-023-09487-9 [doi]

PST - epublish

SO - J Neurodev Disord. 2023 Jun 16;15(1):19. doi: 10.1186/s11689-023-09487-9.

PMID- 37326421

OWN - NLM

STAT- MEDLINE

DCOM- 20230803

LR - 20230807

IS - 1469-5111 (Electronic)

IS - 1461-1457 (Print)

IS - 1461-1457 (Linking)

VI - 26

IP - 7

DP - 2023 Jul 31

TI - Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or

Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.

PG - 451-464

LID - 10.1093/ijnp/pyad029 [doi]

AB - BACKGROUND: Patients with first-episode psychosis or early-phase schizophrenia

are susceptible to olanzapine-associated weight gain and cardiometabolic

dysregulation. This meta-analysis characterized weight and metabolic effects

observed during olanzapine treatment in randomized clinical trials in this

vulnerable patient population. METHODS: PubMed, EMBASE, and Dialog were searched

for randomized controlled trials (RCTs) reporting weight or cardiometabolic

outcomes associated with olanzapine treatment in first-episode psychosis or

early-phase schizophrenia. Random-effects meta-analysis and meta-regression were

conducted using R v4.0.5. RESULTS: Of 1203 records identified, 26 RCTs informed

the analyses. The meta-analytic mean (95% CI) weight gain was 7.53 (6.42-8.63) kg

in studies (n = 19) that reported weight gain with olanzapine treatment.

Stratified by duration, the mean (95% CI) weight gain was significantly higher in

studies >13 weeks in duration than in those lasting ≤13 weeks: 11.35

(10.05-12.65) vs 5.51 (4.73-6.28) kg, respectively. Despite between-study

variability, increases from baseline in most glycemic and lipid parameters were

generally small in studies of both ≤13 and >13 weeks. There were no correlations,

however, between weight gain and metabolic parameter changes when stratified by

study duration. CONCLUSIONS: In RCTs enrolling patients with first-episode

psychosis or early-phase schizophrenia, olanzapine was consistently associated

with weight gain that was greater in studies lasting >13 weeks compared with

those of ≤13 weeks. Metabolic changes observed across studies suggest that RCTs

may underestimate metabolic sequelae vs real-world treatment observations.

Patients with first-episode psychosis or early-phase schizophrenia are vulnerable

to olanzapine-associated weight gain; strategies minimizing olanzapine-associated

weight gain should be carefully considered.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of CINP.

FAU - Correll, Christoph U

AU - Correll CU

AD - Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks,

New York, USA.

AD - Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School

of Medicine at Hofstra/Northwell, Hempstead, New York, USA.

AD - Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin,

Berlin, Germany.

FAU - Højlund, Mikkel

AU - Højlund M

AD - Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public

Health, University of Southern Denmark, Odense, Denmark.

AD - Department of Psychiatry Aabenraa, Mental Health Services Region of Southern

Denmark, Aabenraa, Denmark.

FAU - Graham, Christine

AU - Graham C

AD - Alkermes, Inc., Waltham, Massachusetts, USA.

FAU - Todtenkopf, Mark S

AU - Todtenkopf MS

AD - Alkermes, Inc., Waltham, Massachusetts, USA.

FAU - McDonnell, David

AU - McDonnell D

AD - Alkermes Pharma Ireland Ltd., Dublin, Ireland.

FAU - Simmons, Adam

AU - Simmons A

AD - Alkermes, Inc., Waltham, Massachusetts, USA.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PL - England

TA - Int J Neuropsychopharmacol

JT - The international journal of neuropsychopharmacology

JID - 9815893

RN - N7U69T4SZR (Olanzapine)

RN - 0 (Antipsychotic Agents)

RN - 12794-10-4 (Benzodiazepines)

SB - IM

MH - Humans

MH - Olanzapine/adverse effects

MH - *Antipsychotic Agents/adverse effects

MH - Benzodiazepines/adverse effects

MH - *Schizophrenia/drug therapy/chemically induced

MH - *Psychotic Disorders/drug therapy

MH - Weight Gain

MH - *Cardiovascular Diseases/chemically induced

PMC - PMC10388390

OTO - NOTNLM

OT - Antipsychotic effect

OT - body mass index

OT - metabolic syndrome

OT - psychosis

EDAT- 2023/06/16 13:10

MHDA- 2023/08/03 06:43

CRDT- 2023/06/16 09:02

PHST- 2022/09/29 00:00 [received]

PHST- 2023/03/03 00:00 [revised]

PHST- 2023/06/15 00:00 [accepted]

PHST- 2023/08/03 06:43 [medline]

PHST- 2023/06/16 13:10 [pubmed]

PHST- 2023/06/16 09:02 [entrez]

AID - 7199539 [pii]

AID - pyad029 [pii]

AID - 10.1093/ijnp/pyad029 [doi]

PST - ppublish

SO - Int J Neuropsychopharmacol. 2023 Jul 31;26(7):451-464. doi: 10.1093/ijnp/pyad029.

PMID- 37315478

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230829

IS - 1873-7943 (Electronic)

IS - 0005-7916 (Linking)

VI - 81

DP - 2023 Dec

TI - Effects of an eating club for people with a psychotic disorder on personal

recovery: Results of a randomized controlled trial.

PG - 101871

LID - S0005-7916(23)00038-1 [pii]

LID - 10.1016/j.jbtep.2023.101871 [doi]

AB - BACKGROUND AND OBJECTIVES: Many people with a psychotic disorder are coping with

severe psychosocial limitations related to their illness. The current randomized

controlled trial (RCT) investigates the effects of an eating club intervention

(HospitalitY (HY)) aimed to improve personal and societal recovery. METHODS: In

15 biweekly sessions participants received individual home-based skill training

and guided peer support sessions in groups of three participants from a trained

nurse. A multi-center RCT was conducted (intended sample size: n = 84; n = 7 per

block) in patients with a diagnosis of schizophrenia spectrum receiving community

treatment. HospitalitY was compared to a Waiting List Control (WLC) condition at

three time points (baseline, end-of-treatment (8 months) and follow-up (12

months)) using personal recovery as primary outcome and loneliness, social

support, self-stigma, self-esteem, social skills, (social) functioning,

independency competence, and psychopathology as secondary outcomes. Outcomes were

evaluated with a mixed modeling statistical procedure. RESULTS: The

HY-intervention had no significant effects on personal recovery or secondary

outcomes. More attendance was associated with higher scores on social

functioning. LIMITATIONS: With N = 43 participants included, power was

insufficient. Seven HY-groups were started, from which three discontinued before

the sixth meeting, one HY group stopped due the start of the COVID-19 pandemic.

CONCLUSIONS: Despite a promising pilot study on feasibility, the current RCT did

not show any effects of the HY intervention. A mixed qualitative-quantitative

research methods might be more appropriate for researching the

HospitalitY-intervention to investigate what social and cognitive processes are

at play in this peer guided social intervention.

FAU - Vogel, Jelle Sjoerd

AU - Vogel JS

AD - Lentis Psychiatric Institute, Lentis Research, Hereweg 80, 9725 AG, Groningen,

the Netherlands; University of Groningen, Faculty of Behavioural and Social

Sciences, Grote Kruisstraat 2/1, 9712 TS, Groningen, the Netherlands; University

of Groningen, University Medical Center Groningen, University Center for

Psychiatry, Rob Giel Research Center, P.O. 30001, 9700 RB, Groningen, the

Netherlands. Electronic address: js.vogel@lentis.nl.

FAU - Bruins, Jojanneke

AU - Bruins J

AD - Lentis Psychiatric Institute, Lentis Research, Hereweg 80, 9725 AG, Groningen,

the Netherlands; University of Groningen, University Medical Center Groningen,

University Center for Psychiatry, Rob Giel Research Center, P.O. 30001, 9700 RB,

Groningen, the Netherlands.

FAU - Swart, Marte

AU - Swart M

AD - Lentis Psychiatric Institute, Flexible Assertive Community Treatment Groningen,

Hereweg 80, 9725 AG, Groningen, the Netherlands.

FAU - Liemburg, Edith

AU - Liemburg E

AD - University of Groningen, University Medical Center Groningen, University Center

for Psychiatry, Rob Giel Research Center, P.O. 30001, 9700 RB, Groningen, the

Netherlands.

FAU - van der Gaag, Mark

AU - van der Gaag M

AD - VU University Amsterdam, Department of Clinical Psychology, Van der

Boechorststraat 1, 1081 BR, Amsterdam, the Netherlands; Amsterdam Public Mental

Health Research Institute, Van der Boechorststraat 1, 1081 BR, Amsterdam, the

Netherlands; Parnassia Psychiatric Institute, Department of Psychosis Research,

Zoutkeetsingel 40, 2512 HN, The Hague, the Netherlands.

FAU - Castelein, Stynke

AU - Castelein S

AD - Lentis Psychiatric Institute, Lentis Research, Hereweg 80, 9725 AG, Groningen,

the Netherlands; University of Groningen, Faculty of Behavioural and Social

Sciences, Grote Kruisstraat 2/1, 9712 TS, Groningen, the Netherlands; University

of Groningen, University Medical Center Groningen, University Center for

Psychiatry, Rob Giel Research Center, P.O. 30001, 9700 RB, Groningen, the

Netherlands.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230515

PL - Netherlands

TA - J Behav Ther Exp Psychiatry

JT - Journal of behavior therapy and experimental psychiatry

JID - 0245075

SB - IM

MH - Humans

MH - *COVID-19

MH - *Psychotic Disorders/complications/therapy

MH - *Schizophrenia/complications

MH - Social Support

MH - Self Concept

OTO - NOTNLM

OT - Loneliness

OT - Mental health recovery

OT - Nursing

OT - Randomized controlled trial

OT - Schizophrenia/rehabilitation

OT - Social support

COIS- Declaration of competing interest The authors have no conflict of interest to

declare.

EDAT- 2023/06/15 01:08

MHDA- 2023/08/28 06:41

CRDT- 2023/06/14 18:07

PHST- 2021/12/13 00:00 [received]

PHST- 2023/04/24 00:00 [revised]

PHST- 2023/05/06 00:00 [accepted]

PHST- 2023/08/28 06:41 [medline]

PHST- 2023/06/15 01:08 [pubmed]

PHST- 2023/06/14 18:07 [entrez]

AID - S0005-7916(23)00038-1 [pii]

AID - 10.1016/j.jbtep.2023.101871 [doi]

PST - ppublish

SO - J Behav Ther Exp Psychiatry. 2023 Dec;81:101871. doi:

10.1016/j.jbtep.2023.101871. Epub 2023 May 15.

PMID- 37290345

OWN - NLM

STAT- MEDLINE

DCOM- 20230619

LR - 20230619

IS - 1973-8102 (Electronic)

IS - 0010-9452 (Linking)

VI - 165

DP - 2023 Aug

TI - Kraepelin's schizophasia: Chaotic speech with preservation of comprehension and

activities of daily living.

PG - 160-171

LID - S0010-9452(23)00107-7 [pii]

LID - 10.1016/j.cortex.2023.04.010 [doi]

AB - BACKGROUND: In his classic account of dementia praecox Kraepelin reserved a few

pages for a small number of psychotic patients with disorganized speech but who

retained the ability to cope with their daily lives. CASE REPORT: A 49-year-old

homemaker has been suffering from a continuous hallucinatory-delusional state

since she was 24 years old. Her verbal and written language was chaotic and full

of neologisms, but fluent and grammatically correct. Speech disorganization was

roughly proportional to the need to express ideas and thoughts through creative

speech. She followed verbal, written, and visuo-gestural commands and flawlessly

repeated words and sentences of variable length. She read aloud and discussed the

news properly. She ran the house, cooked for her relatives, and went to the

supermarket and the bank alone. She knew the prices of common goods and handled

money with ease. The unique coexistence of (i) chaotic speech, (ii) preservation

of aural, written, and gestural comprehension, and (iii) organized non-verbal

behavior, in patients (iv) in a chronic delusional-hallucinatory state is the

hallmark of the syndrome of "schizophasia" originally described by Kraepelin. The

main features of Kraepelin's schizophasia are vividly illustrated by videos and

photos of the patient during her daily life. DISCUSSION: The differential

diagnosis of schizophasia is reviewed, especially with the sensory aphasias

(Wernicke's and transcortical), from which the confusional speech of our patient

was differentiated by her preserved ability to repeat and understand spoken and

written language. Because her primary language abilities were spared, the

cardinal deficit seems to lie at the interface where thoughts and ideas are

encoded into expressive language. CONCLUSION: The expression "Kraepelin's

schizophasia" should be restricted to the speech-behavioral dissociation first

observed by Kraepelin in chronic psychotic patients. The term "schizophasia", in

turn, should be kept as a generic designation for any language alteration in

schizophrenia.

FAU - de Oliveira-Souza, Ricardo

AU - de Oliveira-Souza R

AD - The D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil;

The Federal University of the State of Rio de Janeiro, RJ, Brazil. Electronic

address: rdeoliveira@gmail.com.

LA - eng

PT - Case Reports

PT - Review

DEP - 20230517

PL - Italy

TA - Cortex

JT - Cortex; a journal devoted to the study of the nervous system and behavior

JID - 0100725

SB - IM

MH - Humans

MH - Female

MH - Young Adult

MH - Adult

MH - Middle Aged

MH - *Activities of Daily Living

MH - Comprehension

MH - Speech

MH - *Schizophrenia

MH - Hallucinations

OTO - NOTNLM

OT - Disorganized schizophrenia

OT - Hebephrenic schizophrenia

OT - Schizophasia

OT - Transcortical sensory aphasia

OT - Wernicke's aphasia

EDAT- 2023/06/09 01:09

MHDA- 2023/06/19 13:09

CRDT- 2023/06/08 18:08

PHST- 2022/11/27 00:00 [received]

PHST- 2023/02/08 00:00 [revised]

PHST- 2023/04/04 00:00 [accepted]

PHST- 2023/06/19 13:09 [medline]

PHST- 2023/06/09 01:09 [pubmed]

PHST- 2023/06/08 18:08 [entrez]

AID - S0010-9452(23)00107-7 [pii]

AID - 10.1016/j.cortex.2023.04.010 [doi]

PST - ppublish

SO - Cortex. 2023 Aug;165:160-171. doi: 10.1016/j.cortex.2023.04.010. Epub 2023 May

17.

PMID- 37290243

OWN - NLM

STAT- MEDLINE

DCOM- 20230731

LR - 20230731

IS - 1876-2026 (Electronic)

IS - 1876-2018 (Linking)

VI - 86

DP - 2023 Aug

TI - Effects of a six-month yoga intervention on the immune-inflammatory pathway in

antipsychotic-stabilized schizophrenia patients: A randomized controlled trial.

PG - 103636

LID - S1876-2018(23)00192-2 [pii]

LID - 10.1016/j.ajp.2023.103636 [doi]

AB - BACKGROUND: Schizophrenia is a complex neuropsychiatric disorder for which

several etiopathological theories have been proposed, one of the prominent ones

being immune dysfunction. Recent studies on yoga as an add-on therapy have shown

improvement in negative symptoms, cognition, and quality of life in schizophrenia

patients. However, the biological mechanism/s of action of yoga in schizophrenia

are not clear. The current study was aimed at exploring the effects of long-term

(6 months) add-on yoga therapy on the immune inflammatory pathway in

schizophrenia patients. METHODS: Sixty schizophrenia patients were randomized to

add-on yoga therapy (YT=30) and treatment-as-usual (TAU=30) groups of which 21

patients in YT and 20 in TAU group completed the study. Blood samples and

clinical assessments were obtained at baseline and at the end of 6 months. The

plasma levels of nine cytokines (IL-2, IL-4, IL-5, IL-10, IL-12(p70), IL-13,

GM-CSF, IFN-γ, and TNF-α) were quantified using multiplex suspension array. The

clinical assessments included SAPS, SANS, BPRS, PSS, CGI, SOFS and WHOQUOL-BREF.

RESULTS: Patients in the yoga group showed significant reductions in plasma TNF-α

(Z = 2.99, p = 0.003) and IL-5 levels (Z = 2.20, p = 0.03) and greater clinical

improvements in SAPS, SANS, PSS, and SOFS scores as compared to TAU group.

Further, plasma TNF-α levels exhibited a positive correlation with negative

symptoms (r(s) =0.45, p = 0.02) and socio-occupational functioning (r(s) =0.61,

p = 0.002) in the YT group. CONCLUSIONS: The findings of the study suggest that

improvements in schizophrenia psychopathology with yoga interventions are

associated with immuno-modulatory effects.

FAU - Mullapudi, Thrinath

AU - Mullapudi T

AD - Department of Human Genetics, National Institute of Mental Health and

Neurosciences (NIMHANS), Bangalore, India. Electronic address:

thrinath97@gmail.com.

FAU - Debnath, Monojit

AU - Debnath M

AD - Department of Human Genetics, National Institute of Mental Health and

Neurosciences (NIMHANS), Bangalore, India. Electronic address:

monozeet@gmail.com.

FAU - Govindaraj, Ramajayam

AU - Govindaraj R

AD - Department of Neurophysiology, National Institute of Mental Health and

Neurosciences (NIMHANS), Bangalore, India. Electronic address:

ramji.zero@gmail.com.

FAU - Raj, Praveen

AU - Raj P

AD - Department of Psychiatry, National Institute of Mental Health and Neurosciences

(NIMHANS), Bangalore, India. Electronic address: pvr.ggs@gmail.com.

FAU - Banerjee, Moinak

AU - Banerjee M

AD - Human Molecular Genetics Lab, Rajiv Gandhi Centre for Biotechnology (RGCB),

Trivandrum, Kerala, India. Electronic address: moinak@gmail.com.

FAU - Varambally, Shivarama

AU - Varambally S

AD - Department of Psychiatry, National Institute of Mental Health and Neurosciences

(NIMHANS), Bangalore, India; Department of Integrative Medicine, National

Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.

Electronic address: ssv.nimhans@gmail.com.

LA - eng

GR - IA/CPHI/15/1/502026/WTDBT_/DBT-Wellcome Trust India Alliance/India

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230524

PL - Netherlands

TA - Asian J Psychiatr

JT - Asian journal of psychiatry

JID - 101517820

RN - 0 (Antipsychotic Agents)

RN - 0 (Interleukin-5)

RN - 0 (Tumor Necrosis Factor-alpha)

SB - IM

MH - Humans

MH - *Yoga/psychology

MH - *Antipsychotic Agents/therapeutic use

MH - *Schizophrenia/drug therapy

MH - Quality of Life

MH - Interleukin-5/therapeutic use

MH - Tumor Necrosis Factor-alpha

MH - Treatment Outcome

OTO - NOTNLM

OT - Cytokines

OT - Immunomodulation

OT - Inflammation

OT - Pharmacotherapy

OT - Schizophrenia

OT - Yoga therapy

COIS- Declaration of Competing Interest The authors have no conflict of interest to

declare.

EDAT- 2023/06/09 01:09

MHDA- 2023/07/31 06:42

CRDT- 2023/06/08 18:04

PHST- 2023/02/13 00:00 [received]

PHST- 2023/05/20 00:00 [revised]

PHST- 2023/05/21 00:00 [accepted]

PHST- 2023/07/31 06:42 [medline]

PHST- 2023/06/09 01:09 [pubmed]

PHST- 2023/06/08 18:04 [entrez]

AID - S1876-2018(23)00192-2 [pii]

AID - 10.1016/j.ajp.2023.103636 [doi]

PST - ppublish

SO - Asian J Psychiatr. 2023 Aug;86:103636. doi: 10.1016/j.ajp.2023.103636. Epub 2023

May 24.

PMID- 37286548

OWN - NLM

STAT- MEDLINE

DCOM- 20230609

LR - 20230611

IS - 2158-3188 (Electronic)

IS - 2158-3188 (Linking)

VI - 13

IP - 1

DP - 2023 Jun 7

TI - Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main

subscales plus the PANSS-6, and the relationship to subsequent improvement and

trial dropout: a pooled participant-level analysis of 18 placebo-controlled

risperidone and paliperidone trials.

PG - 191

LID - 10.1038/s41398-023-02491-6 [doi]

LID - 191

AB - Greater initial severity on the 30-item Positive and Negative Syndrome Scale

(PANSS-30) correlates positively with antipsychotic-placebo separation and trial

dropout, but it is unknown whether these associations are present also on

PANSS-derived subscales. We assessed the relationship between initial severity

and antipsychotic-placebo separation as measured by PANSS-30 and four PANSS

symptom subscales: the positive (PANSS-POS), negative (PANSS-NEG), general

(PANSS-GEN) and 6-item (PANSS-6) subscales, using patient-level data from 18

placebo-controlled risperidone and paliperidone trials. Analysis of covariance in

the intention-to-treat population (last-observation-carried-forward) was used to

assess antipsychotic-placebo separation and trial dropout. Across 6685

participants (90% schizophrenia, 10% schizoaffective disorder), the initial

severity-by-treatment interaction was statistically significant for PANSS-30

(beta: -0.155; p < 0.001) and all PANSS subscales (beta range: -0.097 to -0.135;

p-value range: < 0.001 to 0.002). In all cases, antipsychotic-placebo differences

increased with initial severity. Judging by the distribution of relative outcomes

(percent remaining symptoms), the interaction was partly explained by an

increased chance of responding, but also by larger numerical responses in those

who did respond, as initial severity increased. Except for PANSS-NEG, high

initial severity on all PANSS scales predicted increased trial dropout, although

not statistically significantly so for PANSS-6. In summary, we thus replicate

previous findings showing greater initial severity to predict larger

antipsychotic-placebo separation and extend these results to four PANSS

subscales. For PANSS-POS and PANSS-GEN, but not for PANSS-NEG and PANSS-6, we

also replicate the association between initial severity and trial dropout.

Patients with low initial negative symptom severity were identified as a group of

particular interest for further study since their results diverged most from the

average both with regard to antipsychotic-placebo separation (low separation

measured by PANSS-NEG) and trial dropout (high level).

FAU - Hieronymus, Fredrik

AU - Hieronymus F

AUID- ORCID: 0000-0003-0930-6068

AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

fredrik.hieronymus@neuro.gu.se.

AD - Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg,

Sweden. fredrik.hieronymus@neuro.gu.se.

FAU - Correll, Christoph Ulrich

AU - Correll CU

AD - The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen

Oaks, NY, USA.

AD - Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of

Psychiatry and Molecular Medicine, Hempstead, NY, USA.

AD - Charité Universitätsmedizin Berlin, Department of Child and Adolescent

Psychiatry, Berlin, Germany.

FAU - Østergaard, Søren Dinesen

AU - Østergaard SD

AUID- ORCID: 0000-0002-8032-6208

AD - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

AD - Department of Affective Disorders, Aarhus University Hospital - Psychiatry,

Aarhus, Denmark.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230607

PL - United States

TA - Transl Psychiatry

JT - Translational psychiatry

JID - 101562664

RN - L6UH7ZF8HC (Risperidone)

RN - 0 (Antipsychotic Agents)

RN - R8P8USM8FR (Paliperidone Palmitate)

SB - IM

MH - Humans

MH - Risperidone/therapeutic use

MH - *Antipsychotic Agents/therapeutic use

MH - Paliperidone Palmitate/therapeutic use

MH - Treatment Outcome

MH - *Schizophrenia/diagnosis/drug therapy

MH - Psychiatric Status Rating Scales

MH - Double-Blind Method

PMC - PMC10247743

COIS- Aarhus University, The Feinstein Institute for Medical Research, and

MedAvante-ProPhase Inc. each hold one-third of the copyright for the Simplified

Negative and Positive Symptoms Interview (SNAPSI). CUC has been a consultant

and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes,

Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel,

CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk,

IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck,

MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan,

Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech,

Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma,

Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and

Otsuka. He served on a Data Safety Monitoring Board for Compass, Lundbeck,

Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from

Janssen and Takeda. He received royalties from UpToDate and is also a stock

option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. SDØ has

received the 2020 Lundbeck Foundation Young Investigator Prize. SDØ owns/has

owned units of mutual funds with stock tickers DKIGI, IAIMWC, SPIC25KL and

WEKAFKI, and has owned units of exchange traded funds with stock tickers BATE,

TRET, QDV5, QDVH, QDVE, SADM, IQQH, USPY, EXH2, 2B76 and EUNL. FH has received

speaker’s fees from H Lundbeck and Janssen.

EDAT- 2023/06/08 01:08

MHDA- 2023/06/09 06:42

CRDT- 2023/06/07 23:16

PHST- 2023/02/07 00:00 [received]

PHST- 2023/05/26 00:00 [accepted]

PHST- 2023/05/19 00:00 [revised]

PHST- 2023/06/09 06:42 [medline]

PHST- 2023/06/08 01:08 [pubmed]

PHST- 2023/06/07 23:16 [entrez]

AID - 10.1038/s41398-023-02491-6 [pii]

AID - 2491 [pii]

AID - 10.1038/s41398-023-02491-6 [doi]

PST - epublish

SO - Transl Psychiatry. 2023 Jun 7;13(1):191. doi: 10.1038/s41398-023-02491-6.

PMID- 37286358

OWN - NLM

STAT- MEDLINE

DCOM- 20230609

LR - 20230611

IS - 1469-7610 (Electronic)

IS - 0021-9630 (Linking)

VI - 64

IP - 7

DP - 2023 Jul

TI - Editorial: What's in a name? Drawing on the examples of autism and schizophrenia,

some reflections on diagnostic labels and their future role in child and

adolescent psychiatry.

PG - 977-979

LID - 10.1111/jcpp.13839 [doi]

AB - Ten years have passed since the release of DSM-5, which brought with it some

notable changes in diagnostic labels. In this editorial, the impact of labels,

and the changes in labels used in child and adolescent psychiatry, are discussed,

with examples drawn from autism and schizophrenia. The diagnostic labels that

children and adolescents receive feed into their treatment access and future

potential but also to their self-identities. Outside of medicine, extensive

budgets and time are spent to test how consumers identify with the labels of

products. Diagnoses are not commercial products, of course, but the choice of

labels used in child and adolescent psychiatry should remain a priority, in light

of their impact on translational science, treatment and on individuals, alongside

the ever-evolving nature of language itself.

FAU - Ronald, Angelica

AU - Ronald A

AD - School of Psychology, Faculty of Health and Medical Sciences, University of

Surrey, Surrey, UK.

LA - eng

PT - Editorial

PT - Research Support, Non-U.S. Gov't

PL - England

TA - J Child Psychol Psychiatry

JT - Journal of child psychology and psychiatry, and allied disciplines

JID - 0375361

SB - IM

MH - Adolescent

MH - Humans

MH - Child

MH - *Autistic Disorder/diagnosis

MH - Adolescent Psychiatry

MH - *Schizophrenia/diagnosis

MH - Language

MH - Diagnostic and Statistical Manual of Mental Disorders

EDAT- 2023/06/08 01:08

MHDA- 2023/06/09 06:42

CRDT- 2023/06/07 21:23

PHST- 2023/05/16 00:00 [accepted]

PHST- 2023/06/09 06:42 [medline]

PHST- 2023/06/08 01:08 [pubmed]

PHST- 2023/06/07 21:23 [entrez]

AID - 10.1111/jcpp.13839 [doi]

PST - ppublish

SO - J Child Psychol Psychiatry. 2023 Jul;64(7):977-979. doi: 10.1111/jcpp.13839.

PMID- 37279958

OWN - NLM

STAT- MEDLINE

DCOM- 20230815

LR - 20230817

IS - 1550-9109 (Electronic)

IS - 0161-8105 (Print)

IS - 0161-8105 (Linking)

VI - 46

IP - 8

DP - 2023 Aug 14

TI - Entering the MATRICS: the adverse effects of CBT-I on neurocognitive functioning

in COMISA individuals.

LID - 10.1093/sleep/zsad164 [doi]

LID - zsad164

FAU - Bastien, Célyne H

AU - Bastien CH

AUID- ORCID: 0000-0002-9236-9125

AD - School of Psychology, Université Laval, Québec, Canada.

FAU - Ellis, Jason G

AU - Ellis JG

AUID- ORCID: 0000-0002-8496-520X

AD - Department of Psychology, Northumbria University, Newcastle-upon-Tyne, UK.

FAU - Perlis, Michael L

AU - Perlis ML

AD - Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.

LA - eng

GR - PJK-179821/CIHR/Canada

PT - Comment

PT - Editorial

PT - Research Support, Non-U.S. Gov't

PL - United States

TA - Sleep

JT - Sleep

JID - 7809084

SB - IM

CON - Sleep. 2023 Aug 14;46(8):. PMID: 37148183

MH - Humans

MH - *Sleep Initiation and Maintenance Disorders

MH - *Schizophrenia

MH - Neuropsychological Tests

MH - *Sleep Apnea Syndromes

MH - *Cognitive Behavioral Therapy

MH - Cognition

PMC - PMC10424159

EDAT- 2023/06/07 01:07

MHDA- 2023/08/15 06:42

PMCR- 2024/06/06

CRDT- 2023/06/06 20:13

PHST- 2024/06/06 00:00 [pmc-release]

PHST- 2023/08/15 06:42 [medline]

PHST- 2023/06/07 01:07 [pubmed]

PHST- 2023/06/06 20:13 [entrez]

AID - 7190855 [pii]

AID - zsad164 [pii]

AID - 10.1093/sleep/zsad164 [doi]

PST - ppublish

SO - Sleep. 2023 Aug 14;46(8):zsad164. doi: 10.1093/sleep/zsad164.

PMID- 37279603

OWN - NLM

STAT- MEDLINE

DCOM- 20230703

LR - 20230703

IS - 1743-6109 (Electronic)

IS - 1743-6095 (Linking)

VI - 20

IP - 7

DP - 2023 Jun 28

TI - Sexual dysfunction related to psychiatric disorders: a systematic review.

PG - 965-976

LID - 10.1093/jsxmed/qdad074 [doi]

AB - BACKGROUND: Sexual dysfunction is thought to be highly prevalent in patients with

psychiatric disorders. Factors such as the use of psychotropic substances (ie,

psychopharmaceuticals and drugs), age, or somatic diseases may contribute to

sexual problems, but the extent to which psychopathology itself affects sexual

functioning is not well understood. AIM: The study sought to provide an overview

of the literature on the prevalence of sexual dysfunction in psychotropic-free

and somatic disease-free psychiatric patients. METHOD: A systematic review

(PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) was

conducted by 2 authors (TH and AWMP) independently, with the review process being

monitored by a third author. Relevant articles on the relationship between sexual

dysfunctions and psychopathology were searched in PubMed, Web of Science, and

PsycINFO from inception until June 16, 2022. The study methods were entered in

the international register of systematic reviews PROSPERO (2021, CRD42021223410).

OUTCOMES: The main outcome measures were sexual dysfunction and sexual

satisfaction. RESULTS: Twenty-four studies were identified, including a total of

1199 patients. These studies focused on depressive disorders (n = 9 studies),

anxiety disorders (n = 7), obsessive- compulsive disorder (OCD) (n = 5),

schizophrenia (n = 4), and posttraumatic stress disorder (n = 2). No studies on

bipolar disorder were found. Reported prevalence rates of sexual dysfunction in

psychiatric disorders were 45% to 93% for depressive disorders, 33% to 75% for

anxiety disorders, 25% to 81% for OCD, and 25% for schizophrenia. The most

affected phase of the sexual response cycle was sexual desire, in both men and

women with depressive disorders, posttraumatic stress disorder, and

schizophrenia. Patients with OCD and anxiety disorders most frequently reported

dysfunction in the orgasm phase, 24% to 44% and 7% to 48%, respectively. CLINICAL

IMPLICATIONS: The high prevalence of sexual dysfunction requires more clinical

attention by means of psychoeducation, clinical guidance, sexual anamnesis, and

additional sexological treatment. STRENGTHS AND LIMITATIONS: This is the first

systematic review on sexual dysfunction in psychotropic-free and somatic

disease-free psychiatric patients. Limitations include the small number of

studies, small sample sizes, the use of multiple questionnaires (some not

validated), which may contribute to bias. CONCLUSION: A limited number of studies

identified a high prevalence of sexual dysfunction in patients with a psychiatric

disorder, with substantial variation between patient groups in frequency and

phase of reported sexual dysfunction.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of The

please e-mail: journals.permissions@oup.com.

FAU - Herder, T

AU - Herder T

AD - Department of Psychiatry, Martini Hospital, Groningen, 9728 NT, the Netherlands.

FAU - Spoelstra, S K

AU - Spoelstra SK

AD - Addiction Care North Netherlands, Groningen, 9728 NT, the Netherlands.

FAU - Peters, A W M

AU - Peters AWM

AD - Lentis Research, Lentis Mental Health Institute, Groningen, 9728 NT, the

Netherlands.

FAU - Knegtering, H

AU - Knegtering H

AD - Lentis Research, Lentis Mental Health Institute, Groningen, 9728 NT, the

Netherlands.

AD - Department of Psychiatry and Rob Giel Research Center, University Medical Center

Groningen, University of Groningen, Groningen, 9728 NT, the Netherlands.

LA - eng

PT - Journal Article

PT - Systematic Review

PL - Netherlands

TA - J Sex Med

JT - The journal of sexual medicine

JID - 101230693

SB - IM

MH - Male

MH - Humans

MH - Female

MH - *Sexual Dysfunction, Physiological/epidemiology/etiology

MH - Sexual Behavior/psychology

MH - *Schizophrenia/epidemiology

MH - Libido/physiology

MH - *Stress Disorders, Post-Traumatic/complications/epidemiology

OTO - NOTNLM

OT - prevalence

OT - psychiatric disorders

OT - sexual dysfunction

EDAT- 2023/06/06 19:13

MHDA- 2023/07/03 06:41

CRDT- 2023/06/06 17:54

PHST- 2022/12/13 00:00 [received]

PHST- 2023/05/03 00:00 [revised]

PHST- 2023/05/06 00:00 [accepted]

PHST- 2023/07/03 06:41 [medline]

PHST- 2023/06/06 19:13 [pubmed]

PHST- 2023/06/06 17:54 [entrez]

AID - 7190127 [pii]

AID - 10.1093/jsxmed/qdad074 [doi]

PST - ppublish

SO - J Sex Med. 2023 Jun 28;20(7):965-976. doi: 10.1093/jsxmed/qdad074.

PMID- 37272857

OWN - NLM

STAT- MEDLINE

DCOM- 20230607

LR - 20231010

IS - 1469-493X (Electronic)

IS - 1361-6137 (Linking)

VI - 6

IP - 6

DP - 2023 Jun 5

TI - Magnetic seizure therapy for people with schizophrenia.

PG - CD012697

LID - 10.1002/14651858.CD012697.pub2 [doi]

LID - CD012697

AB - BACKGROUND: Schizophrenia is one of the most common and disabling mental

disorders. About 20% of people with schizophrenia do not respond to

antipsychotics, which are the mainstay of the treatment for schizophrenia today,

and need to seek other treatment options. Magnetic seizure therapy (MST) is one

of the novel non-invasive brain stimulation techniques that are being

investigated in recent years. OBJECTIVES: To evaluate the efficacy and

tolerability of MST for people with schizophrenia. SEARCH METHODS: On 6 March

2022, we searched the Cochrane Schizophrenia Group's Study-Based Register of

Trials which is based on CENTRAL, CINAHL, ClinicalTrials.Gov, Embase, ISRCTN,

MEDLINE, PsycINFO, PubMed, and WHO ICTRP. SELECTION CRITERIA: All randomised

controlled trials (RCTs) comparing MST alone or plus standard care with ECT or

any other interventions for people with schizophrenia. DATA COLLECTION AND

ANALYSIS: We performed reference screening, study selection, data extraction and

risk of bias and quality assessment in duplicate. We calculated the risk ratios

(RRs) and their 95% confidence intervals (CIs) for binary outcomes and the mean

difference (MD) and their 95% CIs for continuous outcomes. We used the original

risk of bias tool for risk of bias assessment and created a Summary of findings

table using GRADE. MAIN RESULTS: We included one four-week study with 79 adults

in acute schizophrenia, comparing MST plus standard care to ECT plus standard

care in this review. We rated the overall risk of bias as high due to high risk

of bias in the domains of selective reporting and other biases (early termination

and baseline imbalance) and unclear risk of bias in the domain of blinding of

participants and personnel. We found that MST and ECT may not differ in improving

the global state (n = 79, risk ratio (RR) 1.12, 95% confidence interval (CI) 0.73

to 1.70), overall (n = 79, mean difference (MD) -0.20, 95% CI -8.08 to 7.68), the

positive symptoms (n = 79, MD 1.40, 95% CI -1.97 to 4.77) and the negative

symptoms (n = 79, MD -1.00, 95% CI -3.85 to 1.85) in people with schizophrenia.

We found that MST compared to ECT may cause less delayed memory deficit and less

cognitive deterioration (n = 79, number of people with a delayed memory deficit,

RR 0.63, 95% CI 0.41 to 0.96; n = 79, mean change in global cognitive function,

MD 5.80, 95% CI 0.80 to 10.80), but also may improve more cognitive function (n =

47, number of people with any cognitive improvement, RR 3.30, 95% CI 1.29 to

8.47). We found that there may be no difference between the two groups in terms

of leaving the study early due to any reason (n = 79, RR 2.51, 95% CI 0.73 to

8.59), due to adverse effects (n = 79, RR 3.35, 95% CI 0.39 to 28.64) or due to

inefficacy (n = 79, RR 2.52, 95% CI 0.11 to 60.10). Since all findings were

based on one study with high risk of bias and the confidence in the evidence was

very low, we were not sure these comparable or favourable effects of MST over ECT

were its true effects. AUTHORS' CONCLUSIONS: Due to the paucity of data, we

cannot draw any conclusion on the efficacy and tolerability of MST for people

with schizophrenia. Well-designed RCTs are warranted to answer the question.

FAU - Wu, Hui

AU - Wu H

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

AD - Section for Evidence Based Medicine in Psychiatry and Psychotherapy, Department

of Psychiatry and Psychotherapy, School of Medicine, Technical University of

Munich, Munich, Germany.

FAU - Jiang, Jiangling

AU - Jiang J

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Cao, Xinyi

AU - Cao X

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Wang, Jijun

AU - Wang J

AD - Department of EEG Source Imaging, Shanghai Mental Health Center, Shanghai Jiao

Tong University School of Medicine, Shanghai, China.

FAU - Li, Chunbo

AU - Li C

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

PT - Systematic Review

DEP - 20230605

PL - England

TA - Cochrane Database Syst Rev

JT - The Cochrane database of systematic reviews

JID - 100909747

RN - 0 (Antipsychotic Agents)

SB - IM

UOF - doi: 10.1002/14651858.CD012697

MH - Adult

MH - Humans

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/adverse effects

MH - Memory Disorders

PMC - PMC10241155

COIS- HW: was the Managing Editor of Cochrane Schizophrenia Group and was not involved

in any editorial process of this review. JJ: participated in the included study;

he was excluded from data extraction, risk of bias assessment and quality

assessment of this study. XC: none known JW: participated in the included study;

he was excluded from data extraction, risk of bias assessment and quality

assessment of this study. CL: is an Editor of Cochrane Schizophrenia Group and

was not involved in any editorial process of this review. CL is the PI of the

included study; he was excluded from data extraction, risk of bias assessment and

quality assessment of this study.

EDAT- 2023/06/05 13:04

MHDA- 2023/06/07 06:42

PMCR- 2024/06/05

CRDT- 2023/06/05 10:23

PHST- 2024/06/05 00:00 [pmc-release]

PHST- 2023/06/07 06:42 [medline]

PHST- 2023/06/05 13:04 [pubmed]

PHST- 2023/06/05 10:23 [entrez]

AID - CD012697.pub2 [pii]

AID - 10.1002/14651858.CD012697.pub2 [doi]

PST - epublish

SO - Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD012697. doi:

10.1002/14651858.CD012697.pub2.

PMID- 37272079

OWN - NLM

STAT- MEDLINE

DCOM- 20230717

LR - 20230718

IS - 1473-4877 (Electronic)

IS - 0300-7995 (Linking)

VI - 39

IP - 7

DP - 2023 Jul

TI - Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary

analysis of outcomes in adult patients with bipolar I disorder in a randomized,

open-label, parallel-arm, pivotal study.

PG - 1021-1030

LID - 10.1080/03007995.2023.2219155 [doi]

AB - OBJECTIVE: Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new

long-acting injectable antipsychotic formulation for administration every

2 months. A 32-week trial evaluated the safety, tolerability, and

pharmacokinetics of Ari 2MRTU 960 in clinically stable adults with schizophrenia

or bipolar I disorder (BP-I) (per DSM-5 criteria). This secondary analysis

evaluated the safety and efficacy of Ari 2MRTU 960 in the subpopulation of

patients with BP-I. METHODS: Patients with BP-I were randomized to receive Ari

2MRTU 960 (n = 40) every 56 ± 2 days (4 injections scheduled) or aripiprazole

once-monthly 400 mg (AOM 400; n = 41) every 28 ± 2 days (8 injections scheduled).

Data were collected during August 2019-July 2020 across 16 US sites. Primary

safety endpoints included reported adverse events (coded by the Medical

Dictionary for Regulatory Activities preferred term), injection site reactions

(assessments included a Visual Analog Scale [VAS] to evaluate patient-reported

injection-site pain), and motoric symptoms. Secondary endpoints for efficacy

included change from baseline at Week 32 in the Young Mania Rating Scale (YMRS),

Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression -

Bipolar Version (CGI-BP), and Subjective Well-being under Neuroleptic Treatment -

Short Form (SWN-S) scores, and Clinical Global Impression - Improvement (CGI-I)

at Week 32. RESULTS: The incidence of treatment-emergent adverse events (TEAEs)

was similar between Ari 2MRTU 960 (82.5% [33/40]) and AOM 400 (87.8% [36/41];

p = .5468). The most frequently reported TEAE was increased weight (Ari 2MRTU

960: 25.0% [10/40]; AOM 400: 26.8% [11/41]; p = 1). Injection-site pain was

experienced by more patients in the Ari 2MRTU 960 group (25% [10/40]) versus the

AOM 400 group (7.3% [3/41]; p = .0622). Mean (standard deviation [SD]) VAS scores

for patient-reported injection-site pain following the last injection were 1.2

(2.07) for Ari 2MRTU 960 group and 1.3 (2.19) for AOM 400 (p = .9479) (VAS scale

range 0-100 [no pain-extreme pain]). No notable improvement or decline from

baseline was observed in motoric symptoms in either treatment group. Patients in

both treatment groups remained clinically stable for the entire 32-week trial

duration, with minimal difference between treatment groups in the least squares

(LS) mean change from baseline at Week 32 in the YMRS Total (p = .8995), MADRS

Total (p = .3185), and CGI-BP scores (p = .8485), and in mean CGI-I score

(p = .7960). LS mean change from baseline in SWN-S score was greater for Ari

2MRTU 960 than for AOM 400 at Week 32 (p = .0169). CONCLUSIONS: Ari 2MRTU 960 was

well tolerated in patients with BP-I, with efficacy similar to AOM 400. TRIAL

REGISTRATION: ClinicalTrials.gov identifier: NCT04030143.

FAU - McIntyre, Roger S

AU - McIntyre RS

AUID- ORCID: 0000-0003-4733-2523

AD - University of Toronto, Toronto, Canada.

AD - Brain and Cognition Discovery Foundation, Toronto, Canada.

FAU - Such, Pedro

AU - Such P

AUID- ORCID: 0000-0003-1905-1142

AD - H. Lundbeck A/S, Valby, Denmark.

FAU - Yildirim, Murat

AU - Yildirim M

AUID- ORCID: 0000-0001-6192-1047

AD - H. Lundbeck A/S, Valby, Denmark.

FAU - Madera-McDonough, Jessica

AU - Madera-McDonough J

AUID- ORCID: 0000-0003-2887-7480

AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.

FAU - Zhang, Zhen

AU - Zhang Z

AUID- ORCID: 0000-0001-8448-5663

AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.

FAU - Larsen, Frank

AU - Larsen F

AUID- ORCID: 0000-0002-8318-1681

AD - H. Lundbeck A/S, Valby, Denmark.

FAU - Harlin, Matthew

AU - Harlin M

AUID- ORCID: 0000-0001-7087-2734

AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.

LA - eng

SI - ClinicalTrials.gov/NCT04030143

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230609

PL - England

TA - Curr Med Res Opin

JT - Current medical research and opinion

JID - 0351014

RN - 82VFR53I78 (Aripiprazole)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - Adult

MH - Aripiprazole/adverse effects

MH - *Bipolar Disorder/drug therapy

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - Injections

MH - Treatment Outcome

MH - Double-Blind Method

OTO - NOTNLM

OT - Long-acting injectable

OT - Montgomery–Åsberg Depression Rating Scale

OT - Subjective Well-being under Neuroleptic Treatment – Short Form

OT - Young Mania Rating Scale

OT - antipsychotic

EDAT- 2023/06/05 06:42

MHDA- 2023/07/17 06:42

CRDT- 2023/06/05 03:41

PHST- 2023/07/17 06:42 [medline]

PHST- 2023/06/05 06:42 [pubmed]

PHST- 2023/06/05 03:41 [entrez]

AID - 10.1080/03007995.2023.2219155 [doi]

PST - ppublish

SO - Curr Med Res Opin. 2023 Jul;39(7):1021-1030. doi: 10.1080/03007995.2023.2219155.

Epub 2023 Jun 9.

PMID- 37269769

OWN - NLM

STAT- MEDLINE

DCOM- 20230613

LR - 20230615

IS - 1873-7714 (Electronic)

IS - 0163-8343 (Linking)

VI - 83

DP - 2023 Jul-Aug

TI - Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in

patients with schizophrenia spectrum disorders? Results from a pragmatic,

randomised study.

PG - 185-193

LID - S0163-8343(23)00078-6 [pii]

LID - 10.1016/j.genhosppsych.2023.05.003 [doi]

AB - OBJECTIVES: Drug use is prevalent in patients with schizophrenia spectrum

disorders (SSD) but there is limited knowledge about the influence of drug use on

the effectiveness of antipsychotic medication. This secondary explorative study

compared the effectiveness of three antipsychotics in patients with SSD, with and

without drug use. METHODS: The BeSt InTro multi-centre, head to head,

rater-blinded randomised study compared amisulpride, aripiprazole and olanzapine

over a 1-year follow-up period. All patients (n = 144) were aged ≥18 years and

met the ICD-10 criteria for SSD (F20-29). Clinical symptoms were assessed using

the Positive and Negative Syndrome Scale (PANSS). The primary outcome was

reduction of a PANSS positive subscale score. RESULTS: At baseline, 38% of all

patients reported drug use in the last 6 months before inclusion, with cannabis

as the main drug (85%), followed by amphetamine-type stimulants (45%), sedatives

(26%), hallucinogens (19%), cocaine (13%), opiates (4%), GHB (4%), solvents (4%),

analgesics (4%) and anabolic steroids (2%). The predominant pattern was the use

of several drugs. There were no significant overall differences in the PANSS

positive subscale score reduction for the three studied antipsychotics among

patients either with or without drug use. In the drug use group, older patients

treated with amisulpride showed a greater PANSS positive subscale score reduction

during the treatment period compared to younger patients. CONCLUSION: The current

study showed that drug use does not appear to affect the overall effectiveness of

amisulpride, aripiprazole and olanzapine in patients with SSD. However,

amisulpride may be a particularly suitable choice for older patients with drug

use.

FAU - Alisauskiene, Renata

AU - Alisauskiene R

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; NORMENT Centre of Excellence, Haukeland University Hospital,

Bergen, Norway. Electronic address: renata.alisauskiene@helse-bergen.no.

FAU - Johnsen, Erik

AU - Johnsen E

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; NORMENT Centre of Excellence, Haukeland University Hospital,

Bergen, Norway; Department of Clinical Medicine, University of Bergen, Postbox

7804, N-5020 Bergen, Norway. Electronic address: erik.johnsen@helse-bergen.no.

FAU - Gjestad, Rolf

AU - Gjestad R

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; Centre for Research and Education in Forensic Psychiatry,

Haukeland University Hospital, Sandviksleitet 1, N-5035 Bergen, Norway.

Electronic address: rolf.gjestad@helse-bergen.no.

FAU - Kroken, Rune A

AU - Kroken RA

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; NORMENT Centre of Excellence, Haukeland University Hospital,

Bergen, Norway; Department of Clinical Medicine, University of Bergen, Postbox

7804, N-5020 Bergen, Norway. Electronic address:

rune.andreas.kroken@helse-bergen.no.

FAU - Kjelby, Eirik

AU - Kjelby E

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; NORMENT Centre of Excellence, Haukeland University Hospital,

Bergen, Norway. Electronic address: eirik.kjelby@helse-bergen.no.

FAU - Sinkeviciute, Igne

AU - Sinkeviciute I

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; NORMENT Centre of Excellence, Haukeland University Hospital,

Bergen, Norway. Electronic address: igne.sinkeviciute@helse-bergen.no.

FAU - Fathian, Farivar

AU - Fathian F

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; NORMENT Centre of Excellence, Haukeland University Hospital,

Bergen, Norway. Electronic address: Farivar.Fathian@helse-bergen.no.

FAU - Joa, Inge

AU - Joa I

AD - Network for Clinical Psychosis Research, Division of Psychiatry, Stavanger

University Hospital, Stavanger, Norway. Electronic address: inge.joa@sus.no.

FAU - Reitan, Solveig Klæbo

AU - Reitan SK

AD - Department of Mental Health, Faculty of Medicine and Health Sciences, NTNU,

Trondheim, Norway. Electronic address: solveig.reitan@ntnu.no.

FAU - Rettenbacher, Maria

AU - Rettenbacher M

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of

Innsbruck, Innrain, 52, Innsbruck, Austria. Electronic address:

Maria.Rettenbacher@i-med.ac.at.

FAU - Løberg, Else-Marie

AU - Løberg EM

AD - Division of Psychiatry, Haukeland University Hospital, Sandviksleitet 1, N-5035

Bergen, Norway; Department of Addiction Medicine, Haukeland University Hospital,

Østre Murallmenningen 7, Bergen, Norway; Department of Clinical Psychology,

University of Bergen, Christies gate 12, N-5015 Bergen, Norway; NORMENT Centre of

Excellence, Haukeland University Hospital, Bergen, Norway. Electronic address:

else.marie.loeberg@helse-bergen.no.

LA - eng

PT - Journal Article

PT - Multicenter Study

PT - Randomized Controlled Trial

DEP - 20230508

PL - United States

TA - Gen Hosp Psychiatry

JT - General hospital psychiatry

JID - 7905527

RN - N7U69T4SZR (Olanzapine)

RN - 82VFR53I78 (Aripiprazole)

RN - 0 (Antipsychotic Agents)

RN - 8110R61I4U (Amisulpride)

RN - J60AR2IKIC (Clozapine)

RN - L6UH7ZF8HC (Risperidone)

RN - 12794-10-4 (Benzodiazepines)

RN - 0 (Piperazines)

RN - 0 (Thiazoles)

SB - IM

MH - Humans

MH - Adolescent

MH - Adult

MH - Olanzapine/therapeutic use

MH - Aripiprazole/pharmacology/therapeutic use

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - Amisulpride/pharmacology/therapeutic use

MH - *Clozapine/adverse effects

MH - Risperidone/adverse effects

MH - Benzodiazepines/therapeutic use

MH - Piperazines/adverse effects

MH - Thiazoles/adverse effects

MH - Treatment Outcome

OTO - NOTNLM

OT - Amisulpride

OT - Antipsychotics

OT - Aripiprazole

OT - Drug use

OT - Olanzapine

OT - Schizophrenia

COIS- Declaration of Competing Interest None.

EDAT- 2023/06/04 01:08

MHDA- 2023/06/13 06:42

CRDT- 2023/06/03 18:08

PHST- 2022/03/18 00:00 [received]

PHST- 2023/05/01 00:00 [revised]

PHST- 2023/05/03 00:00 [accepted]

PHST- 2023/06/13 06:42 [medline]

PHST- 2023/06/04 01:08 [pubmed]

PHST- 2023/06/03 18:08 [entrez]

AID - S0163-8343(23)00078-6 [pii]

AID - 10.1016/j.genhosppsych.2023.05.003 [doi]

PST - ppublish

SO - Gen Hosp Psychiatry. 2023 Jul-Aug;83:185-193. doi:

10.1016/j.genhosppsych.2023.05.003. Epub 2023 May 8.

PMID- 37267733

OWN - NLM

STAT- MEDLINE

DCOM- 20230612

LR - 20230612

IS - 1879-1379 (Electronic)

IS - 0022-3956 (Linking)

VI - 163

DP - 2023 Jul

TI - Exosome and exosomal contents in schizophrenia.

PG - 365-371

LID - S0022-3956(23)00266-2 [pii]

LID - 10.1016/j.jpsychires.2023.05.072 [doi]

AB - Schizophrenia (SCZ) is a severe mental disorder that affects approximately 1%

general population worldwide and poses a considerable burden to society. Despite

decades of research, its etiology remains unclear, and diagnosis remains

challenging due to its heterogeneous symptoms. Exosomes play a crucial role in

intercellular communication, and their contents, including nucleotides, proteins

and metabolites, have been linked to various diseases. Recent studies have

implicated exosome abnormalities in the pathogenesis of schizophrenia. In this

review, we discuss the current understanding of the relationship between exosomes

and schizophrenia, focusing on the role of exosomal contents in this disease. We

summarize recent findings and provide insights into the potential use of exosomes

as biomarkers for the diagnosis and treatment of schizophrenia.

FAU - Zhang, Tingkai

AU - Zhang T

AD - Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School

of Medicine, Hangzhou, China.

FAU - Fang, Yehong

AU - Fang Y

AD - Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School

of Medicine, Hangzhou, China.

FAU - Wang, Liangliang

AU - Wang L

AD - Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School

of Medicine, Hangzhou, China.

FAU - Gu, Lin

AU - Gu L

AD - RIKEN AIP, Tokyo, Japan; Research Center for Advanced Science and Technology

(RCAST), The University of Tokyo, Tokyo, Japan.

FAU - Tang, Jinsong

AU - Tang J

AD - Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School

of Medicine, Hangzhou, China. Electronic address: tangjinsong@zju.edu.cn.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230525

PL - England

TA - J Psychiatr Res

JT - Journal of psychiatric research

JID - 0376331

RN - 0 (Biomarkers)

RN - 0 (MicroRNAs)

SB - IM

MH - Humans

MH - *Schizophrenia/metabolism

MH - *Exosomes/metabolism

MH - Biomarkers/metabolism

MH - *MicroRNAs/metabolism

OTO - NOTNLM

OT - Biomarker

OT - Exosome

OT - Omics

OT - Schizophrenia

OT - miRNA

COIS- Declaration of competing interest The authors declare none.

EDAT- 2023/06/03 11:42

MHDA- 2023/06/12 06:42

CRDT- 2023/06/02 18:04

PHST- 2022/12/12 00:00 [received]

PHST- 2023/03/06 00:00 [revised]

PHST- 2023/05/25 00:00 [accepted]

PHST- 2023/06/12 06:42 [medline]

PHST- 2023/06/03 11:42 [pubmed]

PHST- 2023/06/02 18:04 [entrez]

AID - S0022-3956(23)00266-2 [pii]

AID - 10.1016/j.jpsychires.2023.05.072 [doi]

PST - ppublish

SO - J Psychiatr Res. 2023 Jul;163:365-371. doi: 10.1016/j.jpsychires.2023.05.072.

Epub 2023 May 25.

PMID- 37264935

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230901

IS - 1440-1614 (Electronic)

IS - 0004-8674 (Print)

IS - 0004-8674 (Linking)

VI - 57

IP - 9

DP - 2023 Sep

TI - A challenge to the dopamine orthodoxy in schizophrenia?

PG - 1198-1199

LID - 10.1177/00048674231177958 [doi]

FAU - Norman, Trevor R

AU - Norman TR

AUID- ORCID: 0000-0003-2903-7096

AD - Austin Hospital and Department of Psychiatry, The University of Melbourne,

Heidelberg, VIC, Australia.

FAU - Olver, James S

AU - Olver JS

AD - Austin Hospital and Department of Psychiatry, The University of Melbourne,

Heidelberg, VIC, Australia.

LA - eng

PT - Editorial

DEP - 20230602

PL - England

TA - Aust N Z J Psychiatry

JT - The Australian and New Zealand journal of psychiatry

JID - 0111052

RN - VTD58H1Z2X (Dopamine)

SB - IM

MH - Humans

MH - *Dopamine

MH - *Schizophrenia/drug therapy

PMC - PMC10466983

COIS- The author(s) declared no potential conflicts of interest with respect to the

research, authorship, and/or publication of this article.

EDAT- 2023/06/02 06:43

MHDA- 2023/08/28 06:42

CRDT- 2023/06/02 05:29

PHST- 2023/08/28 06:42 [medline]

PHST- 2023/06/02 06:43 [pubmed]

PHST- 2023/06/02 05:29 [entrez]

AID - 10.1177_00048674231177958 [pii]

AID - 10.1177/00048674231177958 [doi]

PST - ppublish

SO - Aust N Z J Psychiatry. 2023 Sep;57(9):1198-1199. doi: 10.1177/00048674231177958.

Epub 2023 Jun 2.

PMID- 37261669

OWN - NLM

STAT- MEDLINE

DCOM- 20230619

LR - 20230906

IS - 1179-1934 (Electronic)

IS - 1172-7047 (Linking)

VI - 37

IP - 6

DP - 2023 Jun

TI - Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic

Review and Meta-Analysis of Evidence-Based Management Options.

PG - 499-512

LID - 10.1007/s40263-023-01009-4 [doi]

AB - BACKGROUND: Early non-response is a well-established prognostic marker but

evidence-based and consistent recommendations to manage it are limited. The aim

of this systematic review and meta-analysis was to generate evidence-based

strategies for the management of schizophrenia patients with early non-response

to 2 weeks of antipsychotic treatment. METHODS: We conducted a systematic review

and meta-analysis of randomized trials comparing antipsychotic dose escalation,

switch, augmentation and continuation in individuals with study-defined early

antipsychotic treatment non-response. Eligibility criteria were (1) clinical

trials of primary psychosis treating for at least 2 weeks with antipsychotic

monotherapy with study-defined operationalized criteria for early non-response;

and (2) randomization to at least two of the following treatment strategies: dose

escalation, switch, augmentation, or treatment continuation. Information sources

were Pubmed, PsycINFO, and EMBASE, and risk of bias was assessed using Jadad

scores. Results were synthesized using random-effects meta-analysis, comparing

each intervention with treatment continuation for total symptom change as the

primary outcome, generating standardized mean differences (SMDs) and 95%

confidence intervals (CIs). Studies meeting the selection criteria but providing

insufficient data for a meta-analysis were presented separately. RESULTS: We

screened 454 records by 1 August 2022, of which 12 individual datasets met the

inclusion criteria, representing 947 research participants. Of those studies,

five provided data to include in the meta-analysis (four with early non-response

at 2 weeks, one at 3 weeks). Early non-response was defined within a timeline of

2 weeks in eight datasets, with the remaining datasets ranging between 3 and 4

weeks. The rates of early non-response ranged between 72.0 and 24.1%, and the

endpoint ranged within 4-24 weeks post randomization. Quality was good (i.e.,

Jadad score of ≥3) in 8 of the 12 datasets. Overall, three studies compared

antipsychotic switch versus continuation and two compared antipsychotic switch

versus augmentation, in both cases without significant pooled between-group

differences for total symptom severity (n = 149, SMD 0.18, 95% CI -0.14 to 0.5).

Individually, two relatively large studies for antipsychotic switch versus

continuation found small advantages for switching antipsychotics for total

symptom severity (n = 149, SMD -0.49, 95% CI -1.05 to -0.06). One relatively

large study found an advantage for dose escalation, although this finding has not

been replicated and was not included in the meta-analysis. None of the

alternatives included antipsychotic switch to clozapine. CONCLUSIONS: Despite

robust accuracy of early antipsychotic non-response predicting ultimate response,

the evidence for treatment strategies that should be used for early non-response

after 2-3 weeks is limited. While meta-analytic findings were non-significant,

some individual studies suggest advantages of antipsychotic switch or dose

escalation. Therefore, any conclusions should be interpreted carefully, given the

insufficient high-quality evidence.

FAU - Rubio, Jose M

AU - Rubio JM

AUID- ORCID: 0000-0002-0056-4135

AD - The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health,

Glen Oaks, NY, USA.

AD - Institute of Behavioral Science, The Feinstein Institute for Medical Research,

Manhasset, NY, USA.

AD - Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

FAU - Guinart, Daniel

AU - Guinart D

AUID- ORCID: 0000-0001-5078-6716

AD - The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health,

Glen Oaks, NY, USA.

AD - Institute of Behavioral Science, The Feinstein Institute for Medical Research,

Manhasset, NY, USA.

AD - Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

AD - Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Institut de

Neuropsiquiatria i Addiccions (INAD), Hospital del Mar, Institut Hospital del Mar

d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

FAU - Kane, John M

AU - Kane JM

AUID- ORCID: 0000-0002-2628-9442

AD - The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health,

Glen Oaks, NY, USA.

AD - Institute of Behavioral Science, The Feinstein Institute for Medical Research,

Manhasset, NY, USA.

AD - Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

FAU - Correll, Christoph U

AU - Correll CU

AUID- ORCID: 0000-0002-7254-5646

AD - The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health,

Glen Oaks, NY, USA. ccorrell@northwell.edu.

AD - Institute of Behavioral Science, The Feinstein Institute for Medical Research,

Manhasset, NY, USA. ccorrell@northwell.edu.

AD - Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.

ccorrell@northwell.edu.

AD - Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin

Berlin, Berlin, Germany. ccorrell@northwell.edu.

LA - eng

GR - K23 MH127300/MH/NIMH NIH HHS/United States

GR - K23MH127300/MH/NIMH NIH HHS/United States

PT - Meta-Analysis

PT - Systematic Review

DEP - 20230601

PL - New Zealand

TA - CNS Drugs

JT - CNS drugs

JID - 9431220

RN - 0 (Antipsychotic Agents)

RN - J60AR2IKIC (Clozapine)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/therapeutic use

MH - *Schizophrenia/drug therapy

MH - *Clozapine/therapeutic use

MH - *Psychotic Disorders/drug therapy

MH - Drug Therapy, Combination

EDAT- 2023/06/01 13:10

MHDA- 2023/06/19 13:08

CRDT- 2023/06/01 11:16

PHST- 2023/05/02 00:00 [accepted]

PHST- 2023/06/19 13:08 [medline]

PHST- 2023/06/01 13:10 [pubmed]

PHST- 2023/06/01 11:16 [entrez]

AID - 10.1007/s40263-023-01009-4 [pii]

AID - 10.1007/s40263-023-01009-4 [doi]

PST - ppublish

SO - CNS Drugs. 2023 Jun;37(6):499-512. doi: 10.1007/s40263-023-01009-4. Epub 2023 Jun

PMID- 37249835

OWN - NLM

STAT- MEDLINE

DCOM- 20230828

LR - 20230918

IS - 1573-6709 (Electronic)

IS - 0033-2720 (Linking)

VI - 94

IP - 3

DP - 2023 Sep

TI - Effectiveness of Community-Based Rehabilitation Interventions on Symptoms and

Functioning for People with Schizophrenia: A Systematic Review and Meta-Analysis.

PG - 501-529

LID - 10.1007/s11126-023-10029-8 [doi]

AB - Schizophrenia is a serious mental illness that imposes huge burden of illness on

the society. We aimed to conduct a meta-analytic and systematic review of

literature on the effectiveness of community-based rehabilitation interventions

on symptoms and functioning for people with schizophrenia. The PubMed, Embase,

the Cochrane Library, Web of Science, and CINAHL databases were searched through

April 16 and 17, 2021, including clinical trial registries and previous Cochrane

reviews. We included 24 randomized controlled trials in this review. The content

of interventions varied from single-faceted rehabilitation intervention or

cognitive retraining, to multi-component rehabilitation interventions or case

management. Among 20 studies that reported effects of community-based

rehabilitation interventions on symptoms, the pooled SMDs across all

interventions was 0.94 (95% CI = 0.11, 1.76; P < 0.001; I(2) = 99.1%; n = 3694),

representing a strong effect. 21 included studies showed that community-based

rehabilitation interventions also had beneficial impacts on functioning

(SMD = 1.65; 95% CI = 0.88, 2.43; P < 0.001; I(2) = 98.9%; n = 3734). Overall

quality of evidence was moderate with a high level of heterogeneity.

Community-based rehabilitation interventions have positive effectiveness in

improving patients' symptoms and functioning. Community-based rehabilitation

interventions should therefore be provided as an adjuvant service in addition to

facility-based care for people with schizophrenia.

Media, LLC, part of Springer Nature.

FAU - Ye, Xin

AU - Ye X

AD - Institute for Global Public Policy; LSE-Fudan Research Centre for Global Public

Policy, Fudan University, 220 Handan Road, Yangpu District, Shanghai, 200433,

China.

FAU - Zeng, Fangyi

AU - Zeng F

AD - School of Public Health, Peking University, Haidian District, 38 Xue Yuan Road,

Beijing, 100191, China.

AD - China Center for Health Development Studies, Peking University, Haidian District,

38 Xue Yuan Road, Beijing, 100191, China.

FAU - Wang, Yanshang

AU - Wang Y

AD - School of Public Health, Peking University, Haidian District, 38 Xue Yuan Road,

Beijing, 100191, China.

AD - China Center for Health Development Studies, Peking University, Haidian District,

38 Xue Yuan Road, Beijing, 100191, China.

FAU - Ding, Ruoxi

AU - Ding R

AD - China Center for Health Development Studies, Peking University, Haidian District,

38 Xue Yuan Road, Beijing, 100191, China.

FAU - Zhao, Miaomiao

AU - Zhao M

AD - Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine;

Center for Mental Health Management, China Hospital Development Institute,

Shanghai Jiao Tong University, Shanghai, China.

FAU - Zhu, Dawei

AU - Zhu D

AD - China Center for Health Development Studies, Peking University, Haidian District,

38 Xue Yuan Road, Beijing, 100191, China.

FAU - He, Ping

AU - He P

AD - China Center for Health Development Studies, Peking University, Haidian District,

38 Xue Yuan Road, Beijing, 100191, China. phe@pku.edu.cn.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Review

PT - Systematic Review

DEP - 20230530

PL - United States

TA - Psychiatr Q

JT - The Psychiatric quarterly

JID - 0376465

SB - IM

MH - Humans

MH - *Schizophrenia

OTO - NOTNLM

OT - Community-based rehabilitation

OT - Effectiveness

OT - Functioning

OT - Schizophrenia

OT - Symptoms

EDAT- 2023/05/30 13:07

MHDA- 2023/08/28 06:42

CRDT- 2023/05/30 11:15

PHST- 2023/05/09 00:00 [accepted]

PHST- 2023/08/28 06:42 [medline]

PHST- 2023/05/30 13:07 [pubmed]

PHST- 2023/05/30 11:15 [entrez]

AID - 10.1007/s11126-023-10029-8 [pii]

AID - 10.1007/s11126-023-10029-8 [doi]

PST - ppublish

SO - Psychiatr Q. 2023 Sep;94(3):501-529. doi: 10.1007/s11126-023-10029-8. Epub 2023

May 30.

PMID- 37245485

OWN - NLM

STAT- MEDLINE

DCOM- 20230616

LR - 20230621

IS - 1872-7123 (Electronic)

IS - 0165-1781 (Linking)

VI - 325

DP - 2023 Jul

TI - Efficacy of transcutaneous electrical acupoint stimulation for patients with

first-episode schizophrenia: An 8-week, preliminary, randomized controlled trial.

PG - 115255

LID - S0165-1781(23)00205-6 [pii]

LID - 10.1016/j.psychres.2023.115255 [doi]

AB - Combination therapy with antipsychotics has been investigated for treating

schizophrenia, and has shown clear advantages among non-invasive therapies.

Transcutaneous electrical acupoint stimulation (TEAS) is a novel non-invasive

treatment with definite efficacy in treating mental disorders. The current study

aimed to investigate the efficacy of TEAS in further improving the psychotic

symptoms in patients with first-episode schizophrenia (FES) being treated with

pharmacological drugs. This 8-week, preliminary, sham-controlled, randomized

clinical trial was conducted in patients with FES to compare the efficacy of TEAS

and sham TEAS in combination with aripiprazole treatment. The primary outcome was

a change in the Positive and Negative Syndrome Scale (PANSS) score after ending

the intervention (Week 8). A total of 49 participants completed the whole

treatment cycle. The linear mixed-effects regression for PANSS indicated a

significant time × group interaction (F(2, 116)=9.79, p <0.001). The PANSS score

differed by 8.77 points (95% CI, -2.07 to -15.47 points; p=.01) between the TEAS

group and the sham TEAS group after 8 weeks of treatment; this difference was

significant. This study indicates that 8 weeks of TEAS combined with aripiprazole

treatment can effectively treat FES. Thus, TEAS is an effective combination

therapy to improve the psychiatric symptoms of FES.

FAU - Li, Qifu

AU - Li Q

AD - School of Second Clinical Medicine/The Second Affiliated Hospital, Yunnan

University of Chinese Medicine, Kunming 650500, China.

FAU - Gong, Yi

AU - Gong Y

AD - Yunnan University of Chinese Medicine Teaching Hospital/Kunming Psychiatry

Hospital, Kunming, 650000, China.

FAU - Cui, Yapeng

AU - Cui Y

AD - Engineering Research Center of Molecular and Neuro Imaging of the Ministry of

Education, School of Life Science and Technology, Xidian University, Xian,

710126, China.

FAU - Cheng, Chen

AU - Cheng C

AD - Engineering Research Center of Molecular and Neuro Imaging of the Ministry of

Education, School of Life Science and Technology, Xidian University, Xian,

710126, China.

FAU - Wang, Yin

AU - Wang Y

AD - Engineering Research Center of Molecular and Neuro Imaging of the Ministry of

Education, School of Life Science and Technology, Xidian University, Xian,

710126, China.

FAU - Huang, Gaoyangzi

AU - Huang G

AD - School of Second Clinical Medicine/The Second Affiliated Hospital, Yunnan

University of Chinese Medicine, Kunming 650500, China.

FAU - Gu, Weiqiang

AU - Gu W

AD - Yunnan University of Chinese Medicine Teaching Hospital/Kunming Psychiatry

Hospital, Kunming, 650000, China.

FAU - Meng, Bin

AU - Meng B

AD - Yunnan University of Chinese Medicine Teaching Hospital/Kunming Psychiatry

Hospital, Kunming, 650000, China.

FAU - Wang, Mian

AU - Wang M

AD - Yunnan University of Chinese Medicine Teaching Hospital/Kunming Psychiatry

Hospital, Kunming, 650000, China.

FAU - Wu, Dongniya

AU - Wu D

AD - Yunnan University of Chinese Medicine Teaching Hospital/Kunming Psychiatry

Hospital, Kunming, 650000, China.

FAU - Zhao, Siwen

AU - Zhao S

AD - School of Second Clinical Medicine/The Second Affiliated Hospital, Yunnan

University of Chinese Medicine, Kunming 650500, China.

FAU - Yang, Xuejuan

AU - Yang X

AD - Engineering Research Center of Molecular and Neuro Imaging of the Ministry of

Education, School of Life Science and Technology, Xidian University, Xian,

710126, China.

FAU - Qin, Wei

AU - Qin W

AD - Engineering Research Center of Molecular and Neuro Imaging of the Ministry of

Education, School of Life Science and Technology, Xidian University, Xian,

710126, China.

FAU - Sun, Jinbo

AU - Sun J

AD - Engineering Research Center of Molecular and Neuro Imaging of the Ministry of

Education, School of Life Science and Technology, Xidian University, Xian,

710126, China. Electronic address: sunjb@xidian.edu.cn.

FAU - Guo, Taipin

AU - Guo T

AD - School of Second Clinical Medicine/The Second Affiliated Hospital, Yunnan

University of Chinese Medicine, Kunming 650500, China; Key Laboratory for

Acupuncture, Moxibustion and Tuina Prevention and Treatment of Brain Diseases in

Yunnan Universities, Kunming, China. Electronic address: gtphncs@126.com.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230522

PL - Ireland

TA - Psychiatry Res

JT - Psychiatry research

JID - 7911385

RN - 82VFR53I78 (Aripiprazole)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Transcutaneous Electric Nerve Stimulation

MH - *Schizophrenia/therapy

MH - Aripiprazole/therapeutic use

MH - Acupuncture Points

MH - *Antipsychotic Agents/therapeutic use

OTO - NOTNLM

OT - Aripiprazole

OT - First-episode schizophrenia

OT - Interleukin-2

OT - Interleukin-6

OT - Positive and negative syndrome scale

OT - Transcutaneous electrical acupoint stimulation

COIS- Declaration of Competing Interest The authors of this manuscript declare that

they have no conflicts of interest.

EDAT- 2023/05/29 00:42

MHDA- 2023/06/16 06:42

CRDT- 2023/05/28 18:09

PHST- 2023/01/27 00:00 [received]

PHST- 2023/05/09 00:00 [revised]

PHST- 2023/05/15 00:00 [accepted]

PHST- 2023/06/16 06:42 [medline]

PHST- 2023/05/29 00:42 [pubmed]

PHST- 2023/05/28 18:09 [entrez]

AID - S0165-1781(23)00205-6 [pii]

AID - 10.1016/j.psychres.2023.115255 [doi]

PST - ppublish

SO - Psychiatry Res. 2023 Jul;325:115255. doi: 10.1016/j.psychres.2023.115255. Epub

2023 May 22.

PMID- 37245257

OWN - NLM

STAT- MEDLINE

DCOM- 20230808

LR - 20230809

IS - 1873-6882 (Electronic)

IS - 0959-4388 (Linking)

VI - 81

DP - 2023 Aug

TI - Molecular mechanisms of schizophrenia: Insights from human genetics.

PG - 102731

LID - S0959-4388(23)00056-9 [pii]

LID - 10.1016/j.conb.2023.102731 [doi]

AB - Schizophrenia is a debilitating psychiatric disorder that affects millions of

people worldwide; however, its etiology is poorly understood at the molecular and

neurobiological levels. A particularly important advance in recent years is the

discovery of rare genetic variants associated with a greatly increased risk of

developing schizophrenia. These primarily loss-of-function variants are found in

genes that overlap with those implicated by common variants and are involved in

the regulation of glutamate signaling, synaptic function, DNA transcription, and

chromatin remodeling. Animal models harboring mutations in these large-effect

schizophrenia risk genes show promise in providing additional insights into the

molecular mechanisms of the disease.

FAU - Farsi, Zohreh

AU - Farsi Z

AD - Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,

Cambridge, MA, USA. Electronic address: zfarsi@broadinstitute.org.

FAU - Sheng, Morgan

AU - Sheng M

AD - Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard,

Cambridge, MA, USA; Department of Brain and Cognitive Sciences, Massachusetts

Institute of Technology, Cambridge, MA, USA. Electronic address:

msheng@broadinstitute.org.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230526

PL - England

TA - Curr Opin Neurobiol

JT - Current opinion in neurobiology

JID - 9111376

SB - IM

MH - Animals

MH - Humans

MH - *Schizophrenia/genetics

MH - Mutation

MH - Genetic Predisposition to Disease/genetics

MH - Signal Transduction

MH - Human Genetics

COIS- Declaration of competing interest The authors declare the following financial

interests/personal relationships which may be considered as potential competing

interests: M.S. is cofounder and SAB member of Neumora Therapeutics, and serves

on the SAB of Biogen, ArcLight, Vanqua Bio, Cerevel.

EDAT- 2023/05/28 19:11

MHDA- 2023/08/08 06:42

CRDT- 2023/05/28 18:00

PHST- 2023/03/24 00:00 [received]

PHST- 2023/04/28 00:00 [revised]

PHST- 2023/05/01 00:00 [accepted]

PHST- 2023/08/08 06:42 [medline]

PHST- 2023/05/28 19:11 [pubmed]

PHST- 2023/05/28 18:00 [entrez]

AID - S0959-4388(23)00056-9 [pii]

AID - 10.1016/j.conb.2023.102731 [doi]

PST - ppublish

SO - Curr Opin Neurobiol. 2023 Aug;81:102731. doi: 10.1016/j.conb.2023.102731. Epub

2023 May 26.

PMID- 37232136

OWN - NLM

STAT- MEDLINE

DCOM- 20230711

LR - 20230718

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Print)

IS - 0007-1250 (Linking)

VI - 223

IP - 1

DP - 2023 Jul

TI - The pathophysiology of negative symptoms of schizophrenia: main hypotheses and

open challenges.

PG - 298-300

LID - 10.1192/bjp.2023.63 [doi]

AB - Important developments in the conceptualisation and classification of negative

symptoms have contributed to refining hypotheses on their pathophysiology. The

uptake of recent progress is still only partial and the whole field might make a

leap forward once relevant studies fully make use of assessment tools based on

current conceptualisations.

FAU - Galderisi, Silvana

AU - Galderisi S

AUID- ORCID: 0000-0002-1592-7656

AD - Department of Mental and Physical Health and Preventive Medicine, University of

Campania Luigi Vanvitelli, Naples, Italy.

FAU - Kaiser, Stefan

AU - Kaiser S

AD - Department of Psychiatry, Geneva University Hospitals, Geneva, Switzerland.

LA - eng

PT - Comment

PT - Editorial

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

CON - Br J Psychiatry. 2023 Jul;223(1):301-308. PMID: 36503694

MH - Humans

MH - *Schizophrenia/diagnosis

PMC - PMC10331317

OTO - NOTNLM

OT - Negative symptoms

OT - hypofrontality

OT - neurobiological research

OT - pathophysiology

OT - schizophrenia

COIS- None.

EDAT- 2023/05/26 06:42

MHDA- 2023/07/11 06:42

CRDT- 2023/05/26 04:42

PHST- 2023/07/11 06:42 [medline]

PHST- 2023/05/26 06:42 [pubmed]

PHST- 2023/05/26 04:42 [entrez]

AID - S0007125023000636 [pii]

AID - 10.1192/bjp.2023.63 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jul;223(1):298-300. doi: 10.1192/bjp.2023.63.

PMID- 37232002

OWN - NLM

STAT- MEDLINE

DCOM- 20230913

LR - 20231003

IS - 2574-173X (Electronic)

IS - 2574-173X (Linking)

VI - 43

IP - 3

DP - 2023 Sep

TI - Long-term safety and efficacy of sublingual asenapine for the treatment of

schizophrenia: A phase III extension study with follow-up for 52 weeks

(P06125)-Secondary publication.

PG - 328-337

LID - 10.1002/npr2.12342 [doi]

AB - After completion of a 6-week double-blind trial of asenapine sublingual tablets

(10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of

schizophrenia, including Japanese patients, this open-label study evaluated the

safety and efficacy of a 52-week treatment with asenapine at flexible doses. In

201 subjects, including 44 who had received placebo (P/A group) and 157 who had

received asenapine (A/A group) in the feeder trial, adverse events occurred at

rates of 90.9% and 85.4% and serious adverse events at rates of 11.4% and 20.4%,

respectively. One patient in the P/A group died. No clinically significant

abnormal measurements of body weight, body mass index, or glycated hemoglobin,

fasting plasma glucose, insulin, and prolactin levels were observed. The

sustained efficacy rate, as evaluated by the Positive and Negative Syndrome Scale

total score and other measures, remained at approximately 50% between 6 and

12 months of treatment. These results suggest that long-term treatment with

asenapine is well tolerated and provides sustained efficacy.

Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.

FAU - Kinoshita, Toshihiko

AU - Kinoshita T

AUID- ORCID: 0000-0001-9901-9753

AD - Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.

FAU - Takekita, Yoshiteru

AU - Takekita Y

AD - Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.

FAU - Hiraoka, Shuichi

AU - Hiraoka S

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

FAU - Tamura, Fumihiro

AU - Tamura F

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

FAU - Iwama, Yasuhiro

AU - Iwama Y

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

LA - eng

SI - ClinicalTrials.gov/NCT01142596

PT - Clinical Trial, Phase III

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

DEP - 20230525

PL - United States

TA - Neuropsychopharmacol Rep

JT - Neuropsychopharmacology reports

JID - 101719700

RN - 0 (Antipsychotic Agents)

RN - JKZ19V908O (asenapine)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - Follow-Up Studies

MH - *Schizophrenia/drug therapy

PMC - PMC10496045

OTO - NOTNLM

OT - asenapine

OT - clinical trial

OT - schizophrenia

COIS- Toshihiko Kinoshita received speaker honoraria from Otsuka, Sumitomo Pharma,

Meiji‐Seika Pharma, Janssen Pharmaceutical, Eisai, Daiichi‐Sankyo, Takeda

Pharmaceutical, Lundbeck, and Ono Pharmaceutical. Yoshiteru Takekita has received

grant funding from the Japan Society for the Promotion of Science and speaker's

honoraria from Meiji‐Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical,

Otsuka, Eisai, MSD K.K. Daiichi‐Sankyo, Pfizer, UCB Japan, Takeda Pharmaceutical,

Novartis, and Ono Pharmaceutical. Shuichi Hiraoka, Fumihiro Tamura, and Yasuhiro

Iwama are full‐time employees of Meiji‐Seika Pharma Co. Ltd.

EDAT- 2023/05/26 06:42

MHDA- 2023/09/13 06:42

CRDT- 2023/05/26 03:54

PHST- 2023/04/06 00:00 [revised]

PHST- 2022/11/20 00:00 [received]

PHST- 2023/04/10 00:00 [accepted]

PHST- 2023/09/13 06:42 [medline]

PHST- 2023/05/26 06:42 [pubmed]

PHST- 2023/05/26 03:54 [entrez]

AID - NPR212342 [pii]

AID - 10.1002/npr2.12342 [doi]

PST - ppublish

SO - Neuropsychopharmacol Rep. 2023 Sep;43(3):328-337. doi: 10.1002/npr2.12342. Epub

2023 May 25.

PMID- 37222196

OWN - NLM

STAT- MEDLINE

DCOM- 20230607

LR - 20230626

IS - 1473-6578 (Electronic)

IS - 0951-7367 (Linking)

VI - 36

IP - 4

DP - 2023 Jul 1

TI - The ever-growing case for clozapine in the treatment of schizophrenia: an

obligation for psychiatrists and psychiatry.

PG - 327-336

LID - 10.1097/YCO.0000000000000871 [doi]

AB - PURPOSE OF REVIEW: Clozapine remains the gold standard for treatment-resistant

schizophrenia (TRS). Although the evidence base for its wide-ranging, unique

efficacy continues to expand, clozapine remains alarmingly underutilized in

industrialized countries. Analyzing the causes and consequences of this problem

is crucial for substantially improving the quality of care for TRS patients.

RECENT FINDINGS: Clozapine is the most effective antipsychotic for reducing

all-cause mortality in TRS. In most cases, treatment resistance emerges during

the first psychotic episode. Delaying clozapine treatment has a negative impact

on long-term outcome. Patients' experience with clozapine treatment is largely

positive despite a comparatively high rate of side effects. Patients prefer

clozapine, while psychiatrists regard it as a burden due to concerns regarding

safety and side effect management. Shared decision-making (SDM), which increases

the likelihood of a clozapine recommendation, is not routinely used, possibly due

to stigmatization of TRS patients. SUMMARY: The mortality-reducing effects of

clozapine alone warrant its regular use. Therefore, psychiatrists must not

exclude patients from the decision regarding a clozapine trial by not even

offering it. Rather, they have a clear obligation to align their actions more

closely with the existing evidence and patients' needs and to facilitate the

timely initiation of clozapine.

FAU - Bittner, Robert A

AU - Bittner RA

AD - Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University

Hospital Frankfurt, Goethe University, Frankfurt am Main.

AD - Ernst Strüngmann Institute for Neuroscience (ESI) in Cooperation with Max Planck

Society, Frankfurt am Main, Germany.

FAU - Reif, Andreas

AU - Reif A

AD - Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University

Hospital Frankfurt, Goethe University, Frankfurt am Main.

FAU - Qubad, Mishal

AU - Qubad M

AD - Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University

Hospital Frankfurt, Goethe University, Frankfurt am Main.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230523

PL - United States

TA - Curr Opin Psychiatry

JT - Current opinion in psychiatry

JID - 8809880

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Clozapine/therapeutic use

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/therapeutic use

MH - *Psychotic Disorders/drug therapy

MH - *Psychiatry

EDAT- 2023/05/24 06:42

MHDA- 2023/06/07 06:42

CRDT- 2023/05/24 05:43

PHST- 2023/06/07 06:42 [medline]

PHST- 2023/05/24 06:42 [pubmed]

PHST- 2023/05/24 05:43 [entrez]

AID - 00001504-202307000-00011 [pii]

AID - 10.1097/YCO.0000000000000871 [doi]

PST - ppublish

SO - Curr Opin Psychiatry. 2023 Jul 1;36(4):327-336. doi:

10.1097/YCO.0000000000000871. Epub 2023 May 23.

PMID- 37219412

OWN - NLM

STAT- MEDLINE

DCOM- 20230607

LR - 20230608

IS - 1744-8360 (Electronic)

IS - 1473-7175 (Linking)

VI - 23

IP - 6

DP - 2023 Jun

TI - Selecting the right treatment plan for schizophrenia in postmenopausal women: an

update of the literature.

PG - 515-523

LID - 10.1080/14737175.2023.2215926 [doi]

AB - INTRODUCTION: The transition from reproductive to menopausal status constitutes

amajor rite of passage for women, biologically, psychologically, and socially.

For women with adiagnosis of schizophrenia, this stage of life is complicated by

worsening psychotic symptoms and diminished effectiveness of antipsychotic drugs.

This frequently leads to increased doses and subsequently increased adverse

effects. AREAS COVERED: The aim of this narrative review is to determine what

management changes are needed at this time of life for women with schizophrenia.

Searched and highlighted are the areas of sleep, cognition,

occupation/employment, psychotic symptoms, side effects of treatment, and

non-psychiatric as well as psychiatric co-morbidities which, when not adequately

treated, can undermine quality of life and lead to premature death. EXPERT

OPINION: Many of the problems associated with menopause in women with

schizophrenia can be prevented or remediated. Nevertheless, more research

addressing the changes that occur in women with schizophrenia from pre- to

post-menopause will help to bring clinical attention to this important health

issue.

FAU - Seeman, Mary V

AU - Seeman MV

AUID- ORCID: 0000-0001-6797-3382

AD - Professor Emerita, Department of Psychiatry, University of Toronto, Toronto, ON,

Canada.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230523

PL - England

TA - Expert Rev Neurother

JT - Expert review of neurotherapeutics

JID - 101129944

SB - IM

MH - Female

MH - Humans

MH - *Schizophrenia/drug therapy/complications

MH - Postmenopause

MH - Quality of Life

MH - Menopause/psychology

MH - *Psychotic Disorders/complications

OTO - NOTNLM

OT - Menopause

OT - cognition

OT - comorbidities

OT - occupation

OT - schizophrenia

OT - sleep

OT - treatment

EDAT- 2023/05/23 13:06

MHDA- 2023/06/07 06:42

CRDT- 2023/05/23 09:53

PHST- 2023/06/07 06:42 [medline]

PHST- 2023/05/23 13:06 [pubmed]

PHST- 2023/05/23 09:53 [entrez]

AID - 10.1080/14737175.2023.2215926 [doi]

PST - ppublish

SO - Expert Rev Neurother. 2023 Jun;23(6):515-523. doi: 10.1080/14737175.2023.2215926.

Epub 2023 May 23.

PMID- 37210696

OWN - NLM

STAT- MEDLINE

DCOM- 20230714

LR - 20230718

IS - 1098-2396 (Electronic)

IS - 0887-4476 (Linking)

VI - 77

IP - 5

DP - 2023 Sep

TI - Synaptic dysfunction in schizophrenia.

PG - e22276

LID - 10.1002/syn.22276 [doi]

AB - Schizophrenia is a chronic disease presented with psychotic symptoms, negative

symptoms, impairment in the reward system, and widespread neurocognitive

deterioration. Disruption of synaptic connections in neural circuits is

responsible for the disease's development and progression. Because deterioration

in synaptic connections results in the impaired effective processing of

information. Although structural impairments of the synapse, such as a decrease

in dendritic spine density, have been shown in previous studies, functional

impairments have also been revealed with the development of genetic and molecular

analysis methods. In addition to abnormalities in protein complexes regulating

exocytosis in the presynaptic region and impaired vesicle release, especially,

changes in proteins related to postsynaptic signaling have been reported. In

particular, impairments in postsynaptic density elements, glutamate receptors,

and ion channels have been shown. At the same time, effects on cellular adhesion

molecular structures such as neurexin, neuroligin, and cadherin family proteins

were detected. Of course, the confusing effect of antipsychotic use in

schizophrenia research should also be considered. Although antipsychotics have

positive and negative effects on synapses, studies indicate synaptic

deterioration in schizophrenia independent of drug use. In this review, the

deterioration in synapse structure and function and the effects of antipsychotics

on the synapse in schizophrenia will be discussed.

FAU - Mısır, Emre

AU - Mısır E

AUID- ORCID: 0000-0001-8953-1171

AD - Department of Psychiatry, Baskent University Faculty of Medicine, Ankara, Turkey.

AD - Department of Interdisciplinary Neuroscience, Ankara University, Ankara, Turkey.

FAU - Akay, Güvem Gümüş

AU - Akay GG

AD - Department of Interdisciplinary Neuroscience, Ankara University, Ankara, Turkey.

AD - Faculty of Medicine, Department of Physiology, Ankara University, Ankara, Turkey.

AD - Brain Research Center (AÜBAUM), Ankara University, Ankara, Turkey.

AD - Department of Cellular Neuroscience and Advanced Microscopic Neuroimaging,

Neuroscience and Neurotechnology Center of Excellence (NÖROM), Ankara, Turkey.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230521

PL - United States

TA - Synapse

JT - Synapse (New York, N.Y.)

JID - 8806914

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy/metabolism

MH - *Antipsychotic Agents

MH - Synapses/metabolism

MH - Signal Transduction

OTO - NOTNLM

OT - antipsychotics

OT - dendritic spine

OT - postsynaptic density

OT - synapse

OT - vesicle proteins

EDAT- 2023/05/21 13:12

MHDA- 2023/07/14 13:07

CRDT- 2023/05/21 11:04

PHST- 2023/04/25 00:00 [revised]

PHST- 2022/10/14 00:00 [received]

PHST- 2023/05/07 00:00 [accepted]

PHST- 2023/07/14 13:07 [medline]

PHST- 2023/05/21 13:12 [pubmed]

PHST- 2023/05/21 11:04 [entrez]

AID - 10.1002/syn.22276 [doi]

PST - ppublish

SO - Synapse. 2023 Sep;77(5):e22276. doi: 10.1002/syn.22276. Epub 2023 May 21.

PMID- 37210594

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230911

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 5

DP - 2023 Sep 7

TI - Compositional and Functional Alterations in Intestinal Microbiota in Patients

with Psychosis or Schizophrenia: A Systematic Review and Meta-analysis.

PG - 1239-1255

LID - 10.1093/schbul/sbad049 [doi]

AB - BACKGROUND AND HYPOTHESIS: Intestinal microbiota is intrinsically linked to human

health. Evidence suggests that the composition and function of the microbiome

differs in those with schizophrenia compared with controls. It is not clear how

these alterations functionally impact people with schizophrenia. We performed a

systematic review and meta-analysis to combine and evaluate data on compositional

and functional alterations in microbiota in patients with psychosis or

schizophrenia. STUDY DESIGN: Original studies involving humans and animals were

included. The electronic databases PsycINFO, EMBASE, Web of Science,

PubMed/MEDLINE, and Cochrane were systematically searched and quantitative

analysis performed. STUDY RESULTS: Sixteen original studies met inclusion

criteria (1376 participants: 748 cases and 628 controls). Ten were included in

the meta-analysis. Although observed species and Chao 1 show a decrease in

diversity in people with schizophrenia compared with controls (SMD = -0.14 and

-0.66 respectively), that did not reach statistical significance. We did not find

evidence for variations in richness or evenness of microbiota between patients

and controls overall. Differences in beta diversity and consistent patterns in

microbial taxa were noted across studies. We found increases in Bifidobacterium,

Lactobacillus, and Megasphaera in schizophrenia groups. Variations in brain

structure, metabolic pathways, and symptom severity may be associated with

compositional alterations in the microbiome. The heterogeneous design of studies

complicates a similar evaluation of functional readouts. CONCLUSIONS: The

microbiome may play a role in the etiology and symptomatology of schizophrenia.

Understanding how the implications of alterations in microbial genes for

symptomatic expression and clinical outcomes may contribute to the development of

microbiome targeted interventions for psychosis.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of the

please email: journals.permissions@oup.com.

FAU - Murray, Nuala

AU - Murray N

AD - Department of Psychiatry and Neurobehavioural Science, University College Cork,

Cork, Ireland.

FAU - Al Khalaf, Sukainah

AU - Al Khalaf S

AD - School of Public Health, University College Cork, Cork, Ireland.

AD - INFANT Research Centre, University College Cork, Cork, Ireland.

FAU - Bastiaanssen, Thomaz F S

AU - Bastiaanssen TFS

AD - Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.

AD - APC Microbiome Ireland, University College Cork, Cork, Ireland.

FAU - Kaulmann, David

AU - Kaulmann D

AD - School of Public Health, University College Cork, Cork, Ireland.

FAU - Lonergan, Edgar

AU - Lonergan E

AD - RISE, Early Intervention in Psychosis Service, South Lee Mental Health Services,

Cork, Ireland.

FAU - Cryan, John F

AU - Cryan JF

AD - Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.

AD - APC Microbiome Ireland, University College Cork, Cork, Ireland.

FAU - Clarke, Gerard

AU - Clarke G

AD - Department of Psychiatry and Neurobehavioural Science, University College Cork,

Cork, Ireland.

AD - APC Microbiome Ireland, University College Cork, Cork, Ireland.

FAU - Khashan, Ali S

AU - Khashan AS

AD - School of Public Health, University College Cork, Cork, Ireland.

AD - INFANT Research Centre, University College Cork, Cork, Ireland.

FAU - O'Connor, Karen

AU - O'Connor K

AD - Department of Psychiatry and Neurobehavioural Science, University College Cork,

Cork, Ireland.

AD - RISE, Early Intervention in Psychosis Service, South Lee Mental Health Services,

Cork, Ireland.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

MH - Humans

MH - *Schizophrenia

MH - *Gastrointestinal Microbiome

MH - *Psychotic Disorders

PMC - PMC10483467

OTO - NOTNLM

OT - microbiome

OT - microbiota

OT - psychosis

OT - schizophrenia

EDAT- 2023/05/21 06:42

MHDA- 2023/09/08 06:42

PMCR- 2024/05/20

CRDT- 2023/05/21 00:32

PHST- 2024/05/20 00:00 [pmc-release]

PHST- 2023/09/08 06:42 [medline]

PHST- 2023/05/21 06:42 [pubmed]

PHST- 2023/05/21 00:32 [entrez]

AID - 7175082 [pii]

AID - sbad049 [pii]

AID - 10.1093/schbul/sbad049 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Sep 7;49(5):1239-1255. doi: 10.1093/schbul/sbad049.

PMID- 37209456

OWN - NLM

STAT- MEDLINE

DCOM- 20230606

LR - 20230607

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Linking)

VI - 256

DP - 2023 Jun

TI - The effect of exercise on global, social, daily living and occupational

functioning in people living with schizophrenia: A systematic review and

meta-analysis.

PG - 98-111

LID - S0920-9964(23)00165-2 [pii]

LID - 10.1016/j.schres.2023.04.012 [doi]

AB - BACKGROUND: Schizophrenia is associated with high rates of global, social and

occupational functional impairments. While prior meta-analyses have extensively

examined the impact of exercise on physical and mental health, the impact on

functioning in schizophrenia have yet to be fully established. This review aimed

to update the evidence base regarding the impact of exercise on functioning in

schizophrenia, and explore moderators of effect. METHODS: A systematic search was

conducted to identify randomized controlled trials (RCTs) of exercise evaluating

global functioning versus any comparator in people with schizophrenia; between

group meta-analyses of global functioning (and secondary - social, living skills,

occupational, adverse events) were computed using a random effects model.

Subgroup analyses based on diagnosis and aspects of the intervention were

conducted. RESULTS: 18 full text articles were included, involving 734

participants. A moderate impact of exercise on global functioning was found

(g = 0.40, 95 % C·I. = 0.12 to 0.69, p = 0.006), with a moderate impact of

exercise on social (N = 5, g = 0.54 95 % C.I = 0.16 to 0.9 p = 0.005), and daily

living functioning (N = 3, g = 0.65, 95 % C.I. = 0.07 to 1.22, p = 0.005).

CONCLUSIONS: There is good evidence that exercise can improve the global

functioning of people with schizophrenia, with preliminary evidence for social

and daily living skills; exercise should be considered an important adjunct to

usual care. Higher impacts on global functioning were seen in aerobic

interventions and of at least moderate to vigorous intensity. More research is

required into resistance training, in early psychosis cohorts and to evaluate the

comparison of exercise with other established psychosocial therapies.

FAU - Korman, Nicole

AU - Korman N

AD - Addiction and Mental Health Services, Metro South Health Services, Australia;

School of Medicine, University of Queensland, Brisbane, Australia. Electronic

address: Nicole.korman@health.qld.gov.au.

FAU - Stanton, Robert

AU - Stanton R

AD - School of Health, Medical and Applied Sciences, Central Queensland University,

Rockhampton, Australia.

FAU - Vecchio, Anna

AU - Vecchio A

AD - Addiction and Mental Health Services, Metro South Health Services, Australia.

FAU - Chapman, Justin

AU - Chapman J

AD - Addiction and Mental Health Services, Metro South Health Services, Australia;

Queensland Institute of Medical Research, Brisbane, Australia.

FAU - Parker, Stephen

AU - Parker S

AD - Addiction and Mental Health Services, Metro South Health Services, Australia;

School of Medicine, University of Queensland, Brisbane, Australia; The Prince

Charles Hospital, Metro North Mental Health Services, Australia.

FAU - Martland, Rebecca

AU - Martland R

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

FAU - Siskind, Dan

AU - Siskind D

AD - Addiction and Mental Health Services, Metro South Health Services, Australia;

School of Medicine, University of Queensland, Brisbane, Australia.

FAU - Firth, Joseph

AU - Firth J

AD - Division of Psychology and Mental Health, University of Manchester, Manchester

Academic Health Science Centre, Manchester, UK.

LA - eng

GR - MR/T021780/1/MRC_/Medical Research Council/United Kingdom

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Review

PT - Systematic Review

DEP - 20230518

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

SB - IM

MH - Humans

MH - Quality of Life

MH - Exercise

MH - *Schizophrenia/therapy

MH - *Yoga

MH - *Resistance Training

OTO - NOTNLM

OT - Exercise

OT - Global functioning

OT - Occupational functioning

OT - Physical activity

OT - Schizophrenia

OT - Social functioning

COIS- Declaration of competing interest JF is supported by a University of Manchester

Presidential Fellowship (P123958) and a UK Research and Innovation Future Leaders

Fellowship (MR/T021780/1) and has received honoraria /consultancy fees from

Atheneum, Informa, Gillian Kenny Associates, Big Health, Wood For Trees,

Nutritional Medicine Institute, ParachuteBH, Richmond Foundation and Nirakara,

independent of this work.

EDAT- 2023/05/21 01:05

MHDA- 2023/06/06 06:42

CRDT- 2023/05/20 18:01

PHST- 2022/10/29 00:00 [received]

PHST- 2023/03/28 00:00 [revised]

PHST- 2023/04/19 00:00 [accepted]

PHST- 2023/06/06 06:42 [medline]

PHST- 2023/05/21 01:05 [pubmed]

PHST- 2023/05/20 18:01 [entrez]

AID - S0920-9964(23)00165-2 [pii]

AID - 10.1016/j.schres.2023.04.012 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Jun;256:98-111. doi: 10.1016/j.schres.2023.04.012. Epub 2023

May 18.

PMID- 37209104

OWN - NLM

STAT- MEDLINE

DCOM- 20230713

LR - 20230925

IS - 1741-2854 (Electronic)

IS - 0020-7640 (Print)

IS - 0020-7640 (Linking)

VI - 69

IP - 5

DP - 2023 Aug

TI - The revolving door phenomenon in severe psychiatric disorders: A systematic

review.

PG - 1075-1089

LID - 10.1177/00207640221143282 [doi]

AB - BACKGROUND: The treatment of psychiatric patients has suffered a major change

over the last decades, with long-term hospitalizations being replaced by

short-term stays and appropriate aftercare in outpatient services. Some

chronically ill patients exhibit a pattern of multiple hospitalizations,

designated as the Revolving Door (RD) phenomenon. AIMS: This review aims to

analyse the existing literature regarding sociodemographic, clinical and other

factors associated with multiple hospitalizations in psychiatric facilities.

METHOD: The search performed in the PubMed database for the terms

revolving[Title] AND (psyc*[Title] OR schizo*[Title] OR mental[Title]) presented

30 citations, 8 of which met the eligibility criteria. Four other studies found

in references of these articles were also included in the review. RESULTS: Albeit

the use of different criteria to define the RD phenomenon, it is more likely to

be associated with patients who are younger, single, with low educational level,

unemployed, diagnosed with a psychotic disorder, particularly schizophrenia, and

with alcohol and/or substance use. It is also associated with a younger age on

disease onset, suicidality, noncompliance and voluntary type of admission.

CONCLUSION: Recognizing patients with a RD pattern of admissions and prediction

of rehospitalization can help the development of preventive intervention

strategies and identify potential limitations in existing health care delivery

systems.

FAU - Fonseca Barbosa, Joana

AU - Fonseca Barbosa J

AUID- ORCID: 0000-0001-5007-2561

AD - Clínica Universitária de Psiquiatria e Psicologia Médica, Faculdade de Medicina,

Universidade de Lisboa, Portugal.

FAU - Gama Marques, João

AU - Gama Marques J

AUID- ORCID: 0000-0003-0662-5178

AD - Clínica Universitária de Psiquiatria e Psicologia Médica, Faculdade de Medicina,

Universidade de Lisboa, Portugal.

AD - Consulta de Esquizofrenia Resistente, Hospital Júlio de Matos, Centro Hospitalar

Psiquiátrico de Lisboa, Portugal.

LA - eng

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20230520

PL - England

TA - Int J Soc Psychiatry

JT - The International journal of social psychiatry

JID - 0374726

SB - IM

MH - Humans

MH - *Mental Disorders/epidemiology/therapy/psychology

MH - Hospitalization

MH - *Psychotic Disorders/psychology

MH - Patient Readmission

MH - *Schizophrenia/diagnosis

PMC - PMC10338701

OTO - NOTNLM

OT - Revolving door

OT - admission

OT - homeless

OT - hospital

OT - inpatient

OT - psychiatry

EDAT- 2023/05/20 19:13

MHDA- 2023/07/13 06:42

CRDT- 2023/05/20 14:47

PHST- 2023/07/13 06:42 [medline]

PHST- 2023/05/20 19:13 [pubmed]

PHST- 2023/05/20 14:47 [entrez]

AID - 10.1177_00207640221143282 [pii]

AID - 10.1177/00207640221143282 [doi]

PST - ppublish

SO - Int J Soc Psychiatry. 2023 Aug;69(5):1075-1089. doi: 10.1177/00207640221143282.

Epub 2023 May 20.

PMID- 37199806

OWN - NLM

STAT- MEDLINE

DCOM- 20230605

LR - 20230731

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Print)

IS - 0940-1334 (Linking)

VI - 273

IP - 4

DP - 2023 Jun

TI - Introduction for the follow-up of the Eighth International Kraepelin Symposium at

LMU Munich.

PG - 761-763

LID - 10.1007/s00406-023-01615-9 [doi]

FAU - Annette, Schaub

AU - Annette S

AD - Department of Psychiatry and Psychotherapy, University Hospital, Ludwig

Maximilians University Munich, Nussbaumstr. 7, 803336, Munich, Germany.

annette.schaub@med.uni-muenchen.de.

FAU - Falkai, Peter

AU - Falkai P

AD - Department of Psychiatry and Psychotherapy, University Hospital, Ludwig

Maximilians University Munich, Nussbaumstr. 7, 803336, Munich, Germany.

LA - eng

PT - Editorial

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

SB - IM

MH - Humans

MH - Follow-Up Studies

MH - *Schizophrenia

MH - *Borderline Personality Disorder

PMC - PMC10238296

OTO - NOTNLM

OT - Borderline personality disorder

OT - Cognitive behavior therapy

OT - Early intervention

OT - Metabolic disturbances

OT - Metacognitive training

OT - Psychoeducational and family therapy

OT - Relapse prevention

OT - Schizophrenia

EDAT- 2023/05/18 13:09

MHDA- 2023/06/05 06:42

CRDT- 2023/05/18 11:07

PHST- 2023/06/05 06:42 [medline]

PHST- 2023/05/18 13:09 [pubmed]

PHST- 2023/05/18 11:07 [entrez]

AID - 10.1007/s00406-023-01615-9 [pii]

AID - 1615 [pii]

AID - 10.1007/s00406-023-01615-9 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Jun;273(4):761-763. doi:

10.1007/s00406-023-01615-9.

PMID- 37197864

OWN - NLM

STAT- MEDLINE

DCOM- 20230519

LR - 20230525

IS - 1532-8228 (Electronic)

IS - 0883-9417 (Linking)

VI - 44

DP - 2023 Jun

TI - Narrative enhancement and cognitive therapy for perceived stigma of chronic

schizophrenia: A multicenter randomized controlled trial study.

PG - 59-68

LID - S0883-9417(23)00041-9 [pii]

LID - 10.1016/j.apnu.2023.04.004 [doi]

AB - This study explored the effects of NECT on self-stigma among people with

schizophrenia. Eighty-six participants were recruited and assigned to two groups.

The NECT group received 20-session group meetings, while the control group

received routine care. Self-stigma was measured by Internalized Stigma of Mental

Illness Scale (ISMIS) and Discrimination and Stigma Scale (DISC). Generalized

estimating equations were employed to explore the intervention's effectiveness.

The NECT group showed a significant reduction in ISMIS total scores after 20

sessions and Stopping Self subscale scores of DISC decreased over time. The

intervention is effective for improving self-stigma in people with schizophrenia.

FAU - Huang, Li-Ting

AU - Huang LT

AD - Department of Nursing, Chang Gung University of Science and Technology, No.261,

Wenhua 1st Rd., Guishan Dist., Taoyuan City 33303, Taiwan; Department of Nursing,

College of Nursing, National Yang Ming Chiao Tung University, No. 155, Sec.2,

Linong St. Beitou Dist., Taipei City 112304, Taiwan.. Electronic address:

lthuang@mail.cgust.edu.tw.

FAU - Liu, Chieh-Yu

AU - Liu CY

AD - Department of Health Care Management, National Taipei University of Nursing and

Health Sciences, No.365, Mingde Rd., Beitou Dist., Taipei City 11219, Taiwan.

Electronic address: chiehyu@ntunhs.edu.tw.

FAU - Yang, Chiu-Yueh

AU - Yang CY

AD - College of Nursing, National Yang Ming Chiao Tung University, No. 155, Sec.2,

Linong St. Beitou Dist., Taipei City 112304, Taiwan. Electronic address:

cyyang530904@nycu.edu.tw.

LA - eng

PT - Journal Article

PT - Multicenter Study

PT - Randomized Controlled Trial

DEP - 20230415

PL - United States

TA - Arch Psychiatr Nurs

JT - Archives of psychiatric nursing

JID - 8708534

SB - IM

MH - Humans

MH - *Schizophrenia/therapy

MH - Self Concept

MH - *Cognitive Behavioral Therapy

MH - Social Stigma

MH - Narration

OTO - NOTNLM

OT - Depressive symptoms

OT - Discrimination

OT - Intervention

OT - Schizophrenia

OT - Self-stigma

COIS- Declaration of competing interest None of the authors have any conflicts of

interest to disclose.

EDAT- 2023/05/18 01:07

MHDA- 2023/05/19 06:42

CRDT- 2023/05/17 20:56

PHST- 2022/11/01 00:00 [received]

PHST- 2023/03/10 00:00 [revised]

PHST- 2023/04/09 00:00 [accepted]

PHST- 2023/05/19 06:42 [medline]

PHST- 2023/05/18 01:07 [pubmed]

PHST- 2023/05/17 20:56 [entrez]

AID - S0883-9417(23)00041-9 [pii]

AID - 10.1016/j.apnu.2023.04.004 [doi]

PST - ppublish

SO - Arch Psychiatr Nurs. 2023 Jun;44:59-68. doi: 10.1016/j.apnu.2023.04.004. Epub

2023 Apr 15.

PMID- 37194957

OWN - NLM

STAT- MEDLINE

DCOM- 20230711

LR - 20230718

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Linking)

VI - 223

IP - 1

DP - 2023 Jul

TI - Use of cognitive remediation to treat negative symptoms in schizophrenia: is it

time yet?

PG - 319-320

LID - 10.1192/bjp.2023.50 [doi]

AB - Cognitive remediation is currently recommended to treat cognitive and functional

impairments in patients with schizophrenia. Recently, treatment of negative

symptoms has been proposed as a new target for cognitive remediation. Evidence of

reductions in negative symptoms has been described in different meta-analyses.

However, treating primary negative symptoms is still an open question. Despite

some emerging evidence, more research focused on individuals with primary

negative symptoms is indispensable. In addition, more attention to the role of

moderators and mediators and the use of more specific assessments is necessary.

Nevertheless, cognitive remediation could be considered as one promising option

to treat primary negative symptoms.

FAU - Penadés, Rafael

AU - Penadés R

AUID- ORCID: 0000-0002-1564-3717

AD - Barcelona Clinic Schizophrenia Unit, Hospital Clínic Barcelona Spain; Department

of Clinical Psychology and Psychobiology, University of Barcelona, Sain IDIBAPS,

CIBERSAM, Barcelona, Spain.

FAU - Wykes, Til

AU - Wykes T

AUID- ORCID: 0000-0002-5881-8003

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London.

South London and Maudsley NHS Foundation Trust, London, UK.

LA - eng

PT - Comment

PT - Editorial

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

CON - Br J Psychiatry. 2023 Jul;223(1):321-331. PMID: 36919340

MH - Humans

MH - *Schizophrenia/therapy/diagnosis

MH - *Cognitive Remediation

MH - *Cognition Disorders/psychology

MH - Schizophrenic Psychology

MH - *Cognitive Behavioral Therapy

OTO - NOTNLM

OT - Schizophrenia

OT - cognitive–behavioural therapies

OT - individual psychotherapy

OT - psychotic disorders

OT - rehabilitation

EDAT- 2023/05/17 13:10

MHDA- 2023/07/11 06:42

CRDT- 2023/05/17 08:03

PHST- 2023/07/11 06:42 [medline]

PHST- 2023/05/17 13:10 [pubmed]

PHST- 2023/05/17 08:03 [entrez]

AID - S0007125023000508 [pii]

AID - 10.1192/bjp.2023.50 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jul;223(1):319-320. doi: 10.1192/bjp.2023.50.

PMID- 37184101

OWN - NLM

STAT- MEDLINE

DCOM- 20230711

LR - 20230718

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Linking)

VI - 223

IP - 1

DP - 2023 Jul

TI - The emergence of primary negative symptoms: relevance of timing?

PG - 280-281

LID - 10.1192/bjp.2023.51 [doi]

AB - Negative symptoms are an important symptom dimension in schizophrenia that are

often least responsive to antipsychotic medications. We revisit the current

practice of identifying 'primary' negative symptoms and suggest that its concept

would benefit from a further elaboration of their timing of emergence in relation

to the dynamic neurobiological changes to enhance their utility in clinical

decision-making and research.

FAU - Chen, Eric Yu Hai

AU - Chen EYH

AUID- ORCID: 0000-0002-5247-3593

AD - Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine,

The University of Hong Kong, Hong Kong.

AD - State Key Laboratory of Brain and Cognitive Sciences, The University of Hong

Kong, Hong Kong.

FAU - Wong, Stephanie Ming Yin

AU - Wong SMY

AUID- ORCID: 0000-0002-9535-9846

AD - Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine,

The University of Hong Kong, Hong Kong.

FAU - Hui, Christy Lai Ming

AU - Hui CLM

AUID- ORCID: 0000-0001-6912-208X

AD - Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine,

The University of Hong Kong, Hong Kong.

FAU - Suen, Yi Nam

AU - Suen YN

AUID- ORCID: 0000-0003-2766-8476

AD - Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine,

The University of Hong Kong, Hong Kong.

FAU - Chan, Sherry Kit Wa

AU - Chan SKW

AUID- ORCID: 0000-0003-2712-5826

AD - Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine,

The University of Hong Kong, Hong Kong.

AD - State Key Laboratory of Brain and Cognitive Sciences, The University of Hong

Kong, Hong Kong.

LA - eng

PT - Comment

PT - Editorial

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

RN - 0 (Antipsychotic Agents)

SB - IM

CON - Br J Psychiatry. 2023 Jul;223(1):282-294. PMID: 37194556

MH - Humans

MH - *Schizophrenia/diagnosis/drug therapy

MH - Schizophrenic Psychology

MH - *Antipsychotic Agents/therapeutic use

OTO - NOTNLM

OT - Negative symptoms

OT - clinical decisions

OT - primary negative symptoms

OT - psychopathology

EDAT- 2023/05/15 13:05

MHDA- 2023/07/11 06:42

CRDT- 2023/05/15 08:04

PHST- 2023/07/11 06:42 [medline]

PHST- 2023/05/15 13:05 [pubmed]

PHST- 2023/05/15 08:04 [entrez]

AID - S000712502300051X [pii]

AID - 10.1192/bjp.2023.51 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jul;223(1):280-281. doi: 10.1192/bjp.2023.51.

PMID- 37178944

OWN - NLM

STAT- MEDLINE

DCOM- 20230609

LR - 20230611

IS - 1873-7528 (Electronic)

IS - 0149-7634 (Linking)

VI - 151

DP - 2023 Aug

TI - Comparison of Oncogenes, Tumor Suppressors, and MicroRNAs Between Schizophrenia

and Glioma: The Balance of Power.

PG - 105206

LID - S0149-7634(23)00175-6 [pii]

LID - 10.1016/j.neubiorev.2023.105206 [doi]

AB - The risk of cancer in schizophrenia has been controversial. Confounders of the

issue are cigarette smoking in schizophrenia, and antiproliferative effects of

antipsychotic medications. The author has previously suggested comparison of a

specific cancer like glioma to schizophrenia might help determine a more accurate

relationship between cancer and schizophrenia. To accomplish this goal, the

author performed three comparisons of data; the first a comparison of

conventional tumor suppressors and oncogenes between schizophrenia and cancer

including glioma. This comparison determined schizophrenia has both

tumor-suppressive and tumor-promoting characteristics. A second, larger

comparison between brain-expressed microRNAs in schizophrenia with their

expression in glioma was then performed. This identified a core carcinogenic

group of miRNAs in schizophrenia offset by a larger group of tumor-suppressive

miRNAs. This proposed "balance of power" between oncogenes and tumor suppressors

could cause neuroinflammation. This was assessed by a third comparison between

schizophrenia, glioma and inflammation in asbestos-related lung cancer and

mesothelioma (ALRCM). This revealed that schizophrenia shares more oncogenic

similarity to ALRCM than glioma.

FAU - Brown, James S Jr

AU - Brown JS Jr

AD - Midlothian, P.O. Box 622, VA 23113, United States. Electronic address:

jbrown2185@aol.com.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230511

PL - United States

TA - Neurosci Biobehav Rev

JT - Neuroscience and biobehavioral reviews

JID - 7806090

RN - 0 (MicroRNAs)

SB - IM

MH - Humans

MH - *MicroRNAs/genetics/metabolism

MH - *Schizophrenia/genetics

MH - Oncogenes

MH - *Glioma/genetics

OTO - NOTNLM

OT - Neuroinflammation

OT - glioblastoma

OT - glioma

OT - inflammation

OT - miRNA

OT - microRNA

OT - non-coding RNA

OT - oncogene

OT - oncomir

OT - schizophrenia

OT - tumor suppressor

EDAT- 2023/05/14 01:07

MHDA- 2023/06/09 06:42

CRDT- 2023/05/13 19:28

PHST- 2022/11/29 00:00 [received]

PHST- 2023/04/25 00:00 [revised]

PHST- 2023/04/30 00:00 [accepted]

PHST- 2023/06/09 06:42 [medline]

PHST- 2023/05/14 01:07 [pubmed]

PHST- 2023/05/13 19:28 [entrez]

AID - S0149-7634(23)00175-6 [pii]

AID - 10.1016/j.neubiorev.2023.105206 [doi]

PST - ppublish

SO - Neurosci Biobehav Rev. 2023 Aug;151:105206. doi: 10.1016/j.neubiorev.2023.105206.

Epub 2023 May 11.

PMID- 37165101

OWN - NLM

STAT- MEDLINE

DCOM- 20230831

LR - 20230901

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Print)

IS - 0940-1334 (Linking)

VI - 273

IP - 7

DP - 2023 Oct

TI - Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1

agonist in schizophrenia.

PG - 1543-1556

LID - 10.1007/s00406-023-01580-3 [doi]

AB - Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3

clinical development for the treatment of schizophrenia. Ulotaront was discovered

through a unique, target-agnostic approach optimized to identify drug candidates

lacking D2 and 5-HT2A receptor antagonism, while demonstrating an

antipsychotic-like phenotypic profile in vivo. The mechanism of action (MOA) of

ulotaront is thought to be mediated by agonism at TAAR1 and serotonin 5-HT1A

receptors. Ulotaront has completed two Phase 2 trials (4-week acute study and

26-week open-label extension) which led to Breakthrough Therapy Designation from

the US Food and Drug Administration for the treatment of schizophrenia. In the

double-blind, placebo-controlled, acute study, ulotaront was associated with

significant (p < 0.001) improvement in Positive and Negative Syndrome Scale

(PANSS) total score (effect size [ES]: 0.45), with improvements vs. placebo also

observed across secondary endpoints. Post-hoc analyses of the acute trial

revealed additional evidence to support the effect of ulotaront on negative

symptoms. In the 4-week study, ulotaront was well-tolerated, with an incidence of

adverse events (AEs) numerically lower compared to placebo (45.8% vs. 50.4%; with

a number needed to harm [NNH] for individual ulotaront AEs all > 40). The

open-label extension demonstrated further improvement across schizophrenia

symptoms and confirmed the tolerability of ulotaront, with a 6-month completion

rate of 67%. Based on current data, ulotaront shows potential to be a

first-in-class TAAR1 agonist for the treatment of schizophrenia with a safety and

efficacy profile distinct from current antipsychotics.

FAU - Achtyes, Eric D

AU - Achtyes ED

AD - WMU Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.

FAU - Hopkins, Seth C

AU - Hopkins SC

AD - Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.

FAU - Dedic, Nina

AU - Dedic N

AD - Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.

FAU - Dworak, Heather

AU - Dworak H

AD - Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.

FAU - Zeni, Courtney

AU - Zeni C

AD - Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. Courtney.Zeni@Sunovion.com.

FAU - Koblan, Kenneth

AU - Koblan K

AD - Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230510

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

RN - XMC8VP6RI2 (Trace amine-associated receptor 1)

RN - 0 (SEP-363856)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - United States

MH - Humans

MH - *Schizophrenia/diagnosis

MH - Treatment Outcome

MH - *Antipsychotic Agents/adverse effects

MH - Randomized Controlled Trials as Topic

PMC - PMC10465394

OTO - NOTNLM

OT - Schizophrenia

OT - Serotonin 5-HT1A

OT - Trace amine-associated receptor 1

COIS- Dr. Achtyes has served on advisory boards or consulted for Alkermes, Atheneum,

Janssen, Karuna, Lundbeck/Otsuka, Roche, Sunovion and Teva. He has received

research support from Alkermes, Astellas, Biogen, Boehringer-Ingelheim, InnateVR,

Janssen, National Network of Depression Centers, Neurocrine Biosciences,

Novartis, Otsuka, Pear Therapeutics, and Takeda. He serves as an advisor to

CAPNOS Zero, the World Psychiatric Association and Clubhouse International, and

the SMI Adviser LAI Center of Excellence (all unpaid). Drs. Hopkins, Dedic,

Dworak, Zeni, and Koblan are employees of Sunovion Pharmaceuticals Inc.

EDAT- 2023/05/11 00:42

MHDA- 2023/08/31 06:42

CRDT- 2023/05/10 23:23

PHST- 2023/01/18 00:00 [received]

PHST- 2023/02/26 00:00 [accepted]

PHST- 2023/08/31 06:42 [medline]

PHST- 2023/05/11 00:42 [pubmed]

PHST- 2023/05/10 23:23 [entrez]

AID - 10.1007/s00406-023-01580-3 [pii]

AID - 1580 [pii]

AID - 10.1007/s00406-023-01580-3 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1543-1556. doi:

10.1007/s00406-023-01580-3. Epub 2023 May 10.

PMID- 37163739

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 4

DP - 2023 Jul 4

TI - From the Incoming Editor-in-Chief.

PG - 825-826

LID - 10.1093/schbul/sbad060 [doi]

FAU - Gold, James

AU - Gold J

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland, USA.

LA - eng

PT - Editorial

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

CIN - doi: 10.1093/schbul/sbad059

MH - Humans

MH - *Schizophrenia

MH - Editorial Policies

PMC - PMC10318866

EDAT- 2023/05/10 18:41

MHDA- 2023/07/06 06:42

PMCR- 2024/05/10

CRDT- 2023/05/10 17:03

PHST- 2024/05/10 00:00 [pmc-release]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/05/10 18:41 [pubmed]

PHST- 2023/05/10 17:03 [entrez]

AID - 7159593 [pii]

AID - sbad060 [pii]

AID - 10.1093/schbul/sbad060 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Jul 4;49(4):825-826. doi: 10.1093/schbul/sbad060.

PMID- 37163728

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 4

DP - 2023 Jul 4

TI - Message From Editor-in-Chief of the Schizophrenia Bulletin (2005-2023).

PG - 823-824

LID - 10.1093/schbul/sbad059 [doi]

FAU - Carpenter, William

AU - Carpenter W

AD - Department of Psychiatry, Maryland Psychiatric Research Center, University of

Maryland School of Medicine, Baltimore, MD.

LA - eng

PT - Editorial

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

CIN - doi: 10.1093/schbul/sbad060

MH - Humans

MH - *Schizophrenia

PMC - PMC10318859

EDAT- 2023/05/10 18:41

MHDA- 2023/07/06 06:42

PMCR- 2024/05/10

CRDT- 2023/05/10 16:23

PHST- 2024/05/10 00:00 [pmc-release]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/05/10 18:41 [pubmed]

PHST- 2023/05/10 16:23 [entrez]

AID - 7159585 [pii]

AID - sbad059 [pii]

AID - 10.1093/schbul/sbad059 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Jul 4;49(4):823-824. doi: 10.1093/schbul/sbad059.

PMID- 37161884

OWN - NLM

STAT- MEDLINE

DCOM- 20230619

LR - 20230621

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Print)

IS - 0033-2917 (Linking)

VI - 53

IP - 8

DP - 2023 Jun

TI - Methodological issues in social cognition research in autism spectrum disorder

and schizophrenia spectrum disorder: a systematic review.

PG - 3281-3292

LID - 10.1017/S0033291723001095 [doi]

AB - Recent systematic reviews and meta-analyses conclude that similar social

cognitive impairments are found in autism spectrum disorder (ASD) and

schizophrenia spectrum disorder (SSD). While methodological issues have been

mentioned as a limitation, no study has yet explored the magnitude of

methodological heterogeneity across these studies and its potential impact for

their conclusion. The purpose of this study was to systematically review studies

comparing social cognitive impairments in ASD and SSD with a focus on

methodology. Following the PRISMA guidelines, we searched all publications on

PubMed, PsycINFO, and Embase. Of the 765 studies identified in our data base

searches, 21 cross-sectional studies were included in the review. We found

significant methodological heterogeneity across the studies. In the 21 studies, a

total of 37 different measures of social cognition were used, 25 of which were

only used in 1 study. Across studies, the same measure was often said to be

assessing different constructs of social cognition - a confusion that seems to

reflect the ambiguous definitions of what these measures test in the studies that

introduced them. Moreover, inadequate differential diagnostic assessment of ASD

samples was found in 81% of the studies, and sample characteristics were markedly

varied. The ASD and SSD groups were also often unmatched in terms of medication

usage and substance use disorder history. Future studies must address these

methodological issues before a definite conclusion can be drawn about the

potential similarity of social cognitive impairments in ASD and SSD.

FAU - Konstantin, Grace E

AU - Konstantin GE

AUID- ORCID: 0000-0001-7495-4315

AD - Schizophrenia and Bipolar Disorder Research Program, McLean Hospital, Belmont,

MA, USA.

AD - Department of Psychology, The State University of New York at Binghamton,

Binghamton, NY, USA.

AD - Mental Health Center Amager, University Hospital of Copenhagen, Copenhagen,

Denmark.

FAU - Nordgaard, Julie

AU - Nordgaard J

AD - Mental Health Center Amager, University Hospital of Copenhagen, Copenhagen,

Denmark.

AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences,

University of Copenhagen, Copenhagen, Denmark.

FAU - Henriksen, Mads Gram

AU - Henriksen MG

AD - Mental Health Center Amager, University Hospital of Copenhagen, Copenhagen,

Denmark.

AD - Center for Subjectivity Research, Department of Communication, Faculty of

Humanities, University of Copenhagen, Copenhagen, Denmark.

LA - eng

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20230510

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

SB - IM

MH - Humans

MH - *Autism Spectrum Disorder/psychology

MH - Social Cognition

MH - *Schizophrenia

MH - Cross-Sectional Studies

MH - *Cognitive Dysfunction

MH - Cognition

PMC - PMC10277762

OTO - NOTNLM

OT - autism

OT - differential diagnosis

OT - measurement

OT - medication

OT - schizophrenia

OT - social cognition

OT - substance use disorders

COIS- None were reported.

EDAT- 2023/05/10 12:42

MHDA- 2023/06/19 13:08

CRDT- 2023/05/10 06:12

PHST- 2023/06/19 13:08 [medline]

PHST- 2023/05/10 12:42 [pubmed]

PHST- 2023/05/10 06:12 [entrez]

AID - S0033291723001095 [pii]

AID - 10.1017/S0033291723001095 [doi]

PST - ppublish

SO - Psychol Med. 2023 Jun;53(8):3281-3292. doi: 10.1017/S0033291723001095. Epub 2023

May 10.

PMID- 37145296

OWN - NLM

STAT- MEDLINE

DCOM- 20230612

LR - 20230612

IS - 1179-1926 (Electronic)

IS - 0312-5963 (Linking)

VI - 62

IP - 6

DP - 2023 Jun

TI - Association Between Clozapine Plasma Concentrations and Treatment Response: A

Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis.

PG - 807-818

LID - 10.1007/s40262-023-01247-1 [doi]

AB - BACKGROUND AND OBJECTIVES: Although therapeutic drug monitoring of clozapine is

recommended, its optimisation is often adjusted only on the basis of dosage. The

aim of this study was to assess the link between clozapine plasma concentrations

and clinical response by a meta-analysis of published studies and by an

individual participant data meta-analysis. METHODS: We conducted a computerised

search of bibliographic databases (EMBASE, PubMed, Clinical Trials, and Web of

Science) to identify studies that assessed the relationship between clozapine

serum or plasma concentrations and clinical efficacy. Using pooled data, we

investigated the association between improvement of clinical outcome and

clozapine or norclozapine plasma concentrations, the sum of clozapine and

norclozapine plasma concentrations, and the coefficient of variation of clozapine

plasma concentrations. Using available individual data, we assessed the

relationship between clozapine plasma concentrations and clinical response

(changes in the Brief Psychiatric Rating Scale score) and identified a threshold

level for a favourable clinical response. RESULTS: Fifteen studies satisfied

inclusion criteria. Our meta-analysis showed that responders had clozapine plasma

concentrations that were, on average, 117 ng/mL higher than non-responders. The

patients with plasma clozapine concentrations above the thresholds identified in

each study had a higher likelihood of responding (odds ratio = 2.94, p < 0.001).

Norclozapine plasma concentrations were not associated with a clinical response.

The meta-analysis of individual data supported this result and confirmed the link

between clozapine concentrations and a change in the Brief Psychiatric Rating

Scale score and/or the probability of clinical response. Finally, with the

analysis of the coefficient of variation of clozapine plasma concentrations, we

found that a greater inter-individual fluctuation in plasma concentrations was

associated with a loss of clinical response. CONCLUSIONS: Our work confirmed

that, in contrast to clozapine doses, clozapine plasma concentrations were

related to a favourable clinical response, with a mean difference between

responders and non-responders of 117 ng/mL. A threshold for a treatment response

of 407 ng/mL was determined, with a high discriminatory capacity, and a

sensitivity and specificity of 71% and 89.1%, respectively.

FAU - Tralongo, Federica

AU - Tralongo F

AD - Department of Pharmacology, University of Reims Champagne-Ardenne, HERVI EA 3801,

Reims University Hospital, Reims, France.

AD - Department of Psychiatry, Marne Public Mental Health Institution, Reims

University Hospital, Reims, France.

FAU - Konecki, Céline

AU - Konecki C

AD - Department of Pharmacology, University of Reims Champagne-Ardenne, HERVI EA 3801,

Reims University Hospital, Reims, France.

FAU - Feliu, Catherine

AU - Feliu C

AD - Department of Pharmacology, University of Reims Champagne-Ardenne, HERVI EA 3801,

Reims University Hospital, Reims, France.

FAU - Kaladjian, Arthur

AU - Kaladjian A

AD - Department of Psychiatry, Marne Public Mental Health Institution, Reims

University Hospital, Reims, France.

FAU - Djerada, Zoubir

AU - Djerada Z

AUID- ORCID: 0000-0002-4022-7889

AD - Department of Pharmacology, University of Reims Champagne-Ardenne, HERVI EA 3801,

Reims University Hospital, Reims, France. zoubir.djerada@univ-reims.fr.

LA - eng

PT - Meta-Analysis

PT - Systematic Review

DEP - 20230505

PL - Switzerland

TA - Clin Pharmacokinet

JT - Clinical pharmacokinetics

JID - 7606849

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Clozapine/therapeutic use

MH - *Antipsychotic Agents

MH - *Schizophrenia/drug therapy

MH - Treatment Outcome

EDAT- 2023/05/05 12:42

MHDA- 2023/06/12 06:42

CRDT- 2023/05/05 11:11

PHST- 2023/03/26 00:00 [accepted]

PHST- 2023/06/12 06:42 [medline]

PHST- 2023/05/05 12:42 [pubmed]

PHST- 2023/05/05 11:11 [entrez]

AID - 10.1007/s40262-023-01247-1 [pii]

AID - 10.1007/s40262-023-01247-1 [doi]

PST - ppublish

SO - Clin Pharmacokinet. 2023 Jun;62(6):807-818. doi: 10.1007/s40262-023-01247-1. Epub

2023 May 5.

PMID- 37141764

OWN - NLM

STAT- MEDLINE

DCOM- 20230606

LR - 20230612

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Print)

IS - 0920-9964 (Linking)

VI - 256

DP - 2023 Jun

TI - Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to

enhance cognitive training and neuroplasticity in schizophrenia.

PG - 36-43

LID - S0920-9964(23)00163-9 [pii]

LID - 10.1016/j.schres.2023.04.010 [doi]

AB - N-methyl-d-aspartate glutamate receptor (NMDAR) hypofunction is implicated in the

impaired neuroplasticity and cognitive impairments associated with schizophrenia

(CIAS). We hypothesized that enhancing NMDAR function by inhibiting the glycine

transporter-1 (GLYT1) would improve neuroplasticity and thereby augment benefits

of non-pharmacological cognitive training (CT) strategies. This study examined

whether co-administration of a GLYT1 inhibitor and computerized CT would have

synergistic effects on CIAS. Stable outpatients with schizophrenia participated

in this double-blind, placebo-controlled, within-subject, crossover augmentation

study. Participants received placebo or GLYT1 inhibitor (PF-03463275) for two

5-week periods separated by 2 weeks of washout. PF-03463275 doses (40 or 60 mg

twice daily) were selected to produce high GLYT1 occupancy. To limit

pharmacodynamic variability, only cytochrome P450 2D6 extensive metabolizers were

included. Medication adherence was confirmed daily. Participants received 4 weeks

of CT in each treatment period. Cognitive performance (MATRICS Consensus

Cognitive Battery) and psychotic symptoms (Positive and Negative Syndrome Scale)

were assessed in each period. 71 participants were randomized. PF-03463275 in

combination with CT was feasible, safe, and well-tolerated at the doses

prescribed but did not produce greater improvement in CIAS compared to CT alone.

PF-03463275 was not associated with improved CT learning parameters.

Participation in CT was associated with improvement in MCCB scores.

CI - Published by Elsevier B.V.

FAU - Surti, Toral S

AU - Surti TS

AD - Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare

System, West Haven, CT, United States of America; Abraham Ribicoff Research

Facilities, Connecticut Mental Health Center, New Haven, CT, United States of

America; Department of Psychiatry, Yale University School of Medicine, New Haven,

CT, United States of America. Electronic address: Toral.Surti@yale.edu.

FAU - Ranganathan, Mohini

AU - Ranganathan M

AD - Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare

System, West Haven, CT, United States of America; Abraham Ribicoff Research

Facilities, Connecticut Mental Health Center, New Haven, CT, United States of

America; Department of Psychiatry, Yale University School of Medicine, New Haven,

CT, United States of America.

FAU - Johannesen, Jason K

AU - Johannesen JK

AD - Department of Psychiatry, Yale University School of Medicine, New Haven, CT,

United States of America.

FAU - Gueorguieva, Ralitza

AU - Gueorguieva R

AD - Department of Psychiatry, Yale University School of Medicine, New Haven, CT,

United States of America.

FAU - Deaso, Emma

AU - Deaso E

AD - Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare

System, West Haven, CT, United States of America; Abraham Ribicoff Research

Facilities, Connecticut Mental Health Center, New Haven, CT, United States of

America; Department of Psychiatry, Yale University School of Medicine, New Haven,

CT, United States of America.

FAU - Kenney, Joshua G

AU - Kenney JG

AD - Department of Psychiatry, Yale University School of Medicine, New Haven, CT,

United States of America.

FAU - Krystal, John H

AU - Krystal JH

AD - Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare

System, West Haven, CT, United States of America; Abraham Ribicoff Research

Facilities, Connecticut Mental Health Center, New Haven, CT, United States of

America; Department of Psychiatry, Yale University School of Medicine, New Haven,

CT, United States of America; Mental Health Service Line, Veterans Affairs

Connecticut Healthcare System, West Haven, CT, United States of America.

FAU - D'Souza, Deepak Cyril

AU - D'Souza DC

AD - Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare

System, West Haven, CT, United States of America; Abraham Ribicoff Research

Facilities, Connecticut Mental Health Center, New Haven, CT, United States of

America; Department of Psychiatry, Yale University School of Medicine, New Haven,

CT, United States of America.

LA - eng

SI - ClinicalTrials.gov/NCT01911676

GR - UH3 TR000960/TR/NCATS NIH HHS/United States

GR - UL1 RR024139/RR/NCRR NIH HHS/United States

GR - UL1 TR001863/TR/NCATS NIH HHS/United States

GR - P50 AA012870/AA/NIAAA NIH HHS/United States

GR - UH2 TR000960/TR/NCATS NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

PT - Research Support, U.S. Gov't, Non-P.H.S.

DEP - 20230502

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

RN - 0 (Glycine Plasma Membrane Transport Proteins)

RN - 0 (Antipsychotic Agents)

RN - 0 (1-methyl-1H-imidazole-4-carboxylic acid

(3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo(3.1.0) hex-6-ylmethyl)amide)

SB - IM

MH - Humans

MH - *Schizophrenia/complications/drug therapy

MH - Glycine Plasma Membrane Transport Proteins

MH - Cognitive Training

MH - *Antipsychotic Agents/therapeutic use

MH - Neuronal Plasticity

MH - Double-Blind Method

PMC - PMC10257994

MID - NIHMS1897650

OTO - NOTNLM

OT - Cognition

OT - Glycine transporter

OT - NMDA

OT - Psychosis

OT - Remediation

OT - Schizophrenia

EDAT- 2023/05/05 00:42

MHDA- 2023/06/06 06:42

PMCR- 2024/06/01

CRDT- 2023/05/04 18:05

PHST- 2022/10/23 00:00 [received]

PHST- 2023/03/23 00:00 [revised]

PHST- 2023/04/19 00:00 [accepted]

PHST- 2024/06/01 00:00 [pmc-release]

PHST- 2023/06/06 06:42 [medline]

PHST- 2023/05/05 00:42 [pubmed]

PHST- 2023/05/04 18:05 [entrez]

AID - S0920-9964(23)00163-9 [pii]

AID - 10.1016/j.schres.2023.04.010 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Jun;256:36-43. doi: 10.1016/j.schres.2023.04.010. Epub 2023

May 2.

PMID- 37126037

OWN - NLM

STAT- MEDLINE

DCOM- 20230922

LR - 20230922

IS - 1936-2293 (Electronic)

IS - 1064-1297 (Linking)

VI - 31

IP - 5

DP - 2023 Oct

TI - Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric

and neurological illness: A narrative review.

PG - 978-988

LID - 10.1037/pha0000659 [doi]

AB - Cannabidiol (CBD) is one of the major phytocannabinoids present in the cannabis

plant, with no acute psychotropic effects and a favorable safety and abuse

liability profile. Animal and limited controlled human studies have demonstrated

CBD to have analgesic, anxiolytic, anti-inflammatory, antipsychotic, and

anticonvulsant effects, to name a few possible indications. There is growing

evidence for the use of CBD to treat neurological disorders such as epilepsy,

multiple sclerosis, Parkinson's disease, and Alzheimer's disease. It has been

suggested that CBD improves cognition and neurogenesis. Cognitive impairment is

associated with numerous disorders and can involve deficits in learning, memory,

executive functioning, and attention. The purpose of this review will be to

evaluate the available preclinical and clinical data on CBD for the treatment of

the cognitive impairment associated with several disorders including

schizophrenia, epilepsy, Alzheimer's disease, and others. Preclinical, but not

clinical, studies found evidence for an improvement in cognitive performance

after treatment with CBD. More research is needed to determine whether CBD can be

effectively used as a monotherapy to treat cognitive dysfunction. (PsycInfo

FAU - Ortiz, Rachel

AU - Ortiz R

AD - Institute for Mental Health Policy Research, Centre for Addiction and Mental

Health.

FAU - Rueda, Sergio

AU - Rueda S

AD - Institute for Mental Health Policy Research, Centre for Addiction and Mental

Health.

FAU - Di Ciano, Patricia

AU - Di Ciano P

AUID- ORCID: 0000-0001-8509-295X

AD - Institute for Mental Health Policy Research, Centre for Addiction and Mental

Health.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230501

PL - United States

TA - Exp Clin Psychopharmacol

JT - Experimental and clinical psychopharmacology

JID - 9419066

RN - 19GBJ60SN5 (Cannabidiol)

SB - IM

MH - Animals

MH - Humans

MH - *Cannabidiol/therapeutic use

MH - *Alzheimer Disease/drug therapy

MH - *Cognitive Dysfunction/drug therapy/etiology

MH - *Schizophrenia/drug therapy

MH - *Epilepsy/drug therapy

EDAT- 2023/05/01 12:43

MHDA- 2023/09/22 06:42

CRDT- 2023/05/01 10:53

PHST- 2023/09/22 06:42 [medline]

PHST- 2023/05/01 12:43 [pubmed]

PHST- 2023/05/01 10:53 [entrez]

AID - 2023-67738-001 [pii]

AID - 10.1037/pha0000659 [doi]

PST - ppublish

SO - Exp Clin Psychopharmacol. 2023 Oct;31(5):978-988. doi: 10.1037/pha0000659. Epub

2023 May 1.

PMID- 37118058

OWN - NLM

STAT- MEDLINE

DCOM- 20230925

LR - 20231003

IS - 1740-634X (Electronic)

IS - 0893-133X (Print)

IS - 0893-133X (Linking)

VI - 48

IP - 11

DP - 2023 Oct

TI - Tryptophan challenge in individuals with schizophrenia and healthy controls:

acute effects on circulating kynurenine and kynurenic acid, cognition and

cerebral blood flow.

PG - 1594-1601

LID - 10.1038/s41386-023-01587-3 [doi]

AB - Cognitive impairments predict poor functional outcomes in people with

schizophrenia. These impairments may be causally related to increased levels of

kynurenic acid (KYNA), a major metabolic product of tryptophan (TRYP). In the

brain, KYNA acts as an antagonist of the of α7-nicotinic acetylcholine and NMDA

receptors, both of which are involved in cognitive processes. To examine whether

KYNA plays a role in the pathophysiology of schizophrenia, we compared the acute

effects of a single oral dose of TRYP (6 g) in 32 healthy controls (HC) and 37

people with either schizophrenia (Sz), schizoaffective or schizophreniform

disorder, in a placebo-controlled, randomized crossover study. We examined plasma

levels of KYNA and its precursor kynurenine; selected cognitive measures from the

MATRICS Consensus Cognitive Battery; and resting cerebral blood flow (CBF) using

arterial spin labeling imaging. In both cohorts, the TRYP challenge produced

significant, time-dependent elevations in plasma kynurenine and KYNA. The resting

CBF signal (averaged across all gray matter) was affected differentially, such

that TRYP was associated with higher CBF in HC, but not in participants with a

Sz-related disorder. While TRYP did not significantly impair cognitive test

performance, there was a trend for TRYP to worsen visuospatial memory task

performance in HC. Our results demonstrate that oral TRYP challenge substantially

increases plasma levels of kynurenine and KYNA in both groups, but exerts

differential group effects on CBF. Future studies are required to investigate the

mechanisms underlying these CBF findings, and to evaluate the impact of KYNA

fluctuations on brain function and behavior. (Clinicaltrials.gov: NCT02067975).

Neuropsychopharmacology.

FAU - Hare, Stephanie M

AU - Hare SM

AUID- ORCID: 0000-0002-7350-0351

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

stephanie.hare@som.umaryland.edu.

FAU - Adhikari, Bhim M

AU - Adhikari BM

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Mo, Chen

AU - Mo C

AD - Harvard Medical School, Boston, MA, 02115, USA.

FAU - Chen, Shuo

AU - Chen S

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Wijtenburg, S Andrea

AU - Wijtenburg SA

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Seneviratne, Chamindi

AU - Seneviratne C

AUID- ORCID: 0000-0002-3135-2979

AD - Department of Psychiatry, University of Maryland School of Medicine, Baltimore,

MD, 21201, USA.

FAU - Kane-Gerard, Samuel

AU - Kane-Gerard S

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Sathyasaikumar, Korrapati V

AU - Sathyasaikumar KV

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Notarangelo, Francesca M

AU - Notarangelo FM

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Schwarcz, Robert

AU - Schwarcz R

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Kelly, Deanna L

AU - Kelly DL

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Rowland, Laura M

AU - Rowland LM

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

FAU - Buchanan, Robert W

AU - Buchanan RW

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, 21201, USA.

LA - eng

SI - ClinicalTrials.gov/NCT02067975

GR - P50 MH103222/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

DEP - 20230428

PL - England

TA - Neuropsychopharmacology

JT - Neuropsychopharmacology : official publication of the American College of

Neuropsychopharmacology

JID - 8904907

RN - 343-65-7 (Kynurenine)

RN - 8DUH1N11BX (Tryptophan)

RN - H030S2S85J (Kynurenic Acid)

SB - IM

MH - Rats

MH - Animals

MH - Humans

MH - *Kynurenine

MH - Tryptophan

MH - Kynurenic Acid/metabolism

MH - *Schizophrenia

MH - Cross-Over Studies

MH - Rats, Wistar

MH - Cognition

MH - Cerebrovascular Circulation

PMC - PMC10516920

COIS- RS is co-founder of KyNexis AB, which develops novel drugs targeting kynurenine

pathway metabolism. RWB performs consultation for Boehringer-Ingelheim and serves

on the Data Safety and Monitoring Boards of Roche, Merck and Newron; and on the

Advisory Boards of Merck, Acadia, and Neurocrine. DLK is a consultant for

Janseen, Alkermes and Sunovion. All other authors declare no competing interests.

EDAT- 2023/04/29 06:04

MHDA- 2023/09/25 06:42

PMCR- 2024/10/01

CRDT- 2023/04/28 23:35

PHST- 2022/11/01 00:00 [received]

PHST- 2023/04/06 00:00 [accepted]

PHST- 2023/03/31 00:00 [revised]

PHST- 2024/10/01 00:00 [pmc-release]

PHST- 2023/09/25 06:42 [medline]

PHST- 2023/04/29 06:04 [pubmed]

PHST- 2023/04/28 23:35 [entrez]

AID - 10.1038/s41386-023-01587-3 [pii]

AID - 1587 [pii]

AID - 10.1038/s41386-023-01587-3 [doi]

PST - ppublish

SO - Neuropsychopharmacology. 2023 Oct;48(11):1594-1601. doi:

10.1038/s41386-023-01587-3. Epub 2023 Apr 28.

PMID- 37116354

OWN - NLM

STAT- MEDLINE

DCOM- 20230522

LR - 20230522

IS - 1878-4216 (Electronic)

IS - 0278-5846 (Linking)

VI - 125

DP - 2023 Jul 13

TI - A consideration of the increased risk of schizophrenia due to prenatal maternal

stress, and the possible role of microglia.

PG - 110773

LID - S0278-5846(23)00059-3 [pii]

LID - 10.1016/j.pnpbp.2023.110773 [doi]

AB - Schizophrenia is caused by interaction of a combination of genetic and

environmental factors. Of the latter, prenatal exposure to maternal stress is

reportedly associated with elevated disease risk. The main orchestrators of

inflammatory processes within the brain are microglia, and aberrant microglial

activation/function has been proposed to contribute to the aetiology of

schizophrenia. Here, we evaluate the epidemiological and preclinical evidence

connecting prenatal stress to schizophrenia risk, and consider the possible

mediating role of microglia in the prenatal stress-schizophrenia relationship.

Epidemiological findings are rather consistent in supporting the association,

albeit they are mitigated by effects of sex and gestational timing, while the

evidence for microglial activation is more variable. Rodent models of prenatal

stress generally report lasting effects on offspring neurobiology. However, many

uncertainties remain as to the mechanisms underlying the influence of maternal

stress on the developing foetal brain. Future studies should aim to characterise

the exact processes mediating this aspect of schizophrenia risk, as well as

focussing on how prenatal stress may interact with other risk factors.

FAU - Mawson, Eleanor R

AU - Mawson ER

AD - School of Psychology and Neuroscience, College of Medical, Veterinary and Life

Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

FAU - Morris, Brian J

AU - Morris BJ

AD - School of Psychology and Neuroscience, College of Medical, Veterinary and Life

Sciences, University of Glasgow, Glasgow G12 8QQ, UK. Electronic address:

Brian.Morris@glasgow.ac.uk.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230424

PL - England

TA - Prog Neuropsychopharmacol Biol Psychiatry

JT - Progress in neuro-psychopharmacology & biological psychiatry

JID - 8211617

SB - IM

MH - Humans

MH - Female

MH - Pregnancy

MH - Animals

MH - Microglia

MH - *Schizophrenia/etiology

MH - Brain

MH - Risk Factors

MH - *Prenatal Exposure Delayed Effects

MH - Disease Models, Animal

OTO - NOTNLM

OT - Environmental risk

OT - Maternal stress

OT - Microglia

OT - Prenatal stress

OT - Schizophrenia

COIS- Declaration of Competing Interest The authors have no competing interests to

declare.

EDAT- 2023/04/29 06:04

MHDA- 2023/05/22 06:42

CRDT- 2023/04/28 18:05

PHST- 2022/10/31 00:00 [received]

PHST- 2023/04/07 00:00 [revised]

PHST- 2023/04/18 00:00 [accepted]

PHST- 2023/05/22 06:42 [medline]

PHST- 2023/04/29 06:04 [pubmed]

PHST- 2023/04/28 18:05 [entrez]

AID - S0278-5846(23)00059-3 [pii]

AID - 10.1016/j.pnpbp.2023.110773 [doi]

PST - ppublish

SO - Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jul 13;125:110773. doi:

10.1016/j.pnpbp.2023.110773. Epub 2023 Apr 24.

PMID- 37115116

OWN - NLM

STAT- MEDLINE

DCOM- 20230811

LR - 20230811

IS - 2405-5018 (Electronic)

IS - 2405-500X (Linking)

VI - 9

IP - 8 Pt 1

DP - 2023 Aug

TI - Sudden Cardiac Death and Schizophrenia.

PG - 1319-1320

LID - S2405-500X(23)00108-1 [pii]

LID - 10.1016/j.jacep.2023.02.011 [doi]

FAU - Dimsdale, Joel E

AU - Dimsdale JE

AD - Department of Psychiatry, University of California-San Diego, La Jolla,

California, USA. Electronic address: jdimsdale@health.ucsd.edu.

LA - eng

PT - Comment

PT - Editorial

DEP - 20230426

PL - United States

TA - JACC Clin Electrophysiol

JT - JACC. Clinical electrophysiology

JID - 101656995

SB - IM

CON - JACC Clin Electrophysiol. 2023 Aug;9(8 Pt 1):1310-1318. PMID: 37558287

MH - Humans

MH - *Schizophrenia/complications

MH - Death, Sudden, Cardiac/epidemiology/etiology/prevention & control

MH - *Heart Arrest

OTO - NOTNLM

OT - cardiac arrest

OT - electrophysiology

OT - resuscitation

OT - schizophrenia

EDAT- 2023/04/28 12:43

MHDA- 2023/08/11 06:42

CRDT- 2023/04/28 10:33

PHST- 2023/01/25 00:00 [received]

PHST- 2023/02/08 00:00 [accepted]

PHST- 2023/08/11 06:42 [medline]

PHST- 2023/04/28 12:43 [pubmed]

PHST- 2023/04/28 10:33 [entrez]

AID - S2405-500X(23)00108-1 [pii]

AID - 10.1016/j.jacep.2023.02.011 [doi]

PST - ppublish

SO - JACC Clin Electrophysiol. 2023 Aug;9(8 Pt 1):1319-1320. doi:

10.1016/j.jacep.2023.02.011. Epub 2023 Apr 26.

PMID- 37102321

OWN - NLM

STAT- MEDLINE

DCOM- 20230531

LR - 20230531

IS - 1744-7666 (Electronic)

IS - 1465-6566 (Linking)

VI - 24

IP - 9

DP - 2023 Jun

TI - Narrative review of the advances in the pharmacotherapeutic management of

juvenile-onset schizophrenia.

PG - 1039-1052

LID - 10.1080/14656566.2023.2208269 [doi]

AB - INTRODUCTION: Schizophrenia usually begins with prodromal symptoms in

adolescence. In 39% of patients, onset of psychotic symptoms occurs prior to age

19. Advances in the treatment of psychosis with medications over the last decade

are reviewed in this paper. AREAS COVERED: Understanding how to prescribe

antipsychotics early in schizophrenia requires an understanding of the

pathophysiology of the disease. The current structure of the dopamine hypothesis

is reviewed. Risperidone, paliperidone, olanzapine, quetiapine, and aripiprazole

have become established treatments prior to 2012. Since 2012, lurasidone (2017)

and brexpiprazole (2022) have also been approved. Lurasidone was approved based

on placebo-controlled studies, but brexpiprazole has been approved on the bases

of open safety trials. In comparative trials, aripiprazole was better tolerated

and less likely to cause hyperprolactinemia and metabolic abnormalities. EXPERT

OPINION: Antipsychotics can induce adaptive changes in the brain that predispose

patients to future problems such as tardive dyskinesia and supersensitivity

psychosis. When pathophysiology of schizophrenia, and a clear understanding of

the pharmacology of existing antipsychotics are included in the evidence-based

analysis, use of partial agonists, which are less likely to induce adaptive

changes in the brain and less likely to induce metabolic and prolactin side

effects, become the preferred agents.

FAU - Crump, Chesika J

AU - Crump CJ

AD - Department of Psychiatry and Behavioral Sciences, University of Louisville School

of Medicine and University of Louisville Hospital, Louisville, KY, USA.

FAU - Good, Megan E

AU - Good ME

AD - Department of Psychiatry and Behavioral Sciences, University of Louisville School

of Medicine and University of Louisville Hospital, Louisville, KY, USA.

FAU - Abuelazm, Hagar

AU - Abuelazm H

AD - Department of Psychiatry and Behavioral Sciences, University of Louisville School

of Medicine and University of Louisville Hospital, Louisville, KY, USA.

FAU - El-Mallakh, Rif S

AU - El-Mallakh RS

AD - Department of Psychiatry and Behavioral Sciences, University of Louisville School

of Medicine and University of Louisville Hospital, Louisville, KY, USA.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230501

PL - England

TA - Expert Opin Pharmacother

JT - Expert opinion on pharmacotherapy

JID - 100897346

RN - 0 (Antipsychotic Agents)

RN - 2J3YBM1K8C (brexpiprazole)

RN - 82VFR53I78 (Aripiprazole)

RN - O0P4I5851I (Lurasidone Hydrochloride)

RN - 2S3PL1B6UJ (Quetiapine Fumarate)

SB - IM

MH - Adolescent

MH - Humans

MH - Young Adult

MH - Adult

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - Aripiprazole/therapeutic use

MH - Lurasidone Hydrochloride/therapeutic use

MH - Quetiapine Fumarate/therapeutic use

OTO - NOTNLM

OT - Adolescent schizophrenia

OT - aripiprazole

OT - asenapine

OT - brexpiprazole

OT - lurasidone

OT - negative symptoms

OT - olanzapine

OT - paliperidone

OT - psychosis

OT - quetiapine

OT - risperidone

OT - ziprasidone

EDAT- 2023/04/27 06:42

MHDA- 2023/05/31 06:41

CRDT- 2023/04/27 04:33

PHST- 2023/05/31 06:41 [medline]

PHST- 2023/04/27 06:42 [pubmed]

PHST- 2023/04/27 04:33 [entrez]

AID - 10.1080/14656566.2023.2208269 [doi]

PST - ppublish

SO - Expert Opin Pharmacother. 2023 Jun;24(9):1039-1052. doi:

10.1080/14656566.2023.2208269. Epub 2023 May 1.

PMID- 37100222

OWN - NLM

STAT- MEDLINE

DCOM- 20230616

LR - 20230618

IS - 1872-7972 (Electronic)

IS - 0304-3940 (Linking)

VI - 808

DP - 2023 Jun 21

TI - Cognitive remediation and schizophrenia: Effects on brain complexity.

PG - 137268

LID - S0304-3940(23)00227-6 [pii]

LID - 10.1016/j.neulet.2023.137268 [doi]

AB - The objective of this study is to investigate nonlinear neural dynamics of

chronic patients with schizophrenia following 3 months of cognitive remediation

and to find correlations with neuropsychological measures of cognition. Twenty

nine patients were randomized to Cognitive Training (CT) and Treatment as Usual

(TAU) group. The system complexity is estimated by Correlation Dimension (D(2))

and Largest Lyapunov Exponent (LLE) from the reconstructed attractor of the

underlying system. Significant increase in dimensional complexity (D(2)) over

time is observed in prefrontal and medial frontal-central regions in eyes open

and arithmetic condition; and posterior parietal-occipital region under eyes

closed after 3 months. Dynamical complexity (LLE) significantly decreased over

time in medial left central region under eyes closed and eyes open condition;

prefrontal region in eyes open and lateral right temporal region in arithmetic

condition. Interaction is significant for medial left central region with TAU

group exhibiting greater decrease in LLE compared to CT group. The CT group

showed significant correlation of increased D(2) with focused attention. In this

study it is found that patients with schizophrenia exhibit higher dimensional and

lower dynamical complexity over time indicating improvement in neurodynamics of

underlying physiological system.

FAU - Singh, Jaskirat

AU - Singh J

AD - Computational Neuroscience Lab, UIET, Panjab University, Chandigarh 160014,

India.

FAU - Singh, Sukhwinder

AU - Singh S

AD - Computational Neuroscience Lab, UIET, Panjab University, Chandigarh 160014,

India. Electronic address: sukhdalip@pu.ac.in.

FAU - Gupta, Savita

AU - Gupta S

AD - Computational Neuroscience Lab, UIET, Panjab University, Chandigarh 160014,

India. Electronic address: savitagupta@pu.ac.in.

FAU - Chavan, B S

AU - Chavan BS

AD - Department of Psychiatry, Government Medical College and Hospital, Sector 32,

Chandigarh 160032, India.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230424

PL - Ireland

TA - Neurosci Lett

JT - Neuroscience letters

JID - 7600130

SB - IM

MH - Humans

MH - *Schizophrenia/therapy

MH - *Cognitive Remediation

MH - Electroencephalography

MH - Brain

MH - Cognition/physiology

OTO - NOTNLM

OT - Cognitive Training

OT - Dynamical System

OT - Electroencephalography

OT - Nonlinear Analysis

OT - Schizophrenia

OT - Time Series Complexity

COIS- Declaration of Competing Interest The authors declare that they have no known

competing financial interests or personal relationships that could have appeared

to influence the work reported in this paper.

EDAT- 2023/04/27 00:42

MHDA- 2023/06/16 06:42

CRDT- 2023/04/26 19:27

PHST- 2021/09/22 00:00 [received]

PHST- 2023/04/10 00:00 [revised]

PHST- 2023/04/20 00:00 [accepted]

PHST- 2023/06/16 06:42 [medline]

PHST- 2023/04/27 00:42 [pubmed]

PHST- 2023/04/26 19:27 [entrez]

AID - S0304-3940(23)00227-6 [pii]

AID - 10.1016/j.neulet.2023.137268 [doi]

PST - ppublish

SO - Neurosci Lett. 2023 Jun 21;808:137268. doi: 10.1016/j.neulet.2023.137268. Epub

2023 Apr 24.

PMID- 37086914

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230920

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Linking)

VI - 94

IP - 7

DP - 2023 Oct 1

TI - 40-Hz Auditory Steady-State Responses in Schizophrenia: Toward a Mechanistic

Biomarker for Circuit Dysfunctions and Early Detection and Diagnosis.

PG - 550-560

LID - S0006-3223(23)01210-6 [pii]

LID - 10.1016/j.biopsych.2023.03.026 [doi]

AB - There is converging evidence that 40-Hz auditory steady-state responses (ASSRs)

are robustly impaired in schizophrenia and could constitute a potential biomarker

for characterizing circuit dysfunctions as well as enable early detection and

diagnosis. Here, we provide an overview of the mechanisms involved in 40-Hz

ASSRs, drawing on computational, physiological, and pharmacological data with a

focus on parameters modulating the balance between excitation and inhibition. We

will then summarize findings from electro- and magnetoencephalographic studies in

participants at clinical high risk for psychosis, patients with first-episode

psychosis, and patients with schizophrenia to identify the pattern of deficits

across illness stages, the relationship with clinical variables, and the

prognostic potential. Finally, data on genetics and developmental modifications

will be reviewed, highlighting the importance of late modifications of 40-Hz

ASSRs during adolescence, which are closely related to the underlying changes in

GABA (gamma-aminobutyric acid) interneurons. Together, our review suggests that

40-Hz ASSRs may constitute an informative electrophysiological approach to

characterize circuit dysfunctions in psychosis that could be relevant for the

development of mechanistic biomarkers.

rights reserved.

FAU - Grent-'t-Jong, Tineke

AU - Grent-'t-Jong T

AD - Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin

Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu

Berlin, Berlin, Germany.

FAU - Brickwedde, Marion

AU - Brickwedde M

AD - Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin

Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu

Berlin, Berlin, Germany.

FAU - Metzner, Christoph

AU - Metzner C

AD - Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin

Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu

Berlin, Berlin, Germany; Neural Information Processing Group, Institute of

Software Engineering and Theoretical Computer Science, Technische Universität

Berlin, Berlin, Germany; School of Physics, Engineering and Computer Science,

University of Hertfordshire, Hatfield, United Kingdom.

FAU - Uhlhaas, Peter J

AU - Uhlhaas PJ

AD - Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin

Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu

Berlin, Berlin, Germany; Institute of Neuroscience and Psychology, University of

Glasgow, Glasgow, United Kingdom. Electronic address: peter.uhlhaas@charite.de.

LA - eng

GR - MR/L011689/1/MRC_/Medical Research Council/United Kingdom

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230421

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

RN - 0 (Biomarkers)

SB - IM

MH - Adolescent

MH - Humans

MH - *Schizophrenia/diagnosis

MH - Acoustic Stimulation

MH - Evoked Potentials, Auditory/physiology

MH - *Psychotic Disorders/diagnosis

MH - Electroencephalography

MH - Biomarkers

OTO - NOTNLM

OT - 40-Hz auditory steady state

OT - Biomarker

OT - Excitation/inhibition balance

OT - Oscillations

OT - Schizophrenia

EDAT- 2023/04/23 00:41

MHDA- 2023/09/08 06:42

CRDT- 2023/04/22 19:26

PHST- 2023/02/15 00:00 [received]

PHST- 2023/03/21 00:00 [revised]

PHST- 2023/03/30 00:00 [accepted]

PHST- 2023/09/08 06:42 [medline]

PHST- 2023/04/23 00:41 [pubmed]

PHST- 2023/04/22 19:26 [entrez]

AID - S0006-3223(23)01210-6 [pii]

AID - 10.1016/j.biopsych.2023.03.026 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Oct 1;94(7):550-560. doi: 10.1016/j.biopsych.2023.03.026.

Epub 2023 Apr 21.

PMID- 37078520

OWN - NLM

STAT- MEDLINE

DCOM- 20230522

LR - 20230627

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Print)

IS - 0007-1250 (Linking)

VI - 222

IP - 6

DP - 2023 Jun

TI - The effectiveness of a primary care-based collaborative care model to improve

quality of life in people with severe mental illness: PARTNERS2 cluster

randomised controlled trial.

PG - 246-256

LID - 10.1192/bjp.2023.28 [doi]

AB - BACKGROUND: Individuals living with severe mental illness can have significant

emotional, physical and social challenges. Collaborative care combines clinical

and organisational components. AIMS: We tested whether a primary care-based

collaborative care model (PARTNERS) would improve quality of life for people with

diagnoses of schizophrenia, bipolar disorder or other psychoses, compared with

usual care. METHOD: We conducted a general practice-based, cluster randomised

controlled superiority trial. Practices were recruited from four English regions

and allocated (1:1) to intervention or control. Individuals receiving limited

input in secondary care or who were under primary care only were eligible. The

12-month PARTNERS intervention incorporated person-centred coaching support and

liaison work. The primary outcome was quality of life as measured by the

Manchester Short Assessment of Quality of Life (MANSA). RESULTS: We allocated 39

general practices, with 198 participants, to the PARTNERS intervention (20

practices, 116 participants) or control (19 practices, 82 participants). Primary

outcome data were available for 99 (85.3%) intervention and 71 (86.6%) control

participants. Mean change in overall MANSA score did not differ between the

groups (intervention: 0.25, s.d. 0.73; control: 0.21, s.d. 0.86; estimated fully

adjusted between-group difference 0.03, 95% CI -0.25 to 0.31; P = 0.819). Acute

mental health episodes (safety outcome) included three crises in the intervention

group and four in the control group. CONCLUSIONS: There was no evidence of a

difference in quality of life, as measured with the MANSA, between those

receiving the PARTNERS intervention and usual care. Shifting care to primary care

was not associated with increased adverse outcomes.

FAU - Byng, Richard

AU - Byng R

AUID- ORCID: 0000-0001-7411-9467

AD - Community and Primary Care Research Group, University of Plymouth, UK.

FAU - Creanor, Siobhan

AU - Creanor S

AD - Department of Health and Community Sciences, University of Exeter, UK.

FAU - Jones, Benjamin

AU - Jones B

AD - Department of Health and Community Sciences, University of Exeter, UK.

FAU - Hosking, Joanne

AU - Hosking J

AD - Community and Primary Care Research Group, University of Plymouth, UK.

FAU - Plappert, Humera

AU - Plappert H

AD - Institute for Mental Health, University of Birmingham, UK.

FAU - Bevan, Sheriden

AU - Bevan S

AD - Birmingham Clinical Trials Unit, University of Birmingham, UK.

FAU - Britten, Nicky

AU - Britten N

AD - Department of Health and Community Sciences, University of Exeter, UK.

FAU - Clark, Michael

AU - Clark M

AD - Care Policy and Evaluation Centre, London School of Economics and Political

Science, UK.

FAU - Davies, Linda

AU - Davies L

AD - Division of Population Health, University of Manchester, UK.

FAU - Frost, Julia

AU - Frost J

AD - Department of Health and Community Sciences, University of Exeter, UK.

FAU - Gask, Linda

AU - Gask L

AUID- ORCID: 0000-0002-7918-3967

AD - Division of Population Health, University of Manchester, UK.

FAU - Gibbons, Bliss

AU - Gibbons B

AD - Institute for Mental Health, Coventry and Warwickshire Partnership NHS Trust, UK.

FAU - Gibson, John

AU - Gibson J

AD - The McPin Foundation, UK.

FAU - Hardy, Pollyanna

AU - Hardy P

AD - National Perinatal Epidemiology Unit, Oxford Population Health, Nuffield

Department of Population Health, University of Oxford, UK.

FAU - Hobson-Merrett, Charley

AU - Hobson-Merrett C

AD - Community and Primary Care Research Group, University of Plymouth, UK.

FAU - Huxley, Peter

AU - Huxley P

AUID- ORCID: 0000-0001-5152-8030

AD - School of Medical and Health Sciences, University of Bangor, UK.

FAU - Jeffery, Alison

AU - Jeffery A

AD - Community and Primary Care Research Group, University of Plymouth, UK.

FAU - Marwaha, Steven

AU - Marwaha S

AUID- ORCID: 0000-0002-0303-9942

AD - Institute for Mental Health, University of Birmingham, UK; and Institute for

Mental Health, Birmingham and Solihull Mental Health NHS Foundation Trust, UK.

FAU - Rawcliffe, Tim

AU - Rawcliffe T

AD - Lancashire Care NHS Trust, UK.

FAU - Reilly, Siobhan

AU - Reilly S

AUID- ORCID: 0000-0003-4372-4415

AD - Centre for Applied Dementia Studies, Faculty of Health Studies, University of

Bradford, UK.

FAU - Richards, Debra

AU - Richards D

AD - Community and Primary Care Research Group, University of Plymouth, UK.

FAU - Sayers, Ruth

AU - Sayers R

AD - The McPin Foundation, UK.

FAU - Williams, Lynsey

AU - Williams L

AD - Community and Primary Care Research Group, University of Plymouth, UK.

FAU - Pinfold, Vanessa

AU - Pinfold V

AUID- ORCID: 0000-0003-3007-8805

AD - The McPin Foundation, UK.

FAU - Birchwood, Maximillian

AU - Birchwood M

AD - Health Sciences, University of Warwick, UK.

LA - eng

GR - RP-PG-0611-20004/DH_/Department of Health/United Kingdom

GR - NIHR200625/DH_/Department of Health/United Kingdom

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

MH - Humans

MH - Quality of Life

MH - *Mental Disorders/therapy/complications

MH - *Bipolar Disorder/psychology

MH - *Psychotic Disorders/complications

MH - *Schizophrenia/therapy/complications

MH - Cost-Benefit Analysis

PMC - PMC10201334

OTO - NOTNLM

OT - Primary care

OT - bipolar affective disorders

OT - outcome studies

OT - randomised controlled trial

OT - schizophrenia

COIS- R.B. received additional support from the National Institute for Health Research

(NIHR) Applied Research Collaboration South West Peninsula. M.B. received

additional support from the NIHR Applied Research Collaboration East Midlands and

is partly supported by NIHR Applied Research Collaboration West Midlands. R.B.,

V.P. and M.B. received an NIHR Policy Research Programme grant to examine the

implementation of PARTNERS. R.B. is a member of the Health Technology Assessment

Prioritisation Committee A. All remaining authors have no conflicts of interest

to declare.

EDAT- 2023/04/20 13:41

MHDA- 2023/05/22 06:41

CRDT- 2023/04/20 07:22

PHST- 2023/05/22 06:41 [medline]

PHST- 2023/04/20 13:41 [pubmed]

PHST- 2023/04/20 07:22 [entrez]

AID - S0007125023000284 [pii]

AID - 10.1192/bjp.2023.28 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jun;222(6):246-256. doi: 10.1192/bjp.2023.28.

PMID- 37075639

OWN - NLM

STAT- MEDLINE

DCOM- 20230619

LR - 20230619

IS - 1873-7862 (Electronic)

IS - 0924-977X (Linking)

VI - 72

DP - 2023 Jul

TI - Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic

review and dose-response meta-analysis.

PG - 40-49

LID - S0924-977X(23)00066-4 [pii]

LID - 10.1016/j.euroneuro.2023.03.015 [doi]

AB - Antipsychotic-induced akathisia is severely distressing. We aimed to investigate

relationships between antipsychotic doses and akathisia risk. We searched for

randomised controlled trials that investigated monotherapy of 17 antipsychotics

in adults with acute schizophrenia until 06 March 2022. The primary outcome was

the number of participants with akathisia, which was analysed with odds ratios

(ORs). We applied one-stage random-effects dose-response meta-analyses using

restricted cubic splines to model the dose-response relationships. We included 98

studies (343 dose arms, 34,225 participants), most of which were short-term and

had low-to-moderate risk of bias. We obtained data on all antipsychotics except

clozapine and zotepine. In patients with acute exacerbations of chronic

schizophrenia, from moderate to high certainty of evidence, our analysis showed

that sertindole and quetiapine carried negligible risks for akathisia across

examined doses (flat curves), while most of the other antipsychotics had their

risks increase initially with increasing doses and then either plateaued

(hyperbolic curves) or continued to rise (monotonic curves), with maximum ORs

ranging from 1.76 with 95% Confidence Intervals [1.24, 2.52] for risperidone at

5.4 mg/day to OR 11.92 [5.18, 27.43] for lurasidone at 240 mg/day. We found

limited or no data on akathisia risk in patients with predominant negative

symptoms, first-episode schizophrenia, or elderly patients. In conclusion,

liability of akathisia varies between antipsychotics and is dose-related. The

dose-response curves for akathisia in most antipsychotics are either monotonic or

hyperbolic, indicating that higher doses carry a greater or equal risk compared

to lower doses.

FAU - Wu, Hui

AU - Wu H

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany. Electronic address: hui-zx.wu@tum.de.

FAU - Siafis, Spyridon

AU - Siafis S

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany.

FAU - Wang, Dongfang

AU - Wang D

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany.

FAU - Burschinski, Angelika

AU - Burschinski A

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany.

FAU - Schneider-Thoma, Johannes

AU - Schneider-Thoma J

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany.

FAU - Priller, Josef

AU - Priller J

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany; University of Edinburgh and UK Dementia

Research Institute, Edinburgh, UK; Institute of Psychiatry, Psychology &

Neuroscience, King's College London, London, UK; Neuropsychiatrie, Charité

Universitätsmedizin Berlin and German Center for Neurodegenerative Diseases,

Berlin, Germany.

FAU - Davis, John M

AU - Davis JM

AD - Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA;

Maryland Psychiatric Research Center, Baltimore, MD, USA.

FAU - Leucht, Stefan

AU - Leucht S

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Technical

University of Munich, Munich, Germany; Institute of Psychiatry, Psychology and

Neuroscience, Department of Psychiatry, Department of Psychosis Studies, King's

College London, London, UK.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

DEP - 20230417

PL - Netherlands

TA - Eur Neuropsychopharmacol

JT - European neuropsychopharmacology : the journal of the European College of

Neuropsychopharmacology

JID - 9111390

RN - 0 (Antipsychotic Agents)

RN - L6UH7ZF8HC (Risperidone)

RN - 2S3PL1B6UJ (Quetiapine Fumarate)

SB - IM

MH - Humans

MH - Adult

MH - Aged

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy/chemically induced

MH - Psychomotor Agitation/drug therapy

MH - Risperidone/therapeutic use

MH - Quetiapine Fumarate/therapeutic use

OTO - NOTNLM

OT - Dose-effect

OT - Dosing

OT - Extrapyramidal symptoms

OT - Movement disorders

OT - Randomised controlled trials

OT - Side effects

COIS- Conflict of Interest In the past 3 years, SL has received honoraria as a

consultant/advisor and/or for lectures from Angelini, Böhringer Ingelheim,

Geodon&Richter, Janssen, Johnson&Johnson, Lundbeck, LTS Lohmann, MSD, Otsuka,

Recordati, SanofiAventis, Sandoz, Sunovion, TEVA, Mitsubishi. All the other

authors have no conflict of interest to declare.

EDAT- 2023/04/20 00:41

MHDA- 2023/06/19 13:08

CRDT- 2023/04/19 18:06

PHST- 2023/01/19 00:00 [received]

PHST- 2023/03/27 00:00 [revised]

PHST- 2023/03/31 00:00 [accepted]

PHST- 2023/06/19 13:08 [medline]

PHST- 2023/04/20 00:41 [pubmed]

PHST- 2023/04/19 18:06 [entrez]

AID - S0924-977X(23)00066-4 [pii]

AID - 10.1016/j.euroneuro.2023.03.015 [doi]

PST - ppublish

SO - Eur Neuropsychopharmacol. 2023 Jul;72:40-49. doi:

10.1016/j.euroneuro.2023.03.015. Epub 2023 Apr 17.

PMID- 37070475

OWN - NLM

STAT- MEDLINE

DCOM- 20231005

LR - 20231014

IS - 1814-1412 (Electronic)

IS - 1562-2975 (Linking)

VI - 24

IP - 8

DP - 2023 Oct

TI - A systematic review and meta-analysis of optical coherence tomography studies in

schizophrenia, bipolar disorder and major depressive disorder.

PG - 707-720

LID - 10.1080/15622975.2023.2203231 [doi]

AB - OBJECTIVES: Due to the common neurodevelopmental origin and easy accessibility,

the retina serves as a surrogate marker for changes in the brain. Hence, Optical

Coherence Tomography (OCT), a tool to examine the neuronal layers of retina has

gained importance in investigating psychiatric disorders. Several studies in the

last decade have reported retinal structural alterations in schizophrenia (SCZ),

bipolar disorder (BD), and major depressive disorder (MDD). However, the findings

are inconsistent. Hence, we conducted a meta-analysis to investigate alterations

in OCT parameters in patients with SCZ, BD and MDD. METHODS: We searched

electronic databases for studies that examined OCT parameters in patients with

SCZ, BD and MDD published up to January 2023. The primary outcome measures were

thickness and volumes of the retinal Nerve Fibre Layer (RNFL). We conducted

meta-analysis using a random effects model. RESULTS: The searches yielded 2638

publications of which 43 studies were included in the final analysis across all

disorders. Compared to controls, the RNFL was thinner in SCZ patients (SMD =

-0.37, p = <0.001) and BD patients (SMD = -0.67, p = < 0.001), but not in MDD

patients (SMD = -0.08, p = 0.54). On quadrant wise analysis, temporal quadrant

RNFL was thinner in SCZ but not in BD, while all other quadrants were thinner in

both SCZ and BD. CONCLUSION: We found significant reductions in RNFL thickness in

SCZ and BD, but not in MDD. The differential involvement in various quadrants and

parameters across the disorders has potential implications for using retinal

parameters as a diagnostic biomarker.

FAU - Prasannakumar, Akash

AU - Prasannakumar A

AUID- ORCID: 0000-0002-0945-6691

AD - Department of Psychiatry, National Institute of Mental Health and Neurosciences,

Bangalore, Karnataka, India.

FAU - Kumar, Vijay

AU - Kumar V

AUID- ORCID: 0000-0003-4949-4083

AD - Department of Psychiatry, National Institute of Mental Health and Neurosciences,

Bangalore, Karnataka, India.

FAU - Mailankody, Pooja

AU - Mailankody P

AD - Department of Neurology, National Institute of Mental Health and Neurosciences,

Bangalore, Karnataka, India.

FAU - Appaji, Abhishek

AU - Appaji A

AUID- ORCID: 0000-0002-1978-6037

AD - Department of Medical Electronics, BMS College of Engineering, Bangalore,

Karnataka, India.

AD - Department of Opthalmology, University Eye Clinic Maastricht, Maastricht

University, Maastricht, The Netherlands.

FAU - Battu, Rajani

AU - Battu R

AD - Department of Opthalmology, Centre for Eye Genetics and Research, Bangalore,

Karnataka, India.

FAU - Berendschot, Tos T J M

AU - Berendschot TTJM

AUID- ORCID: 0000-0002-8101-939X

AD - Department of Opthalmology, University Eye Clinic Maastricht, Maastricht

University, Maastricht, The Netherlands.

FAU - Rao, Naren P

AU - Rao NP

AD - Department of Psychiatry, National Institute of Mental Health and Neurosciences,

Bangalore, Karnataka, India.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Review

PT - Systematic Review

DEP - 20230525

PL - England

TA - World J Biol Psychiatry

JT - The world journal of biological psychiatry : the official journal of the World

Federation of Societies of Biological Psychiatry

JID - 101120023

SB - IM

MH - Humans

MH - *Depressive Disorder, Major/diagnostic imaging

MH - *Bipolar Disorder/diagnostic imaging

MH - *Schizophrenia/diagnostic imaging

MH - Tomography, Optical Coherence/methods

MH - Brain/diagnostic imaging

OTO - NOTNLM

OT - Psychosis

OT - mood disorder

OT - optical coherence tomography

OT - retina

EDAT- 2023/04/19 06:00

MHDA- 2023/10/05 06:44

CRDT- 2023/04/18 05:23

PHST- 2023/10/05 06:44 [medline]

PHST- 2023/04/19 06:00 [pubmed]

PHST- 2023/04/18 05:23 [entrez]

AID - 10.1080/15622975.2023.2203231 [doi]

PST - ppublish

SO - World J Biol Psychiatry. 2023 Oct;24(8):707-720. doi:

10.1080/15622975.2023.2203231. Epub 2023 May 25.

PMID- 37060470

OWN - NLM

STAT- MEDLINE

DCOM- 20230512

LR - 20230512

IS - 1432-2072 (Electronic)

IS - 0033-3158 (Linking)

VI - 240

IP - 6

DP - 2023 Jun

TI - Phosphodiesterase inhibitors in psychiatric disorders.

PG - 1201-1219

LID - 10.1007/s00213-023-06361-3 [doi]

AB - RATIONALE: Challenges in drug development for psychiatric disorders have left

much room for the introduction of novel treatments with better therapeutic

efficacies and indices. As a result, intense research has focused on identifying

new targets for developing such pharmacotherapies. One of these targets may be

the phosphodiesterase (PDE) class of enzymes, which play important roles in

intracellular signaling. Due to their critical roles in cellular pathways, these

enzymes affect diverse neurobiological functions from learning and memory

formation to neuroinflammation. OBJECTIVES: In this paper, we reviewed studies on

the use of PDE inhibitors (PDEIs) in preclinical models and clinical trials of

psychiatric disorders including depression, anxiety, schizophrenia,

post-traumatic stress disorder (PTSD), bipolar disorder (BP), sexual dysfunction,

and feeding disorders. RESULTS: PDEIs are able to improve symptoms of psychiatric

disorders in preclinical models through activating the cAMP-PKA-CREB and cGMP-PKG

pathways, attenuating neuroinflammation and oxidative stress, and stimulating

neural plasticity. The most promising therapeutic candidates to emerge from these

preclinical studies are PDE2 and PDE4 inhibitors for depression and anxiety and

PDE1 and PDE10 inhibitors for schizophrenia. Furthermore, PDE3 and 4 inhibitors

have shown promising results in clinical trials in patients with depression and

schizophrenia. CONCLUSIONS: Larger and better designed clinical studies of PDEIs

in schizophrenia, depression, and anxiety are warranted to facilitate their

translation into the clinic. Regarding the other conditions discussed in this

review (most notably PTSD and BP), better characterization of the effects of

PDEIs in preclinical models is required before clinical studies.

part of Springer Nature.

FAU - Sadeghi, Mohammad Amin

AU - Sadeghi MA

AD - Toxicology Research Center, AJA University of Medical Sciences, Tehran, Iran.

AD - Department of Pharmacology, School of Medicine, AJA University of Medical

Sciences, Tehran, Iran.

FAU - Nassireslami, Ehsan

AU - Nassireslami E

AD - Toxicology Research Center, AJA University of Medical Sciences, Tehran, Iran.

AD - Department of Pharmacology, School of Medicine, AJA University of Medical

Sciences, Tehran, Iran.

FAU - Yousefi Zoshk, Mojtaba

AU - Yousefi Zoshk M

AD - Trauma Research Center, AJA University of Medical Sciences, Tehran, Iran.

AD - Department of Pediatrics, AJA University of Medical Sciences, Tehran, Iran.

FAU - Hosseini, Yasaman

AU - Hosseini Y

AD - Cognitive Neuroscience Center, School of Medicine, AJA University of Medical

Sciences, Tehran, Iran.

FAU - Abbasian, Kourosh

AU - Abbasian K

AD - Management and Health Economics Department, AJA University of Medical Sciences,

Tehran, Iran.

FAU - Chamanara, Mohsen

AU - Chamanara M

AD - Toxicology Research Center, AJA University of Medical Sciences, Tehran, Iran.

chamanaramohsen@gmail.com.

AD - Department of Pharmacology, School of Medicine, AJA University of Medical

Sciences, Tehran, Iran. chamanaramohsen@gmail.com.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230415

PL - Germany

TA - Psychopharmacology (Berl)

JT - Psychopharmacology

JID - 7608025

RN - EC 3.1.4.- (Phosphoric Diester Hydrolases)

RN - 0 (Phosphodiesterase 4 Inhibitors)

SB - IM

MH - Humans

MH - Neuroinflammatory Diseases

MH - *Mental Disorders/drug therapy

MH - Phosphoric Diester Hydrolases/metabolism

MH - *Phosphodiesterase 4 Inhibitors

MH - *Schizophrenia/drug therapy

OTO - NOTNLM

OT - Anxiety

OT - Bipolar disorder

OT - Depression

OT - Phosphodiesterase

OT - Phosphodiesterase inhibitor

OT - Post-traumatic stress disorder

OT - Schizophrenia

EDAT- 2023/04/16 06:00

MHDA- 2023/05/12 07:06

CRDT- 2023/04/15 11:14

PHST- 2022/10/28 00:00 [received]

PHST- 2023/03/27 00:00 [accepted]

PHST- 2023/05/12 07:06 [medline]

PHST- 2023/04/16 06:00 [pubmed]

PHST- 2023/04/15 11:14 [entrez]

AID - 10.1007/s00213-023-06361-3 [pii]

AID - 10.1007/s00213-023-06361-3 [doi]

PST - ppublish

SO - Psychopharmacology (Berl). 2023 Jun;240(6):1201-1219. doi:

10.1007/s00213-023-06361-3. Epub 2023 Apr 15.

PMID- 37043223

OWN - NLM

STAT- MEDLINE

DCOM- 20230609

LR - 20230611

IS - 2168-6238 (Electronic)

IS - 2168-622X (Print)

IS - 2168-622X (Linking)

VI - 80

IP - 6

DP - 2023 Jun 1

TI - Effort-Cost Decision-making Among Individuals With Schizophrenia: A Systematic

Review and Meta-analysis.

PG - 548-557

LID - 10.1001/jamapsychiatry.2023.0553 [doi]

AB - IMPORTANCE: Motivational impairments in schizophrenia are by definition

associated with poor outcome. It is postulated that the reduction of

goal-directed behavior arises from abnormal trade-offs between rewards and

efforts. OBJECTIVE: To examine whether schizophrenia is associated with

impairments in effort-cost decision-making. DATA SOURCES: For this systematic

review and meta-analysis, the PubMed, ScienceDirect, PsycINFO, Embase, and

ClinicalTrials.gov databases were searched from inception to July 2022 for

studies that investigated effort-cost decision-making in schizophrenia. Search

terms included effort, cost, and schizophrenia. STUDY SELECTION: Consensual

criteria for inclusion were peer-reviewed studies published in English that used

a computerized effort-cost decision-making behavioral paradigm and compared

individuals with schizophrenia with control individuals. DATA EXTRACTION AND

SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-analyses

reporting guideline was used for abstracting data. Data were extracted

independently by 2 authors and then pooled using random-effects sizes and

bayesian approaches. MAIN OUTCOMES AND MEASURES: The main outcomes were

performance on effort-cost decision-making tasks requiring an effort-reward

trade-off, measured by Hedges g effect size. Effects of moderators were tested

with meta-regressions and subgroup analyses. RESULTS: Twenty studies involving

1503 participants were included: 837 individuals with schizophrenia (541 [64.6%]

male; mean [SD] age, 35.89 [6.70] years) and 666 control individuals without

schizophrenia (360 [54.1%] male; mean [SD] age, 34.16 [5.92] years). Participants

with schizophrenia had significantly reduced willingness to expend effort for

rewards compared with controls (k = 20; effect size, 0.43; 95% CI, 0.30-0.56;

P < .001; I2 = 33.1%; Q test P = .08). The magnitude of the deficit was

significantly greater for high-reward trials. The severity of negative symptoms

was negatively associated with effort-cost decision-making (k = 8; effect size,

-0.33; 95% CI, -0.50 to -0.15; P < .001), while participants with a high number

of negative symptoms had a significantly larger impairment in effort-cost

decision-making (k = 5; effect size, 0.47; 95% CI, 0.10-0.84; P = .01).

CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis,

schizophrenia was associated with deficits in effort allocation as indexed by

effort-cost decision-making tasks. Understanding the cognitive and

neurobiological mechanisms driving effort allocation impairments may assist in

developing novel interventions.

FAU - Blouzard, Elodie

AU - Blouzard E

AD - University Grenoble Alpes, Inserm, Grenoble Institut Neurosciences, Grenoble,

France.

FAU - Pouchon, Arnaud

AU - Pouchon A

AD - University Grenoble Alpes, Inserm, Grenoble Institut Neurosciences, Grenoble,

France.

AD - Adult Psychiatry Department, CHU Grenoble Alpes, Grenoble, France.

FAU - Polosan, Mircea

AU - Polosan M

AD - University Grenoble Alpes, Inserm, Grenoble Institut Neurosciences, Grenoble,

France.

AD - Adult Psychiatry Department, CHU Grenoble Alpes, Grenoble, France.

FAU - Bastin, Julien

AU - Bastin J

AD - University Grenoble Alpes, Inserm, Grenoble Institut Neurosciences, Grenoble,

France.

FAU - Dondé, Clément

AU - Dondé C

AD - University Grenoble Alpes, Inserm, Grenoble Institut Neurosciences, Grenoble,

France.

AD - Adult Psychiatry Department, CHU Grenoble Alpes, Grenoble, France.

AD - Adult Psychiatry Department, Centre Hospitalier Alpes-Isère, Saint-Egrève,

France.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Systematic Review

PL - United States

TA - JAMA Psychiatry

JT - JAMA psychiatry

JID - 101589550

SB - IM

MH - Humans

MH - Male

MH - Adult

MH - Female

MH - *Schizophrenia/diagnosis

MH - Bayes Theorem

MH - Motivation

MH - Reward

PMC - PMC10099175

COIS- Conflict of Interest Disclosures: Dr Polosan reported receiving financial support

from Boston Scientific for an investigator-initiated trial and personal fees from

Lundbeck outside the submitted work. Dr Dondé reported receiving grants from the

French National Research Agency and personal fees from Lundbeck outside the

submitted work. No other disclosures were reported.

EDAT- 2023/04/13 06:00

MHDA- 2023/06/09 06:42

PMCR- 2024/04/12

CRDT- 2023/04/12 11:33

PHST- 2024/04/12 00:00 [pmc-release]

PHST- 2023/06/09 06:42 [medline]

PHST- 2023/04/13 06:00 [pubmed]

PHST- 2023/04/12 11:33 [entrez]

AID - 2803754 [pii]

AID - yoi230015 [pii]

AID - 10.1001/jamapsychiatry.2023.0553 [doi]

PST - ppublish

SO - JAMA Psychiatry. 2023 Jun 1;80(6):548-557. doi: 10.1001/jamapsychiatry.2023.0553.

PMID- 37030089

OWN - NLM

STAT- MEDLINE

DCOM- 20230612

LR - 20230612

IS - 1876-2026 (Electronic)

IS - 1876-2018 (Linking)

VI - 84

DP - 2023 Jun

TI - Retinal microvasculature in schizophrenia: A meta-analysis with trial sequential

analysis of studies assessing vessel density using Optical Coherence Tomography

Angiography.

PG - 103570

LID - S1876-2018(23)00125-9 [pii]

LID - 10.1016/j.ajp.2023.103570 [doi]

AB - We performed a series of random-effects meta-analyses on cross-sectional studies

assessing vessel density (VD) using Optical Coherence Tomography Angiography

(OCTA) in schizophrenia. Five studies with a total sample size of 410

(schizophrenia-192;healthy-218) were analysed. Supplementary Trial Sequential

Analyses (TSA) was also performed. Meta-analyses revealed significantly lower VD

in schizophrenia patients compared to healthy controls in the peripapillary

region of the optic disc, including both superior hemisphere and inferior

hemisphere. TSA validated these significant effects. We conclude that reduced VD

at the peripapillary region of the optic disc as measured by OCTA may have the

potential to be a schizophrenia biomarker.

FAU - Janti, Siddharam S

AU - Janti SS

AD - Department of Ophthalmology, All India Institute of Medical Sciences, Bibinagar,

Hyderabad, Telangana, India.

FAU - Tikka, Sai Krishna

AU - Tikka SK

AD - Department of Psychiatry, All India Institute of Medical Sciences, Bibinagar,

Hyderabad, Telangana, India. Electronic address: saikiatry@gmail.com.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230328

PL - Netherlands

TA - Asian J Psychiatr

JT - Asian journal of psychiatry

JID - 101517820

SB - IM

MH - Humans

MH - Fluorescein Angiography/methods

MH - *Retinal Vessels/diagnostic imaging

MH - Tomography, Optical Coherence/methods

MH - Cross-Sectional Studies

MH - *Schizophrenia/diagnostic imaging

MH - Microvessels/diagnostic imaging

OTO - NOTNLM

OT - Endothelial dysfunction

OT - Neuroinflammation

OT - Psychotic disorders

COIS- Declaration of Competing Interest There are no conflicts of interest.

EDAT- 2023/04/09 06:00

MHDA- 2023/06/12 06:42

CRDT- 2023/04/08 18:05

PHST- 2023/02/23 00:00 [received]

PHST- 2023/03/24 00:00 [revised]

PHST- 2023/03/25 00:00 [accepted]

PHST- 2023/06/12 06:42 [medline]

PHST- 2023/04/09 06:00 [pubmed]

PHST- 2023/04/08 18:05 [entrez]

AID - S1876-2018(23)00125-9 [pii]

AID - 10.1016/j.ajp.2023.103570 [doi]

PST - ppublish

SO - Asian J Psychiatr. 2023 Jun;84:103570. doi: 10.1016/j.ajp.2023.103570. Epub 2023

Mar 28.

PMID- 37029882

OWN - NLM

STAT- MEDLINE

DCOM- 20230803

LR - 20230804

IS - 1724-6059 (Electronic)

IS - 1121-8428 (Print)

IS - 1121-8428 (Linking)

VI - 36

IP - 6

DP - 2023 Jul

TI - Chronic kidney disease and severe mental illness: a scoping review.

PG - 1519-1547

LID - 10.1007/s40620-023-01599-8 [doi]

AB - BACKGROUND: People who have severe mental illness experience higher rates of

long-term conditions and die on average 15-20 years earlier than people who do

not have severe mental illness, a phenomenon known as the mortality gap.

Long-term conditions, such as diabetes, impact health outcomes for people who

have severe mental illness, however there is limited recognition of the

relationship between chronic kidney disease and severe mental illness. Therefore,

the aim of this scoping review was to explore the available evidence on the

relationship between chronic kidney disease and severe mental illness. METHODS:

Electronic databases, including MEDLINE, Embase, CINAHL, and PsycINFO were

searched. The database searches were limited to articles published between

January 2000-January 2022, due to significant progress that has been made in the

detection, diagnosis and treatment of both SMI and CKD. Articles were eligible

for inclusion if they explored the relationship between SMI and CKD (Stages 1-5)

in terms of prevalence, risk factors, clinical outcomes, and access to treatment

and services. Severe mental illness was defined as conditions that can present

with psychosis, including schizophrenia, schizoaffective disorder, bipolar

disorder, and other psychotic disorders. Thirty articles were included in the

review. RESULTS: The included studies illustrated that there is an increased risk

of chronic kidney disease amongst people who have severe mental illness, compared

to those who do not. However, people who have severe mental illness and chronic

kidney disease are less likely to receive specialist nephrology care, are less

likely to be evaluated for a transplant, and have higher rates of mortality.

CONCLUSION: In conclusion, there is a dearth of literature in this area, but the

available literature suggests there are significant health inequalities in kidney

care amongst people who have severe mental illness. Further research is needed to

understand the factors that contribute to this relationship, and to develop

strategies to improve both clinical outcomes and access to kidney care.

FAU - Carswell, Claire

AU - Carswell C

AD - Department of Health Sciences, University of York, York, UK.

claire.carswell@york.ac.uk.

AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, Northern

Ireland, UK. claire.carswell@york.ac.uk.

FAU - Cogley, Clodagh

AU - Cogley C

AD - School of Psychology, University College Dublin, Dublin, Ireland.

FAU - Bramham, Kate

AU - Bramham K

AD - King's College Hospital NHS Trust, London, UK.

FAU - Chilcot, Joseph

AU - Chilcot J

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London,

London, UK.

FAU - Noble, Helen

AU - Noble H

AD - School of Nursing and Midwifery, Queen's University Belfast, Belfast, Northern

Ireland, UK.

FAU - Siddiqi, Najma

AU - Siddiqi N

AD - Department of Health Sciences, University of York, York, UK.

AD - Hull York Medical School, York, UK.

AD - Bradford District Care NHS Foundation Trust, Bradford, UK.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230408

PL - Italy

TA - J Nephrol

JT - Journal of nephrology

JID - 9012268

SB - IM

MH - Humans

MH - *Mental Disorders/epidemiology/therapy

MH - *Psychotic Disorders/epidemiology/therapy

MH - *Schizophrenia/therapy

MH - *Bipolar Disorder/therapy

MH - *Renal Insufficiency, Chronic/diagnosis/epidemiology/therapy

PMC - PMC10393892

OTO - NOTNLM

OT - Chronic kidney disease

OT - Health inequalities

OT - Kidney failure

OT - Mental health

OT - Mental illness

COIS- The authors have no conflicts or competing interests to declare.

EDAT- 2023/04/09 06:00

MHDA- 2023/08/03 06:43

CRDT- 2023/04/08 11:19

PHST- 2022/11/08 00:00 [received]

PHST- 2023/02/12 00:00 [accepted]

PHST- 2023/08/03 06:43 [medline]

PHST- 2023/04/09 06:00 [pubmed]

PHST- 2023/04/08 11:19 [entrez]

AID - 10.1007/s40620-023-01599-8 [pii]

AID - 1599 [pii]

AID - 10.1007/s40620-023-01599-8 [doi]

PST - ppublish

SO - J Nephrol. 2023 Jul;36(6):1519-1547. doi: 10.1007/s40620-023-01599-8. Epub 2023

Apr 8.

PMID- 37029492

OWN - NLM

STAT- MEDLINE

DCOM- 20230927

LR - 20230927

IS - 1741-2854 (Electronic)

IS - 0020-7640 (Linking)

VI - 69

IP - 6

DP - 2023 Sep

TI - Quality of Life of people with Schizophrenia: A meta-analysis.

PG - 1444-1452

LID - 10.1177/00207640231164019 [doi]

AB - BACKGROUND: Schizophrenia is a severe, chronic mental disorder that causes many

psychosocial problems. In order to reveal these problems, it is necessary to

measure the quality of life of people with schizophrenia. AIM: The aim of this

meta-analysis is to compare the quality of life of people with schizophrenia and

healthy subjects. METHODS: Literature search was conducted in the Web of Science

Core Collection database including the dates of January 2000 and March 2021. The

systematic search provided 464 potentially relevant studies. The final sample

consisted of 18 studies. RESULTS: The results of using a random effects model for

analysis indicated that schizophrenia subjects showed considerably lower quality

of life scores compared to healthy controls. CONCLUSION: Determining the quality

of people with schizophrenia will help us to create effective psychosocial

intervention programs.

FAU - Attepe Özden, Seda

AU - Attepe Özden S

AUID- ORCID: 0000-0002-2488-9583

AD - Department of Social Work Baskent University, Ankara, Turkey.

FAU - Tekindal, Melike

AU - Tekindal M

AD - Department of Social Work, İzmir Katip Çelebi University, İzmir, Turkey.

FAU - Tekindal, Mustafa Agah

AU - Tekindal MA

AD - Department of Biostatistics, İzmir Katip Çelebi University, İzmir, Turkey.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230407

PL - England

TA - Int J Soc Psychiatry

JT - The International journal of social psychiatry

JID - 0374726

SB - IM

MH - Humans

MH - *Quality of Life

MH - *Schizophrenia

OTO - NOTNLM

OT - meta-analysis

OT - people with schizophrenia

OT - quality of life

OT - schizophrenia

EDAT- 2023/04/09 06:00

MHDA- 2023/09/27 06:42

CRDT- 2023/04/08 01:42

PHST- 2023/09/27 06:42 [medline]

PHST- 2023/04/09 06:00 [pubmed]

PHST- 2023/04/08 01:42 [entrez]

AID - 10.1177/00207640231164019 [doi]

PST - ppublish

SO - Int J Soc Psychiatry. 2023 Sep;69(6):1444-1452. doi: 10.1177/00207640231164019.

Epub 2023 Apr 7.

PMID- 37028258

OWN - NLM

STAT- MEDLINE

DCOM- 20230515

LR - 20230615

IS - 1872-7123 (Electronic)

IS - 0165-1781 (Linking)

VI - 324

DP - 2023 Jun

TI - Effect of HD-tDCS on white matter integrity and associated cognitive function in

chronic schizophrenia: A double-blind, sham-controlled randomized trial.

PG - 115183

LID - S0165-1781(23)00134-8 [pii]

LID - 10.1016/j.psychres.2023.115183 [doi]

AB - Schizophrenia is a disabling major mental disorder, which includes critical

deficits in cognitive function, for which no effective intervention currently

exists. The aim of our double-blind, randomized, sham-controlled trial was to

evaluate the effects of high-definition transcranial direct current stimulation

(HD-tDCS) on the cognitive deficits in schizophrenia. This study sample consisted

of 56 individuals with chronic schizophrenia, randomly allocated to either the

active stimulation or sham group. The treatment consisted of ten consecutive days

of HD-tDCS, 20 min/day, applied over the left dorsolateral prefrontal lobe.

Changes in clinical outcomes, cognitive assessments, and diffusion tensor imaging

were evaluated pre- to post-intervention. Matched-healthy controls (HCs) were

included to identify white matter changes in patients with schizophrenia before

treatment. Compared to HCs, schizophrenia was associated with reduced integrity

of the white matter tracts of the corpus callosum and corona radiata. HD-tDCS

enhanced integrity in the corpus callosum and anterior and superior corona

radiata, which was associated with the change in cognitive performance. HD-tDCS

offers a potential approach to improve cognition deficits in schizophrenia

through a modulatory effect on white matter tracts. Given the lack of approved

treatments for cognitive deficits, these findings are clinically relevant.

FAU - Xu, Hui

AU - Xu H

AD - Key Laboratory of Brain, Cognition and Education Science, Ministry of Education,

Institute for Brain Research and Rehabilitation, and Guangdong Key Laboratory of

Mental Health and Cognitive Science, South China Normal University, Guangzhou,

China; Peter Boris Centre for Addictions Research, McMaster University, Hamilton,

Canada.

FAU - Zhou, Yongjie

AU - Zhou Y

AD - Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Shenzhen, China.

FAU - Wang, Jiesi

AU - Wang J

AD - CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of

Sciences, Beijing, China.

FAU - Liang, Zhen

AU - Liang Z

AD - Guangdong Provincial Key Laboratory of Biomedical Measurements and Ultrasound

Imaging, School of Biomedical Engineering, Health Science Center, Shenzhen

University, Shenzhen, China.

FAU - Wang, Yang

AU - Wang Y

AD - College of Management, Shenzhen University, Shenzhen, China.

FAU - Wu, Weibin

AU - Wu W

AD - The Third People's Hospital of Foshan, Foshan, China.

FAU - Liu, Yiliang

AU - Liu Y

AD - The Third People's Hospital of Foshan, Foshan, China.

FAU - Liu, Xia

AU - Liu X

AD - Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Shenzhen, China.

FAU - Zhang, Xin

AU - Zhang X

AD - Shenzhen Mental Health Center, Shenzhen Kangning Hospital, Shenzhen, China.

FAU - Huo, Lijuan

AU - Huo L

AD - Key Laboratory of Brain, Cognition and Education Science, Ministry of Education,

Institute for Brain Research and Rehabilitation, and Guangdong Key Laboratory of

Mental Health and Cognitive Science, South China Normal University, Guangzhou,

China; Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou

Medical University, Guangzhou, China. Electronic address: emily.hlj@163.com.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230327

PL - Ireland

TA - Psychiatry Res

JT - Psychiatry research

JID - 7911385

SB - IM

MH - Humans

MH - *Schizophrenia/complications/therapy

MH - *Transcranial Direct Current Stimulation

MH - Diffusion Tensor Imaging

MH - *White Matter/diagnostic imaging

MH - Cognition

MH - Double-Blind Method

MH - Prefrontal Cortex

OTO - NOTNLM

OT - Cognitve deficits

OT - Diffusion tensor imaging

OT - High-definition transcranial direct current stimulation

OT - Randomized controlled trial

OT - Schizophrenia

COIS- Declaration of Competing Interest The authors declare no conflicts of interest.

EDAT- 2023/04/08 06:00

MHDA- 2023/05/15 06:42

CRDT- 2023/04/07 18:14

PHST- 2023/01/17 00:00 [received]

PHST- 2023/03/24 00:00 [revised]

PHST- 2023/03/26 00:00 [accepted]

PHST- 2023/05/15 06:42 [medline]

PHST- 2023/04/08 06:00 [pubmed]

PHST- 2023/04/07 18:14 [entrez]

AID - S0165-1781(23)00134-8 [pii]

AID - 10.1016/j.psychres.2023.115183 [doi]

PST - ppublish

SO - Psychiatry Res. 2023 Jun;324:115183. doi: 10.1016/j.psychres.2023.115183. Epub

2023 Mar 27.

PMID- 37022779

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 4

DP - 2023 Jul 4

TI - Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic

Disorders: I. Clinical Outcomes.

PG - 837-850

LID - 10.1093/schbul/sbad023 [doi]

AB - BACKGROUND: Social determinants of health (SDoHs) are receiving growing attention

and are particularly relevant to persons with schizophrenia-spectrum psychotic

disorders (SSPDs), considering their heightened risk of comorbidities, cognitive

and functional decline, and early mortality. Yet, we did not find any

comprehensive review of multiple SDoHs in SSPD. STUDY DESIGN: We conducted a

scoping review of meta-analyses and systematic reviews of nine major SDoHs in

SSPD. STUDY RESULTS: Childhood abuse, parental psychopathology, parental

communication problems, bullying, and urban settings with lower socioeconomic

status were major risk factors for the greater incidence of SSPD and/or worse

health. Social network size was inversely associated with overall psychopathology

and negative symptoms. Experiences of racial/ethnic discrimination correlated

with the prevalence of psychotic symptoms and experiences. Compared to native

populations, the risk of psychosis was higher in immigrants, refugees, and

asylees. Social fragmentation was associated with an increased prevalence of

schizophrenia. Homeless populations had a 30-fold higher prevalence of

schizophrenia than the general population. Seriously mentally ill people were 2.7

times more likely to report food insecurity than controls. The prevalence of

non-affective psychosis in prisoners was 2.0%-6.5%, compared to 0.3% in the

general population. Certain potentially positive factors like family and

community resilience remain poorly studied. CONCLUSIONS: SDoHs are associated

with higher rates of and worse outcomes in SSPD. Well-designed longitudinal

studies are needed to understand SDoHs' contribution to health in persons with

SSPD, to develop interventions, and to implement changes in clinical care and

public health policies that would reduce adverse health impacts of SDoHs.

Positive SDoHs deserve greater attention.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of the

please email: journals.permissions@oup.com.

FAU - Jester, Dylan J

AU - Jester DJ

AD - Department of Psychiatry, University of California, San Diego, CA, USA.

FAU - Thomas, Michael L

AU - Thomas ML

AD - Department of Psychology, Colorado State University, Fort Collins, CO, USA.

FAU - Sturm, Emily T

AU - Sturm ET

AD - Department of Psychology, Colorado State University, Fort Collins, CO, USA.

FAU - Harvey, Philip D

AU - Harvey PD

AD - Department of Psychiatry, University of Miami Miller School of Medicine, and

Research Service, Bruce W. Carter Miami VA Medical Center, Miami, FL, USA.

FAU - Keshavan, Matcheri

AU - Keshavan M

AD - Department of Psychiatry, Beth Israel Deaconess medical Center and Harvard

Medical School, Boston, MA, USA.

FAU - Davis, Beshaun J

AU - Davis BJ

AD - Department of Psychiatry, University of Maryland School of Medicine, Baltimore,

MD, USA.

FAU - Saxena, Shekhar

AU - Saxena S

AD - Global Health and Population, Harvard T H Chan School of Public Health, Boston,

MA, USA.

FAU - Tampi, Rajesh

AU - Tampi R

AD - Department of Psychiatry, Creighton University School of Medicine, Omaha, NE,

USA.

FAU - Leutwyler, Heather

AU - Leutwyler H

AD - Department of Physiological Nursing, University of California, San Francisco, CA,

USA.

FAU - Compton, Michael T

AU - Compton MT

AD - Department of Psychiatry, Columbia University College of Physicians and Surgeons,

New York, NY, USA.

FAU - Palmer, Barton W

AU - Palmer BW

AD - Department of Psychiatry, University of California, San Diego, CA, USA.

AD - Veterans Affairs San Diego Healthcare System, Mental Illness Research, Education,

and Clinical Center, San Diego, CA, USA.

FAU - Jeste, Dilip V

AU - Jeste DV

AD - Department of Psychiatry, University of California, San Diego, CA, USA.

LA - eng

GR - R01 MH121546/MH/NIMH NIH HHS/United States

GR - R01MH120201/MH/NIMH NIH HHS/United States

GR - T32 MH019934/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Review

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

CIN - Schizophr Bull. 2023 Jul 4;49(4):867-880. PMID: 37023360

MH - Humans

MH - Child

MH - *Schizophrenia/epidemiology/diagnosis

MH - Social Determinants of Health

MH - *Psychotic Disorders/psychology

MH - Risk Factors

MH - Psychopathology

PMC - PMC10318890

OTO - NOTNLM

OT - childhood trauma

OT - homelessness

OT - immigration

OT - poverty

OT - racism

OT - social connections

EDAT- 2023/04/07 06:00

MHDA- 2023/07/06 06:42

PMCR- 2024/04/06

CRDT- 2023/04/06 12:02

PHST- 2024/04/06 00:00 [pmc-release]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/04/07 06:00 [pubmed]

PHST- 2023/04/06 12:02 [entrez]

AID - 7109996 [pii]

AID - sbad023 [pii]

AID - 10.1093/schbul/sbad023 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Jul 4;49(4):837-850. doi: 10.1093/schbul/sbad023.

PMID- 37005977

OWN - NLM

STAT- MEDLINE

DCOM- 20230922

LR - 20231019

IS - 1559-1174 (Electronic)

IS - 1535-1084 (Linking)

VI - 25

IP - 3

DP - 2023 Sep

TI - Up-Regulation of S100 Gene Family in Brain Samples of a Subgroup of Individuals

with Schizophrenia: Meta-analysis.

PG - 388-401

LID - 10.1007/s12017-023-08743-4 [doi]

AB - The S100 proteins family is known to affect neuroinflammation and astrocyte

activation, which have been suggested to be contributors to the pathogenesis of

schizophrenia. We conducted a systematic meta-analysis of S100 genes differential

expression in postmortem samples of patients with schizophrenia vs. healthy

controls, following the commonly used Preferred Reporting Items for Systematic

Reviews and Meta-Analysis (PRISMA) guidelines. Twelve microarray datasets met the

inclusion criteria (overall 511 samples, 253 schizophrenia and 258 controls were

analyzed). Nine out of 21 genes were significantly up-regulated or with tendency

for up-regulation. A per-sample fold change analysis indicated that the S100

genes' up-regulation was concentrated in a subgroup of the patients. None of the

genes have been found to be down-regulated. ANXA3, which encodes Annexin 3

protein and was associated with neuroinflammation, was up-regulated and

positively correlated with the S100 genes' expression pattern. In addition,

astrocytes and endothelial cell markers were significantly correlated with S100A8

expression. S100 correlation with ANXA3 and endothelial cell markers suggests

that the up-regulation we detected reflects increased inflammation. However, it

might also reflect astrocytes abundance or activation. The fact that S100

proteins were shown to be up-regulated in blood samples and other body fluids of

patients with schizophrenia suggests a potential role as biomarkers, which might

help disease subtyping, and the development of etiological treatments for immune

dysregulation in schizophrenia.

Media, LLC, part of Springer Nature.

FAU - Shamir, Anat

AU - Shamir A

AD - The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

FAU - Yitzhaky, Assif

AU - Yitzhaky A

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

FAU - Segev, Aviv

AU - Segev A

AD - The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

AD - Shalvata Mental Health Center, 13 Aliat Hanoar St, 45100, Hod Hasharon, Israel.

FAU - Haroutunian, Vahram

AU - Haroutunian V

AD - Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York,

NY, USA.

AD - Department of Psychiatry (MIRECC), James J Peters VA Medical Center, Bronx, NY,

USA.

FAU - Katsel, Pavel

AU - Katsel P

AD - Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York,

NY, USA.

FAU - Hertzberg, Libi

AU - Hertzberg L

AD - The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.

libi.hertzberg@gmail.com.

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel. libi.hertzberg@gmail.com.

AD - Shalvata Mental Health Center, 13 Aliat Hanoar St, 45100, Hod Hasharon, Israel.

libi.hertzberg@gmail.com.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

DEP - 20230402

PL - United States

TA - Neuromolecular Med

JT - Neuromolecular medicine

JID - 101135365

RN - 0 (S100 Proteins)

SB - IM

MH - Humans

MH - Up-Regulation

MH - *Schizophrenia/genetics

MH - Neuroinflammatory Diseases

MH - Brain/metabolism

MH - S100 Proteins/genetics/metabolism

OTO - NOTNLM

OT - Gene expression

OT - Meta-analysis

OT - S100

OT - Schizophrenia

EDAT- 2023/04/04 06:00

MHDA- 2023/09/22 06:42

CRDT- 2023/04/03 02:45

PHST- 2022/12/01 00:00 [received]

PHST- 2023/03/12 00:00 [accepted]

PHST- 2023/09/22 06:42 [medline]

PHST- 2023/04/04 06:00 [pubmed]

PHST- 2023/04/03 02:45 [entrez]

AID - 10.1007/s12017-023-08743-4 [pii]

AID - 10.1007/s12017-023-08743-4 [doi]

PST - ppublish

SO - Neuromolecular Med. 2023 Sep;25(3):388-401. doi: 10.1007/s12017-023-08743-4. Epub

2023 Apr 2.

PMID- 37003472

OWN - NLM

STAT- MEDLINE

DCOM- 20230908

LR - 20230920

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Linking)

VI - 94

IP - 7

DP - 2023 Oct 1

TI - Beyond the Binary: Gender Inclusivity in Schizophrenia Research.

PG - 543-549

LID - S0006-3223(23)01169-1 [pii]

LID - 10.1016/j.biopsych.2023.03.018 [doi]

AB - Schizophrenia is a severe neuropsychiatric disorder with significant differences

in the incidence and symptomology between cisgender men and women. In recent

years, considerably more attention has been on the inclusion of sex and gender in

schizophrenia research. However, the majority of this research has failed to

consider gender outside of the socially constructed binary of men and women. As a

result, little is known about schizophrenia in transgender and

gender-nonconforming populations. In this review, we present evidence showing

that transgender and gender-nonconforming individuals have elevated risk of

developing schizophrenia, and we discuss minority stress theory and other

potential factors that may contribute to this risk. The need for inclusion of

transgender and gender-nonconforming communities in schizophrenia research is

emphasized, alongside a discussion on considerations and challenges associated

with this type of research. Finally, we offer specific strategies to make

research on schizophrenia, and research on other neuropsychiatric disorders, more

inclusive of those populations that do not fall within the socially constructed

gender binary. If we are to succeed in the development of more personalized

therapeutic approaches for all, a better understanding of the variability of the

human brain is needed.

rights reserved.

FAU - Nolan, Caitlin J

AU - Nolan CJ

AD - Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.

FAU - Roepke, Troy A

AU - Roepke TA

AD - Department of Animal Sciences, School of Environmental and Biological Sciences,

Rutgers, The State University of New Jersey, New Brunswick, New Jersey.

FAU - Perreault, Melissa L

AU - Perreault ML

AD - Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.

Electronic address: perreaum@uoguelph.ca.

LA - eng

GR - R01 MH123544/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230331

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

SB - IM

MH - Male

MH - Humans

MH - Female

MH - *Schizophrenia

MH - Gender Identity

MH - *Transgender Persons/psychology

OTO - NOTNLM

OT - Gender nonconforming

OT - Nonbinary

OT - Schizophrenia

OT - Trans man

OT - Trans woman

OT - Transgender

EDAT- 2023/04/02 06:00

MHDA- 2023/09/08 06:42

CRDT- 2023/04/01 19:28

PHST- 2022/12/19 00:00 [received]

PHST- 2023/02/24 00:00 [revised]

PHST- 2023/03/20 00:00 [accepted]

PHST- 2023/09/08 06:42 [medline]

PHST- 2023/04/02 06:00 [pubmed]

PHST- 2023/04/01 19:28 [entrez]

AID - S0006-3223(23)01169-1 [pii]

AID - 10.1016/j.biopsych.2023.03.018 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Oct 1;94(7):543-549. doi: 10.1016/j.biopsych.2023.03.018.

Epub 2023 Mar 31.

PMID- 37003432

OWN - NLM

STAT- MEDLINE

DCOM- 20230501

LR - 20230517

IS - 1573-2517 (Electronic)

IS - 0165-0327 (Print)

IS - 0165-0327 (Linking)

VI - 332

DP - 2023 Jul 1

TI - Effects of COVID-19 pandemic on depression in patients with schizophrenia: A

mini-review of the current evidence.

PG - 143-149

LID - S0165-0327(23)00445-7 [pii]

LID - 10.1016/j.jad.2023.03.087 [doi]

AB - BACKGROUND: Since the emergence of COVID-19, there have been concerns about the

psychological effects of the pandemic on people's mental health around the world.

Individuals with psychotic disorders like schizophrenia (SCZ) may be more prone

to develop mood disorders during the lockdowns due to their limited access to

healthcare, reduced social support, and probable cognitive impairment. METHODS:

We conducted a systematic search on PubMed and Scopus to explore the effects of

the pandemic on depressive symptoms in individuals with SCZ. A total of 12

studies were included. RESULTS: Overall, studies suggested higher depression

rates in patients with SCZ compared to healthy controls. Isolation due to the

COVID-19 infection emerged as a risk factor for the development of depressive

symptoms. However, results regarding the longitudinal changes of depression in

SCZ patients during the lockdowns were inconsistent. LIMITATIONS: The small

sample sizes of studies, different depression scales and stages of the lockdowns,

as well as the different government policies and restriction levels across the

countries limit the conclusions of the present review. CONCLUSIONS: Our review

suggests an increased probability of depression in patients with SCZ during the

pandemic. Identifying the risk factors for developing depression in this

population helps find new, suitable approaches to address patients' needs and

lower the adverse psychological effects of the pandemic.

FAU - Seyedmirzaei, Homa

AU - Seyedmirzaei H

AD - School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

FAU - Katebian, Saba

AU - Katebian S

AD - School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

FAU - Pourkand, Donya

AU - Pourkand D

AD - School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

FAU - Cattarinussi, Giulia

AU - Cattarinussi G

AD - Department of Neuroscience (DNS), University of Padova, Padua, Italy; Padova

Neuroscience Center, University of Padova, Padua, Italy.

FAU - Sambataro, Fabio

AU - Sambataro F

AD - Department of Neuroscience (DNS), University of Padova, Padua, Italy; Padova

Neuroscience Center, University of Padova, Padua, Italy.

FAU - Brambilla, Paolo

AU - Brambilla P

AD - Department of Pathophysiology and Transplantation, University of Milan, Milan,

Italy; Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda

Ospedale Maggiore Policlinico, Milan, Italy.

FAU - Delvecchio, Giuseppe

AU - Delvecchio G

AD - Department of Pathophysiology and Transplantation, University of Milan, Milan,

Italy. Electronic address: giuseppe.delvecchio@policlinico.mi.it.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230331

PL - Netherlands

TA - J Affect Disord

JT - Journal of affective disorders

JID - 7906073

SB - IM

MH - Humans

MH - *COVID-19/epidemiology

MH - Pandemics

MH - *Schizophrenia/epidemiology

MH - Depression/epidemiology/etiology/psychology

MH - Communicable Disease Control

MH - Anxiety/psychology

PMC - PMC10063456

OTO - NOTNLM

OT - COVID-19

OT - COVID-19 pandemic

OT - Depression

OT - Schizophrenia

COIS- Conflict of interest None.

EDAT- 2023/04/02 06:00

MHDA- 2023/05/01 06:42

CRDT- 2023/04/01 19:28

PHST- 2022/10/13 00:00 [received]

PHST- 2023/03/14 00:00 [revised]

PHST- 2023/03/20 00:00 [accepted]

PHST- 2023/05/01 06:42 [medline]

PHST- 2023/04/02 06:00 [pubmed]

PHST- 2023/04/01 19:28 [entrez]

AID - S0165-0327(23)00445-7 [pii]

AID - 10.1016/j.jad.2023.03.087 [doi]

PST - ppublish

SO - J Affect Disord. 2023 Jul 1;332:143-149. doi: 10.1016/j.jad.2023.03.087. Epub

2023 Mar 31.

PMID- 37002951

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 4

DP - 2023 Jul 4

TI - Pharmacological Interventions for the Prevention of Antipsychotic-Induced Weight

Gain in People With Schizophrenia: A Cochrane Systematic Review and

Meta-Analysis.

PG - 833-835

LID - 10.1093/schbul/sbad037 [doi]

AB - Patients with schizophrenia are burdened by higher rates of obesity,

cardiovascular disease and reduced life expectancy than the general population.

In addition to illness, genetic and lifestyle factors, the associated weight gain

and metabolic adverse effects of antipsychotic (AP) medications are known to

exacerbate and accelerate these cardiometabolic problems significantly. Given the

detrimental consequences of weight gain and other metabolic disturbances, there

is an urgent need for safe and effective strategies to manage these issues as

early on as possible. This review summarizes the literature of adjunctive

pharmacological interventions aimed at preventing AP-induced weight gain.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of the

please email: journals.permissions@oup.com.

FAU - Agarwal, Sri Mahavir

AU - Agarwal SM

AD - Complex Care and Recovery, Centre for Addiction and Mental Health, Toronto,

Canada.

AD - Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto,

TorontoCanada.

AD - Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto,

Toronto, Canada.

AD - Banting and Best Diabetes Institute, University of Toronto, Toronto, Canada.

FAU - Stogios, Nicolette

AU - Stogios N

AUID- ORCID: 0000-0001-9136-4923

AD - Complex Care and Recovery, Centre for Addiction and Mental Health, Toronto,

Canada.

AD - Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto,

TorontoCanada.

FAU - Faulkner, Guy E J

AU - Faulkner GEJ

AD - School of Kinesiology, University of British Columbia, Vancouver, Canada.

FAU - Hahn, Margaret

AU - Hahn M

AUID- ORCID: 0000-0001-8884-9946

AD - Complex Care and Recovery, Centre for Addiction and Mental Health, Toronto,

Canada.

AD - Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto,

TorontoCanada.

AD - Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto,

Toronto, Canada.

AD - Banting and Best Diabetes Institute, University of Toronto, Toronto, Canada.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy/chemically induced

MH - *Antipsychotic Agents/adverse effects

MH - Weight Gain

MH - Obesity/chemically induced/prevention & control

MH - *Cardiovascular Diseases/drug therapy

PMC - PMC10318865

OTO - NOTNLM

OT - adjunctive medications

OT - antipsychotic-induced weight gain

OT - cochrane

OT - meta-analysis

OT - prevention

OT - systematic review

COIS- MH has consultant fees from Alkermes, Inc. However, she declares that she did not

receive any direct payment for completion of this review. All other funding

details and conflicts of interest can be found in the main Cochrane report.

EDAT- 2023/04/02 06:00

MHDA- 2023/07/06 06:42

PMCR- 2024/07/03

CRDT- 2023/04/01 17:22

PHST- 2024/07/03 00:00 [pmc-release]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/04/02 06:00 [pubmed]

PHST- 2023/04/01 17:22 [entrez]

AID - 7099517 [pii]

AID - sbad037 [pii]

AID - 10.1093/schbul/sbad037 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Jul 4;49(4):833-835. doi: 10.1093/schbul/sbad037.

PMID- 37002818

OWN - NLM

STAT- MEDLINE

DCOM- 20230814

LR - 20230814

IS - 2044-8341 (Electronic)

IS - 1476-0835 (Linking)

VI - 96

IP - 3

DP - 2023 Sep

TI - Assessing the delivering of iMAgery-focused therapy for PSychosis (iMAPS) via

telehealth.

PG - 678-696

LID - 10.1111/papt.12463 [doi]

AB - OBJECTIVES: To examine the feasibility and acceptability of a novel telehealth

(video-conferencing software and telephone calls) imagery-based therapeutic

intervention for people experiencing persecutory delusions. Utilising a multiple

baseline case series design and exploring imagery-focused therapy for psychosis

(iMAPS). DESIGN: A non-concurrent A-B multiple baseline design was used. METHODS:

Participants experiencing persecutory delusions and self-reporting a psychosis or

schizophrenia-spectrum diagnosis were recruited through online adverts. On

completion of assessments, participants were randomly assigned to multiple

baseline assessments, of between three and five sessions. Six therapy sessions

followed, consisting of imagery formulation, safe-place imagery creation,

compassionate imagery, imagery manipulation and rescripting. Participants

completed pre- and post-measures and sessional measures via an online survey

software or in semi-structured interviews. Two weeks post-intervention, a final

measure was completed exploring any potential adverse effects of psychotherapy.

RESULTS: Five female participants completed all baseline and therapeutic

sessions, suggesting the therapy was and mode of delivery was feasible and

acceptable. Results indicate strong effect sizes across PANSS positive subscale

and mood, as well as participants reporting a clinically significant change in at

least one measure, for example, PSYRATS. All participants reported a reduction in

the realness and compelling nature of distressing imagery. CONCLUSIONS: Results

suggest delivering a telehealth imagery-focused therapy is acceptable and

feasibly delivered via telehealth. A control group and blinding of assessments

would strengthen the methodological limitations present.

published by John Wiley & Sons Ltd on behalf of The British Psychological

Society.

FAU - Cairns, Aimee J J

AU - Cairns AJJ

AUID- ORCID: 0000-0002-6090-3602

AD - Clinical Psychology, Lancaster University, Health Innovation Campus, Bailrigg,

Lancaster, LA1 4YW, UK.

FAU - Kelly, James

AU - Kelly J

AUID- ORCID: 0000-0003-0228-015X

AD - Clinical Psychology, Lancaster University, Health Innovation Campus, Bailrigg,

Lancaster, LA1 4YW, UK.

AD - North Manchester General Hospital, Greater Manchester Mental Health NHS

Foundation Trust, Manchester, UK.

FAU - Taylor, Christopher D J

AU - Taylor CDJ

AUID- ORCID: 0000-0002-1989-883X

AD - Community Mental Health Team, Pennine Care NHS Foundation Trust, Humphrey House,

Angouleme Way, Bury, Bl9 0EQ, UK.

AD - Division of Psychology and Mental Health, School of Health Sciences, Manchester

Academic Health Science Centre, University of Manchester, Zochonis Building,

Brunswick Street, Manchester, M13 9PL, UK.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230401

PL - England

TA - Psychol Psychother

JT - Psychology and psychotherapy

JID - 101135751

SB - IM

MH - Humans

MH - Female

MH - Imagery, Psychotherapy

MH - *Psychotic Disorders/therapy

MH - *Schizophrenia/therapy

MH - Delusions/therapy

MH - *Telemedicine

OTO - NOTNLM

OT - case series

OT - imagery

OT - imagery-intervention

OT - mental imagery

OT - psychosis

OT - schizophrenia

EDAT- 2023/04/02 06:00

MHDA- 2023/08/14 06:42

CRDT- 2023/04/01 06:22

PHST- 2022/11/02 00:00 [received]

PHST- 2023/03/23 00:00 [accepted]

PHST- 2023/08/14 06:42 [medline]

PHST- 2023/04/02 06:00 [pubmed]

PHST- 2023/04/01 06:22 [entrez]

AID - 10.1111/papt.12463 [doi]

PST - ppublish

SO - Psychol Psychother. 2023 Sep;96(3):678-696. doi: 10.1111/papt.12463. Epub 2023

Apr 1.

PMID- 36994656

OWN - NLM

STAT- MEDLINE

DCOM- 20230522

LR - 20230627

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Print)

IS - 0007-1250 (Linking)

VI - 222

IP - 6

DP - 2023 Jun

TI - Optimising plasma clozapine levels to improve treatment response: an individual

patient data meta-analysis and receiver operating characteristic curve analysis.

PG - 241-245

LID - 10.1192/bjp.2023.27 [doi]

AB - BACKGROUND: Although clozapine is the most efficacious medication for

treatment-refractory schizophrenia, not all patients will have an adequate

response. Optimising clozapine dose using therapeutic drug monitoring could

therefore maximise response. AIMS: Using individual patient data, we undertook a

receiver operating characteristic (ROC) curve analysis to determine an optimal

therapeutic range for clozapine levels to guide clinical practice. METHOD: We

conducted a systematic review of PubMed, PsycINFO and Embase for studies that

provided individual participant level data on clozapine levels and response.

These data were analysed using ROC curves to determine the prediction performance

of plasma clozapine levels for treatment response. RESULTS: We included data on

294 individual participants from nine studies. ROC analysis yielded an area under

the curve of 0.612. The clozapine level at the point of optimal diagnostic

benefit was 372 ng/mL; at this level, the response sensitivity was 57.3%, and

specificity 65.7%. The interquartile range for treatment response was 223-558

ng/mL. There was no improvement in ROC performance with mixed models including

patient gender, age or length of trial. Clozapine dose and clozapine

concentration to dose ratio did not provide significantly meaningful prediction

of response to clozapine. CONCLUSIONS: Clozapine dose should be optimised based

on clozapine therapeutic levels. We found that a range between 250 and 550 ng/mL

could be recommended, while noting that a level of >350 ng/mL is the most optimal

for response. Although some patients may not respond without clozapine levels

>550 ng/mL, the benefits should be weighed against the increased risk of adverse

drug reactions.

FAU - Northwood, Korinne

AU - Northwood K

AD - Metro South Addiction and Mental Health Service, Metro South Health, Australia

and Faculty of Medicine, University of Queensland, Australia.

FAU - Pearson, E

AU - Pearson E

AD - College of Medicine and Public Health, Flinders University, Australia.

FAU - Arnautovska, U

AU - Arnautovska U

AD - Metro South Addiction and Mental Health Service, Metro South Health, Australia

and Faculty of Medicine, University of Queensland, Australia.

FAU - Kisely, S

AU - Kisely S

AUID- ORCID: 0000-0003-4021-2924

AD - Metro South Addiction and Mental Health Service, Metro South Health, Australia

and Faculty of Medicine, University of Queensland, Australia.

FAU - Pawar, M

AU - Pawar M

AD - Metro South Addiction and Mental Health Service, Metro South Health, Australia.

FAU - Sharma, M

AU - Sharma M

AD - Department of Mental Health, Monash Health, Australia.

FAU - Vitangcol, K

AU - Vitangcol K

AD - Faculty of Medicine, University of Queensland, Australia.

FAU - Wagner, E

AU - Wagner E

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Germany.

FAU - Warren, N

AU - Warren N

AD - Metro South Addiction and Mental Health Service, Metro South Health, Australia

and Faculty of Medicine, University of Queensland, Australia.

FAU - Siskind, Dan

AU - Siskind D

AUID- ORCID: 0000-0002-2072-9216

AD - Metro South Addiction and Mental Health Service, Metro South Health, Australia

and Faculty of Medicine, University of Queensland, Australia.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Systematic Review

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

RN - J60AR2IKIC (Clozapine)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Clozapine/therapeutic use

MH - *Antipsychotic Agents/therapeutic use

MH - ROC Curve

MH - *Schizophrenia/diagnosis

MH - Psychiatric Status Rating Scales

PMC - PMC10201335

OTO - NOTNLM

OT - Clozapine

OT - ROC curve

OT - individual patient data meta-analysis

OT - optimisation

OT - therapeutic drug monitoring

COIS- N.W. has received speaker fees from Otsuka, Lundbeck and Janssen. E.W. has been

invited to advisory boards from Recordati. D.S. and S.K. are members of the

British Journal of Psychiatry editorial board, however, they did not take part in

the review or decision-making process of this paper. The remaining authors have

no conflicts of interest to declare.

EDAT- 2023/03/31 06:00

MHDA- 2023/05/22 06:42

CRDT- 2023/03/30 04:32

PHST- 2023/05/22 06:42 [medline]

PHST- 2023/03/31 06:00 [pubmed]

PHST- 2023/03/30 04:32 [entrez]

AID - S0007125023000272 [pii]

AID - 10.1192/bjp.2023.27 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jun;222(6):241-245. doi: 10.1192/bjp.2023.27.

PMID- 36977612

OWN - NLM

STAT- MEDLINE

DCOM- 20230623

LR - 20230625

IS - 1097-4547 (Electronic)

IS - 0360-4012 (Linking)

VI - 101

IP - 8

DP - 2023 Aug

TI - SMAD genes are up-regulated in brain and blood samples of individuals with

schizophrenia.

PG - 1224-1235

LID - 10.1002/jnr.25188 [doi]

AB - Schizophrenia is a severe psychiatric disorder, with heritability around 80%, but

a not fully understood pathophysiology. Signal transduction through the mothers

against decapentaplegic (SMADs) are eight different proteins involved in the

regulation of inflammatory processes, cell cycle, and tissue patterning. The

literature is not consistent regarding the differential expression of SMAD genes

among subjects with schizophrenia. In this article, we performed a systematic

meta-analysis of the expression of SMAD genes in 423 brain samples (211

schizophrenia vs. 212 healthy controls), integrating 10 datasets from two public

repositories, following the PRISMA guidelines. We found a statistically

significant up-regulation of SMAD1, SMAD4, SMAD5, and SMAD7, and a tendency for

up-regulation of SMAD3 and SMAD9 in brain samples of patients with schizophrenia.

Overall, six of the eight genes showed a tendency for up-regulation, and none of

them was found to have a tendency for down-regulation. SMAD1 and SMAD4 were

up-regulated also in blood samples of 13 individuals with schizophrenia versus

eight healthy controls, suggesting the SMAD genes' potential role as biomarkers

of schizophrenia. Furthermore, SMAD genes' expression levels were significantly

correlated with those of Sphingosine-1-phosphate receptor-1 (S1PR1), which is

known to regulate inflammatory processes. Our meta-analysis supports the

involvement of SMAD genes in the pathophysiology of schizophrenia through their

role in inflammatory processes, as well as demonstrates the importance of gene

expression meta-analysis for improving our understanding of psychiatric diseases.

Periodicals LLC.

FAU - Wolf, Ammie

AU - Wolf A

AD - The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

FAU - Yitzhaky, Assif

AU - Yitzhaky A

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

FAU - Hertzberg, Libi

AU - Hertzberg L

AUID- ORCID: 0000-0002-7895-8089

AD - The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

AD - Shalvata Mental Health Center, 13 Aliat Hanoar St., Hod Hasharon, 45100, Israel.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230328

PL - United States

TA - J Neurosci Res

JT - Journal of neuroscience research

JID - 7600111

RN - 0 (Smad3 Protein)

RN - 0 (Transforming Growth Factor beta)

SB - IM

MH - Humans

MH - *Schizophrenia/genetics

MH - Signal Transduction/physiology

MH - Smad3 Protein/metabolism

MH - Brain/metabolism

MH - Transforming Growth Factor beta/metabolism

OTO - NOTNLM

OT - gene expression

OT - meta-analysis

OT - signal transduction through the mothers against decapentaplegic

EDAT- 2023/03/29 06:00

MHDA- 2023/06/23 06:42

CRDT- 2023/03/28 21:52

PHST- 2023/03/04 00:00 [revised]

PHST- 2022/10/22 00:00 [received]

PHST- 2023/03/08 00:00 [accepted]

PHST- 2023/06/23 06:42 [medline]

PHST- 2023/03/29 06:00 [pubmed]

PHST- 2023/03/28 21:52 [entrez]

AID - 10.1002/jnr.25188 [doi]

PST - ppublish

SO - J Neurosci Res. 2023 Aug;101(8):1224-1235. doi: 10.1002/jnr.25188. Epub 2023 Mar

28.

PMID- 36973079

OWN - NLM

STAT- MEDLINE

DCOM- 20230608

LR - 20230609

IS - 1545-5300 (Electronic)

IS - 0014-7370 (Linking)

VI - 62

IP - 2

DP - 2023 Jun

TI - The effect of multiple family therapy on mental health problems and family

functioning: A systematic review and meta-analysis.

PG - 499-514

LID - 10.1111/famp.12876 [doi]

AB - The aim of this systematic review and meta-analysis was to provide an overview of

existing controlled trials focusing on the impact of multiple family therapy

(MFT) on mental health problems and family functioning, and to examine the

efficacy of MFT. Relevant studies were selected following a screening of 3376

studies identified by a systematic search of seven databases. The following data

were extracted: participant characteristics, program characteristics, study

characteristics, and information of mental health problems and/or family

functioning. A total of 31 peer-reviewed, English, controlled studies evaluating

the effect of MFT were included in the systematic review. Sixteen studies

presenting 16 trials were included in the meta-analysis. All but one of the

studies was at risk of bias, with problems concerning confounding, selection of

participants and missing data. The findings confirm that MFT is offered in

diverse settings, with studies presenting a variety of therapeutic modalities,

focal problems, and populations. Individual studies reported some positive

findings, including improvements in mental health, vocational outcomes, and

social functioning. The findings of the meta-analysis suggest that MFT is

associated with improvements in symptoms of schizophrenia. However, this effect

was found not to be significant due to the large amount of heterogeneity. In

addition, MFT was associated with small improvements in family functioning. We

found little evidence to suggest that MFT successfully alleviates mood and

conduct problems. To conclude, more methodologically rigorous research is needed

to further examine the potential benefits of MFT, as well as the working

mechanisms and core components of MFT.

of Family Process Institute.

FAU - van Es, Carlijn Maria

AU - van Es CM

AUID- ORCID: 0000-0002-5172-8232

AD - ARQ Centrum'45, Nienoord 13, 1112 XE, Diemen, The Netherlands.

AD - ARQ National Psychotrauma Centre, 1112 XE, Diemen, The Netherlands.

AD - Department of Clinical Psychology, Utrecht University, Utrecht, The Netherlands.

FAU - El Khoury, Beatrice

AU - El Khoury B

AD - Department of Clinical Psychology, Utrecht University, Utrecht, The Netherlands.

AD - Borderless NGO, Saida Hwy, Beirut, 1001, Lebanon.

FAU - van Dis, Eva A M

AU - van Dis EAM

AD - Department of Clinical Psychology, Utrecht University, Utrecht, The Netherlands.

FAU - Te Brake, Hans

AU - Te Brake H

AUID- ORCID: 0000-0003-1687-117X

AD - ARQ National Psychotrauma Centre, 1112 XE, Diemen, The Netherlands.

AD - ARQ Centre of Expertise for the Impact of Disasters and Crises, Nienoord 13, 1112

XE, Diemen, The Netherlands.

FAU - van Ee, Elisa

AU - van Ee E

AUID- ORCID: 0000-0002-8434-2029

AD - Psychotraumacentrum Zuid Nederland, Reinier van Arkel, Bethaniestraat 10, 5211

LJ, 's-Hertogenbosch, The Netherlands.

AD - Faculteit der Sociale Wetenschappen, Radboud Universiteit, Thomas van

Aquinostraat 4, Nijmegen, 6525, Gelderland, The Netherlands.

FAU - Boelen, Paul A

AU - Boelen PA

AUID- ORCID: 0000-0003-4125-4739

AD - ARQ Centrum'45, Nienoord 13, 1112 XE, Diemen, The Netherlands.

AD - ARQ National Psychotrauma Centre, 1112 XE, Diemen, The Netherlands.

AD - Department of Clinical Psychology, Utrecht University, Utrecht, The Netherlands.

FAU - Mooren, Trudy

AU - Mooren T

AUID- ORCID: 0000-0003-0819-8640

AD - ARQ Centrum'45, Nienoord 13, 1112 XE, Diemen, The Netherlands.

AD - ARQ National Psychotrauma Centre, 1112 XE, Diemen, The Netherlands.

AD - Department of Clinical Psychology, Utrecht University, Utrecht, The Netherlands.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

DEP - 20230327

PL - United States

TA - Fam Process

JT - Family process

JID - 0400666

SB - IM

MH - Humans

MH - *Family Therapy

MH - Mental Health

MH - *Schizophrenia

OTO - NOTNLM

OT - family functioning

OT - mental health problems

OT - meta-analysis

OT - multiple family therapy

OT - systematic review

EDAT- 2023/03/28 06:00

MHDA- 2023/06/08 06:42

CRDT- 2023/03/27 21:45

PHST- 2023/02/28 00:00 [revised]

PHST- 2021/12/14 00:00 [received]

PHST- 2023/03/02 00:00 [accepted]

PHST- 2023/06/08 06:42 [medline]

PHST- 2023/03/28 06:00 [pubmed]

PHST- 2023/03/27 21:45 [entrez]

AID - 10.1111/famp.12876 [doi]

PST - ppublish

SO - Fam Process. 2023 Jun;62(2):499-514. doi: 10.1111/famp.12876. Epub 2023 Mar 27.

PMID- 36971864

OWN - NLM

STAT- MEDLINE

DCOM- 20230831

LR - 20231013

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Print)

IS - 0940-1334 (Linking)

VI - 273

IP - 7

DP - 2023 Oct

TI - Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the

treatment of cognitive impairment associated with schizophrenia.

PG - 1557-1566

LID - 10.1007/s00406-023-01576-z [doi]

AB - Schizophrenia is a psychiatric disorder characterised by symptoms in three

domains: positive (e.g. delusions, hallucinations), negative (e.g. social

withdrawal, lack of motivation) and cognitive (e.g. working memory and executive

function impairment). Cognitive impairment associated with schizophrenia (CIAS)

is a major burden for patients and negatively impacts many aspects of a patient's

life. Antipsychotics are the standard-of-care treatment for schizophrenia but

only address positive symptoms. So far there are no approved pharmacotherapies

for the treatment of CIAS. Iclepertin (BI 425809) is a novel, potent and

selective glycine transporter 1 (GlyT1) inhibitor, under development by

Boehringer Ingelheim for the treatment of CIAS. Phase I studies have shown it to

be safe and well tolerated in healthy volunteers, and central target engagement

(inhibition of GlyT1) was achieved in a dose-dependent manner from 5 to 50 mg in

healthy volunteers. A Phase II study has demonstrated that iclepertin is safe and

well tolerated in patients with schizophrenia and improves cognition at doses of

10 mg and 25 mg. Phase III studies are ongoing to confirm these initial positive

safety and efficacy findings with the 10 mg dose, and if successful, iclepertin

could become the first approved pharmacotherapy used to treat CIAS.

FAU - Rosenbrock, Holger

AU - Rosenbrock H

AD - Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

FAU - Desch, Michael

AU - Desch M

AD - Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

FAU - Wunderlich, Glen

AU - Wunderlich G

AUID- ORCID: 0000-0003-4945-2342

AD - Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT

06877, USA. glen.wunderlich@boehringer-ingelheim.com.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230327

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

RN - 0 (Glycine Plasma Membrane Transport Proteins)

RN - 0 (BI 425809)

RN - 0 (Organic Chemicals)

SB - IM

CIN - Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1399-1401. PMID: 37603079

MH - Humans

MH - *Schizophrenia/complications/drug therapy

MH - Glycine Plasma Membrane Transport Proteins

MH - *Cognitive Dysfunction/drug therapy/etiology

MH - Organic Chemicals

MH - Clinical Trials, Phase II as Topic

PMC - PMC10465677

OTO - NOTNLM

OT - BI 425809

OT - Cognitive impairment

OT - GlyT1 inhibitor

OT - Iclepertin

OT - NMDA receptor

OT - Schizophrenia

COIS- HR and MD are employees of Boehringer Ingelheim Pharma GmbH & Co. KG and GW is an

employee of Boehringer Ingelheim Pharmaceuticals Inc.

EDAT- 2023/03/28 06:00

MHDA- 2023/08/31 06:41

CRDT- 2023/03/27 11:16

PHST- 2022/11/28 00:00 [received]

PHST- 2023/02/20 00:00 [accepted]

PHST- 2023/08/31 06:41 [medline]

PHST- 2023/03/28 06:00 [pubmed]

PHST- 2023/03/27 11:16 [entrez]

AID - 10.1007/s00406-023-01576-z [pii]

AID - 1576 [pii]

AID - 10.1007/s00406-023-01576-z [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi:

10.1007/s00406-023-01576-z. Epub 2023 Mar 27.

PMID- 36959286

OWN - NLM

STAT- MEDLINE

DCOM- 20230529

LR - 20230606

IS - 1476-5497 (Electronic)

IS - 0307-0565 (Linking)

VI - 47

IP - 6

DP - 2023 Jun

TI - Mechanism and treatments of antipsychotic-induced weight gain.

PG - 423-433

LID - 10.1038/s41366-023-01291-8 [doi]

AB - The long-term use of antipsychotics (APs) may cause a variety of diseases, such

as metabolic syndrome, antipsychotic-induced weight gain (AIWG), and even

obesity. This paper reviews the various mechanisms of AIWG and obesity in detail,

involving genetics, the central nervous system, the neuroendocrine system, and

the gut microbiome. The common drug and non-drug therapies used in clinical

practice are also introduced, providing the basis for research on the molecular

mechanisms and the future selection of treatments.

FAU - Ye, Wujie

AU - Ye W

AUID- ORCID: 0000-0001-7794-5692

AD - School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing,

100029, China.

FAU - Xing, Jingyu

AU - Xing J

AD - School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing,

100029, China.

FAU - Yu, Zekai

AU - Yu Z

AD - School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing,

100029, China.

FAU - Hu, Xingang

AU - Hu X

AD - Internal encephalopathy of traditional Chinese medicine, Dongfang Hospital of

Beijing University of Chinese Medicine, Beijing, 100078, China.

xinganghu@163.com.

FAU - Zhao, Yan

AU - Zhao Y

AUID- ORCID: 0000-0003-4911-7974

AD - School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing,

100029, China. yanzh3232@126.com.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230323

PL - England

TA - Int J Obes (Lond)

JT - International journal of obesity (2005)

JID - 101256108

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - Weight Gain

MH - Obesity/drug therapy

MH - *Metabolic Syndrome/chemically induced/drug therapy

EDAT- 2023/03/25 06:00

MHDA- 2023/05/29 06:42

CRDT- 2023/03/24 00:20

PHST- 2022/11/23 00:00 [received]

PHST- 2023/02/28 00:00 [accepted]

PHST- 2023/02/26 00:00 [revised]

PHST- 2023/05/29 06:42 [medline]

PHST- 2023/03/25 06:00 [pubmed]

PHST- 2023/03/24 00:20 [entrez]

AID - 10.1038/s41366-023-01291-8 [pii]

AID - 10.1038/s41366-023-01291-8 [doi]

PST - ppublish

SO - Int J Obes (Lond). 2023 Jun;47(6):423-433. doi: 10.1038/s41366-023-01291-8. Epub

2023 Mar 23.

PMID- 36958998

OWN - NLM

STAT- MEDLINE

DCOM- 20230630

LR - 20230704

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Print)

IS - 0006-3223 (Linking)

VI - 94

IP - 2

DP - 2023 Jul 15

TI - Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in

Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement

Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.

PG - 164-173

LID - S0006-3223(23)00042-2 [pii]

LID - 10.1016/j.biopsych.2023.01.015 [doi]

AB - BACKGROUND: Patients with schizophrenia show reduced NMDA glutamate

receptor-dependent auditory plasticity, which is rate limiting for auditory

cognitive remediation (AudRem). We evaluate the utility of behavioral and

neurophysiological pharmacodynamic target engagement biomarkers, using a

d-serine+AudRem combination. METHODS: Forty-five participants with schizophrenia

or schizoaffective disorder were randomized to 3 once-weekly AudRem visits +

double-blind d-serine (80, 100, or 120 mg/kg) or placebo in 3 dose cohorts of 12

d-serine and 3 placebo-treated participants each. In AudRem, participants

indicated which paired tone was higher in pitch. The primary outcome was

plasticity improvement, operationalized as change in pitch threshold between

AudRem tones [(test tone Hz - reference tone Hz)/reference tone Hz] between the

initial plateau pitch threshold (mean of trials 20-30 of treatment visit 1) to

pitch threshold at the end of visit(s). Target engagement was assessed by

electroencephalography outcomes, including mismatch negativity (pitch primary).

RESULTS: There was a significant overall treatment effect for plasticity

improvement (p = .014). Plasticity improvement was largest within the 80 and 100

mg/kg groups (p < .001, d > 0.67), while 120 mg/kg and placebo-treated

participants showed nonsignificant within-group changes. Plasticity improvement

was seen after a single treatment and was sustained on subsequent treatments.

Target engagement was demonstrated by significantly larger mismatch negativity

(p = .049, d = 1.0) for the 100 mg/kg dose versus placebo. CONCLUSIONS: Our

results demonstrate sufficient proof of principle for continued development of

both the d-serine+AudRem combination and our target engagement methodology. The

ultimate utility is dependent on the results of an ongoing larger, longer study

of the combination for clinically relevant outcomes.

rights reserved.

FAU - Sehatpour, Pejman

AU - Sehatpour P

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York; Nathan Kline Institute, Orangeburg, New York.

FAU - Iosifescu, Dan V

AU - Iosifescu DV

AD - Nathan Kline Institute, Orangeburg, New York; Psychiatry, New York University

Grossman School of Medicine, New York, New York.

FAU - De Baun, Heloise M

AU - De Baun HM

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York.

FAU - Shope, Constance

AU - Shope C

AD - Nathan Kline Institute, Orangeburg, New York.

FAU - Mayer, Megan R

AU - Mayer MR

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York.

FAU - Gangwisch, James

AU - Gangwisch J

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Dias, Elisa

AU - Dias E

AD - Nathan Kline Institute, Orangeburg, New York; Psychiatry, New York University

Grossman School of Medicine, New York, New York.

FAU - Sobeih, Tarek

AU - Sobeih T

AD - Nathan Kline Institute, Orangeburg, New York.

FAU - Choo, Tse-Hwei

AU - Choo TH

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Wall, Melanie M

AU - Wall MM

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Medalia, Alice

AU - Medalia A

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Saperstein, Alice M

AU - Saperstein AM

AD - Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Kegeles, Lawrence S

AU - Kegeles LS

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Girgis, Ragy R

AU - Girgis RR

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Carlson, Marlene

AU - Carlson M

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York.

FAU - Kantrowitz, Joshua T

AU - Kantrowitz JT

AD - Area Psychosis, New York State Psychiatric Institute, New York, New York;

Psychiatry, College of Physicians and Surgeons, Columbia University, New York,

New York; Nathan Kline Institute, Orangeburg, New York. Electronic address:

jk3380@cumc.columbia.edu.

LA - eng

SI - ClinicalTrials.gov/NCT03711500

GR - R33 MH116093/MH/NIMH NIH HHS/United States

GR - R61 MH116093/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

DEP - 20230128

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

RN - 452VLY9402 (Serine)

RN - 0 (Receptors, N-Methyl-D-Aspartate)

RN - 6384-92-5 (N-Methylaspartate)

RN - 0 (Excitatory Amino Acid Agonists)

RN - 3KX376GY7L (Glutamic Acid)

RN - 0 (Antipsychotic Agents)

SB - IM

CIN - Biol Psychiatry. 2023 Jul 15;94(2):106-107. PMID: 37380254

MH - Humans

MH - *Schizophrenia/drug therapy

MH - Serine

MH - Receptors, N-Methyl-D-Aspartate

MH - N-Methylaspartate/pharmacology/therapeutic use

MH - Excitatory Amino Acid Agonists/pharmacology/therapeutic use

MH - Glutamic Acid/pharmacology

MH - Double-Blind Method

MH - Neuronal Plasticity

MH - *Antipsychotic Agents/therapeutic use

PMC - PMC10313776

MID - NIHMS1869375

OTO - NOTNLM

OT - Auditory learning

OT - Clinical trial

OT - Mismatch negativity

OT - NMDA receptor

OT - Schizophrenia

OT - Target engagement

COIS- Conflict of Interest Disclosures: Dr. Kantrowitz reports having received

consulting payments within the last 24 months from Alphasights, Medscape, Putnam,

techspert.io, Health Monitor, Third Bridge, MEDACorp, Trinity, Globaldata, GKA,

Clearview, Clarivate, Health Advances, ECRI Institute, ExpertConnect, Acsel

Health, Slingshot, Antheum, Guidepoint, L.E.K., SmartAnalyst, First Thought,

Wedbush, Jefferies, Otsuka, Vox Neuro and Reckner. He has served on the MedinCell

Psychiatry, Merck, Leal and the Karuna Advisory Boards. He has conducted clinical

research supported by the NIMH, Sunovion, Roche, Cerevance, Click, Neurocrine,

Corcept, Taisho and Boehringer Ingelheim within the last 24 months. He owns a

small number of shares of common stock from GSK. Drs Sehatpour, Shope, Gangwisch,

Dias Sobeih Wall, Saperstein and Kegeles and Mr. Choo and Ms. De Baun, Mayer and

Carlson reported no biomedical financial interests or potential conflicts of

interest.

EDAT- 2023/03/24 06:00

MHDA- 2023/06/30 06:42

PMCR- 2024/07/15

CRDT- 2023/03/23 23:04

PHST- 2022/08/10 00:00 [received]

PHST- 2023/01/11 00:00 [revised]

PHST- 2023/01/13 00:00 [accepted]

PHST- 2024/07/15 00:00 [pmc-release]

PHST- 2023/06/30 06:42 [medline]

PHST- 2023/03/24 06:00 [pubmed]

PHST- 2023/03/23 23:04 [entrez]

AID - S0006-3223(23)00042-2 [pii]

AID - 10.1016/j.biopsych.2023.01.015 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Jul 15;94(2):164-173. doi: 10.1016/j.biopsych.2023.01.015.

Epub 2023 Jan 28.

PMID- 36958491

OWN - NLM

STAT- MEDLINE

DCOM- 20230414

LR - 20230421

IS - 1573-2517 (Electronic)

IS - 0165-0327 (Linking)

VI - 331

DP - 2023 Jun 15

TI - Systematic review and meta-analysis of retinal microvascular caliber in bipolar

disorder, major depressive disorder, and schizophrenia.

PG - 342-351

LID - S0165-0327(23)00380-4 [pii]

LID - 10.1016/j.jad.2023.03.040 [doi]

AB - BACKGROUND: Individuals with a severe mental illness (SMI), such as bipolar

disorder (BD), major depressive disorder (MDD), and schizophrenia (SZ), have

increased rates of cardiovascular and cerebrovascular disease. Interestingly, it

has been reported that retinal microvessels, a proxy cerebrovascular measure,

non-invasively assessed via retinal imaging, predict future cardiovascular

disease, with some studies also showing anomalous retinal microvascular caliber

in SMI. Therefore, this review and meta-analysis evaluated whether retinal

microvascular caliber differs between individuals with SMI vs controls and

summarized current findings. METHODS: A systematic literature search for retinal

microvascular caliber and SMI was conducted in Embase and MEDLINE. Studies needed

to be published in English before 2022 December 1st and examine retinal

microvascular caliber in individuals diagnosed with a SMI. Finally, a

meta-analysis of arteriolar and venular caliber in SMI case-controlled studies

was also conducted. RESULTS: The search yielded 65 unique articles, 11 were

included in the review and 6 in the meta-analysis. The meta-analysis found that

the SMI group had significantly wider venules than controls (SMD = 0.53; 95 %

CI = 0.24, 0.81; p = 0.0004) but not arterioles (SMD = 0.07; 95 % CI = -0.29,

0.44; p = 0.70). Additionally, the systematic review found that poorer retinal

microvascular health is associated with greater illness severity. LIMITATIONS:

Large heterogeneity of findings and small sample size. CONCLUSION: This

systematic review and meta-analysis found that SMI, specifically SZ, is

associated with wider retinal venules. Retinal imaging, a fast, cost-effective,

and non-invasive assay of cerebrovascular health, may provide insight into the

pathophysiological processes of SMI. However, future longitudinal studies

investigating these findings are warranted.

FAU - Kennedy, Kody G

AU - Kennedy KG

AD - Centre for Youth Bipolar Disorder, Centre for Addictions and Mental Health,

Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto,

Canada.

FAU - Mio, Megan

AU - Mio M

AD - Centre for Youth Bipolar Disorder, Centre for Addictions and Mental Health,

Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto,

Canada.

FAU - Goldstein, Benjamin I

AU - Goldstein BI

AD - Centre for Youth Bipolar Disorder, Centre for Addictions and Mental Health,

Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto,

Canada.

FAU - Brambilla, Paolo

AU - Brambilla P

AD - Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda

Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and

Transplantation, University of Milan, Milan, Italy.

FAU - Delvecchio, Giuseppe

AU - Delvecchio G

AD - Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda

Ospedale Maggiore Policlinico, Milan, Italy. Electronic address:

giuseppe.delvecchio@policlinico.mi.it.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Review

PT - Systematic Review

DEP - 20230321

PL - Netherlands

TA - J Affect Disord

JT - Journal of affective disorders

JID - 7906073

SB - IM

MH - Humans

MH - *Bipolar Disorder

MH - *Depressive Disorder, Major/diagnostic imaging/complications

MH - *Schizophrenia/complications

MH - Retina

MH - *Cerebrovascular Disorders

OTO - NOTNLM

OT - Bipolar disorder, major depressive disorder

OT - Retinal microvascular caliber

OT - Schizophrenia

COIS- Conflict of interest None.

EDAT- 2023/03/24 06:00

MHDA- 2023/04/14 06:42

CRDT- 2023/03/23 20:29

PHST- 2022/01/20 00:00 [received]

PHST- 2023/03/06 00:00 [revised]

PHST- 2023/03/09 00:00 [accepted]

PHST- 2023/04/14 06:42 [medline]

PHST- 2023/03/24 06:00 [pubmed]

PHST- 2023/03/23 20:29 [entrez]

AID - S0165-0327(23)00380-4 [pii]

AID - 10.1016/j.jad.2023.03.040 [doi]

PST - ppublish

SO - J Affect Disord. 2023 Jun 15;331:342-351. doi: 10.1016/j.jad.2023.03.040. Epub

2023 Mar 21.

PMID- 36949248

OWN - NLM

STAT- MEDLINE

DCOM- 20230615

LR - 20230624

IS - 1752-8062 (Electronic)

IS - 1752-8054 (Print)

IS - 1752-8054 (Linking)

VI - 16

IP - 6

DP - 2023 Jun

TI - A randomized, single-dose, crossover study of the effects of ulotaront on

electrocardiogram intervals in subjects with schizophrenia.

PG - 1063-1074

LID - 10.1111/cts.13512 [doi]

AB - This study (NCT04369391) evaluated the effects of ulotaront (SEP-363856), a novel

trace amine-associated receptor 1 (TAAR1) agonist in development for

schizophrenia, on electrocardiogram parameters. Study design was a randomized,

single-dose, three-period crossover (ulotaront 150 mg, placebo, moxifloxacin

400 mg). Sixty subjects with schizophrenia completed all periods. Ulotaront had

no clinically relevant effect on heart rate, PR interval, or QRS duration. In

by-time-point analysis (secondary analysis), the upper bound of the two-sided 90%

confidence interval for ΔΔQTcF (QT interval corrected for heart rate using

Fridericia's formula) was below 10 ms at all time points for ulotaront. In

concentration-QTc analysis (primary analysis), a linear mixed-effects model with

ulotaront and its major metabolite SEP-383103 was selected as the primary model

based on prespecified criteria. Effect on ∆∆QTcF exceeding 10 ms can be excluded

within observed ranges of ulotaront and SEP-383103 plasma concentrations up to

~574 and ~272 ng/mL, respectively. The upper bound of 90% CI for ΔΔQTcF can be

predicted to be below 10 ms at the highest anticipated clinical exposure,

currently defined as steady-state mean C(max) at ulotaront 100 mg/day in CYP2D6

poor metabolizers, ~416 and ~211 ng/mL for ulotaront and SEP-383103,

respectively. Assay sensitivity was demonstrated by the QTc effect caused by

moxifloxacin. In conclusion, ulotaront is unlikely to cause clinically relevant

QTc prolongation in patients with schizophrenia at the anticipated maximum

therapeutic dose.

by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology

and Therapeutics.

FAU - Tsukada, Hironobu

AU - Tsukada H

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

AD - Sumitomo Pharma Co., Ltd., Tokyo, Japan.

FAU - Milanovic, Snezana M

AU - Milanovic SM

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

FAU - Darpo, Borje

AU - Darpo B

AD - Clario, Rochester, New York, USA.

FAU - Xue, Hongqi

AU - Xue H

AD - Clario, Rochester, New York, USA.

FAU - Xiong, Kuangnan

AU - Xiong K

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

FAU - Tripp, Emily

AU - Tripp E

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

FAU - Lennek, Lisa

AU - Lennek L

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

FAU - Worden, MaryAlice

AU - Worden M

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

FAU - Hopkins, Seth C

AU - Hopkins SC

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

FAU - Galluppi, Gerald R

AU - Galluppi GR

AUID- ORCID: 0000-0001-6705-3084

AD - Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20230328

PL - United States

TA - Clin Transl Sci

JT - Clinical and translational science

JID - 101474067

RN - 0 (SEP-363856)

RN - U188XYD42P (Moxifloxacin)

RN - 0 (Fluoroquinolones)

SB - IM

MH - Humans

MH - Moxifloxacin

MH - Cross-Over Studies

MH - *Fluoroquinolones

MH - *Schizophrenia/diagnosis/drug therapy

MH - Electrocardiography

MH - Double-Blind Method

MH - Heart Rate

MH - Dose-Response Relationship, Drug

PMC - PMC10264939

COIS- H.T. is an employee of Sumitomo Pharma Co., Ltd., the parent company of Sunovion

Pharmaceuticals Inc. S.M.M., K.X., E.T., L.L., M.A.W., S.C.H., and G.R.G. are

employees of Sunovion Pharmaceuticals Inc. B.D. serves as consultant for Clario

and owns stock and is eligible for stock options in the company. H.X. is an

employee of Clario. Clario was contracted by Sunovion Pharmaceuticals to

contribute to this study.

EDAT- 2023/03/24 06:00

MHDA- 2023/06/15 06:42

CRDT- 2023/03/23 00:24

PHST- 2023/03/01 00:00 [revised]

PHST- 2022/12/07 00:00 [received]

PHST- 2023/03/03 00:00 [accepted]

PHST- 2023/06/15 06:42 [medline]

PHST- 2023/03/24 06:00 [pubmed]

PHST- 2023/03/23 00:24 [entrez]

AID - CTS13512 [pii]

AID - 10.1111/cts.13512 [doi]

PST - ppublish

SO - Clin Transl Sci. 2023 Jun;16(6):1063-1074. doi: 10.1111/cts.13512. Epub 2023 Mar

28.

PMID- 36948435

OWN - NLM

STAT- MEDLINE

DCOM- 20230728

LR - 20231003

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Print)

IS - 0006-3223 (Linking)

VI - 94

IP - 4

DP - 2023 Aug 15

TI - Ancestral, Pregnancy, and Negative Early-Life Risks Shape Children's Brain

(Dis)similarity to Schizophrenia.

PG - 332-340

LID - S0006-3223(23)01160-5 [pii]

LID - 10.1016/j.biopsych.2023.03.009 [doi]

AB - BACKGROUND: Familial, obstetric, and early-life environmental risks for

schizophrenia spectrum disorder (SSD) alter normal cerebral development, leading

to the formation of characteristic brain deficit patterns prior to onset of

symptoms. We hypothesized that the insidious effects of these risks may increase

brain similarity to adult SSD deficit patterns in prepubescent children. METHODS:

We used data collected by the Adolescent Brain Cognitive Development (ABCD) Study

(N = 8940, age = 9.9 ± 0.1 years, 4307/4633 female/male), including 727 (age =

9.9 ± 0.1 years, 351/376 female/male) children with family history of SSD, to

evaluate unfavorable cerebral effects of ancestral SSD history, pre/perinatal

environment, and negative early-life environment. We used a regional

vulnerability index to measure the alignment of a child's cerebral patterns with

the adult SSD pattern derived from a large meta-analysis of case-control

differences. RESULTS: In children with a family history of SSD, the regional

vulnerability index captured significantly more variance in ancestral history

than traditional whole-brain and regional brain measurements. In children with

and without family history of SSD, the regional vulnerability index also captured

more variance associated with negative pre/perinatal environment and early-life

experiences than traditional brain measurements. CONCLUSIONS: In summary, in a

cohort in which most children will not develop SSD, familial, pre/perinatal, and

early developmental risks can alter brain patterns in the direction observed in

adult patients with SSD. Individual similarity to adult SSD patterns may provide

an early biomarker of the effects of genetic and developmental risks on the brain

prior to psychotic or prodromal symptom onset.

rights reserved.

FAU - Kochunov, Peter

AU - Kochunov P

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland. Electronic address:

pkochunov@som.umaryland.edu.

FAU - Ma, Yizhou

AU - Ma Y

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Hatch, Kathryn S

AU - Hatch KS

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Gao, Si

AU - Gao S

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Acheson, Ashley

AU - Acheson A

AD - Department of Psychiatry, University of Arkansas for Medical Sciences, Little

Rock, Arkansas.

FAU - Jahanshad, Neda

AU - Jahanshad N

AD - Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck

School of Medicine of University of the Sunshine Coast, Marina del Rey,

California.

FAU - Thompson, Paul M

AU - Thompson PM

AD - Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck

School of Medicine of University of the Sunshine Coast, Marina del Rey,

California.

FAU - Adhikari, Bhim M

AU - Adhikari BM

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Bruce, Heather

AU - Bruce H

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Van der Vaart, Andrew

AU - Van der Vaart A

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Chiappelli, Joshua

AU - Chiappelli J

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Du, Xiaoming

AU - Du X

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Sotiras, Aris

AU - Sotiras A

AD - Department of Radiology, Washington University School of Medicine, St. Louis,

Missouri.

FAU - Kvarta, Mark D

AU - Kvarta MD

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Ma, Tianzhou

AU - Ma T

AD - Department of Epidemiology and Biostatistics, University of Maryland, College

Park, Maryland.

FAU - Chen, Shuo

AU - Chen S

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

FAU - Hong, L Elliot

AU - Hong LE

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, Maryland.

LA - eng

GR - R01 MH116948/MH/NIMH NIH HHS/United States

GR - R01 EB015611/EB/NIBIB NIH HHS/United States

GR - RF1 NS114628/NS/NINDS NIH HHS/United States

GR - R01 MH116147/MH/NIMH NIH HHS/United States

GR - RF1 MH123163/MH/NIMH NIH HHS/United States

GR - P50 MH103222/MH/NIMH NIH HHS/United States

GR - U01 MH108148/MH/NIMH NIH HHS/United States

GR - R01 MH117601/MH/NIMH NIH HHS/United States

GR - R01 MH112180/MH/NIMH NIH HHS/United States

GR - S10 OD023696/OD/NIH HHS/United States

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, N.I.H., Extramural

DEP - 20230321

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

SB - IM

MH - Adult

MH - Pregnancy

MH - Adolescent

MH - Humans

MH - Child

MH - Male

MH - Female

MH - *Schizophrenia/genetics

MH - *Psychotic Disorders

MH - Brain

MH - Cognition

PMC - PMC10511664

MID - NIHMS1886023

OTO - NOTNLM

OT - Adolescence

OT - Big data

OT - Brain development

OT - Imaging

OT - Individual prediction

OT - Schizophrenia

COIS- Financial Discloses and Conflict of Interest LEH has received or plans to receive

research funding or consulting fees on research projects from Mitsubishi, Your

Energy Systems LLC, Neuralstem, Taisho, Heptares, Pfizer, Luye Pharma, Sound

Pharma, IGC Pharma, Takeda, and Regeneron. None was involved in the design,

analysis or outcomes of the study. PT and NJ received grant support from Biogen,

Inc. (Boston, USA) for research unrelated to the topic of this manuscript. All

other authors report no biomedical financial interests or potential conflicts of

interest.

EDAT- 2023/03/23 06:00

MHDA- 2023/07/28 06:43

PMCR- 2024/08/15

CRDT- 2023/03/22 20:30

PHST- 2022/10/14 00:00 [received]

PHST- 2023/03/07 00:00 [revised]

PHST- 2023/03/07 00:00 [accepted]

PHST- 2024/08/15 00:00 [pmc-release]

PHST- 2023/07/28 06:43 [medline]

PHST- 2023/03/23 06:00 [pubmed]

PHST- 2023/03/22 20:30 [entrez]

AID - S0006-3223(23)01160-5 [pii]

AID - 10.1016/j.biopsych.2023.03.009 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Aug 15;94(4):332-340. doi: 10.1016/j.biopsych.2023.03.009.

Epub 2023 Mar 21.

PMID- 36933197

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 4

DP - 2023 Jul 4

TI - Rare Copy Number Variation in Schizophrenia and Implications for Treatment.

PG - 827-828

LID - 10.1093/schbul/sbad028 [doi]

FAU - Docherty, Anna R

AU - Docherty AR

AUID- ORCID: 0000-0001-7139-7007

AD - Department of Psychiatry, Huntsman Mental Health Institute, University of Utah

School of Medicine, Salt Lake City, UT, USA.

AD - The Virginia Commonwealth University, Virginia Institute for Psychiatric and

Behavioral Genetics, Richmond, VA, USA.

LA - eng

GR - R01 MH123489/MH/NIMH NIH HHS/United States

GR - R01MH123489/NH/NIH HHS/United States

PT - Comment

PT - Editorial

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

CON - Schizophr Bull. 2023 Jul 4;49(4):881-892. PMID: 36454006

MH - Humans

MH - *Schizophrenia/genetics/therapy

MH - DNA Copy Number Variations

MH - Genetic Predisposition to Disease

PMC - PMC10318860

COIS- The author has no conflicts of interest to report. The views expressed here are

independent and do not reflect the views of the International Society for

Psychiatric Genetics.

EDAT- 2023/03/19 06:00

MHDA- 2023/07/06 06:42

PMCR- 2024/03/18

CRDT- 2023/03/18 13:22

PHST- 2024/03/18 00:00 [pmc-release]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/03/19 06:00 [pubmed]

PHST- 2023/03/18 13:22 [entrez]

AID - 7080515 [pii]

AID - sbad028 [pii]

AID - 10.1093/schbul/sbad028 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Jul 4;49(4):827-828. doi: 10.1093/schbul/sbad028.

PMID- 36928351

OWN - NLM

STAT- MEDLINE

DCOM- 20230526

LR - 20230726

IS - 1740-634X (Electronic)

IS - 0893-133X (Print)

IS - 0893-133X (Linking)

VI - 48

IP - 7

DP - 2023 Jun

TI - The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in

patients with schizophrenia in a randomized trial.

PG - 1052-1059

LID - 10.1038/s41386-023-01560-0 [doi]

AB - Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor

function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a

D-amino acid oxidase (DAAO) inhibitor that increases the glutamate co-agonist

D-serine levels, is being developed for the treatment of cognitive impairment

associated with schizophrenia. We conducted a biomarker study in patients,

assessing several endpoints related to physiological outcomes of NMDA receptor

modulation to determine whether luvadaxistat affects neural circuitry biomarkers

relevant to NMDA receptor function and schizophrenia. This was a randomized,

placebo-controlled, double-blind, two-period crossover phase 2a study assessing

luvadaxistat 50 mg and 500 mg for 8 days in 31 patients with schizophrenia. There

were no treatment effects of luvadaxistat at either dose in eyeblink

conditioning, a cerebellar-dependent learning measure, compared with placebo. We

observed a nominally significant improvement in mismatch negativity (MMN) and a

statistical trend to improvement for auditory steady-state response at 40 Hz, in

both cases with 50 mg, but not with 500 mg, compared with placebo. Although the

data should be interpreted cautiously owing to the small sample size, they

suggest that luvadaxistat can improve an illness-related circuitry biomarker at

doses associated with partial DAAO inhibition. These results are consistent with

50 mg, but not higher doses, showing a signal of efficacy in cognitive endpoints

in a larger phase 2, 12-week study conducted in parallel. Thus, MMN responses

after a short treatment period may predict cognitive function improvement. MMN

and ASSR should be considered as biomarkers in early trials addressing NMDA

receptor hypofunction.

FAU - O'Donnell, Patricio

AU - O'Donnell P

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

patricio.odonnell@sagerx.com.

AD - McLean Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA,

USA. patricio.odonnell@sagerx.com.

FAU - Dong, Cheng

AU - Dong C

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Murthy, Venkatesha

AU - Murthy V

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Asgharnejad, Mahnaz

AU - Asgharnejad M

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Du, Xiaoming

AU - Du X

AUID- ORCID: 0000-0001-7206-5282

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, USA.

FAU - Summerfelt, Ann

AU - Summerfelt A

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, USA.

FAU - Lu, Hong

AU - Lu H

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Xu, Lin

AU - Xu L

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Wendland, Jens R

AU - Wendland JR

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Dunayevich, Eduardo

AU - Dunayevich E

AD - Neurocrine Biosciences, Inc., San Diego, CA, USA.

FAU - Buhl, Derek L

AU - Buhl DL

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

FAU - Litman, Robert

AU - Litman R

AD - CBH Health, Gaithersburg, MD, USA.

FAU - Hetrick, William P

AU - Hetrick WP

AD - Department of Psychological and Brain Sciences, Indiana University, Bloomington,

IN, USA.

FAU - Hong, L Elliot

AU - Hong LE

AD - Maryland Psychiatric Research Center, Department of Psychiatry, University of

Maryland School of Medicine, Baltimore, MD, USA.

FAU - Rosen, Laura B

AU - Rosen LB

AD - Takeda Pharmaceuticals USA, Inc, Cambridge, MA, USA.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230316

PL - England

TA - Neuropsychopharmacology

JT - Neuropsychopharmacology : official publication of the American College of

Neuropsychopharmacology

JID - 8904907

RN - 0 (Receptors, N-Methyl-D-Aspartate)

RN - 0 (Enzyme Inhibitors)

RN - 0 (Excitatory Amino Acid Agonists)

RN - 452VLY9402 (Serine)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy

MH - Receptors, N-Methyl-D-Aspartate

MH - Cerebellum

MH - Cognition

MH - Enzyme Inhibitors

MH - Excitatory Amino Acid Agonists

MH - Serine

PMC - PMC10018616

COIS- POD and DLB were employed at Takeda Pharmaceuticals USA, Inc. throughout the

conception and execution of the study and are currently employees and

shareholders of Sage Therapeutics. CD, VM, MA, HL, LX, JRW, and LBR are employees

of Takeda Pharmaceuticals USA, Inc., and shareholders of Takeda Pharmaceutical

Company Limited. ED is an employee of Neurocrine Biosciences Inc. and was

employed at Takeda when the study was initiated. LEH has received or plans to

receive research funding or consulting fees from Heptares Therapuetics Ltd, Luye

Pharma Group, Mitsubishi, Neuralstem Inc., Pfizer, Regeneron, Sound Pharma,

Taisho Pharmaceutical, Takeda, and Your Energy Systems LLC. XD, AS, RL, and WPH

have nothing to disclose.

EDAT- 2023/03/18 06:00

MHDA- 2023/05/26 06:42

CRDT- 2023/03/17 09:05

PHST- 2022/09/14 00:00 [received]

PHST- 2023/02/24 00:00 [accepted]

PHST- 2023/02/23 00:00 [revised]

PHST- 2023/05/26 06:42 [medline]

PHST- 2023/03/18 06:00 [pubmed]

PHST- 2023/03/17 09:05 [entrez]

AID - 10.1038/s41386-023-01560-0 [pii]

AID - 1560 [pii]

AID - 10.1038/s41386-023-01560-0 [doi]

PST - ppublish

SO - Neuropsychopharmacology. 2023 Jun;48(7):1052-1059. doi:

10.1038/s41386-023-01560-0. Epub 2023 Mar 16.

PMID- 36919340

OWN - NLM

STAT- MEDLINE

DCOM- 20230711

LR - 20230718

IS - 1472-1465 (Electronic)

IS - 0007-1250 (Print)

IS - 0007-1250 (Linking)

VI - 223

IP - 1

DP - 2023 Jul

TI - Psychosocial and behavioural interventions for the negative symptoms of

schizophrenia: a systematic review of efficacy meta-analyses.

PG - 321-331

LID - 10.1192/bjp.2023.21 [doi]

AB - BACKGROUND: Currently there is no first-line treatment recommended for the

negative symptoms of schizophrenia. Psychosocial and behavioural interventions

are widely used to reduce the burden of negative symptoms. Meta-analytic studies

have summarised the evidence for specific approaches but not compared evidence

quality and benefit. AIM: To review and evaluate the evidence from meta-analytic

studies of psychosocial and behavioural interventions for the negative symptoms

of schizophrenia. METHOD: A systematic literature search was undertaken to

identify all meta-analyses evaluating psychosocial and behavioural interventions

reporting on negative symptom outcomes in people with schizophrenia. Data on

intervention, study characteristics, acceptability and outcome were extracted.

Risk of bias was evaluated. Results were summarised descriptively, and evidence

ranked on methodological quality. RESULTS: In total, 31 systematic reviews met

the inclusion criteria evaluating the efficacy of negative symptom interventions

on 33 141 participants. Exercise interventions showed effect sizes (reduction in

negative symptoms) ranging from -0.59 to -0.24 and psychological interventions

ranging from -0.65 to -0.04. Attrition ranged between 12% to 32%. Across the

studies considered heterogeneity varied substantially (range 0-100). Most of the

reviews were of very low to low methodological quality. Methodological quality

ranking suggested that the effect size for cognitive remediation and exercise

therapy may be more robust compared with other approaches. CONCLUSIONS: Most of

the interventions considered had a small-to-moderate effect size, good

acceptability levels but very few had negative symptoms as the primary

intervention target. To improve the confidence of these effect sizes being

replicated in clinical settings future studies should minimise risk of bias.

FAU - Cella, Matteo

AU - Cella M

AUID- ORCID: 0000-0002-5701-0336

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK;

and South London and the Maudsley NHS Trust, UK.

FAU - Roberts, Safina

AU - Roberts S

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK;

and South London and the Maudsley NHS Trust, UK.

FAU - Pillny, Matthias

AU - Pillny M

AUID- ORCID: 0000-0003-2395-8433

AD - Clinical Psychology and Psychotherapy, Institute for Psychology, Universität

Hamburg, Germany.

FAU - Riehle, Marcel

AU - Riehle M

AD - Clinical Psychology and Psychotherapy, Institute for Psychology, Universität

Hamburg, Germany.

FAU - O'Donoghue, Brian

AU - O'Donoghue B

AD - Department of Psychiatry, University College Dublin, Ireland; and Centre for

Youth Mental Health, University of Melbourne, Australia.

FAU - Lyne, John

AU - Lyne J

AD - Royal College of Surgeons in Ireland, Ireland; and Health Service Executive,

Newcastle Hospital, Ireland.

FAU - Tomlin, Paul

AU - Tomlin P

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

FAU - Valmaggia, Lucia

AU - Valmaggia L

AUID- ORCID: 0000-0001-6099-8464

AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK;

South London and the Maudsley NHS Trust, UK; and Katholieke Leuven Universitet,

Belgium.

FAU - Preti, Antonio

AU - Preti A

AD - Department of Neuroscience, University of Turin, Italy.

LA - eng

PT - Journal Article

PT - Review

PT - Systematic Review

PL - England

TA - Br J Psychiatry

JT - The British journal of psychiatry : the journal of mental science

JID - 0342367

SB - IM

CIN - Br J Psychiatry. 2023 Jul;223(1):319-320. PMID: 37194957

MH - Humans

MH - Behavior Therapy

MH - *Cognitive Behavioral Therapy

MH - Psychosocial Intervention

MH - *Schizophrenia/therapy

PMC - PMC10331321

OTO - NOTNLM

OT - Psychosis

OT - negative symptoms

OT - psychosocial

OT - review

OT - schizophrenia

COIS- All authors declare no conflict of interest.

EDAT- 2023/03/16 06:00

MHDA- 2023/07/11 06:42

CRDT- 2023/03/15 03:23

PHST- 2023/07/11 06:42 [medline]

PHST- 2023/03/16 06:00 [pubmed]

PHST- 2023/03/15 03:23 [entrez]

AID - S0007125023000211 [pii]

AID - 10.1192/bjp.2023.21 [doi]

PST - ppublish

SO - Br J Psychiatry. 2023 Jul;223(1):321-331. doi: 10.1192/bjp.2023.21.

PMID- 36889432

OWN - NLM

STAT- MEDLINE

DCOM- 20230328

LR - 20230417

IS - 1873-7064 (Electronic)

IS - 0028-3908 (Print)

IS - 0028-3908 (Linking)

VI - 230

DP - 2023 Jun 1

TI - The crosstalk between 5-HT(2A)R and mGluR2 in schizophrenia.

PG - 109489

LID - S0028-3908(23)00079-5 [pii]

LID - 10.1016/j.neuropharm.2023.109489 [doi]

AB - Schizophrenia is a severe brain disorder that usually produces a lifetime of

disability. First generation or typical antipsychotics such as haloperidol and

second generation or atypical antipsychotics such as clozapine and risperidone

remain the current standard for schizophrenia treatment. In some patients with

schizophrenia, antipsychotics produce complete remission of positive symptoms,

such as hallucinations and delusions. However, antipsychotic drugs are

ineffective against cognitive deficits and indeed treated schizophrenia patients

have small improvements or even deterioration in several cognitive domains. This

underlines the need for novel and more efficient therapeutic targets for

schizophrenia treatment. Serotonin and glutamate have been identified as key

parts of two neurotransmitter systems involved in fundamental brain processes.

Serotonin (or 5-hydroxytryptamine) 5-HT(2A) receptor (5-HT(2A)R) and metabotropic

glutamate 2 receptor (mGluR2) are G protein-coupled receptors (GPCRs) that

interact at epigenetic and functional levels. These two receptors can form GPCR

heteromeric complexes through which their pharmacology, function and trafficking

becomes affected. Here we review past and current research on the

5-HT(2A)R-mGluR2 heterocomplex and its potential implication in schizophrenia and

antipsychotic drug action. This article is part of the Special Issue on "The

receptor-receptor interaction as a new target for therapy".

FAU - Saha, Somdatta

AU - Saha S

AD - Department of Physiology and Biophysics, Virginia Commonwealth University School

of Medicine, Richmond, VA, 23298, USA.

FAU - González-Maeso, Javier

AU - González-Maeso J

AD - Department of Physiology and Biophysics, Virginia Commonwealth University School

of Medicine, Richmond, VA, 23298, USA. Electronic address:

javier.maeso@vcuhealth.org.

LA - eng

GR - R01 MH084894/MH/NIMH NIH HHS/United States

GR - P30 DA033934/DA/NIDA NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Review

DEP - 20230306

PL - England

TA - Neuropharmacology

JT - Neuropharmacology

JID - 0236217

RN - 0 (Antipsychotic Agents)

RN - 333DO1RDJY (Serotonin)

RN - 0 (metabotropic glutamate receptor 2)

RN - 0 (Glutamates)

RN - 0 (Receptor, Serotonin, 5-HT2A)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy

MH - *Antipsychotic Agents/pharmacology/therapeutic use

MH - Serotonin

MH - Glutamates

MH - Receptor, Serotonin, 5-HT2A

PMC - PMC10103009

MID - NIHMS1883677

OTO - NOTNLM

OT - Antipsychotics

OT - Epigenetics

OT - G protein-coupled receptor (GPCR)

OT - GPCR dimerization

OT - Metabotropic glutamate 2 receptor

OT - Psychedelics

OT - Schizophrenia

OT - Serotonin 5-HT(2A) receptor

COIS- Declaration of competing interest J.G.-M. has or has had sponsored research

contracts with Terran Biosciences and Noetic Fund, and serves on scientific

advisory boards for Adelia Therapeutics and Cognesy Therapeutics. S.S. declares

no conflict of interest.

EDAT- 2023/03/09 06:00

MHDA- 2023/03/28 17:15

PMCR- 2024/06/01

CRDT- 2023/03/08 19:30

PHST- 2023/01/13 00:00 [received]

PHST- 2023/02/26 00:00 [revised]

PHST- 2023/03/05 00:00 [accepted]

PHST- 2024/06/01 00:00 [pmc-release]

PHST- 2023/03/28 17:15 [medline]

PHST- 2023/03/09 06:00 [pubmed]

PHST- 2023/03/08 19:30 [entrez]

AID - S0028-3908(23)00079-5 [pii]

AID - 10.1016/j.neuropharm.2023.109489 [doi]

PST - ppublish

SO - Neuropharmacology. 2023 Jun 1;230:109489. doi: 10.1016/j.neuropharm.2023.109489.

Epub 2023 Mar 6.

PMID- 36878476

OWN - NLM

STAT- MEDLINE

DCOM- 20230609

LR - 20230916

IS - 1469-7610 (Electronic)

IS - 0021-9630 (Print)

IS - 0021-9630 (Linking)

VI - 64

IP - 7

DP - 2023 Jul

TI - Practitioner Review: Psychosis in children and adolescents.

PG - 980-988

LID - 10.1111/jcpp.13777 [doi]

AB - Psychotic symptoms, including hallucinations, delusions, and disorganized

thinking and behaviors, are the hallmarks of schizophrenia; but may also present

in the context of other psychiatric and medical conditions. Many children and

adolescents describe psychotic-like experiences, which can be associated with

other types of psychopathology and past experiences (e.g., trauma, substance use,

and suicidality). However, most youth reporting such experiences do not have, nor

will ever develop, schizophrenia or another psychotic disorder. Accurate

assessment is critical because these different presentations have different

diagnostic and treatment implications. For this review, we focus primarily on the

diagnosis and treatment of early onset schizophrenia. In addition, we review the

development of community-based first-episode psychosis programming, and the

importance of early intervention and coordinated care.

FAU - Sunshine, Anna

AU - Sunshine A

AD - Department of Psychiatry, University of Washington, Seattle, WA, USA.

FAU - McClellan, Jon

AU - McClellan J

AUID- ORCID: 0000-0002-0101-1073

AD - Department of Psychiatry, University of Washington, Seattle, WA, USA.

LA - eng

GR - K08 MH126171/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Review

DEP - 20230306

PL - England

TA - J Child Psychol Psychiatry

JT - Journal of child psychology and psychiatry, and allied disciplines

JID - 0375361

SB - IM

MH - Adolescent

MH - Child

MH - Humans

MH - *Psychotic Disorders/diagnosis/therapy

MH - *Schizophrenia/diagnosis/therapy

MH - Hallucinations/etiology/therapy

MH - Suicidal Ideation

MH - Psychopathology

MH - Delusions/psychology

PMC - PMC10501332

MID - NIHMS1916871

OTO - NOTNLM

OT - Psychosis

OT - genetics

OT - schizophrenia

EDAT- 2023/03/07 06:00

MHDA- 2023/06/09 06:42

CRDT- 2023/03/06 19:52

PHST- 2023/01/20 00:00 [accepted]

PHST- 2023/06/09 06:42 [medline]

PHST- 2023/03/07 06:00 [pubmed]

PHST- 2023/03/06 19:52 [entrez]

AID - 10.1111/jcpp.13777 [doi]

PST - ppublish

SO - J Child Psychol Psychiatry. 2023 Jul;64(7):980-988. doi: 10.1111/jcpp.13777. Epub

2023 Mar 6.

PMID- 36856480

OWN - NLM

STAT- MEDLINE

DCOM- 20230604

LR - 20230609

IS - 1440-1819 (Electronic)

IS - 1323-1316 (Linking)

VI - 77

IP - 6

DP - 2023 Jun

TI - Asenapine add-on treatment for schizophrenia adults who received antipsychotics:

A 52-week, open-label study.

PG - 365-366

LID - 10.1111/pcn.13540 [doi]

FAU - Kishi, Taro

AU - Kishi T

AUID- ORCID: 0000-0002-9237-2236

AD - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake,

Japan.

FAU - Iwama, Yasuhiro

AU - Iwama Y

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

FAU - Sasagawa, Yuji

AU - Sasagawa Y

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

FAU - Hiraoka, Shuichi

AU - Hiraoka S

AUID- ORCID: 0000-0002-4151-5022

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

FAU - Kamei, Aya

AU - Kamei A

AD - Meiji Seika Pharma Co., Ltd., Tokyo, Japan.

FAU - Iwata, Nakao

AU - Iwata N

AD - Department of Psychiatry, Fujita Health University School of Medicine, Toyoake,

Japan.

LA - eng

PT - Clinical Trial

PT - Letter

DEP - 20230317

PL - Australia

TA - Psychiatry Clin Neurosci

JT - Psychiatry and clinical neurosciences

JID - 9513551

RN - 0 (Antipsychotic Agents)

RN - JKZ19V908O (asenapine)

RN - 0 (Dibenzocycloheptenes)

SB - IM

MH - Adult

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - Dibenzocycloheptenes/therapeutic use

MH - *Schizophrenia/drug therapy

MH - Treatment Outcome

EDAT- 2023/03/02 06:00

MHDA- 2023/06/02 06:42

CRDT- 2023/03/01 09:23

PHST- 2023/02/02 00:00 [revised]

PHST- 2022/11/06 00:00 [received]

PHST- 2023/02/26 00:00 [accepted]

PHST- 2023/06/02 06:42 [medline]

PHST- 2023/03/02 06:00 [pubmed]

PHST- 2023/03/01 09:23 [entrez]

AID - 10.1111/pcn.13540 [doi]

PST - ppublish

SO - Psychiatry Clin Neurosci. 2023 Jun;77(6):365-366. doi: 10.1111/pcn.13540. Epub

2023 Mar 17.

PMID- 36841956

OWN - NLM

STAT- MEDLINE

DCOM- 20230706

LR - 20230718

IS - 1745-1701 (Electronic)

IS - 0586-7614 (Print)

IS - 0586-7614 (Linking)

VI - 49

IP - 4

DP - 2023 Jul 4

TI - Visuospatial Learning Selectively Enhanced by Personalized Transcranial Magnetic

Stimulation over Parieto-Hippocampal Network among Patients at Clinical High-Risk

for Psychosis.

PG - 923-932

LID - 10.1093/schbul/sbad015 [doi]

AB - BACKGROUND AND HYPOTHESIS: Cognitive deficits in visuospatial learning (VSL) are

highly associated with an increased risk of developing psychosis among

populations with clinical high risk (CHR) for psychosis. Early interventions

targeting VSL enhancement are warranted in CHR but remain rudimentary. We

investigated whether personalized transcranial magnetic stimulation (TMS) over

the left parieto-hippocampal network could improve VSL performance in CHR

patients and if it could reduce the risk of psychosis conversion within 1 year.

STUDY DESIGN: Sixty-five CHR patients were randomized to receive active or sham

TMS treatments using an accelerated TMS protocol, consisting of 10 sessions of 20

Hz TMS treatments within 2 days. TMS target was defined by individual

parieto-hippocampal functional connectivity and precisely localized by individual

structural magnetic resonance imaging. VSL performance was measured using Brief

Visuospatial Memory Test-Revised included in measurement and treatment research

to improve cognition in schizophrenia consensus cognitive battery (MCCB).

Fifty-eight CHR patients completed the TMS treatments and MCCB assessments and

were included in the data analysis. STUDY RESULTS: We observed significant VSL

improvements in the active TMS subgroup (Cohen's d = 0.71, P < .001) but not in

the sham TMS subgroup (Cohen's d = 0.07, P = .70). In addition, active TMS

improved the precision of VSL performance. At a 1-year follow-up, CHR patients

who received active TMS showed a lower psychosis conversion rate than those who

received sham TMS (6.7% vs 28.0%, χ2 = 4.45, P = .03). CONCLUSIONS: Our findings

demonstrate that personalized TMS in the left parieto-hippocampal network may be

a promising preventive intervention that improves VSL in CHR patients and reduces

the risk of psychosis conversion at follow-up.

CI - © The Author(s) 2023. Published by Oxford University Press on behalf of the

please email: journals.permissions@oup.com.

FAU - Tang, Yingying

AU - Tang Y

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Xu, Lihua

AU - Xu L

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Zhu, Tianyuan

AU - Zhu T

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Cui, Huiru

AU - Cui H

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Qian, Zhenying

AU - Qian Z

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Kong, Gai

AU - Kong G

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Tang, Xiaochen

AU - Tang X

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Wei, Yanyan

AU - Wei Y

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Zhang, Tianhong

AU - Zhang T

AUID- ORCID: 0000-0002-5379-7119

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Hu, Yegang

AU - Hu Y

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Sheng, Jianhua

AU - Sheng J

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

FAU - Wang, Jijun

AU - Wang J

AD - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center,

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

AD - Brain Science and Technology Research Center, Shanghai Jiao Tong University,

Shanghai, China.

AD - CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT),

Chinese Academy of Science, Shanghai, China.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

PL - United States

TA - Schizophr Bull

JT - Schizophrenia bulletin

JID - 0236760

SB - IM

MH - Humans

MH - Transcranial Magnetic Stimulation/methods

MH - *Psychotic Disorders

MH - *Schizophrenia/complications/therapy

MH - *Cognition Disorders

MH - *Cognitive Dysfunction/etiology/prevention & control

PMC - PMC10318868

OTO - NOTNLM

OT - Brief Visuospatial Memory Test-Revised

OT - MATRICS Consensus Cognitive Battery

OT - accelerated TMS protocol

OT - clinical high risk for psychosis

OT - risk of developing psychosis

EDAT- 2023/02/27 06:00

MHDA- 2023/07/06 06:42

PMCR- 2024/02/26

CRDT- 2023/02/26 03:53

PHST- 2024/02/26 00:00 [pmc-release]

PHST- 2023/07/06 06:42 [medline]

PHST- 2023/02/27 06:00 [pubmed]

PHST- 2023/02/26 03:53 [entrez]

AID - 7058426 [pii]

AID - sbad015 [pii]

AID - 10.1093/schbul/sbad015 [doi]

PST - ppublish

SO - Schizophr Bull. 2023 Jul 4;49(4):923-932. doi: 10.1093/schbul/sbad015.

PMID- 36811809

OWN - NLM

STAT- MEDLINE

DCOM- 20230814

LR - 20230814

IS - 1573-904X (Electronic)

IS - 0724-8741 (Linking)

VI - 40

IP - 7

DP - 2023 Jul

TI - Current State and Opportunities with Long-acting Injectables: Industry

Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables"

Working Group.

PG - 1601-1631

LID - 10.1007/s11095-022-03391-y [doi]

AB - Long-acting injectable (LAI) formulations can provide several advantages over the

more traditional oral formulation as drug product opportunities. LAI formulations

can achieve sustained drug release for extended periods of time, which results in

less frequent dosing requirements leading to higher patient adherence and more

optimal therapeutic outcomes. This review article will provide an industry

perspective on the development and associated challenges of long-acting

injectable formulations. The LAIs described herein include polymer-based

formulations, oil-based formulations, and crystalline drug suspensions. The

review discusses manufacturing processes, including quality controls,

considerations of the Active Pharmaceutical Ingredient (API), biopharmaceutical

properties and clinical requirements pertaining to LAI technology selection, and

characterization of LAIs through in vitro, in vivo and in silico approaches.

Lastly, the article includes a discussion around the current lack of suitable

compendial and biorelevant in vitro models for the evaluation of LAIs and its

subsequent impact on LAI product development and approval.

FAU - Bauer, Andrea

AU - Bauer A

AD - Sunovion Pharmaceuticals, Marlborough, MA, 01752, USA.

FAU - Berben, Philippe

AU - Berben P

AD - UCB Pharma SA, Braine-l'Alleud, Belgium.

FAU - Chakravarthi, Sudhir S

AU - Chakravarthi SS

AD - Bristol Myers Squibb, New Brunswick, NJ, 08901, USA.

FAU - Chattorraj, Sayantan

AU - Chattorraj S

AD - GlaxoSmithKline, Collegeville, PA, 19426, USA.

FAU - Garg, Ashish

AU - Garg A

AD - Eli Lilly and Company, Indianapolis, IN, USA.

FAU - Gourdon, Betty

AU - Gourdon B

AD - Biogen, Cambridge, MA, 02142, USA.

FAU - Heimbach, Tycho

AU - Heimbach T

AD - Merck & Co., Inc., Rahway, NJ, 07065, USA.

FAU - Huang, Ye

AU - Huang Y

AD - AbbVie Inc., North Chicago, IL, 60064, USA.

FAU - Morrison, Christopher

AU - Morrison C

AD - GlaxoSmithKline, Collegeville, PA, 19426, USA.

FAU - Mundhra, Deepak

AU - Mundhra D

AD - GlaxoSmithKline, Collegeville, PA, 19426, USA.

FAU - Palaparthy, Ramesh

AU - Palaparthy R

AD - Gilead Sciences, Foster City, CA, 94404, USA.

FAU - Saha, Pratik

AU - Saha P

AD - GlaxoSmithKline, Collegeville, PA, 19426, USA.

FAU - Siemons, Maxime

AU - Siemons M

AD - Janssen R&D, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.

FAU - Shaik, Naveed A

AU - Shaik NA

AD - Gilead Sciences, Foster City, CA, 94404, USA.

FAU - Shi, Yi

AU - Shi Y

AD - AbbVie Inc., North Chicago, IL, 60064, USA.

FAU - Shum, Sara

AU - Shum S

AD - Takeda Development Center Americas, Inc., Cambridge, MA, 02139, USA.

FAU - Thakral, Naveen K

AU - Thakral NK

AD - Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.

FAU - Urva, Shweta

AU - Urva S

AD - Eli Lilly and Company, Indianapolis, IN, USA.

FAU - Vargo, Ryan

AU - Vargo R

AD - Merck & Co., Inc., Rahway, NJ, 07065, USA.

FAU - Koganti, Venkat R

AU - Koganti VR

AD - Bristol Myers Squibb, New Brunswick, NJ, 08901, USA. venkat.koganti@bms.com.

FAU - Barrett, Stephanie E

AU - Barrett SE

AUID- ORCID: 0000-0002-9681-1750

AD - Merck & Co., Inc., Rahway, NJ, 07065, USA. stephanie_barrett@merck.com.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230222

PL - United States

TA - Pharm Res

JT - Pharmaceutical research

JID - 8406521

RN - 0 (Antipsychotic Agents)

RN - 0 (Delayed-Action Preparations)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/therapeutic use

MH - *Schizophrenia/drug therapy

MH - Delayed-Action Preparations

MH - Injections

MH - Drug Liberation

OTO - NOTNLM

OT - drug product development

OT - formulation development

OT - long-acting injectables

OT - pre-clinical assessments

OT - quality attributes

EDAT- 2023/02/23 06:00

MHDA- 2023/08/14 06:43

CRDT- 2023/02/22 16:00

PHST- 2022/06/16 00:00 [received]

PHST- 2022/09/06 00:00 [accepted]

PHST- 2023/08/14 06:43 [medline]

PHST- 2023/02/23 06:00 [pubmed]

PHST- 2023/02/22 16:00 [entrez]

AID - 10.1007/s11095-022-03391-y [pii]

AID - 10.1007/s11095-022-03391-y [doi]

PST - ppublish

SO - Pharm Res. 2023 Jul;40(7):1601-1631. doi: 10.1007/s11095-022-03391-y. Epub 2023

Feb 22.

PMID- 36810627

OWN - NLM

STAT- MEDLINE

DCOM- 20230829

LR - 20230830

IS - 1435-1463 (Electronic)

IS - 0300-9564 (Print)

IS - 0300-9564 (Linking)

VI - 130

IP - 9

DP - 2023 Sep

TI - Microglia and microbiome in schizophrenia: can immunomodulation improve symptoms?

PG - 1187-1193

LID - 10.1007/s00702-023-02605-w [doi]

AB - In this overview, influences of microglia activation and disturbances of the

microbiome in the devastating disorder schizophrenia are discussed. Despite

previous assumptions of a primary neurodegenerative character of this disorder,

current research underlines the important autoimmunological and inflammatory

processes here. Early disturbances of microglial cells as well as cytokines could

lead to weakness of the immunological system in the prodromal phase and then

fully manifest in patients with schizophrenia. Measurements of microbiome

features might allow identifying the prodromal phase. In conclusion, such

thinking would imply several new therapeutic options regulating immune processes

by old or new anti-inflammatory agents in patients.

FAU - Juckel, Georg

AU - Juckel G

AUID- ORCID: 0000-0001-9860-9620

AD - Department of Psychiatry, Ruhr-University Bochum, LWL-University Hospital,

Alexandrinenstr.1, 44791, Bochum, Germany. georg.juckel@rub.de.

FAU - Freund, Nadja

AU - Freund N

AD - Department of Psychiatry, Ruhr-University Bochum, LWL-University Hospital,

Alexandrinenstr.1, 44791, Bochum, Germany.

LA - eng

PT - Journal Article

PT - Review

DEP - 20230221

PL - Austria

TA - J Neural Transm (Vienna)

JT - Journal of neural transmission (Vienna, Austria : 1996)

JID - 9702341

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy

MH - Microglia

MH - Immunomodulation

MH - *Microbiota

MH - Immunity

PMC - PMC10460707

OTO - NOTNLM

OT - Immunomodulation

OT - Microbiome

OT - Microglia

OT - Schizophrenia

EDAT- 2023/02/23 06:00

MHDA- 2023/08/29 12:43

CRDT- 2023/02/22 14:43

PHST- 2023/01/10 00:00 [received]

PHST- 2023/02/13 00:00 [accepted]

PHST- 2023/08/29 12:43 [medline]

PHST- 2023/02/23 06:00 [pubmed]

PHST- 2023/02/22 14:43 [entrez]

AID - 10.1007/s00702-023-02605-w [pii]

AID - 2605 [pii]

AID - 10.1007/s00702-023-02605-w [doi]

PST - ppublish

SO - J Neural Transm (Vienna). 2023 Sep;130(9):1187-1193. doi:

10.1007/s00702-023-02605-w. Epub 2023 Feb 21.

PMID- 36788653

OWN - NLM

STAT- MEDLINE

DCOM- 20230718

LR - 20230718

IS - 1447-0349 (Electronic)

IS - 1445-8330 (Linking)

VI - 32

IP - 4

DP - 2023 Aug

TI - Effects of empowerment-based illness management on the medication adherence and

recovery of persons with schizophrenia: A systematic review and meta-analysis.

PG - 1008-1024

LID - 10.1111/inm.13123 [doi]

AB - Medication adherence and recovery rates are <50% among persons with

schizophrenia; therefore, this health concern needs attention. Empowerment is a

vital element for behavioural change, but previous studies have presented

different results and lack specific connotations about empowerment. Therefore,

this study systematically reviewed and meta-analysed the effects of

empowerment-based illness management on the medication adherence and recovery of

persons with schizophrenia. The databases searched included the PROSPERO

registration network, Cochrane Library, PubMed, Embase, CINAHL, PsycAricle, and

Airiti Library. The research steps were based on PRISMA. RoB 2.0 was used for

article quality evaluation, the effect size was calculated using RevMan software,

and the random-effect model and standardized mean differences (SMD) were

established. Eight randomized controlled trials (RCTs) involving 859 participants

were used to investigate the effect of empowerment on medication adherence. The

trials involved the use of effective strategies as inducing medication

motivation, promoting self-medication management, and providing support

resources. A moderate effect was observed (SMD = 0.58, 95% CI 0.18-0.99). Ten

RCTs involving 1473 participants were used to investigate the effect of

empowerment on recovery. These trials involved the use of such effective

strategies as using self-strength, connecting external forces, understanding

personal needs, and overcoming self-stigma. A moderate effect was observed

(SMD = 0.55, 95% CI 0.10-0.99). Empowerment in illness management can effectively

promote the medication adherence and recovery of persons with schizophrenia. In

the future, nurses can use self-strength care to promote medication motivation

and connect internal and external forces to assist a person's medication

adherence and recovery.

FAU - Hsieh, Wen-Ling

AU - Hsieh WL

AD - School of Nursing, National Taipei University of Nursing and Health Sciences,

Taipei City, Taiwan.

AD - Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan.

FAU - Li, I-Hsien

AU - Li IH

AD - School of Nursing, National Taipei University of Nursing and Health Sciences,

Taipei City, Taiwan.

AD - Cardinal Tien Junior College of Healthcare and Management, New Taipei City,

Taiwan.

FAU - Liu, Wen-I

AU - Liu WI

AUID- ORCID: 0000-0003-2525-2928

AD - School of Nursing, National Taipei University of Nursing and Health Sciences,

Taipei City, Taiwan.

LA - eng

GR - MOST 110-2314-B-227-004-MY3/National Science and Technology Council, Taiwan/

PT - Journal Article

PT - Meta-Analysis

PT - Review

PT - Systematic Review

DEP - 20230214

PL - Australia

TA - Int J Ment Health Nurs

JT - International journal of mental health nursing

JID - 101140527

MH - Humans

MH - *Medication Adherence

MH - Motivation

MH - *Schizophrenia/drug therapy

MH - Randomized Controlled Trials as Topic

OTO - NOTNLM

OT - empowerment

OT - medication adherence

OT - meta-analysis

OT - recovery

OT - schizophrenia

OT - systematic review

EDAT- 2023/02/16 06:00

MHDA- 2023/07/18 13:07

CRDT- 2023/02/15 00:33

PHST- 2022/11/18 00:00 [revised]

PHST- 2022/07/21 00:00 [received]

PHST- 2023/01/16 00:00 [accepted]

PHST- 2023/07/18 13:07 [medline]

PHST- 2023/02/16 06:00 [pubmed]

PHST- 2023/02/15 00:33 [entrez]

AID - 10.1111/inm.13123 [doi]

PST - ppublish

SO - Int J Ment Health Nurs. 2023 Aug;32(4):1008-1024. doi: 10.1111/inm.13123. Epub

2023 Feb 14.

PMID- 36764569

OWN - NLM

STAT- MEDLINE

DCOM- 20231003

LR - 20231016

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Print)

IS - 0006-3223 (Linking)

VI - 94

IP - 9

DP - 2023 Nov 1

TI - The Cutting Edge of Epigenetic Clocks: In Search of Mechanisms Linking Aging and

Mental Health.

PG - 694-705

LID - S0006-3223(23)00057-4 [pii]

LID - 10.1016/j.biopsych.2023.02.001 [doi]

AB - Individuals with psychiatric disorders are at increased risk of age-related

diseases and early mortality. Recent studies demonstrate that this link between

mental health and aging is reflected in epigenetic clocks, aging biomarkers based

on DNA methylation. The reported relationships between epigenetic clocks and

mental health are mostly correlational, and the mechanisms are poorly understood.

Here, we review recent progress concerning the molecular and cellular processes

underlying epigenetic clocks as well as novel technologies enabling further

studies of the causes and consequences of epigenetic aging. We then review the

current literature on how epigenetic clocks relate to specific aspects of mental

health, such as stress, medications, substance use, health behaviors, and symptom

clusters. We propose an integrated framework where mental health and epigenetic

aging are each broken down into multiple distinct processes, which are then

linked to each other, using stress and schizophrenia as examples. This framework

incorporates the heterogeneity and complexity of both mental health conditions

and aging, may help reconcile conflicting results, and provides a basis for

further hypothesis-driven research in humans and model systems to investigate

potentially causal mechanisms linking aging and mental health.

rights reserved.

FAU - Harvanek, Zachary M

AU - Harvanek ZM

AD - Department of Psychiatry, Yale University School of Medicine, New Haven,

Connecticut.

FAU - Boks, Marco P

AU - Boks MP

AD - Department of Psychiatry, University Medical Center Utrecht Brain Center,

University of Utrecht, Utrecht, the Netherlands.

FAU - Vinkers, Christiaan H

AU - Vinkers CH

AD - Department of Psychiatry, Amsterdam University Medical Center, location Vrije

Universiteit Amsterdam, Amsterdam, the Netherlands; Mood, Anxiety, Psychosis,

Sleep & Stress program, Amsterdam Neuroscience, Vrije Universiteit Amsterdam,

Amsterdam, the Netherlands.

FAU - Higgins-Chen, Albert T

AU - Higgins-Chen AT

AD - Department of Psychiatry, Yale University School of Medicine, New Haven,

Connecticut; Department of Pathology, Yale University School of Medicine, New

Haven, Connecticut. Electronic address: a.higginschen@yale.edu.

LA - eng

GR - R01 AG065403/AG/NIA NIH HHS/United States

GR - R01 AG060110/AG/NIA NIH HHS/United States

GR - T32 MH019961/MH/NIMH NIH HHS/United States

GR - R01 AG057912/AG/NIA NIH HHS/United States

GR - R01 AG068937/AG/NIA NIH HHS/United States

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20230209

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

SB - IM

MH - Humans

MH - *Mental Health

MH - Epigenesis, Genetic

MH - Aging/genetics

MH - DNA Methylation

MH - *Schizophrenia/genetics

MH - Epigenomics

PMC - PMC10409884

MID - NIHMS1874435

OTO - NOTNLM

OT - Aging

OT - Biomarkers

OT - Clocks

OT - Epigenetics

OT - Schizophrenia

OT - Stress

COIS- Disclosures: AHC received consulting fees from FOXO Technologies and

TruDiagnostic concerning epigenetic clocks. AHC is named on two epigenetic clock

inventions owned by Yale University. A clock based on the PC clock methodology is

licensed to Elysium Health. None of these commercial entities were involved in

the conceptualization, preparation, review, approval, or submission of this

manuscript. All other authors report no biomedical financial interests or

potential conflicts of interest.

EDAT- 2023/02/11 06:00

MHDA- 2023/10/03 06:47

PMCR- 2024/11/01

CRDT- 2023/02/10 19:28

PHST- 2022/07/31 00:00 [received]

PHST- 2023/01/31 00:00 [revised]

PHST- 2023/02/01 00:00 [accepted]

PHST- 2024/11/01 00:00 [pmc-release]

PHST- 2023/10/03 06:47 [medline]

PHST- 2023/02/11 06:00 [pubmed]

PHST- 2023/02/10 19:28 [entrez]

AID - S0006-3223(23)00057-4 [pii]

AID - 10.1016/j.biopsych.2023.02.001 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Nov 1;94(9):694-705. doi: 10.1016/j.biopsych.2023.02.001.

Epub 2023 Feb 9.

PMID- 36740470

OWN - NLM

STAT- MEDLINE

DCOM- 20230630

LR - 20230703

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Linking)

VI - 94

IP - 2

DP - 2023 Jul 15

TI - Lessons Learned From Parsing Genetic Risk for Schizophrenia Into Biological

Pathways.

PG - 121-130

LID - S0006-3223(22)01701-2 [pii]

LID - 10.1016/j.biopsych.2022.10.009 [doi]

AB - The clinically heterogeneous presentation of schizophrenia is compounded by the

heterogeneity of risk factors and neurobiological correlates of the disorder.

Genome-wide association studies in schizophrenia have uncovered a remarkably high

number of genetic variants, but the biological pathways they impact upon remain

largely unidentified. Among the diverse methodological approaches employed to

provide a more granular understanding of genetic risk for schizophrenia, the use

of biological labels, such as gene ontologies, regulome approaches, and gene

coexpression have all provided novel perspectives into how genetic risk

translates into the neurobiology of schizophrenia. Here, we review the salient

aspects of parsing polygenic risk for schizophrenia into biological pathways. We

argue that parsed scores, compared to standard polygenic risk scores, may afford

a more biologically plausible and accurate physiological modeling of the

different dimensions involved in translating genetic risk into brain mechanisms,

including multiple brain regions, cell types, and maturation stages. We discuss

caveats, opportunities, and pitfalls inherent in the parsed risk approach.

rights reserved.

FAU - Pergola, Giulio

AU - Pergola G

AD - Department of Translational Biomedicine and Neuroscience, University of Bari Aldo

Moro, Bari, Italy. Electronic address: giulio.pergola@uniba.it.

FAU - Penzel, Nora

AU - Penzel N

AD - Department of Translational Biomedicine and Neuroscience, University of Bari Aldo

Moro, Bari, Italy.

FAU - Sportelli, Leonardo

AU - Sportelli L

AD - Department of Translational Biomedicine and Neuroscience, University of Bari Aldo

Moro, Bari, Italy.

FAU - Bertolino, Alessandro

AU - Bertolino A

AD - Department of Translational Biomedicine and Neuroscience, University of Bari Aldo

Moro, Bari, Italy.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20221028

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

SB - IM

CIN - Biol Psychiatry. 2023 Jul 15;94(2):100-102. PMID: 37380252

MH - Humans

MH - *Genome-Wide Association Study

MH - *Schizophrenia/genetics

MH - Brain

MH - Risk Factors

MH - Multifactorial Inheritance/genetics

MH - Genetic Predisposition to Disease/genetics

OTO - NOTNLM

OT - Gene ontology

OT - Parsing genetic risk

OT - Reference-based approaches

OT - Regulomics

OT - Schizophrenia

OT - Weighted gene coexpression network analysis

EDAT- 2023/02/06 06:00

MHDA- 2023/06/30 06:42

CRDT- 2023/02/05 21:59

PHST- 2022/04/16 00:00 [received]

PHST- 2022/09/10 00:00 [revised]

PHST- 2022/10/06 00:00 [accepted]

PHST- 2023/06/30 06:42 [medline]

PHST- 2023/02/06 06:00 [pubmed]

PHST- 2023/02/05 21:59 [entrez]

AID - S0006-3223(22)01701-2 [pii]

AID - 10.1016/j.biopsych.2022.10.009 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Jul 15;94(2):121-130. doi: 10.1016/j.biopsych.2022.10.009.

Epub 2022 Oct 28.

PMID- 36738379

OWN - NLM

STAT- MEDLINE

DCOM- 20230703

LR - 20230704

IS - 1557-1920 (Electronic)

IS - 1557-1912 (Print)

IS - 1557-1912 (Linking)

VI - 25

IP - 4

DP - 2023 Aug

TI - Evaluation of an Audio-Visual Novela to Improve COVID-19 Knowledge and Safe

Practices Among Spanish-Speaking Individuals with Schizophrenia.

PG - 889-898

LID - 10.1007/s10903-023-01456-7 [doi]

AB - In the United States, the health and economic consequences of the COVID-19

pandemic have disproportionately affected the Latinx community. Within the Latinx

community, people with schizophrenia-spectrum disorders are more susceptible to

exposure to the virus. Given their increased risk of contracting and getting sick

from the virus, efforts targeting the Latinx population should focus on

increasing knowledge and safe practices associated with COVID-19. We developed a

10 min animated, Spanish-language audio-visual novela designed to improve

knowledge, attitudes, and behaviors regarding COVID-19. Latinx adults with

schizophrenia (N = 100) at a community mental health center in Los Angeles were

randomly assigned to watch the novela or a non-COVID video (control group).

Participants completed surveys immediately before and one month after viewing the

material. One month after watching the audio-visual novela, subjects endorsed a

greater likelihood of seeking a COVID-19 vaccine than control subjects. No other

significant differences were observed between the two conditions. The findings of

this study suggest that the presentation of health information in a relevant,

engaging, and appealing manner may be useful way to improving salutary health

behaviors of Latinx people with schizophrenia-spectrum disorders.

FAU - Kopelowicz, Alex

AU - Kopelowicz A

AUID- ORCID: 0000-0001-8103-3928

AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of

Medicine at UCLA, Los Angeles, CA, USA. Akopelowicz@dhs.lacounty.gov.

AD - Olive View-UCLA Medical Center, 14445 Olive View Drive, Cottage H-2, Sylmar, CA,

91342, USA. Akopelowicz@dhs.lacounty.gov.

FAU - Lopez, Steven R

AU - Lopez SR

AD - Department of Psychology, University of Southern California, Los Angeles, CA,

USA.

FAU - Molina, Gregory B

AU - Molina GB

AD - School of Pharmacy, University of Southern California, Los Angeles, CA, USA.

FAU - Baron, Melvin

AU - Baron M

AD - School of Pharmacy, University of Southern California, Los Angeles, CA, USA.

FAU - Franco, Richard

AU - Franco R

AD - Department of Psychiatry and Biobehavioral Sciences, David Geffen School of

Medicine at UCLA, Los Angeles, CA, USA.

FAU - Mayer, Doe

AU - Mayer D

AD - School of Cinematic Arts, University of Southern California, Los Angeles, CA,

USA.

LA - eng

GR - HE-10/David Geffen School of Medicine, University of California, Los Angeles/

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20230204

PL - United States

TA - J Immigr Minor Health

JT - Journal of immigrant and minority health

JID - 101256527

RN - 0 (COVID-19 Vaccines)

SB - IM

MH - Adult

MH - Humans

MH - United States/epidemiology

MH - *COVID-19

MH - *Schizophrenia

MH - COVID-19 Vaccines

MH - Pandemics

MH - Health Knowledge, Attitudes, Practice

PMC - PMC9898851

OTO - NOTNLM

OT - Audio-visual novela

OT - COVID-19

OT - Health education

OT - Latinx

OT - Schizophrenia

EDAT- 2023/02/05 06:00

MHDA- 2023/07/03 06:41

CRDT- 2023/02/04 11:16

PHST- 2023/01/25 00:00 [accepted]

PHST- 2023/07/03 06:41 [medline]

PHST- 2023/02/05 06:00 [pubmed]

PHST- 2023/02/04 11:16 [entrez]

AID - 10.1007/s10903-023-01456-7 [pii]

AID - 1456 [pii]

AID - 10.1007/s10903-023-01456-7 [doi]

PST - ppublish

SO - J Immigr Minor Health. 2023 Aug;25(4):889-898. doi: 10.1007/s10903-023-01456-7.

Epub 2023 Feb 4.

PMID- 36717018

OWN - NLM

STAT- MEDLINE

DCOM- 20230612

LR - 20230612

IS - 1872-8111 (Electronic)

IS - 0168-0102 (Linking)

VI - 192

DP - 2023 Jul

TI - VDAC genes down-regulation in brain samples of individuals with schizophrenia is

revealed by a systematic meta-analysis.

PG - 83-92

LID - S0168-0102(23)00022-6 [pii]

LID - 10.1016/j.neures.2023.01.012 [doi]

AB - Mitochondrial dysfunction was shown to be involved in schizophrenia

pathophysiology. Abnormal energy states can lead to alterations in neural

function and thereby to the cognitive and behavioral aberrations characteristics

of schizophrenia. Voltage-dependent anion-selective channels (VDAC) are located

in the outer mitochondrial membrane and are involved in mitochondrial energy

production. Only few studies explored VDAC genes' expression in schizophrenia,

and their results were not consistent. We conducted a systematic meta-analysis of

ten brain samples gene expression datasets (overall 368 samples, 179

schizophrenia, 189 controls). In addition, we conducted a meta-analysis of three

blood samples datasets (overall 300 samples, 167 schizophrenia, 133 controls).

Pairwise correlation analysis was conducted between the VDAC and proteasome

subunit genes' expression patterns. VDAC1, VDAC2 and VDAC3 showed significant

down-regulation in brain samples of patients with schizophrenia. They also showed

significant positive correlations with the proteasome subunit genes' expression

levels. Our findings suggest that VDAC genes might play a role in mitochondrial

dysfunction in schizophrenia. VDAC1 was down-regulated also in blood samples,

which suggests its potential role as a biomarker for schizophrenia. The

correlation with proteasome subunits, which were previously shown to be

down-regulated in a subgroup of the patients, suggests that our findings might

characterize a subgroup of the patients. This direction has the potential to lead

to patients' stratification and more precisely-targeted therapy and necessitates

further study.

reserved.

FAU - Segev, Shaked

AU - Segev S

AD - Sackler School of Medicine, Tel-Aviv University, Israel.

FAU - Yitzhaky, Assif

AU - Yitzhaky A

AD - Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot,

Israel.

FAU - Ben Shachar, Dorit

AU - Ben Shachar D

AD - Psychobiology Research Lab, Department of Neuroscience, The Ruth and Bruce

Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Israel.

FAU - Hertzberg, Libi

AU - Hertzberg L

AD - Sackler School of Medicine, Tel-Aviv University, Israel; Shalvata Mental Health

Center, Israel; Department of Physics of Complex Systems, Weizmann Institute of

Science, Rehovot, Israel. Electronic address: libi.hertzberg@gmail.com.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230127

PL - Ireland

TA - Neurosci Res

JT - Neuroscience research

JID - 8500749

RN - EC 3.4.25.1 (Proteasome Endopeptidase Complex)

RN - 0 (Protein Isoforms)

SB - IM

MH - Humans

MH - Down-Regulation

MH - *Proteasome Endopeptidase Complex/genetics

MH - *Schizophrenia/genetics

MH - Protein Isoforms/genetics

MH - Gene Expression

MH - Brain

OTO - NOTNLM

OT - Gene expression

OT - Meta-analysis, brain samples

OT - Mitochondrial dysfunction

OT - Schizophrenia

OT - VDAC

EDAT- 2023/01/31 06:00

MHDA- 2023/06/12 06:42

CRDT- 2023/01/30 19:28

PHST- 2022/11/05 00:00 [received]

PHST- 2023/01/23 00:00 [revised]

PHST- 2023/01/26 00:00 [accepted]

PHST- 2023/06/12 06:42 [medline]

PHST- 2023/01/31 06:00 [pubmed]

PHST- 2023/01/30 19:28 [entrez]

AID - S0168-0102(23)00022-6 [pii]

AID - 10.1016/j.neures.2023.01.012 [doi]

PST - ppublish

SO - Neurosci Res. 2023 Jul;192:83-92. doi: 10.1016/j.neures.2023.01.012. Epub 2023

Jan 27.

PMID- 36702660

OWN - NLM

STAT- MEDLINE

DCOM- 20230630

LR - 20230703

IS - 1873-2402 (Electronic)

IS - 0006-3223 (Linking)

VI - 94

IP - 2

DP - 2023 Jul 15

TI - Integrative Brain Network and Salience Models of Psychopathology and Cognitive

Dysfunction in Schizophrenia.

PG - 108-120

LID - S0006-3223(22)01637-7 [pii]

LID - 10.1016/j.biopsych.2022.09.029 [doi]

AB - Brain network models of cognitive control are central to advancing our

understanding of psychopathology and cognitive dysfunction in schizophrenia. This

review examines the role of large-scale brain organization in schizophrenia, with

a particular focus on a triple-network model of cognitive control and its role in

aberrant salience processing. First, we provide an overview of the triple network

involving the salience, frontoparietal, and default mode networks and highlight

the central role of the insula-anchored salience network in the aberrant mapping

of salient external and internal events in schizophrenia. We summarize the

extensive evidence that has emerged from structural, neurochemical, and

functional brain imaging studies for aberrancies in these networks and their

dynamic temporal interactions in schizophrenia. Next, we consider the hypothesis

that atypical striatal dopamine release results in misattribution of salience to

irrelevant external stimuli and self-referential mental events. We propose an

integrated triple-network salience-based model incorporating striatal dysfunction

and sensitivity to perceptual and cognitive prediction errors in the insula node

of the salience network and postulate that dysregulated dopamine modulation of

salience network-centered processes contributes to the core clinical phenotype of

schizophrenia. Thus, a powerful paradigm to characterize the neurobiology of

schizophrenia emerges when we combine conceptual models of salience with

large-scale cognitive control networks in a unified manner. We conclude by

discussing potential therapeutic leads on restoring brain network dysfunction in

schizophrenia.

FAU - Menon, Vinod

AU - Menon V

AD - Department of Psychiatry and Behavioral Sciences, Stanford University School of

Medicine, Stanford, California; Department of Neurology and Neurological

Sciences, Stanford University School of Medicine, Stanford, California; Wu Tsai

Neurosciences Institute, Stanford University School of Medicine, Stanford,

California. Electronic address: menon@stanford.edu.

FAU - Palaniyappan, Lena

AU - Palaniyappan L

AD - Department of Psychiatry and Robarts Research Institute, University of Western

Ontario, London, Ontario, Canada; Lawson Health Research Institute, London,

Ontario, Canada; Douglas Mental Health University Institute, Montreal, Quebec,

Canada; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.

FAU - Supekar, Kaustubh

AU - Supekar K

AD - Department of Psychiatry and Behavioral Sciences, Stanford University School of

Medicine, Stanford, California; Wu Tsai Neurosciences Institute, Stanford

University School of Medicine, Stanford, California.

LA - eng

PT - Journal Article

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

PT - Review

DEP - 20221004

PL - United States

TA - Biol Psychiatry

JT - Biological psychiatry

JID - 0213264

RN - VTD58H1Z2X (Dopamine)

SB - IM

MH - Humans

MH - *Schizophrenia/complications/diagnostic imaging/drug therapy

MH - Dopamine

MH - Brain/diagnostic imaging

MH - *Cognitive Dysfunction

MH - Psychopathology

MH - Magnetic Resonance Imaging

MH - Brain Mapping

MH - Nerve Net/diagnostic imaging

OTO - NOTNLM

OT - Dopamine

OT - Prediction error

OT - Psychopathology

OT - Salience

OT - Schizophrenia

OT - Triple network

EDAT- 2023/01/27 06:00

MHDA- 2023/06/30 06:42

CRDT- 2023/01/26 21:59

PHST- 2022/03/25 00:00 [received]

PHST- 2022/08/09 00:00 [revised]

PHST- 2022/09/06 00:00 [accepted]

PHST- 2023/06/30 06:42 [medline]

PHST- 2023/01/27 06:00 [pubmed]

PHST- 2023/01/26 21:59 [entrez]

AID - S0006-3223(22)01637-7 [pii]

AID - 10.1016/j.biopsych.2022.09.029 [doi]

PST - ppublish

SO - Biol Psychiatry. 2023 Jul 15;94(2):108-120. doi: 10.1016/j.biopsych.2022.09.029.

Epub 2022 Oct 4.

PMID- 36700595

OWN - NLM

STAT- MEDLINE

DCOM- 20230602

LR - 20230602

IS - 1440-1819 (Electronic)

IS - 1323-1316 (Linking)

VI - 77

IP - 6

DP - 2023 Jun

TI - Does short-term antipsychotic discontinuation of up to 3 weeks worsen symptoms in

acute schizophrenia? A pooled analysis of placebo washout data.

PG - 338-344

LID - 10.1111/pcn.13534 [doi]

AB - AIM: This study aimed to examine symptom changes during short-term

discontinuation of antipsychotics up to 3 weeks including the placebo washout

phase in acute schizophrenia. METHODS: The data from three double-blind,

randomized, controlled trials comparing lurasidone versus placebo in patients

with acute exacerbation of schizophrenia were analyzed. Symptom severity was

assessed using the Positive and Negative Syndrome Scale (PANSS) total and the

Clinical Global Impression-Severity scale (CGI-S) scores. The scores before and

after the antipsychotic discontinuation phase were compared, and factors

associated with score changes were explored. RESULTS: Among 2154 patients

participating in the trials, 600 who received antipsychotic monotherapy and

completed the antipsychotic discontinuation phase were included in the analysis.

No patients received clozapine. The mean duration of the discontinuation phase

was 5.9 ± 2.5 days. The PANSS total and CGI-S scores significantly changed from

94.0 ± 9.5 to 95.4 ± 10.5 (P < 0.001) and from 4.9 ± 0.6 to 4.9 ± 0.7

(P = 0.041), respectively, during this phase; however, the absolute difference

was minimal. The score changes were not associated with the type or dose of prior

antipsychotics, or the duration or strategy (abrupt vs gradual) of antipsychotic

discontinuation. CONCLUSIONS: Symptoms may not worsen to a clinically meaningful

degree after short-term discontinuation of non-clozapine antipsychotics up to

3 weeks in patients with acute exacerbation of schizophrenia, suggesting that

antipsychotic efficacy persists at least several days after discontinuation. This

finding supports once-daily dosing regimen of antipsychotics and abrupt

antipsychotic discontinuation when switching to another antipsychotic.

& Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.

FAU - Takeuchi, Hiroyoshi

AU - Takeuchi H

AUID- ORCID: 0000-0002-8844-4786

AD - Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

FAU - Watabe, Kei

AU - Watabe K

AD - Department of Data Science, Drug Development Division, Sumitomo Pharma Co., Ltd.,

Tokyo, Japan.

LA - eng

PT - Journal Article

PT - Meta-Analysis

DEP - 20230307

PL - Australia

TA - Psychiatry Clin Neurosci

JT - Psychiatry and clinical neurosciences

JID - 9513551

RN - 0 (Antipsychotic Agents)

RN - O0P4I5851I (Lurasidone Hydrochloride)

RN - J60AR2IKIC (Clozapine)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/therapeutic use

MH - *Schizophrenia/drug therapy

MH - Lurasidone Hydrochloride

MH - *Clozapine

MH - Double-Blind Method

MH - Treatment Outcome

MH - Randomized Controlled Trials as Topic

OTO - NOTNLM

OT - antipsychotics

OT - discontinuation

OT - placebo washout

OT - schizophrenia

EDAT- 2023/01/27 06:00

MHDA- 2023/06/02 06:42

CRDT- 2023/01/26 08:33

PHST- 2022/12/30 00:00 [revised]

PHST- 2022/11/12 00:00 [received]

PHST- 2023/01/22 00:00 [accepted]

PHST- 2023/06/02 06:42 [medline]

PHST- 2023/01/27 06:00 [pubmed]

PHST- 2023/01/26 08:33 [entrez]

AID - 10.1111/pcn.13534 [doi]

PST - ppublish

SO - Psychiatry Clin Neurosci. 2023 Jun;77(6):338-344. doi: 10.1111/pcn.13534. Epub

2023 Mar 7.

PMID- 36681884

OWN - NLM

STAT- MEDLINE

DCOM- 20230705

LR - 20230705

IS - 1365-2850 (Electronic)

IS - 1351-0126 (Linking)

VI - 30

IP - 4

DP - 2023 Aug

TI - Mental health recovery for people with schizophrenia in Southeast Asia: A

systematic review.

PG - 620-636

LID - 10.1111/jpm.12902 [doi]

AB - WHAT IS KNOWN ON THE SUBJECT?: Mental health recovery has become a more prevalent

approach to empowering people with schizophrenia (PWS), especially in western

countries. However, despite the benefits, there is a lack of evidence regarding

its practice in developing countries such as Southeast Asian Countries. The

optimal treatment for PWS has not yet been identified, since most mental health

care is provided in hospital-based settings in Southeast Asia. Mental health

treatment in Southeast Asia is highly influenced by cultural norms, values, and

practices. WHAT THE PAPER ADDS TO EXISTING KNOWLEDGE?: The findings highlight the

importance of integrating cultural aspects into the treatment of people with

schizophrenia. The sample of unique elements in Southeast Asian mental health

recovery include using a close neighbour/cadre as social support and using

religious activity to increase hope. Lack of government support, high level of

employment, and stigma are the biggest barriers in the PWS recovery process. WHAT

IS THE IMPLICATION FOR PRACTICE?: There is a research gap regarding the awareness

and implementation of mental health recovery in psychiatric programs across the

Southeast Asian region which likely impacts the effectiveness of the treatment.

The review shows that little research has explored the concept of personal

recovery in Southeast Asian Countries. ABSTRACT: INTRODUCTION: Recovery has

become an important approach used by mental health services around the world.

Many mental health systems have taken steps to move towards more

recovery-oriented practices and service delivery. Therefore, establishing

recovery-oriented services in developing countries like those in the Southeast

Asian region requires a detailed understanding of the cultural norms, values, and

current mental health practices. AIMS: To investigate the mental health practices

that promote recovery, its barrier in Southeast Asia, and to determine if they

align with the CHIME recovery model. METHOD: Electronic databases MEDLINE,

EMBASE, CINAHL, PsycINFO and SCOPUS, were searched [PROSPERO] (CRD42021227962).

Peer-reviewed English language articles from 2004 to January 2021 were included.

Methodological quality was assessed using the CASP checklist, and thematic

synthesis of included studies was conducted. RESULTS: Thirty-one studies met

inclusion criteria. Several themes illustrated mental health recovery services

and the current obstacles identified in South-east Asian studies. Connection

includes peer support and support groups, relationship status, and limited

opportunities to become involved in the community. Hope is found in cultural

concepts of hope, stimulating recovery through mental health programs, whilst

lack of knowledge and education are the main barriers. Ethnicity is linked to a

high level of stigma, but ethnicity also builds identity. Meaning and

spirituality manifest in religious activities as the catalyst for recovery.

Finally, the opposite of Empowerment is seen in the tendency of people with

schizophrenia to remain in a passive position. Further barriers to empowerment

are unemployment and a lack of social support. DISCUSSION: In Southeast Asia, the

elements of culture, religiosity, and communality are essential to mental health

recovery. The obstacles to recovery are relate to human rights, social support,

family involvement, and continuity of care. IMPLICATIONS FOR PRACTICE: This

review explores the concept of mental health recovery for people who are

experiencing psychosis and living in Southeast Asian countries. The evidence may

contribute to the further development of mental health programs in this region.

John Wiley & Sons Ltd.

FAU - Murwasuminar, Bandu

AU - Murwasuminar B

AUID- ORCID: 0000-0002-1692-8650

AD - School of Nursing and Midwifery, Faculty of Medicine, Nursing and Health

Sciences, Monash University, Frankston, Victoria, Australia.

AD - West Java Mental Hospital, West Java, Indonesia.

FAU - Munro, Ian

AU - Munro I

AUID- ORCID: 0000-0002-3125-6952

AD - School of Nursing and Midwifery, Faculty of Medicine, Nursing and Health

Sciences, Monash University, Frankston, Victoria, Australia.

FAU - Recoche, Katrina

AU - Recoche K

AUID- ORCID: 0000-0002-0992-6809

AD - School of Nursing and Midwifery, Faculty of Medicine, Nursing and Health

Sciences, Monash University, Frankston, Victoria, Australia.

LA - eng

GR - S-227/LPDP.3/2019/Lembaga Pengelola Dana Pendidikan/

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20230205

PL - England

TA - J Psychiatr Ment Health Nurs

JT - Journal of psychiatric and mental health nursing

JID - 9439514

MH - Humans

MH - *Schizophrenia/therapy

MH - *Mental Health Recovery

MH - *Psychotic Disorders

MH - Mental Health

MH - Asia, Southeastern

OTO - NOTNLM

OT - Southeast Asia

OT - adult psychiatry

OT - cultural/ethnicity

OT - psychosis

OT - recovery

OT - schizophrenia

OT - systematic literature review

EDAT- 2023/01/23 06:00

MHDA- 2023/07/05 06:42

CRDT- 2023/01/22 06:42

PHST- 2022/10/26 00:00 [revised]

PHST- 2021/11/21 00:00 [received]

PHST- 2023/01/05 00:00 [accepted]

PHST- 2023/07/05 06:42 [medline]

PHST- 2023/01/23 06:00 [pubmed]

PHST- 2023/01/22 06:42 [entrez]

AID - 10.1111/jpm.12902 [doi]

PST - ppublish

SO - J Psychiatr Ment Health Nurs. 2023 Aug;30(4):620-636. doi: 10.1111/jpm.12902.

Epub 2023 Feb 5.

PMID- 36655855

OWN - NLM

STAT- MEDLINE

DCOM- 20230120

LR - 20230424

IS - 1541-2563 (Electronic)

IS - 1541-2563 (Linking)

VI - 20

IP - 1

DP - 2023 Dec

TI - A Systematic Review on the Association between Schizophrenia and Bipolar Disorder

with Chronic Obstructive Pulmonary Disease.

PG - 31-43

LID - 10.1080/15412555.2022.2154646 [doi]

AB - A systematic review aimed to investigate the association between schizophrenia

and bipolar disorder and chronic obstructive pulmonary disease (COPD), its

prevalence and incidence, potential factors associated with its occurrence and

its impact on mortality among these patients. We performed the literature search

in PubMed, Scopus and PsycInfo from inception to February 2022 and identified 19

studies: ten cross-sectional, 5 that included cross-sectional and longitudinal

analyses, and 4 retrospective cohort studies. The reported prevalence of COPD

ranged from 2.6% to 52.7% in patients with schizophrenia and between 3.0% and

12.9% in patients with bipolar disorder. Two studies reported an annual incidence

of COPD of 2.21 cases/100 person-years in patients with schizophrenia and 2.03

cases/100 person-years in patients with bipolar disorder. Among the risk factors

evaluated in three studies, only advanced age was consistently associated with

the presence/occurrence of COPD in patients with schizophrenia and bipolar

disorder; the role of tobacco consumption was not investigated in those three

studies. According to two studies, the likelihood of mortality from COPD showed

an over 3-fold increase in patients with schizophrenia and a 2-fold increase in

those with bipolar disorder compared to the overall population; COPD was also

associated with increased inpatient mortality. Available data indicate that COPD

in patients with schizophrenia and bipolar disorder is a major public health

problem. National and international health organizations should strive to

specifically address this issue by creating awareness about this health problem

and developing specific programs for screening and early intervention aimed to

reduce the burden of COPD in these populations.

FAU - Jaén-Moreno, María José

AU - Jaén-Moreno MJ

AD - Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba,

Spain.

AD - Departamento de Ciencias Morfológicas y Sociosanitarias, Facultad de Medicina y

Enfermería, Universidad de Córdoba, Córdoba, Spain.

FAU - Rico-Villademoros, Fernando

AU - Rico-Villademoros F

AD - Instituto de Neurociencias, Universidad de Granada, Granada, Spain.

FAU - Ruiz-Rull, Cristina

AU - Ruiz-Rull C

AD - Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba,

Spain.

AD - Unidad de Gestión Clínica de Medicina Familiar y Comunitaria, Hospital

Universitario Reina Sofía, Córdoba, Spain.

FAU - Laguna-Muñoz, David

AU - Laguna-Muñoz D

AD - Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba,

Spain.

AD - Unidad de Gestión Clínica de Salud Mental, Hospital Universitario Reina Sofía,

Córdoba, Spain.

FAU - Del Pozo, Gloria Isabel

AU - Del Pozo GI

AD - Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba,

Spain.

AD - Unidad de Gestión Clínica de Salud Mental, Hospital Universitario Reina Sofía,

Córdoba, Spain.

FAU - Sarramea, Fernando

AU - Sarramea F

AD - Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba,

Spain.

AD - Departamento de Ciencias Morfológicas y Sociosanitarias, Facultad de Medicina y

Enfermería, Universidad de Córdoba, Córdoba, Spain.

AD - Unidad de Gestión Clínica de Salud Mental, Hospital Universitario Reina Sofía,

Córdoba, Spain.

AD - Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Oviedo,

Spain.

LA - eng

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

PT - Systematic Review

PL - England

TA - COPD

JT - COPD

JID - 101211769

SB - IM

MH - Humans

MH - *Pulmonary Disease, Chronic Obstructive

MH - *Bipolar Disorder/complications/epidemiology

MH - *Schizophrenia/complications/epidemiology

MH - Cross-Sectional Studies

MH - Retrospective Studies

MH - Prevalence

OTO - NOTNLM

OT - Chronic obstructive pulmonary disease

OT - bipolar disorder

OT - incidence

OT - mortality

OT - prevalence

OT - schizophrenia

OT - smoking

EDAT- 2023/01/20 06:00

MHDA- 2023/01/21 06:00

CRDT- 2023/01/19 08:03

PHST- 2023/01/19 08:03 [entrez]

PHST- 2023/01/20 06:00 [pubmed]

PHST- 2023/01/21 06:00 [medline]

AID - 10.1080/15412555.2022.2154646 [doi]

PST - ppublish

SO - COPD. 2023 Dec;20(1):31-43. doi: 10.1080/15412555.2022.2154646.

PMID- 36623822

OWN - NLM

STAT- MEDLINE

DCOM- 20230705

LR - 20230711

IS - 1751-7893 (Electronic)

IS - 1751-7885 (Print)

IS - 1751-7885 (Linking)

VI - 17

IP - 7

DP - 2023 Jul

TI - Gender differences in outcomes of early intervention services for first episode

psychosis.

PG - 715-723

LID - 10.1111/eip.13367 [doi]

AB - AIMS: There is growing interest in early intervention in psychotic disorders.

However, gender differences in the outcomes of such treatment have not been

studied in a randomized clinical trial. METHODS: Patients diagnosed with

schizophrenia spectrum disorders with less than 6 months antipsychotic exposure

entered a cluster randomized trial of early intervention services compared to

usual care in the Recovery After an Initial Schizophrenia Episode Early Treatment

Program (RAISE-ETP) study. Masked evaluators assessed the Quality of Life Scale

(QLS) and the Positive and Negative Syndrome Scale (PANSS) every 6 months. Our

secondary analyses examined gender differences in baseline characteristics,

2-year gender outcomes, and intervention responses. RESULTS: Altogether 404

individuals aged 15-40 entered the study: 111 (27.4%) women and 293 (72.5%) men.

At baseline, women were significantly more likely to have been married (p = .007)

and to be living independently (p = .012) than men. Women were also more likely

to be diagnosed with schizoaffective disorder, bipolar type (p = .006) and scored

higher on the depression subscale of the PANSS (p = .0004) but not the CDSS.

Women were less likely to use or abuse cannabis (p = .0004), though no less

likely to abuse alcohol. Controlling for these differences, there were no

significant gender differences in the QLS or PANSS outcomes. CONCLUSION: Baseline

gender differences in comorbid substance use and prevalence of mood symptoms in

women with first episode psychosis are consistent with previous studies. The

absence of significant gender differences in outcomes with early intervention has

not been previously reported in a multi-site randomized US clinical trial.

FAU - Hong, Seong I

AU - Hong SI

AD - Yale Medical School, New Haven, Connecticut, USA.

FAU - Bennett, Daniel

AU - Bennett D

AD - University of Southern California, Los Angeles, California, USA.

FAU - Rosenheck, Robert A

AU - Rosenheck RA

AUID- ORCID: 0000-0003-4314-4592

AD - Yale Medical School, New Haven, Connecticut, USA.

AD - VA New England Mental Illness, Research and Clinical Center, West Haven,

Connecticut, USA.

LA - eng

SI - ClinicalTrials.gov/NCT01321177

GR - R03 MH125253/MH/NIMH NIH HHS/United States

GR - 1R03MH125253-01/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

DEP - 20230109

PL - Australia

TA - Early Interv Psychiatry

JT - Early intervention in psychiatry

JID - 101320027

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Male

MH - Humans

MH - Female

MH - Quality of Life

MH - Sex Factors

MH - *Psychotic Disorders/diagnosis/epidemiology/therapy

MH - *Schizophrenia/diagnosis

MH - *Antipsychotic Agents/therapeutic use

PMC - PMC10329725

MID - NIHMS1862569

OTO - NOTNLM

OT - coordinated specialty care

OT - early intervention

OT - gender outcomes

OT - schizophrenia

COIS- Conflicts of Interest. The Authors have no conflicts of interest to report.

EDAT- 2023/01/10 06:00

MHDA- 2023/07/05 06:42

PMCR- 2024/07/01

CRDT- 2023/01/09 19:32

PHST- 2022/09/30 00:00 [revised]

PHST- 2022/06/16 00:00 [received]

PHST- 2023/01/02 00:00 [accepted]

PHST- 2024/07/01 00:00 [pmc-release]

PHST- 2023/07/05 06:42 [medline]

PHST- 2023/01/10 06:00 [pubmed]

PHST- 2023/01/09 19:32 [entrez]

AID - 10.1111/eip.13367 [doi]

PST - ppublish

SO - Early Interv Psychiatry. 2023 Jul;17(7):715-723. doi: 10.1111/eip.13367. Epub

2023 Jan 9.

PMID- 36528441

OWN - NLM

STAT- MEDLINE

DCOM- 20230606

LR - 20230607

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Linking)

VI - 256

DP - 2023 Jun

TI - What social determinants can tell us about schizophrenia.

PG - 114-116

LID - S0920-9964(22)00400-5 [pii]

LID - 10.1016/j.schres.2022.10.017 [doi]

FAU - Malaspina, Dolores

AU - Malaspina D

AD - Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic

address: dolores.malaspina@mssm.edu.

LA - eng

PT - Editorial

DEP - 20221216

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Social Determinants of Health

EDAT- 2022/12/18 06:00

MHDA- 2023/06/06 06:42

CRDT- 2022/12/17 22:04

PHST- 2022/06/13 00:00 [received]

PHST- 2022/09/05 00:00 [revised]

PHST- 2022/10/30 00:00 [accepted]

PHST- 2023/06/06 06:42 [medline]

PHST- 2022/12/18 06:00 [pubmed]

PHST- 2022/12/17 22:04 [entrez]

AID - S0920-9964(22)00400-5 [pii]

AID - 10.1016/j.schres.2022.10.017 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Jun;256:114-116. doi: 10.1016/j.schres.2022.10.017. Epub 2022

Dec 16.

PMID- 36477405

OWN - NLM

STAT- MEDLINE

DCOM- 20230605

LR - 20230605

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Print)

IS - 0940-1334 (Linking)

VI - 273

IP - 4

DP - 2023 Jun

TI - Effects of psychological treatments on functioning in people with Schizophrenia:

a systematic review and meta-analysis of randomized controlled trials.

PG - 779-810

LID - 10.1007/s00406-022-01526-1 [doi]

AB - Functioning is recognized as a key treatment goal in alleviating the burden of

schizophrenia. Psychological interventions can play an important role in

improving functioning in this population, but the evidence on their efficacy is

limited. We therefore aimed to evaluate the effect of psychological interventions

in functioning for patients with schizophrenia. To conduct this systematic review

and meta-analysis, we searched for published and unpublished randomized

controlled trials (RCTs) in EMBASE, MEDLINE, PsycINFO, BIOSIS, Cochrane Library,

WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov

and the Study register of the Cochrane Schizophrenia Group. The outcome

functioning was measured with validated scales. We performed random-effects

pairwise meta-analysis to calculate standardized mean differences (SMDs) with 95%

confidence intervals (CIs). We included 58 RCTs (5048 participants).

Psychological interventions analyzed together (SMD = - 0.37, 95% CI - 0.49 to

- 0.25), cognitive behavioral therapy (30 RCTs, SMD = - 0.26, 95% CI - 0.39 to

- 0.12), and third wave cognitive-behavioral therapies (15 RCTs, SMD = - 0.60,

95% CI - 0.83 to - 0.37) were superior to control in improving functioning,

while creative therapies (8 RCTs, SMD = 0.01, 95% CI - 0.38 to 0.39), integrated

therapies (4 RCTs, SMD = - 0.21, 95% CI - 1.20 to 0.78) and other therapies (4

RCTs, SMD = - 0.74, 95% CI - 1.52 to 0.04) did not show a benefit.

Psychological interventions, in particular cognitive behavioral therapy and third

wave cognitive behavioral therapies, have shown a therapeutic effect on

functioning. The confidence in the estimate was evaluated as very low due to risk

of bias, heterogeneity and possible publication bias.

FAU - Bighelli, Irene

AU - Bighelli I

AUID- ORCID: 0000-0002-5661-5149

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts

Der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich,

Germany. irene.bighelli@tum.de.

FAU - Wallis, Sofia

AU - Wallis S

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts

Der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich,

Germany.

FAU - Reitmeir, Cornelia

AU - Reitmeir C

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts

Der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich,

Germany.

FAU - Schwermann, Felicitas

AU - Schwermann F

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts

Der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich,

Germany.

FAU - Salahuddin, Nurul Husna

AU - Salahuddin NH

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts

Der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich,

Germany.

FAU - Leucht, Stefan

AU - Leucht S

AD - Department of Psychiatry and Psychotherapy, School of Medicine, Klinikum Rechts

Der Isar, Technical University of Munich, Ismaningerstraße 22, 81675, Munich,

Germany.

LA - eng

GR - 701717/h2020 marie skłodowska-curie actions/

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

DEP - 20221208

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

SB - IM

MH - Humans

MH - Psychotherapy

MH - Randomized Controlled Trials as Topic

MH - *Cognitive Behavioral Therapy

MH - *Schizophrenia/therapy

PMC - PMC10238355

OTO - NOTNLM

OT - Functioning

OT - Meta-analysis

OT - Psychological interventions

OT - Schizophrenia

OT - Systematic review

COIS- In the past 3 years, SL has received honoraria for service as a consultant or

adviser and/or for lectures from Angelini, Böhringer Ingelheim, Geodon & Richter,

Janssen, Johnson&Johnson, Lundbeck, LTS Lohmann, MSD, Otsuka, Recordati,

SanofiAventis, Sandoz, Sunovion, TEVA, ROVI and EISAI. IB, SW, CR, FS and NHS

declare no competing interests.

EDAT- 2022/12/09 06:00

MHDA- 2023/06/05 06:42

CRDT- 2022/12/08 11:41

PHST- 2021/07/19 00:00 [received]

PHST- 2022/11/15 00:00 [accepted]

PHST- 2023/06/05 06:42 [medline]

PHST- 2022/12/09 06:00 [pubmed]

PHST- 2022/12/08 11:41 [entrez]

AID - 10.1007/s00406-022-01526-1 [pii]

AID - 1526 [pii]

AID - 10.1007/s00406-022-01526-1 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Jun;273(4):779-810. doi:

10.1007/s00406-022-01526-1. Epub 2022 Dec 8.

PMID- 36460745

OWN - NLM

STAT- MEDLINE

DCOM- 20230825

LR - 20230825

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Linking)

VI - 273

IP - 6

DP - 2023 Sep

TI - Importance of the dysregulation of the kynurenine pathway on cognition in

schizophrenia: a systematic review of clinical studies.

PG - 1317-1328

LID - 10.1007/s00406-022-01519-0 [doi]

AB - Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which

hamper daily functioning causing disability and costs for society. Biological

determinants underlying cognitive impairment are only partially understood and

there are no convincing pharmacological targets able to improve cognitive

outcome. Mounting evidence has shown the involvement of the kynurenine pathway in

the pathophysiology of schizophrenia, also concerning cognitive symptoms.

Therefore, the action of specific metabolites of kynurenine could affects

cognition in schizophrenia. To evaluate the impact of the metabolites of

kynurenine pathway on cognitive functions in schizophrenia spectrum disorders,

with a focus on the modulating role of gender, to identify predictors of

cognitive functioning and hypothetical pharmacological targets able to resize

disability by improving cognition, thus functioning and quality of life. A

systematic review was performed in PubMed/MEDLINE and Embase according to

Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies

measuring the direct impact of kynurenine metabolites on cognitive performances

in living individuals with schizophrenia spectrum disorders were included in the

review. Six studies were included. The activation of the kynurenine pathway

resulted associated with greater cognitive deficits in patients with

schizophrenia and both elevations and reduction of metabolites seemed able to

affect cognitive outcome. No modulating role of sex emerged. This systematic

review provides evidence that the activation of the kynurenine pathway affects

cognition in patients with schizophrenia and highlights this pathway as a

possible future target for developing novel drugs toward this still unmet

clinical need. However, evidence is still limited and future studies are needed

to further clarify the relationship between kynurenine pathway and cognition in

schizophrenia.

FAU - Sapienza, Jacopo

AU - Sapienza J

AD - IRCCS San Raffaele Scientific Institute, Milan, Italy.

FAU - Spangaro, Marco

AU - Spangaro M

AD - IRCCS San Raffaele Scientific Institute, Milan, Italy.

FAU - Guillemin, Gilles J

AU - Guillemin GJ

AD - Neuroinflammation Group, Macquarie Medicine School, Macquarie University, Sydney,

NSW, Australia.

FAU - Comai, Stefano

AU - Comai S

AUID- ORCID: 0000-0002-5686-7194

AD - IRCCS San Raffaele Scientific Institute, Milan, Italy. stefano.comai@unipd.it.

AD - Department of Psychiatry, McGill University, Montreal, QC, Canada.

stefano.comai@unipd.it.

AD - Department of Pharmaceutical and Pharmacological Sciences, University of Padua,

Padua, Italy. stefano.comai@unipd.it.

AD - Department of Biomedical Sciences, University of Padua, Padua, Italy.

stefano.comai@unipd.it.

FAU - Bosia, Marta

AU - Bosia M

AD - IRCCS San Raffaele Scientific Institute, Milan, Italy.

AD - School of Medicine, Vita Salute San Raffaele University, Milan, Italy.

LA - eng

GR - GR-2019-12369523/Ministero della Salute/

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20221202

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

RN - 343-65-7 (Kynurenine)

RN - H030S2S85J (Kynurenic Acid)

SB - IM

MH - Humans

MH - Kynurenine/metabolism

MH - Quality of Life

MH - *Schizophrenia

MH - *Psychotic Disorders/metabolism

MH - Cognition

MH - Kynurenic Acid/metabolism

OTO - NOTNLM

OT - Cytokines

OT - Inflammation

OT - Kynurenic acid

OT - Psychosis

OT - Quinolinic acid

OT - Tryptophan

EDAT- 2022/12/03 06:00

MHDA- 2023/08/25 06:42

CRDT- 2022/12/02 23:29

PHST- 2022/07/13 00:00 [received]

PHST- 2022/11/15 00:00 [accepted]

PHST- 2023/08/25 06:42 [medline]

PHST- 2022/12/03 06:00 [pubmed]

PHST- 2022/12/02 23:29 [entrez]

AID - 10.1007/s00406-022-01519-0 [pii]

AID - 10.1007/s00406-022-01519-0 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Sep;273(6):1317-1328. doi:

10.1007/s00406-022-01519-0. Epub 2022 Dec 2.

PMID- 36424289

OWN - NLM

STAT- MEDLINE

DCOM- 20230606

LR - 20230607

IS - 1573-2509 (Electronic)

IS - 0920-9964 (Linking)

VI - 256

DP - 2023 Jun

TI - Computerized cognitive and social cognition training in schizophrenia for

impulsive aggression.

PG - 117-125

LID - S0920-9964(22)00418-2 [pii]

LID - 10.1016/j.schres.2022.11.004 [doi]

AB - BACKGROUND: Schizophrenia is associated with an elevated risk for impulsive

aggression for which there are few psychosocial treatment options. Neurocognitive

and social cognitive deficits have been associated with aggression with social

cognitive deficits seemingly a more proximal contributor. The current study

examined the effects of combining cognitive and social cognition treatment on

impulsive aggression among inpatients with chronic schizophrenia and

schizoaffective disorder and a history of aggression compared to cognitive

remediation treatment alone. METHODS: The two-center study randomized 130

participants to receive 36 sessions of either a combination of cognitive

remediation and social cognition treatment or cognitive remediation plus a

computer-based control. Participants had at least one aggressive incident within

the past year or a Life History of Aggression (LHA) score of 5 or more.

Participants completed measures of neurocognition, social cognition, symptom

severity, and aggression at baseline and endpoint. RESULTS: Study participants

were mostly male (84.5 %), had a mean age 34.9 years, and 11.5 years of

education. Both Cognitive Remediation Training (CRT) plus Social Cognition

Training (SCT) and CRT plus control groups were associated with significant

reductions in aggression measures with no group differences except on a block of

the Taylor Aggression Paradigm (TAP), a behavioral task of aggression which

favored the CRT plus SCT group. Both groups showed significant improvements in

neurocognition and social cognition measures with CRT plus SCT being associated

with greater improvements. CONCLUSION: CRT proved to be an effective

non-pharmacological treatment in reducing impulsive aggression in schizophrenia

inpatient participants with a history of aggressive episodes. The addition of

social cognitive training did not enhance this anti-aggression treatment effect

but did augment the CRT effect on cognitive functions, on emotion recognition and

on mentalizing capacity of our participants.

FAU - Khan, Anzalee

AU - Khan A

AD - Nathan S. Kline Institute for Psychiatric Research, 140 Orangeburg Road,

Orangeburg, NY 10962, USA; Manhattan Psychiatric Center, 1 Wards Island Complex,

Wards Island, NY 10035, USA. Electronic address: anzalee.khan@nki.rfmh.org.

FAU - Lindenmayer, Jean-Pierre

AU - Lindenmayer JP

AD - Nathan S. Kline Institute for Psychiatric Research, 140 Orangeburg Road,

Orangeburg, NY 10962, USA; Manhattan Psychiatric Center, 1 Wards Island Complex,

Wards Island, NY 10035, USA; New York University School of Medicine, 550 1st

Ave., New York, NY 10016, USA.

FAU - Insel, Beverly

AU - Insel B

AD - Mount Sinai Medical Center, 5 East 98th Street, New York, NY 10029, USA.

FAU - Seddo, Mary

AU - Seddo M

AD - Long Island University, 1 University Plaza, Brooklyn, NY 11201, USA.

FAU - Demirli, Ecem

AU - Demirli E

AD - Weill Cornell Medical Center, 21 Bloomingdale Road, White Plains, NY 10605, USA.

FAU - DeFazio, Kayla

AU - DeFazio K

AD - Weill Cornell Medical Center, 21 Bloomingdale Road, White Plains, NY 10605, USA.

FAU - Sullivan, Mark

AU - Sullivan M

AD - Weill Cornell Medical Center, 21 Bloomingdale Road, White Plains, NY 10605, USA.

FAU - Hoptman, Matthew J

AU - Hoptman MJ

AD - Nathan S. Kline Institute for Psychiatric Research, 140 Orangeburg Road,

Orangeburg, NY 10962, USA; New York University School of Medicine, 550 1st Ave.,

New York, NY 10016, USA.

FAU - Ahmed, Anthony O

AU - Ahmed AO

AD - Weill Cornell Medical Center, 21 Bloomingdale Road, White Plains, NY 10605, USA.

LA - eng

GR - UL1 TR000457/TR/NCATS NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

DEP - 20221121

PL - Netherlands

TA - Schizophr Res

JT - Schizophrenia research

JID - 8804207

SB - IM

MH - Humans

MH - Male

MH - Adult

MH - Female

MH - *Schizophrenia/complications/therapy

MH - Social Cognition

MH - *Psychotic Disorders/complications/therapy/psychology

MH - Aggression

MH - Treatment Outcome

MH - Cognition

MH - *Cognitive Remediation

OTO - NOTNLM

OT - Aggression

OT - Cognitive remediation training

OT - Impulsivity

OT - Schizophrenia

OT - Social cognition training

COIS- Declaration of competing interest The authors report no conflicts of interest.

EDAT- 2022/11/25 06:00

MHDA- 2023/06/06 06:42

CRDT- 2022/11/24 22:12

PHST- 2022/05/20 00:00 [received]

PHST- 2022/09/22 00:00 [revised]

PHST- 2022/11/05 00:00 [accepted]

PHST- 2023/06/06 06:42 [medline]

PHST- 2022/11/25 06:00 [pubmed]

PHST- 2022/11/24 22:12 [entrez]

AID - S0920-9964(22)00418-2 [pii]

AID - 10.1016/j.schres.2022.11.004 [doi]

PST - ppublish

SO - Schizophr Res. 2023 Jun;256:117-125. doi: 10.1016/j.schres.2022.11.004. Epub 2022

Nov 21.

PMID- 36410728

OWN - NLM

STAT- MEDLINE

DCOM- 20230512

LR - 20230512

IS - 1472-8206 (Electronic)

IS - 0767-3981 (Linking)

VI - 37

IP - 3

DP - 2023 Jun

TI - Animal models for the evaluation of antipsychotic agents.

PG - 447-460

LID - 10.1111/fcp.12855 [doi]

AB - Schizophrenia, the most serious among psychoses, has negative symptoms such as

anhedonia, avolition and apathy, and cognitive defects in addition to positive

symptoms such as hallucinations and delusions characterising all psychotic

disorders. Traditional antipsychotics had dopamine D(2) receptor antagonism as

their principal mechanism of action, with disabling extrapyramidal symptoms as

corollary. Newer atypical agents with diverse receptor actions introduced to

circumvent this issue, nevertheless, had varied side effects such as

agranulocytosis, insulin resistance, seizures, and cardiac events. Also, symptoms

in cognitive and negative domains do not respond well even to newer agents

creating an unmet need. Designing a valid animal model with translational

relevance for a complex disease such as schizophrenia is a tedious process.

Induction or suppression of certain animal behaviours by test compounds

(behavioural models) and antagonising effects induced by compounds with psychotic

potential (pharmacological models) are the conventional models used. One among

the major disadvantages with conventional models is that these paradigms are

induced acutely and relate to aberration of a single neurotransmitter system,

which is in sharp contrast to the chronic nature and interplay of multiple

neurotransmitter systems in psychotic diseases. However, with progress in

elucidation of disease mechanisms, novel models are generated utilising

developmental, genetic, and environmental factors (neurodevelopmental models) to

effectively reflect the human disease pathogenesis and clinical manifestations,

but with paucity of studies assessing the impact of drugs on them. This review

presents an overview of schizophrenia hypotheses, requisites of a valid animal

model, available animal models with their advantages and disadvantages.

Wiley & Sons Ltd.

FAU - Ayyar, Porkodi

AU - Ayyar P

AUID- ORCID: 0000-0002-0573-9301

AD - Department of Pharmacology, SRM Medical College Hospital and Research Centre, SRM

Institute of Science and Technology, SRM nagar, Kanchipuram, Chennai, India.

FAU - Ravinder, Jamuna Rani

AU - Ravinder JR

AD - Department of Pharmacology, SRM Medical College Hospital and Research Centre, SRM

Institute of Science and Technology, SRM nagar, Kanchipuram, Chennai, India.

LA - eng

PT - Journal Article

PT - Review

DEP - 20221204

PL - England

TA - Fundam Clin Pharmacol

JT - Fundamental & clinical pharmacology

JID - 8710411

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Animals

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - Models, Animal

OTO - NOTNLM

OT - conditioned avoidance response

OT - latent inhibition

OT - neurodevelopmental models

OT - pre-pulse inhibition

OT - schizophrenia

EDAT- 2022/11/22 06:00

MHDA- 2023/05/12 07:06

CRDT- 2022/11/21 20:12

PHST- 2022/10/04 00:00 [revised]

PHST- 2021/12/24 00:00 [received]

PHST- 2022/11/19 00:00 [accepted]

PHST- 2023/05/12 07:06 [medline]

PHST- 2022/11/22 06:00 [pubmed]

PHST- 2022/11/21 20:12 [entrez]

AID - 10.1111/fcp.12855 [doi]

PST - ppublish

SO - Fundam Clin Pharmacol. 2023 Jun;37(3):447-460. doi: 10.1111/fcp.12855. Epub 2022

Dec 4.

PMID- 36401749

OWN - NLM

STAT- MEDLINE

DCOM- 20230731

LR - 20230801

IS - 1435-1463 (Electronic)

IS - 0300-9564 (Print)

IS - 0300-9564 (Linking)

VI - 130

IP - 8

DP - 2023 Aug

TI - Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum

disorders and inflammatory cytokine profile trial (TargetFlame): study design and

methodology of a multicentre randomized, placebo-controlled trial.

PG - 1039-1048

LID - 10.1007/s00702-022-02566-6 [doi]

AB - Neuroinflammation has been proposed to impact symptomatology in patients with

schizophrenia spectrum disorders. While previous studies have shown equivocal

effects of treatments with add-on anti-inflammatory drugs such as Aspirin,

N-acetylcysteine and Celecoxib, none have used a subset of prospectively

recruited patients exhibiting an inflammatory profile. The aim of the study is to

evaluate the efficacy and safety as well as the cost-effectiveness of a treatment

with 400 mg Celecoxib added to an ongoing antipsychotic treatment in patients

with schizophrenia spectrum disorders exhibiting an inflammatory profile. The

"Add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and

inflammatory cytokine profile trial (TargetFlame)" is a multicentre randomized,

placebo-controlled phase III investigator-initiated clinical trial with the

following two arms: patients exhibiting an inflammatory profile receiving either

add-on Celecoxib 400 mg/day or add-on placebo. A total of 199 patients will be

assessed for eligibility by measuring blood levels of three pro-inflammatory

cytokines, and 109 patients with an inflammatory profile, i.e. inflamed, will be

randomized, treated for 8 weeks and followed-up for additional four months. The

primary endpoint will be changes in symptom severity as assessed by total

Positive and Negative Syndrome Scale (PANSS) score changes from baseline to week

8. Secondary endpoints include various other measures of psychopathology and

safety. Additional health economic analyses will be performed. TargetFlame is the

first study aimed at evaluating the efficacy, safety and cost-effectiveness of

the antiphlogistic agent Celecoxib in a subset of patients with schizophrenia

spectrum disorders exhibiting an inflammatory profile. With TargetFlame, we

intended to investigate a novel precision medicine approach towards

anti-inflammatory antipsychotic treatment augmentation using drug repurposing.

Clinical trial registration: http://www.drks.de/DRKS00029044 and

https://trialsearch.who.int/Trial2.aspx?TrialID=DRKS00029044.

FAU - Strube, Wolfgang

AU - Strube W

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany.

FAU - Aksar, Aslihan

AU - Aksar A

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany.

FAU - Bauer, Ingrid

AU - Bauer I

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany.

FAU - Barbosa, Susana

AU - Barbosa S

AD - Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur,

Centre National de La Recherche Scientifique, Valbonne, France.

FAU - Benros, Michael

AU - Benros M

AD - CORE-Copenhagen Research Centre for Mental Health, Mental Health Centre

Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.

FAU - Blankenstein, Christiane

AU - Blankenstein C

AD - Münchner Studienzentrum, School of Medicine, Technical University of Munich,

Munich, Germany.

FAU - Campana, Mattia

AU - Campana M

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Davidovic, Laetitia

AU - Davidovic L

AD - Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur,

Centre National de La Recherche Scientifique, Valbonne, France.

FAU - Glaichenhaus, Nicolas

AU - Glaichenhaus N

AD - Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur,

Centre National de La Recherche Scientifique, Valbonne, France.

FAU - Falkai, Peter

AU - Falkai P

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Görlitz, Thomas

AU - Görlitz T

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany.

FAU - Hansbauer, Maximilian

AU - Hansbauer M

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany.

FAU - Heilig, Daniel

AU - Heilig D

AD - Department of Health Economics, Center for Public Health, Medical University of

Vienna, Vienna, Austria.

FAU - Khalfallah, Olfa

AU - Khalfallah O

AD - Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur,

Centre National de La Recherche Scientifique, Valbonne, France.

FAU - Leboyer, Marion

AU - Leboyer M

AD - Univ Paris Est Créteil, INSERM U955, IMRB, Translational Neuro-Psychiatry

Laboratory, AP-HP, Hôpitaux Universitaires Henri Mondor, Département

Médico-Universitaire de Psychiatrie Et d'Addictologie (DMU IMPACT), Fédération

Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT),

Fondation FondaMental, 94010, Créteil, France.

FAU - Martinuzzi, Emanuela

AU - Martinuzzi E

AD - Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur,

Centre National de La Recherche Scientifique, Valbonne, France.

FAU - Mayer, Susanne

AU - Mayer S

AD - Department of Health Economics, Center for Public Health, Medical University of

Vienna, Vienna, Austria.

FAU - Moussiopoulou, Joanna

AU - Moussiopoulou J

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Papazova, Irina

AU - Papazova I

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany.

FAU - Perić, Natasa

AU - Perić N

AD - Department of Health Economics, Center for Public Health, Medical University of

Vienna, Vienna, Austria.

FAU - Wagner, Elias

AU - Wagner E

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Schneider-Axmann, Thomas

AU - Schneider-Axmann T

AD - Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich,

Munich, Germany.

FAU - Simon, Judit

AU - Simon J

AD - Department of Health Economics, Center for Public Health, Medical University of

Vienna, Vienna, Austria.

AD - Department of Psychiatry, University of Oxford, Oxford, UK.

FAU - Hasan, Alkomiet

AU - Hasan A

AD - Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty,

University of Augsburg, Bezirkskrankenhaus Augsburg, Geschwister-Schönert-Str. 1,

86156, Augsburg, Germany. alkomiet.hasan@med.uni-augsburg.de.

LA - eng

SI - DRKS/DRKS00029044

PT - Clinical Trial, Phase III

PT - Journal Article

PT - Multicenter Study

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20221119

PL - Austria

TA - J Neural Transm (Vienna)

JT - Journal of neural transmission (Vienna, Austria : 1996)

JID - 9702341

RN - JCX84Q7J1L (Celecoxib)

RN - 0 (Antipsychotic Agents)

RN - 0 (Cytokines)

SB - IM

MH - Humans

MH - Celecoxib/therapeutic use

MH - *Antipsychotic Agents/adverse effects

MH - *Schizophrenia/drug therapy

MH - Double-Blind Method

MH - Treatment Outcome

MH - Cytokines

PMC - PMC10374797

OTO - NOTNLM

OT - Celecoxib

OT - Inflammation

OT - Precision medicine

OT - Precision psychiatry

OT - Schizophrenia

OT - Targeted therapy

COIS- WS has received a speaker's honorarium from Mag&More GmbH and neurocare and was a

member of the advisory board of Recordati. EW was a member of the advisory board

of Recordati. PF is a co-editor of the German (DGPPN) Schizophrenia treatment

guidelines and a co-author of the WFSBP schizophrenia treatment guidelines. He is

on the advisory boards and receives speaker fees from Janssen, Lundbeck, Otsuka,

Servier and Richter. AH is co-editor of the German (DGPPN) Schizophrenia

treatment guidelines and first-author of the WFSBP schizophrenia treatment

guidelines. He has been on the advisory boards and has received speaker fees from

Janssen, Lundbeck and Otsuka. All other authors declare no competing financial

interests.

EDAT- 2022/11/20 06:00

MHDA- 2023/07/31 11:42

CRDT- 2022/11/19 11:17

PHST- 2022/09/15 00:00 [received]

PHST- 2022/11/02 00:00 [accepted]

PHST- 2023/07/31 11:42 [medline]

PHST- 2022/11/20 06:00 [pubmed]

PHST- 2022/11/19 11:17 [entrez]

AID - 10.1007/s00702-022-02566-6 [pii]

AID - 2566 [pii]

AID - 10.1007/s00702-022-02566-6 [doi]

PST - ppublish

SO - J Neural Transm (Vienna). 2023 Aug;130(8):1039-1048. doi:

10.1007/s00702-022-02566-6. Epub 2022 Nov 19.

PMID- 36305919

OWN - NLM

STAT- MEDLINE

DCOM- 20230721

LR - 20230721

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Linking)

VI - 273

IP - 5

DP - 2023 Aug

TI - Altered neural mechanism of social reward anticipation in individuals with

schizophrenia and social anhedonia.

PG - 1029-1039

LID - 10.1007/s00406-022-01505-6 [doi]

AB - Altered social reward anticipation could be found in schizophrenia (SCZ) patients

and individuals with high levels of social anhedonia (SA). However, few research

investigated the putative neural processing for altered social reward

anticipation in these populations on the SCZ spectrum. This study aimed to

examine the underlying neural mechanisms of social reward anticipation in these

populations. Twenty-three SCZ patients and 17 healthy controls (HC), 37 SA

individuals and 50 respective HCs completed the Social Incentive Delay (SID)

imaging task while they were undertaking MRI brain scans. We used the group

contrast to examine the alterations of BOLD activation and functional

connectivity (FC, psychophysiological interactions analysis). We then

characterized the beta-series social brain network (SBN) based on the

meta-analysis results from NeuroSynth and examined their prediction effects on

real-life social network (SN) characteristics using the partial least squared

regression analysis. The results showed that SCZ patients exhibited

hypo-activation of the left medial frontal gyrus and the negative FCs with the

left parietal regions, while individuals with SA showed the hyper-activation of

the left middle frontal gyrus when anticipating social reward. For the

beta-series SBNs, SCZ patients had strengthened cerebellum-temporal FCs, while SA

individuals had strengthened left frontal regions FCs. However, such FCs of the

SBN failed to predict the real-life SN characteristics. These preliminary

findings suggested that SCZ patients and SA individuals appear to exhibit altered

neural processing for social reward anticipation, and such neural activities

showed a weakened association with real-life SN characteristics.

FAU - Zhang, Yi-Jing

AU - Zhang YJ

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Hu, Hui-Xin

AU - Hu HX

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Wang, Ling-Ling

AU - Wang LL

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Wang, Xuan

AU - Wang X

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Wang, Yi

AU - Wang Y

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Huang, Jia

AU - Huang J

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Wang, Ya

AU - Wang Y

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China.

FAU - Lui, Simon S Y

AU - Lui SSY

AD - Department of Psychiatry, School of Clinical Medicine, The University of Hong

Kong, Hong Kong Special Administrative Region, China.

FAU - Hui, Li

AU - Hui L

AD - The Affiliated Guangji Hospital of Soochow University, Medical College of Soochow

University, Suzhou, Jiangsu, China.

FAU - Chan, Raymond C K

AU - Chan RCK

AUID- ORCID: 0000-0002-3414-450X

AD - Neuropsychology and Applied Cognitive Neuroscience Laboratory, Institute of

Psychology, CAS Key Laboratory of Mental Health, Chinese Academy of Sciences, 16

Lincui Road, Beijing, China. rckchan@psych.ac.cn.

AD - Department of Psychology, University of Chinese Academy of Sciences, Beijing,

China. rckchan@psych.ac.cn.

LA - eng

GR - 31871114/National Science Foundation China/

GR - BE2020661/Jiangsu Provincial Key Research and Development Program/

GR - E2CX3415CX/the Scientific Foundation of Institute of Psychology, Chinese Academy

of Sciences/

PT - Journal Article

PT - Meta-Analysis

DEP - 20221028

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

SB - IM

MH - Humans

MH - *Schizophrenia/diagnostic imaging

MH - Anhedonia/physiology

MH - Brain/diagnostic imaging

MH - Reward

MH - Motivation

MH - Magnetic Resonance Imaging

OTO - NOTNLM

OT - Schizophrenia

OT - Social anhedonia

OT - Social brain network

OT - Social functioning

OT - Social network

OT - Social reward anticipation

EDAT- 2022/10/29 06:00

MHDA- 2023/07/21 06:44

CRDT- 2022/10/28 11:23

PHST- 2022/05/07 00:00 [received]

PHST- 2022/10/14 00:00 [accepted]

PHST- 2023/07/21 06:44 [medline]

PHST- 2022/10/29 06:00 [pubmed]

PHST- 2022/10/28 11:23 [entrez]

AID - 10.1007/s00406-022-01505-6 [pii]

AID - 10.1007/s00406-022-01505-6 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Aug;273(5):1029-1039. doi:

10.1007/s00406-022-01505-6. Epub 2022 Oct 28.

PMID- 36264184

OWN - NLM

STAT- MEDLINE

DCOM- 20230605

LR - 20230606

IS - 1556-3669 (Electronic)

IS - 1530-5627 (Linking)

VI - 29

IP - 6

DP - 2023 Jun

TI - Randomized Controlled Trials of Digital Mental Health Interventions on Patients

with Schizophrenia Spectrum Disorder: A Systematic Review.

PG - 798-812

LID - 10.1089/tmj.2022.0135 [doi]

AB - Background: This systematic review aimed to examine the study protocol of Digital

Mental Health Interventions (DMHIs) and to review the effect of DMHIs among

patients with Schizophrenia Spectrum Disorder (SSD). Methods: This review

followed the guideline of Preferred Reporting Items for Systematic Reviews and

Meta-Analyses (PRISMA). A systematic literature search was performed using

PubMed, CINAHL, Embase, and PsycINFO electronic databases to identify randomized

clinical trials without any limit on the publication year. Overall, 18 studies

were selected and evaluated for the quality assessment utilizing the Risk of Bias

2 tool of Cochranes' Collaboration. In the quality assessment, four studies

evaluated as overall high risk of bias were excluded from the selection, and the

final 14 studies were chosen. Results: No DMHIs were provided for acute

schizophrenia-related symptoms, and there were some studies related to

schizophrenia-related symptoms (26.4%). Some studies for improving cognitive

function (42.9%) were reported, and there was a significant effect when

interventions that were proven to be effective when implemented in a face-to-face

manner were delivered using various online devices and sensory stimuli. Nearly

half of the studies reported intervention frequency and time (57.1%), and those

with unclear reports relied either on a mobile app or telemedicine and were

designed to self-pace the frequency and speed of the intervention. Conclusion:

Based on our findings, it will be possible to understand the characteristics of

DMHIs, without physical contact, for only SSD patients, providing a basis for

digital mental health services.

FAU - Song, MoonJu

AU - Song M

AD - Division of Admission Management and Policy Development, National Center for

Mental health, Seoul, Republic of Korea.

AD - College of Nursing, Korea University, Seoul, Republic of Korea.

FAU - Song, Yul-Mai

AU - Song YM

AD - Department of Nursing, Honam University, Gwangju, Republic of Korea.

LA - eng

PT - Journal Article

PT - Review

PT - Systematic Review

DEP - 20221019

PL - United States

TA - Telemed J E Health

JT - Telemedicine journal and e-health : the official journal of the American

Telemedicine Association

JID - 100959949

SB - IM

MH - Humans

MH - Mental Health

MH - *Schizophrenia/therapy

MH - Randomized Controlled Trials as Topic

MH - *Mobile Applications

OTO - NOTNLM

OT - COVID-19

OT - digital

OT - intervention

OT - mental health

OT - schizophrenia

OT - telemedicine

EDAT- 2022/10/21 06:00

MHDA- 2023/06/05 06:42

CRDT- 2022/10/20 10:06

PHST- 2023/06/05 06:42 [medline]

PHST- 2022/10/21 06:00 [pubmed]

PHST- 2022/10/20 10:06 [entrez]

AID - 10.1089/tmj.2022.0135 [doi]

PST - ppublish

SO - Telemed J E Health. 2023 Jun;29(6):798-812. doi: 10.1089/tmj.2022.0135. Epub 2022

Oct 19.

PMID- 36154947

OWN - NLM

STAT- MEDLINE

DCOM- 20231006

LR - 20231010

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Linking)

VI - 53

IP - 12

DP - 2023 Sep

TI - Effectiveness of enhancing contact model on reducing family caregiving burden and

improving psychological wellbeing among caregivers of persons with schizophrenia

in rural China.

PG - 5756-5766

LID - 10.1017/S0033291722002987 [doi]

AB - BACKGROUND: It is unclear whether the enhancing contact model (ECM) intervention

is effective in reducing family caregiving burden and improving hope and quality

of life (QOL) among family caregivers of persons with schizophrenia (FCPWS).

METHODS: We conducted a cluster randomized controlled trial in FCPWS in eight

rural townships in Xinjin, Chengdu, China. In total, 253 FCPWS were randomly

allocated to the ECM, psychoeducational family intervention (PFI), or treatment

as usual (TAU) group. FCPWS in three groups were assessed caregiving burden, QOL

and state of hope at baseline (T0), post-intervention (T1), 3-month (T2), and

9-month (T3) follow-up, respectively. RESULTS: Compared with participants in the

TAU group, participants in the ECM group had statistically significantly lower

caregiving burden scores both at T1 and T2 (p = 0.0059 and 0.0257, respectively).

Compared with participants in the TAU group, participants in the PFI group had

statistically significantly higher QOL scores in T1 (p = 0.0406), while

participants in the ECM group had statistically significantly higher QOL scores

in T3 (p = 0.0240). Participants in both ECM and PFI groups had statistically

significantly higher hope scores than those in the TAU group at T1 (p = 0.0160

and 0.0486, respectively). CONCLUSIONS: This is the first study to explore the

effectiveness of ECM on reducing family caregiving burden and improving hope and

QOL in rural China. The results indicate the ECM intervention, a comprehensive

and multifaceted intervention, is more effective than the PFI in various aspects

of mental wellbeing among FCPWS. Future research needs to confirm ECM's

effectiveness in various population.

FAU - Wang, Yi-Zhou

AU - Wang YZ

AD - Department of Social Work and Social Administration, University of Hong Kong,

Hong Kong.

FAU - Weng, Xue

AU - Weng X

AD - Institute of Advanced Studies in Humanities and Social Sciences, Beijing Normal

University, Zhuhai, China.

FAU - Zhang, Tian-Ming

AU - Zhang TM

AD - Department of Social Work, Shanghai University, Shanghai, China.

FAU - Li, Ming

AU - Li M

AD - Chengdu Xinjin Second People's Hospital, Chengdu, China.

FAU - Luo, Wei

AU - Luo W

AD - Chengdu Xinjin Second People's Hospital, Chengdu, China.

FAU - Wong, Yin-Ling Irene

AU - Wong YI

AD - School of Social Policy & Practice, University of Pennsylvania, USA.

FAU - Yang, Lawrence H

AU - Yang LH

AD - Department of Social and Behavioral Sciences, New York University, USA.

AD - Department of Epidemiology, Columbia University, NY, USA.

FAU - Thornicroft, Graham

AU - Thornicroft G

AD - Centre for Global Mental Health and Centre for Implementation Science, Institute

of Psychiatry, Psychology and Neuroscience, King's College London, UK.

FAU - Lu, Lin

AU - Lu L

AD - Peking University Sixth Hospital, Peking University Institute of Mental Health,

Beijing, China.

FAU - Ran, Mao-Sheng

AU - Ran MS

AUID- ORCID: 0000-0001-7343-3729

AD - Department of Social Work and Social Administration, University of Hong Kong,

Hong Kong.

AD - Mental Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan,

China.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20220926

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

SB - IM

MH - Humans

MH - *Caregivers/psychology

MH - *Schizophrenia/therapy/epidemiology

MH - Quality of Life

MH - Family/psychology

MH - China/epidemiology

OTO - NOTNLM

OT - China

OT - enhancing contact model

OT - family caregivers

OT - rural area

OT - schizophrenia

EDAT- 2022/09/27 06:00

MHDA- 2023/10/06 06:43

CRDT- 2022/09/26 15:09

PHST- 2023/10/06 06:43 [medline]

PHST- 2022/09/27 06:00 [pubmed]

PHST- 2022/09/26 15:09 [entrez]

AID - S0033291722002987 [pii]

AID - 10.1017/S0033291722002987 [doi]

PST - ppublish

SO - Psychol Med. 2023 Sep;53(12):5756-5766. doi: 10.1017/S0033291722002987. Epub 2022

Sep 26.

PMID- 36047035

OWN - NLM

STAT- MEDLINE

DCOM- 20230913

LR - 20230920

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Print)

IS - 0033-2917 (Linking)

VI - 53

IP - 10

DP - 2023 Jul

TI - Aerobic exercise enhances cognitive training effects in first-episode

schizophrenia: randomized clinical trial demonstrates cognitive and functional

gains.

PG - 4751-4761

LID - 10.1017/S0033291722001696 [doi]

AB - BACKGROUND: Cognitive training (CT) and aerobic exercise both show promising

moderate impact on cognition and everyday functioning in schizophrenia. Aerobic

exercise is hypothesized to increase brain-derived neurotrophic factor (BDNF) and

thereby synaptic plasticity, leading to increased learning capacity. Systematic

CT should take advantage of increased learning capacity and be more effective

when combined with aerobic exercise. METHODS: We examined the impact of a 6-month

program of cognitive training & exercise (CT&E) compared to cognitive training

alone (CT) in 47 first-episode schizophrenia outpatients. All participants were

provided the same Posit Science computerized CT, 4 h/week, using BrainHQ and

SocialVille programs. The CT&E group also participated in total body circuit

training exercises to enhance aerobic conditioning. Clinic and home-based

exercise were combined for a target of 150 min per week. RESULTS: The MATRICS

Consensus Cognitive Battery Overall Composite improved significantly more with

CT&E than with CT alone (p = 0.04), particularly in the first 3 months (6.5 v.

2.2 T-score points, p < 0.02). Work/school functioning improved substantially

more with CT&E than with CT alone by 6 months (p < 0.001). BDNF gain tended to

predict the amount of cognitive gain but did not reach significance. The

cognitive gain by 3 months predicted the amount of work/school functioning

improvement at 6 months. The amount of exercise completed was strongly associated

with the degree of cognitive and work/school functioning improvement.

CONCLUSIONS: Aerobic exercise significantly enhances the impact of CT on

cognition and functional outcome in first-episode schizophrenia, apparently

driven by the amount of exercise completed.

FAU - Nuechterlein, Keith H

AU - Nuechterlein KH

AUID- ORCID: 0000-0002-8179-8952

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

AD - Department of Psychology, University of California, Los Angeles, USA.

FAU - McEwen, Sarah C

AU - McEwen SC

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Ventura, Joseph

AU - Ventura J

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Subotnik, Kenneth L

AU - Subotnik KL

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Turner, Luana R

AU - Turner LR

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Boucher, Michael

AU - Boucher M

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Casaus, Laurie R

AU - Casaus LR

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Distler, Margaret G

AU - Distler MG

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

FAU - Hayata, Jacqueline N

AU - Hayata JN

AD - Department of Psychiatry and Biobehavioral Sciences, Semel Institute for

Neuroscience & Human Behavior, University of California, Los Angeles, USA.

LA - eng

SI - ClinicalTrials.gov/NCT02267070

GR - R34 MH102529/MH/NIMH NIH HHS/United States

GR - P50 MH066286/MH/NIMH NIH HHS/United States

GR - R01 MH110544/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, N.I.H., Extramural

PT - Research Support, Non-U.S. Gov't

DEP - 20220808

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

RN - 0 (Brain-Derived Neurotrophic Factor)

SB - IM

MH - Humans

MH - *Schizophrenia/therapy/complications

MH - Brain-Derived Neurotrophic Factor

MH - Cognitive Training

MH - Exercise/psychology

MH - Cognition

PMC - PMC10388302

OTO - NOTNLM

OT - aerobic exercise

OT - cognition

OT - cognitive training

OT - first episode

OT - functional outcome

OT - schizophrenia

COIS- Dr Nuechterlein reports medication and supplemental research grant support from

Janssen Scientific Affairs, LLC., and has served as a consultant to Astellas,

Genentech, Janssen, Medincell, Otsuka, Takeda, and Teva. He is an officer in the

nonprofit company, MATRICS Assessment, Inc., which publishes the MCCB, but

receives no financial compensation. Dr Ventura has received funding from Brain

Plasticity, Inc., Genentech, Inc., and Janssen Scientific Affairs, LLC, and has

served as a consultant to Boehringer-Ingelheim, GmbH, and Brain Plasticity, Inc.

Dr Subotnik has received lecture honoraria from Janssen. Other authors report no

potential conflicts of interest.

EDAT- 2022/09/02 06:00

MHDA- 2023/09/13 06:41

CRDT- 2022/09/01 03:13

PHST- 2023/09/13 06:41 [medline]

PHST- 2022/09/02 06:00 [pubmed]

PHST- 2022/09/01 03:13 [entrez]

AID - S0033291722001696 [pii]

AID - 10.1017/S0033291722001696 [doi]

PST - ppublish

SO - Psychol Med. 2023 Jul;53(10):4751-4761. doi: 10.1017/S0033291722001696. Epub 2022

Aug 8.

PMID- 35900474

OWN - NLM

STAT- MEDLINE

DCOM- 20230605

LR - 20230605

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Linking)

VI - 273

IP - 4

DP - 2023 Jun

TI - Relationship between patterns of cannabis use and functional and symptomatic

trajectories in first-episode psychosis.

PG - 765-778

LID - 10.1007/s00406-022-01441-5 [doi]

AB - Cannabis use is common in first-episode psychosis (FEP) but evidence is mixed

about the extent to which cannabis use predicts symptoms and functional outcomes

among those who seek treatment. This study sought to characterize cannabis use

patterns and examine the relationship with clinical outcomes, including

interactions with early intervention services (EIS). Data were drawn from the

Recovery After an Initial Schizophrenia Episode-Early Treatment Program

(RAISE-ETP) study including FEP individuals receiving treatment at sites

randomized to provide either EIS (NAVIGATE) or community care (CC). Cannabis use

was assessed monthly and symptom and functioning data were collected at baseline,

6, 12, 18, and 24 months. Among the 404 participants enrolled, 334 were

classified into four cannabis use groups (consistent, sporadic, stopped, and

never users) based on their use during the first year. Consistent and sporadic

cannabis users were younger, whereas those who had stopped using were older.

Sporadic users had the highest depression and the lowest functioning at baseline

and improved less during treatment in negative emotions and intrapsychic

foundations (e.g., motivation and sense of purpose) than non-users. However,

sporadic users who received NAVIGATE improved more in overall symptoms and

functioning than those who received CC. Consistent users did not tend to differ

in their trajectories from non-users. Individuals with FEP who use cannabis

sporadically showed less clinical improvement than non-users. However, EIS

treatment reduced the negative effects of sporadic cannabis use on clinical

outcomes. Those who use cannabis sporadically may have unique needs that require

attention in EIS.

FAU - Wright, Abigail C

AU - Wright AC

AUID- ORCID: 0000-0001-7046-2049

AD - Center of Excellence for Psychosocial and Systemic Research, Department of

Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

abigailcwright24@gmail.com.

AD - Harvard Medical School, Boston, MA, USA. abigailcwright24@gmail.com.

FAU - Browne, Julia

AU - Browne J

AD - Center of Excellence for Psychosocial and Systemic Research, Department of

Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

AD - Harvard Medical School, Boston, MA, USA.

AD - Geriatric Research, Education and Clinical Center, Durham VA Health Care System,

Durham, NC, USA.

FAU - Cather, Corinne

AU - Cather C

AD - Center of Excellence for Psychosocial and Systemic Research, Department of

Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

AD - Harvard Medical School, Boston, MA, USA.

FAU - Meyer-Kalos, Piper

AU - Meyer-Kalos P

AD - Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical

School, Minneapolis, MN, USA.

FAU - Mueser, Kim T

AU - Mueser KT

AD - Center for Psychiatric Rehabilitation, Boston University, Boston, MA, USA.

mueser@bu.edu.

LA - eng

GR - R03 MH112053/MH/NIMH NIH HHS/United States

GR - HHSN-271-2009-00019C/MH/NIMH NIH HHS/United States

PT - Journal Article

PT - Randomized Controlled Trial

DEP - 20220728

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

SB - IM

MH - Humans

MH - *Cannabis

MH - *Psychotic Disorders/drug therapy

MH - *Schizophrenia/therapy

OTO - NOTNLM

OT - Coordinated specialty care

OT - Early intervention

OT - Outcomes

OT - Substance use

OT - Trajectories

OT - Treatment

EDAT- 2022/07/29 06:00

MHDA- 2023/06/05 06:42

CRDT- 2022/07/28 11:24

PHST- 2021/05/27 00:00 [received]

PHST- 2022/05/29 00:00 [accepted]

PHST- 2023/06/05 06:42 [medline]

PHST- 2022/07/29 06:00 [pubmed]

PHST- 2022/07/28 11:24 [entrez]

AID - 10.1007/s00406-022-01441-5 [pii]

AID - 10.1007/s00406-022-01441-5 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Jun;273(4):765-778. doi:

10.1007/s00406-022-01441-5. Epub 2022 Jul 28.

PMID- 35839173

OWN - NLM

STAT- MEDLINE

DCOM- 20230612

LR - 20230612

IS - 1471-1788 (Electronic)

IS - 1365-1501 (Linking)

VI - 27

IP - 2

DP - 2023 Jun

TI - Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a

systematic review and meta-analysis.

PG - 171-178

LID - 10.1080/13651501.2022.2100264 [doi]

AB - BACKGROUND: Risperidone has been significant correlated with a direct effect of

interleukin-6 (IL-6) levels in patients with schizophrenia. This fact allows the

opportunity to link the probable immunomodulatory effect of antipsychotic

medication. Specially, a proper functioning of IL-6 pathway plays a potential

role in the treatment or development of schizophrenia. OBJECTIVE: Our primary aim

was to perform a systematic review and meta-analysis to determine the effect of

risperidone on IL-6 levels in individuals with schizophrenia. METHODS: Studies

were identified through a systematic search using PubMed, Scopus, and Web of

Science databases. The articles found were subjected to the inclusion and

exclusion criteria; then, the mean and standardised differences were extracted to

calculate the standardised mean differences using the CMA software. RESULTS: IL-6

levels in individuals with schizophrenia were compared before and after receiving

risperidone as treatment. Increased levels of IL-6 levels were observed in

individuals with schizophrenia who received risperidone (point estimate 0.249,

lower limit 0.042, upper limit 0.455, p-value 0.018). In the Asian population

sub-analysis, no statistically significant differences were observed (point

estimate 0.103, lower limit -0.187, upper limit 0.215, p value 0.890). When we

compared individuals with schizophrenia to the control groups, a significant

increase of IL-6 levels was observed in the group with schizophrenia (point

estimate 0.248, lower limit 0.024, upper limit 0.472, p-value 0.30). CONCLUSIONS:

Risperidone appears to play an important role in IL-6 levels in schizophrenia.

Potential implications of increased IL-6 levels in people with schizophrenia

should be considered in future studies.KEY POINTSIncreased levels of IL-6 levels

were observed in individuals with schizophrenia who received

risperidone.Risperidone appears to play an important role in IL-6 levels in

schizophrenia.This study could serve for future research focussed on IL-6.

FAU - Ramos-Méndez, Miguel Angel

AU - Ramos-Méndez MA

AD - División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de

Tabasco, Villahermosa, Mexico.

FAU - Tovilla-Zárate, Carlos Alfonso

AU - Tovilla-Zárate CA

AD - División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma

de Tabasco, Comalcalco, Mexico.

FAU - Juárez-Rojop, Isela Esther

AU - Juárez-Rojop IE

AD - División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de

Tabasco, Villahermosa, Mexico.

FAU - Villar-Soto, Mario

AU - Villar-Soto M

AD - Hospital Regional de Alta Especialidad de Salud Mental, Villahermosa, Mexico.

FAU - Genis-Mendoza, Alma Delia

AU - Genis-Mendoza AD

AD - Laboratorio de Genómica de Enfermedades Psiquiátricas y Neurodegenerativas,

Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico.

FAU - González-Castro, Thelma Beatriz

AU - González-Castro TB

AD - División Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez

Autónoma de Tabasco, Jalpa de Méndez, Mexico.

FAU - López-Narváez, María Lilia

AU - López-Narváez ML

AD - Hospital Chiapas Nos Une Dr. Gilberto Gómez Maza, Secretaría de Salud de Chiapas,

Tuxtla Gutiérrez, Mexico.

FAU - Martínez-Magaña, José Jaime

AU - Martínez-Magaña JJ

AD - Laboratorio de Genómica de Enfermedades Psiquiátricas y Neurodegenerativas,

Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico.

FAU - Castillo-Avila, Rosa Giannina

AU - Castillo-Avila RG

AD - División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de

Tabasco, Villahermosa, Mexico.

FAU - Villar-Juárez, Guillermo Efrén

AU - Villar-Juárez GE

AD - Escuela de Ciencias de la Salud, Universidad Anáhuac Querétaro, Querétaro,

Mexico.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Review

PT - Systematic Review

DEP - 20220715

PL - England

TA - Int J Psychiatry Clin Pract

JT - International journal of psychiatry in clinical practice

JID - 9709509

RN - L6UH7ZF8HC (Risperidone)

RN - 0 (Interleukin-6)

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - Risperidone/adverse effects

MH - *Schizophrenia/drug therapy

MH - Interleukin-6

MH - *Antipsychotic Agents/adverse effects

OTO - NOTNLM

OT - IL-6 levels

OT - Risperidone

OT - meta-analysis

OT - schizophrenia

EDAT- 2022/07/16 06:00

MHDA- 2023/06/12 06:42

CRDT- 2022/07/15 13:33

PHST- 2023/06/12 06:42 [medline]

PHST- 2022/07/16 06:00 [pubmed]

PHST- 2022/07/15 13:33 [entrez]

AID - 10.1080/13651501.2022.2100264 [doi]

PST - ppublish

SO - Int J Psychiatry Clin Pract. 2023 Jun;27(2):171-178. doi:

10.1080/13651501.2022.2100264. Epub 2022 Jul 15.

PMID- 35730361

OWN - NLM

STAT- MEDLINE

DCOM- 20230901

LR - 20230918

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Print)

IS - 0033-2917 (Linking)

VI - 53

IP - 11

DP - 2023 Aug

TI - Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis

of (18)FDG-PET studies in schizophrenia.

PG - 4880-4897

LID - 10.1017/S003329172200174X [doi]

AB - BACKGROUND: Impaired brain metabolism may be central to schizophrenia

pathophysiology, but the magnitude and consistency of metabolic dysfunction is

unknown. METHODS: We searched MEDLINE, PsychINFO and EMBASE between 01/01/1980

and 13/05/2021 for studies comparing regional brain glucose metabolism using

(18)FDG-PET, in schizophrenia/first-episode psychosis v. controls. Effect sizes

(Hedges g) were pooled using a random-effects model. Primary measures were

regional absolute and relative CMRGlu in frontal, temporal, parietal and

occipital lobes, basal ganglia and thalamus. RESULTS: Thirty-six studies (1335

subjects) were included. Frontal absolute glucose metabolism (Hedge's g = -0.74 ±

0.54, p = 0.01; I(2) = 67%) and metabolism relative to whole brain (g = -0.44 ±

0.34, p = 0.01; I(2) = 55%) were lower in schizophrenia v. controls with moderate

heterogeneity. Absolute frontal metabolism was lower in chronic (g = -1.18 ±

0.73) v. first-episode patients (g = -0.09 ± 0.88) and controls. Medicated

patients showed frontal hypometabolism relative to controls (-1.04 ± 0.26) while

metabolism in drug-free patients did not differ significantly from controls.

There were no differences in parietal, temporal or occipital lobe or thalamic

metabolism in schizophrenia v. controls. Excluding outliers, absolute basal

ganglia metabolism was lower in schizophrenia v. controls (-0.25 ± 0.24, p =

0.049; I(2) = 5%). Studies identified reporting voxel-based morphometry measures

of absolute (18)FDG uptake (eight studies) were also analysed using signed

differential mapping analysis, finding lower (18)FDG uptake in the left anterior

cingulate gyrus (Z = -4.143; p = 0.007) and the left inferior orbital frontal

gyrus (Z = -4.239; p = 0.02) in schizophrenia. CONCLUSIONS: We report evidence

for hypometabolism with large effect sizes in the frontal cortex in schizophrenia

without consistent evidence for alterations in other brain regions. Our findings

support the hypothesis of hypofrontality in schizophrenia.

FAU - Townsend, Leigh

AU - Townsend L

AUID- ORCID: 0000-0002-2037-7847

AD - Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith

Hospital, London, UK.

FAU - Pillinger, Toby

AU - Pillinger T

AD - Department of Psychosis Studies, Institute of Psychiatry, Psychology &

Neuroscience, King's College London, London, UK.

FAU - Selvaggi, Pierluigi

AU - Selvaggi P

AD - Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience,

King's College London, London, UK.

AD - Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy.

FAU - Veronese, Mattia

AU - Veronese M

AD - Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience,

King's College London, London, UK.

AD - Department of Information Engineering, University of Padua, Padua, Italy.

FAU - Turkheimer, Federico

AU - Turkheimer F

AD - Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience,

King's College London, London, UK.

FAU - Howes, Oliver

AU - Howes O

AD - Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith

Hospital, London, UK.

AD - Department of Psychosis Studies, Institute of Psychiatry, Psychology &

Neuroscience, King's College London, London, UK.

LA - eng

GR - WT_/Wellcome Trust/United Kingdom

GR - 094849/Z/10/Z/WT_/Wellcome Trust/United Kingdom

GR - MC-A656-5QD30/MRC_/Medical Research Council/United Kingdom

GR - DH_/Department of Health/United Kingdom

PT - Journal Article

PT - Meta-Analysis

PT - Research Support, Non-U.S. Gov't

PT - Systematic Review

DEP - 20220622

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

RN - IY9XDZ35W2 (Glucose)

RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18)

SB - IM

MH - Humans

MH - *Glucose

MH - *Schizophrenia/diagnostic imaging/metabolism

MH - Fluorodeoxyglucose F18/metabolism

MH - Brain/diagnostic imaging/metabolism

MH - Positron-Emission Tomography

PMC - PMC10476075

OTO - NOTNLM

OT - F-18-deoxyglucose (FDG)

OT - glucose

OT - metabolism

OT - positron emission tomography (PET)

OT - schizophrenia

COIS- Professor Howes is a part-time employee of Lundbeck A/v and has received

investigator-initiated research funding from and/or participated in

advisory/speaker meetings organised by Angellini, Astra-Zeneca, Autifony, Biogen,

Boehringer-Ingelheim, Eli Lilly, Heptares, Invicro, Jansenn, Lundbeck,

Lyden-Delta, Mylan, Neurocrine, Otsuka, Sunovion, Rand, Recordati and Roche. Dr

Pillinger has contributed to speaker meetings organised by Sunovion, Lundbeck,

Otsuka, Schwabe Pharma and Recordati. No other authors report conflicts of

interest. The opinions expressed do not necessarily reflect those of Lundbeck

A/v. For the purpose of open access, this paper has been published under the

creative common licence (CC-BY).

EDAT- 2022/06/23 06:00

MHDA- 2023/09/01 06:43

CRDT- 2022/06/22 04:32

PHST- 2023/09/01 06:43 [medline]

PHST- 2022/06/23 06:00 [pubmed]

PHST- 2022/06/22 04:32 [entrez]

AID - S003329172200174X [pii]

AID - 10.1017/S003329172200174X [doi]

PST - ppublish

SO - Psychol Med. 2023 Aug;53(11):4880-4897. doi: 10.1017/S003329172200174X. Epub 2022

Jun 22.

PMID- 35672956

OWN - NLM

STAT- MEDLINE

DCOM- 20230913

LR - 20230920

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Print)

IS - 0033-2917 (Linking)

VI - 53

IP - 10

DP - 2023 Jul

TI - Sustained specialized and family treatment in first-episode schizophrenia or

related disorders: a 5-year randomized controlled trial.

PG - 4316-4323

LID - 10.1017/S003329172200099X [doi]

AB - BACKGROUND: The long-term outcome of first-episode schizophrenia needs

improvement. Here, we evaluate the effectiveness of 5 years sustained specialist

treatment (ST), ST including Parent groups (ST + P) or treatment as usual (TAU)

on psychotic relapse and social functioning. METHODS: A three condition

randomized, parallel assigned, single-blind efficacy trial, in which 198

first-episode psychosis (FEP) patients aged 15-28 years were included. The effect

on time to first relapse, first relapse rates, mean number of relapses per

patient, and time to the improvement of social functioning were analyzed using

Cox regression or ANOVA. RESULTS: We found no significant differences between

treatment conditions in the ITT analysis concerning time to first relapse, nor

first relapse rate. Mean number of relapses per patient differed at a trend level

between ST, ST + P or TAU conditions, respectively: 0.72; 0.62 or 1.02 (p =

0.069). No evidence was found for differential effect of treatment conditions on

social functioning. CONCLUSION: Five years sustained ST of FEP nor addition of

parent groups increased time to first relapse or reduced first relapse rate,

compared to sustained TAU. Indications for favorable effects of parent groups

were found on relapses per patient.

FAU - de Haan, Lieuwe

AU - de Haan L

AUID- ORCID: 0000-0002-3820-7926

AD - Department of Psychiatry, Early Psychosis, Amsterdam UMC, Amsterdam.

FAU - Linszen, Don

AU - Linszen D

AD - Department of Psychiatry, Early Psychosis, Amsterdam UMC, Amsterdam.

FAU - Wouters, Luuk

AU - Wouters L

AD - Department of Psychiatry, Early Psychosis, Amsterdam UMC, Amsterdam.

FAU - Zwinderman, Koos

AU - Zwinderman K

AD - Departement of Epidemiology, Amsterdam UMC, Amsterdam.

FAU - Dingemans, Peter

AU - Dingemans P

AD - Department of Psychiatry, Early Psychosis, Amsterdam UMC, Amsterdam.

LA - eng

PT - Journal Article

PT - Randomized Controlled Trial

PT - Research Support, Non-U.S. Gov't

DEP - 20220608

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Humans

MH - *Schizophrenia/drug therapy

MH - Single-Blind Method

MH - *Psychotic Disorders/drug therapy

MH - Secondary Prevention

MH - *Antipsychotic Agents/therapeutic use

MH - Recurrence

PMC - PMC10388306

OTO - NOTNLM

OT - family treatment

OT - first episode of psychosis

OT - psychotic relapse

OT - randomized controlled trial

OT - schizophrenia

OT - social functioning specialist treatment

COIS- All authors have declared that there are no conflicts of interest in relation to

the subject of this study.

EDAT- 2022/06/09 06:00

MHDA- 2023/09/13 06:42

CRDT- 2022/06/08 01:43

PHST- 2023/09/13 06:42 [medline]

PHST- 2022/06/09 06:00 [pubmed]

PHST- 2022/06/08 01:43 [entrez]

AID - S003329172200099X [pii]

AID - 10.1017/S003329172200099X [doi]

PST - ppublish

SO - Psychol Med. 2023 Jul;53(10):4316-4323. doi: 10.1017/S003329172200099X. Epub 2022

Jun 8.

PMID- 35634965

OWN - NLM

STAT- MEDLINE

DCOM- 20230925

LR - 20231003

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Linking)

VI - 53

IP - 9

DP - 2023 Jul

TI - Relapse prevention through health technology program reduces hospitalization in

schizophrenia.

PG - 4114-4120

LID - 10.1017/S0033291722000794 [doi]

AB - BACKGROUND: Psychiatric hospitalization is a major driver of cost in the

treatment of schizophrenia. Here, we asked whether a technology-enhanced approach

to relapse prevention could reduce days spent in a hospital after discharge.

METHODS: The Improving Care and Reducing Cost (ICRC) study was a

quasi-experimental clinical trial in outpatients with schizophrenia conducted

between 26 February 2013 and 17 April 2015 at 10 different sites in the USA in an

outpatient setting. Patients were between 18 and 60 years old with a diagnosis of

schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise

specified. Patients received usual care or a technology-enhanced relapse

prevention program during a 6-month period after discharge. The health technology

program included in-person, individualized relapse prevention planning with

treatments delivered via smartphones and computers, as well as a web-based

prescriber decision support program. The main outcome measure was days spent in a

psychiatric hospital during 6 months after discharge. RESULTS: The study included

462 patients, of which 438 had complete baseline data and were thus used for

propensity matching and analysis. Control participants (N = 89; 37 females) were

enrolled first and received usual care for relapse prevention followed by 349

participants (128 females) who received technology-enhanced relapse prevention.

During 6-month follow-up, 43% of control and 24% of intervention participants

were hospitalized (χ2 = 11.76, p<0.001). Days of hospitalization were reduced by

5 days (mean days: b = -4.58, 95% CI -9.03 to -0.13, p = 0.044) in the

intervention condition compared to control. CONCLUSIONS: These results suggest

that technology-enhanced relapse prevention is an effective and feasible way to

reduce rehospitalization days among patients with schizophrenia.

FAU - Homan, Philipp

AU - Homan P

AUID- ORCID: 0000-0001-9034-148X

AD - Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research,

Manhasset, NY, USA.

AD - Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

AD - Department of Psychiatry, Donald and Barbara Zucker School of Medicine at

Hofstra/Northwell, Hempstead, NY, USA.

AD - Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital

of the University of Zurich, Zurich, Switzerland.

AD - Neuroscience Center Zurich, University and ETH, Zurich, Switzerland.

FAU - Schooler, Nina R

AU - Schooler NR

AD - Department of Psychiatry, SUNY Downstate Medical School, Brooklyn, NY, USA.

FAU - Brunette, Mary F

AU - Brunette MF

AD - Department of Psychiatry, Dartmouth-Hitchcock, Geisel School of Medicine at

Dartmouth, Hanover, NH, USA.

FAU - Rotondi, Armando

AU - Rotondi A

AD - Department of Critical Care Medicine, Clinical and Translational Sciences

Institute, University of Pittsburgh, Pittsburgh, PA, USA.

AD - Mental Illness Research, Education and Clinical Center, U.S. Department of

Veterans Affairs Medical Center, Pittsburgh, PA, USA.

FAU - Ben-Zeev, Dror

AU - Ben-Zeev D

AD - Department of Psychiatry and Behavioral Sciences, Behavioral Research in

Technology and Engineering (BRiTE) Center, University of Washington School of

Medicine, Seattle, WA, USA.

FAU - Gottlieb, Jennifer D

AU - Gottlieb JD

AD - Cambridge Health Alliance, Division of Population Behavioral Health Innovation

and Harvard Medical School Department of Psychiatry, Cambridge, MA, USA.

FAU - Mueser, Kim T

AU - Mueser KT

AD - Center for Psychiatric Rehabilitation, Boston University, Boston, MA, USA.

FAU - Achtyes, Eric D

AU - Achtyes ED

AD - Cherry Health and Pine Rest Christian Mental Health Services, Grand Rapids, MI,

USA.

AD - Division of Psychiatry and Behavioral Medicine, Michigan State University College

of Human Medicine, Grand Rapids, MI, USA.

FAU - Gingerich, Susan

AU - Gingerich S

AD - Independent Consultant and Trainer in Narberth, Narberth, Pennsylvania, USA.

FAU - Marcy, Patricia

AU - Marcy P

AD - Vanguard Research Group, Glen Oaks, NY, USA.

FAU - Meyer-Kalos, Piper

AU - Meyer-Kalos P

AD - University of Minnesota Medical School, Department of Psychiatry & Behavioral

Sciences, Minneapolis, MN, USA.

FAU - Hauser, Marta

AU - Hauser M

AD - Vanguard Research Group, Glen Oaks, NY, USA.

FAU - John, Majnu

AU - John M

AD - Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research,

Manhasset, NY, USA.

AD - Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

AD - Department of Mathematics, Hofstra University, Hempstead, NY, USA.

FAU - Robinson, Delbert G

AU - Robinson DG

AD - Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research,

Manhasset, NY, USA.

AD - Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

AD - Department of Psychiatry, Donald and Barbara Zucker School of Medicine at

Hofstra/Northwell, Hempstead, NY, USA.

FAU - Kane, John M

AU - Kane JM

AD - Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research,

Manhasset, NY, USA.

AD - Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen

Oaks, NY, USA.

AD - Department of Psychiatry, Donald and Barbara Zucker School of Medicine at

Hofstra/Northwell, Hempstead, NY, USA.

LA - eng

PT - Clinical Trial

PT - Journal Article

PT - Research Support, U.S. Gov't, Non-P.H.S.

DEP - 20220530

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

SB - IM

MH - Adolescent

MH - Adult

MH - Female

MH - Humans

MH - Middle Aged

MH - Young Adult

MH - Biomedical Technology

MH - Hospitalization

MH - *Psychotic Disorders/prevention & control

MH - *Schizophrenia/prevention & control/diagnosis

MH - Secondary Prevention/methods

OTO - NOTNLM

OT - Schizophrenia

OT - decision support systems

OT - inpatient hospitalization days

OT - relapse prevention

OT - smartphones

OT - technology provided care

OT - web-provided treatments

EDAT- 2022/06/01 06:00

MHDA- 2023/09/21 06:42

CRDT- 2022/05/31 10:48

PHST- 2023/09/21 06:42 [medline]

PHST- 2022/06/01 06:00 [pubmed]

PHST- 2022/05/31 10:48 [entrez]

AID - S0033291722000794 [pii]

AID - 10.1017/S0033291722000794 [doi]

PST - ppublish

SO - Psychol Med. 2023 Jul;53(9):4114-4120. doi: 10.1017/S0033291722000794. Epub 2022

May 30.

PMID- 35379032

OWN - NLM

STAT- MEDLINE

DCOM- 20230925

LR - 20230925

IS - 1558-691X (Electronic)

IS - 0033-2941 (Linking)

VI - 126

IP - 5

DP - 2023 Oct

TI - False Memories in Individuals With Stabilized Schizophrenia.

PG - 2119-2140

LID - 10.1177/00332941221083213 [doi]

AB - This study aimed to examine the false memories in individuals with stabilized

schizophrenia. Using the Deese, Roediger, and McDermott (DRM) task, schizophrenia

patients and matched healthy controls had to recall words from each DRM list.

Following the presentation of the DRM lists, the participants performed a

recognition task. Neuropsychological tests were also administered. Results

demonstrated that patients with schizophrenia recalled and recognized

significantly fewer studied words than the healthy participants. This failure in

retrieval is likely to result from a lack of encoding strategies. Results also

showed that a stabilized schizophrenic pathology neither increased nor reduced

false memories. Patients and controls showed high levels of false memories.

Signal detection analyses revealed that patients discarded the critical word as

not having been studied, relying on a lax decision criterion (based on

familiarity, best guess or chance). Although false memories fell within the

normal range for both groups, in individuals with schizophrenia they probably

result from deficient encoding processes. Nevertheless, correlational analyses

did not show which cognitive deficits contribute to false memories in

schizophrenia.

FAU - Robin, Frédérique

AU - Robin F

AUID- ORCID: 0000-0003-4977-1044

AD - Nantes Université, Univ Angers Laboratoire de psychologie des Pays de la Loire,

LPPL, UR 4638, F-44000 Nantes, France.

FAU - Salomé, Franck

AU - Salomé F

AD - Nantes Université, Univ Angers Laboratoire de psychologie des Pays de la Loire,

LPPL, UR 4638, F-44000 Nantes, France.

FAU - El Haj, Mohamad

AU - El Haj M

AD - Nantes Université, Univ Angers Laboratoire de psychologie des Pays de la Loire,

LPPL, UR 4638, F-44000 Nantes, France.

LA - eng

PT - Journal Article

PT - Review

DEP - 20220404

PL - United States

TA - Psychol Rep

JT - Psychological reports

JID - 0376475

SB - IM

MH - Humans

MH - *Schizophrenia

MH - Semantics

MH - Memory

MH - Mental Recall

MH - Recognition, Psychology

MH - Repression, Psychology

OTO - NOTNLM

OT - Deese, Roediger, and McDermott paradigm

OT - cognitive impairments

OT - false memory

OT - schizophrenia

EDAT- 2022/04/06 06:00

MHDA- 2023/09/25 06:43

CRDT- 2022/04/05 05:26

PHST- 2023/09/25 06:43 [medline]

PHST- 2022/04/06 06:00 [pubmed]

PHST- 2022/04/05 05:26 [entrez]

AID - 10.1177/00332941221083213 [doi]

PST - ppublish

SO - Psychol Rep. 2023 Oct;126(5):2119-2140. doi: 10.1177/00332941221083213. Epub 2022

Apr 4.

PMID- 35338378

OWN - NLM

STAT- MEDLINE

DCOM- 20230605

LR - 20230605

IS - 1433-8491 (Electronic)

IS - 0940-1334 (Print)

IS - 0940-1334 (Linking)

VI - 273

IP - 4

DP - 2023 Jun

TI - Metacognitive training for psychosis (MCT): past, present, and future.

PG - 811-817

LID - 10.1007/s00406-022-01394-9 [doi]

AB - This article provides an overview and retrospective on metacognitive training for

psychosis (MCT), which first appeared approximately 2 decades ago. We recount how

our empirical understanding of psychosis at that time led to the first

preliminary version of the program. We describe setbacks and challenges that led

to major changes, including revisions to existing modules (e.g., more focus on

metacognitive variables, particularly on decision confidence as one of the

primary targets of treatment) and the creation of new modules addressing mood, as

well as attempts to improve sustainability of effects via homework exercises and

a smartphone app ( www.uke.de/mct_app ). We have also enhanced dissemination

efforts by creating new culturally sensitive language versions and facilitating

low-threshold training through e-learning courses ( www.uke.de/e-mct ). Finally,

we discuss several meta-analyses on the efficacy of MCT that have been published

over the last decade. While reviews were initially inconsistent, possibly

reflecting the insufficient statistical power and lower design quality of the

first MCT studies, more recent meta-analyses have confirmed the efficacy of MCT

on positive symptoms, insight, and cognitive biases, which has led to the

inclusion of MCT in some national treatment guidelines for schizophrenia.

FAU - Moritz, Steffen

AU - Moritz S

AUID- ORCID: 0000-0001-8601-0143

AD - Department of Psychiatry and Psychotherapy, University Medical Center

Hamburg-Eppendorf, Hamburg, Germany. moritz@uke.uni-hamburg.de.

FAU - Menon, Mahesh

AU - Menon M

AD - Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.

AD - BC Psychosis Program, Vancouver Coastal Health, Vancouver, BC, Canada.

FAU - Balzan, Ryan

AU - Balzan R

AD - College of Education, Psychology and Social Work, Flinders University, Bedford

Park, SA, Australia.

AD - Orama Institute, Flinders University, Bedford Park, SA, Australia.

FAU - Woodward, Todd S

AU - Woodward TS

AD - Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.

AD - Mental Health and Addictions Research Institute, Vancouver, BC, Canada.

LA - eng

PT - Journal Article

PT - Review

DEP - 20220325

PL - Germany

TA - Eur Arch Psychiatry Clin Neurosci

JT - European archives of psychiatry and clinical neuroscience

JID - 9103030

SB - IM

MH - Humans

MH - Retrospective Studies

MH - *Cognitive Behavioral Therapy

MH - *Psychotic Disorders/therapy

MH - *Schizophrenia/therapy/diagnosis

MH - *Metacognition

MH - Treatment Outcome

PMC - PMC8956140

OTO - NOTNLM

OT - Cognitive biases

OT - Metacognitive training

OT - Psychosis

OT - Schizophrenia

OT - Social cognition

COIS- The authors have contributed to the development of metacognitive training.

EDAT- 2022/03/27 06:00

MHDA- 2023/06/05 06:42

CRDT- 2022/03/26 05:31

PHST- 2021/05/28 00:00 [received]

PHST- 2022/03/01 00:00 [accepted]

PHST- 2023/06/05 06:42 [medline]

PHST- 2022/03/27 06:00 [pubmed]

PHST- 2022/03/26 05:31 [entrez]

AID - 10.1007/s00406-022-01394-9 [pii]

AID - 1394 [pii]

AID - 10.1007/s00406-022-01394-9 [doi]

PST - ppublish

SO - Eur Arch Psychiatry Clin Neurosci. 2023 Jun;273(4):811-817. doi:

10.1007/s00406-022-01394-9. Epub 2022 Mar 25.

PMID- 35325582

OWN - NLM

STAT- MEDLINE

DCOM- 20230717

LR - 20230718

IS - 1531-1937 (Electronic)

IS - 0897-1900 (Linking)

VI - 36

IP - 4

DP - 2023 Aug

TI - Practical Approaches to Antipsychotic-Associated Corrected QT Interval

Prolongation in Patients With Serious Mental Illness: A Review of Cases.

PG - 817-829

LID - 10.1177/08971900221078249 [doi]

AB - Background: There is no consensus for assessment and management of patients with

serious mental illness (SMI) who are at risk for cardiac morbidity and mortality

due to antipsychotic-associated QTc prolongation. Objective: The objective of

this review was to assess methods for risk scoring, QT correction calculation,

and clinical management in SMI patients with antipsychotic-associated QTc

prolongation. Methods: A search was performed in PubMed for case reports that

described QTc prolongation in adult patients with schizophrenia or bipolar

disorder prescribed an antipsychotic. Reports published in North America between

2000 and 2020 were eligible. The Mayo, Tisdale, and RISQ-PATH scoring tools were

applied to cases to categorize risk level. Results: Seventeen cases were

included. Most patients were prescribed a second-generation antipsychotic for

schizophrenia, with baseline and maximum QTc values of 429 milliseconds and 545

milliseconds, respectively. The Mayo scoring tool identified 17 (100%) cases as

"high risk," Tisdale identified 9 (53%) cases as "moderate risk" and 7 (41%)

cases as "low risk," while RISQ-PATH identified 9 (53%) cases as "not low risk"

and 8 (47%) cases as "low risk." Three cases reported the QT correction formula

utilized (18%). The most common intervention to address antipsychotic-associated

QTc prolongation was switching to a different antipsychotic (35%). Approximately

one third of patients experienced Torsades de Pointes. Conclusion: There is a

lack of standardization for antipsychotic-associated QTc prolongation risk

assessment and management in patients with SMI. This review provides real-world

data representing actual clinical practice.

FAU - Cunha, Alexandra L

AU - Cunha AL

AD - Department of Clinical Sciences, High Point University Fred Wilson School of

Pharmacy, High Point, NC, USA. RINGGOLD: 465018

FAU - Schwartz, Shaina E

AU - Schwartz SE

AUID- ORCID: 0000-0002-6040-8425

AD - Department of Clinical Sciences, High Point University Fred Wilson School of

Pharmacy, High Point, NC, USA. RINGGOLD: 465018

FAU - Cooper, Julie B

AU - Cooper JB

AD - Department of Clinical Sciences, High Point University Fred Wilson School of

Pharmacy, High Point, NC, USA. RINGGOLD: 465018

LA - eng

PT - Journal Article

PT - Review

DEP - 20220324

PL - United States

TA - J Pharm Pract

JT - Journal of pharmacy practice

JID - 8900945

RN - 0 (Antipsychotic Agents)

SB - IM

MH - Adult

MH - Humans

MH - *Antipsychotic Agents/adverse effects

MH - *Long QT Syndrome/chemically induced/diagnosis

MH - Electrocardiography

MH - *Torsades de Pointes/chemically induced

MH - *Schizophrenia/drug therapy

MH - Risk Factors

OTO - NOTNLM

OT - cardiology

OT - medication safety

EDAT- 2022/03/25 06:00

MHDA- 2023/07/17 06:42

CRDT- 2022/03/24 20:09

PHST- 2023/07/17 06:42 [medline]

PHST- 2022/03/25 06:00 [pubmed]

PHST- 2022/03/24 20:09 [entrez]

AID - 10.1177/08971900221078249 [doi]

PST - ppublish

SO - J Pharm Pract. 2023 Aug;36(4):817-829. doi: 10.1177/08971900221078249. Epub 2022

Mar 24.

PMID- 35257646

OWN - NLM

STAT- MEDLINE

DCOM- 20230619

LR - 20230621

IS - 1469-8978 (Electronic)

IS - 0033-2917 (Print)

IS - 0033-2917 (Linking)

VI - 53

IP - 8

DP - 2023 Jun

TI - Acceptability of cognitive remediation for schizophrenia: a systematic review and

meta-analysis of randomized controlled trials.

PG - 3661-3671

LID - 10.1017/S0033291722000319 [doi]

AB - BACKGROUND: Acceptability is an important factor for predicting intervention use

and potential treatment outcomes in psychosocial interventions. Cognitive

remediation (CR) improves cognition and functioning in people with a diagnosis of

schizophrenia, but its acceptability, and the impact of participants and

treatment characteristics, remain to be investigated. Few studies provide a

direct measure of acceptability, but treatment drop-out rates are often available

and represent a valid surrogate. METHOD: The systematic search conducted for the

most comprehensive CR outcomes database for schizophrenia was updated in December

2020. Eligible studies were randomized clinical trials comparing CR with any

other control condition in patients diagnosed with schizophrenia spectrum

disorders and that also reported drop-out in treatment and control arms

separately. Acceptability was measured as odd-ratios (OR) of drop-out. RESULTS:

Of 2119 identified reports, 151 studies, reporting 169 comparisons between CR and

control interventions with 10 477 participants were included in the analyses. The

overall rate of drop-out was 16.58% for CR programs and 15.21% for control

conditions. In the meta-analysis, no difference emerged between CR interventions

and controls [OR 1.10, 95% confidence interval (CI) 0.96-1.25, p = 0.177].

Factors improving acceptability were: inpatient only recruitment, participants

with fewer years of education and lower premorbid IQ, the presence of all CR core

elements, and the presence of techniques to transfer cognitive gains into

real-world functioning. CONCLUSIONS: CR for people diagnosed with schizophrenia

is effective and has a good acceptability profile, similar to that of other

evidence-based psychosocial interventions.

FAU - Vita, Antonio

AU - Vita A

AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,

Italy.

AD - Department of Mental Health and Addiction Services, ASST Spedali Civili of

Brescia, Brescia, Italy.

FAU - Barlati, Stefano

AU - Barlati S

AUID- ORCID: 0000-0002-1784-3915

AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,

Italy.

AD - Department of Mental Health and Addiction Services, ASST Spedali Civili of

Brescia, Brescia, Italy.

FAU - Ceraso, Anna

AU - Ceraso A

AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,

Italy.

FAU - Deste, Giacomo

AU - Deste G

AD - Department of Mental Health and Addiction Services, ASST Spedali Civili of

Brescia, Brescia, Italy.

FAU - Nibbio, Gabriele

AU - Nibbio G

AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia,

Italy.

FAU - Wykes, Til

AU - Wykes T

AD - Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience,

King's College London, London, UK.

AD - South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill,

London, UK.

LA - eng

PT - Journal Article

PT - Meta-Analysis

PT - Systematic Review

DEP - 20220308

PL - England

TA - Psychol Med

JT - Psychological medicine

JID - 1254142

SB - IM

MH - Humans

MH - *Schizophrenia/therapy

MH - *Cognitive Remediation/methods

MH - Randomized Controlled Trials as Topic

MH - Treatment Outcome

MH - Cognition

PMC - PMC10277755

OTO - NOTNLM

OT - Acceptability

OT - cognitive remediation

OT - drop-out

OT - meta-analysis

OT - schizophrenia

OT - systematic review

COIS- Prof. Wykes reports grants from National Institute for Health Research during the

conduct of the study; and being the creator of CIRCuiTs, a CR software. The other

authors have declared that there are no conflicts of interest in relation to the

subject of this study.

EDAT- 2022/03/09 06:00

MHDA- 2023/06/19 13:08

CRDT- 2022/03/08 08:44

PHST- 2023/06/19 13:08 [medline]

PHST- 2022/03/09 06:00 [pubmed]

PHST- 2022/03/08 08:44 [entrez]

AID - S0033291722000319 [pii]

AID - 10.1017/S0033291722000319 [doi]

PST - ppublish

SO - Psychol Med. 2023 Jun;53(8):3661-3671. doi: 10.1017/S0033291722000319. Epub 2022

Mar 8.

PMID- 35193729

OWN - NLM

STAT- MEDLINE

DCOM- 20230531

LR - 20230604

IS - 1092-8529 (Print)

IS - 1092-8529 (Linking)

VI - 28

IP - 3

DP - 2023 Jun

TI - The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III

clinical trials in bipolar mania, bipolar depression, and schizophrenia.

PG - 319-330

LID - 10.1017/S109285292200013X [doi]

AB - OBJECTIVE: To investigate the effect of cariprazine on cognitive symptom change

across bipolar I disorder and schizophrenia. METHODS: Post hoc analyses of 3- to

8-week pivotal studies in bipolar I depression and mania were conducted; one

schizophrenia trial including the Cognitive Drug Research System attention

battery was also analyzed. Outcomes of interest: Montgomery-Åsberg Depression

Rating Scale [MADRS], Functioning Assessment Short Test [FAST], Positive and

Negative Syndrome Scale [PANSS]). LSMDs in change from baseline to end of study

were reported in the overall intent-to-treat population and in patient subsets

with specified levels of baseline cognitive symptoms or performance. RESULTS: In

patients with bipolar depression and at least mild cognitive symptoms, LSMDs were

statistically significant for cariprazine vs placebo on MADRS item 6 (3 studies;

1.5 mg=-0.5 [P<.001]; 3 mg/d=-0.2 [P<.05]) and on the FAST Cognitive subscale (1

study; 1.5 mg/d=-1.4; P=.0039). In patients with bipolar mania and at least mild

cognitive symptoms, the LSMD in PANSS Cognitive subscale score was statistically

significant for cariprazine vs placebo (3 studies; -2.1; P=.001). In patients

with schizophrenia and high cognitive impairment, improvement in power of

attention was observed for cariprazine 3 mg/d vs placebo (P=.0080), but not for

cariprazine 6 mg/d; improvement in continuity of attention was observed for

cariprazine 3 mg/d (P=.0012) and 6 mg/d (P=.0073). CONCLUSION: These post hoc

analyses provide preliminary evidence of greater improvements for cariprazine vs

placebo across cognitive measures in patients with bipolar I depression and

mania, and schizophrenia, suggesting potential benefits for cariprazine in

treating cognitive symptoms.

FAU - McIntyre, Roger S

AU - McIntyre RS

AUID- ORCID: 0000-0003-4733-2523

AD - Mood Disorders Psychopharmacology Unit, University of Toronto, Toronto, ON,

Canada.

FAU - Daniel, David G

AU - Daniel DG

AD - Signant Health, McLean, VA, USA.

AD - Department of Psychiatry and Behavioral Sciences, George Washington University,

Washington, DC, USA.

FAU - Vieta, Eduard

AU - Vieta E

AD - Department of Psychiatry and Psychology, Hospital Clinic, University of

Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.

FAU - Laszlovszky, István

AU - Laszlovszky I

AD - Medical Division, Gedeon Richter Plc., Budapest, Hungary.

FAU - Goetghebeur, Pascal J

AU - Goetghebeur PJ

AD - Signant Health, Reading, UK.

FAU - Earley, Willie R

AU - Earley WR

AD - Clinical Development, AbbVie, Madison, NJ, USA.

FAU - Patel, Mehul D

AU - Patel MD

AD - Medical Affairs, AbbVie, Madison, NJ, USA.

LA - eng

PT - Clinical Trial, Phase II

PT - Clinical Trial, Phase III

PT - Journal Article

PT - Research Support, Non-U.S. Gov't

DEP - 20220223

PL - United States

TA - CNS Spectr

JT - CNS spectrums

JID - 9702877

RN - 0 (Antipsychotic Agents)

RN - F6RJL8B278 (cariprazine)

SB - IM

MH - Humans

MH - *Antipsychotic Agents/therapeutic use

MH - *Bipolar Disorder/diagnosis

MH - Cognition

MH - Double-Blind Method

MH - Mania/drug therapy

MH - *Schizophrenia/drug therapy

MH - Treatment Outcome

OTO - NOTNLM

OT - Cognition

OT - bipolar depression

OT - bipolar disorder

OT - cariprazine

OT - cognitive symptoms

OT - post hoc analysis

OT - schizophrenia

EDAT- 2022/02/24 06:00

MHDA- 2023/05/31 06:42

CRDT- 2022/02/23 05:30

PHST- 2023/05/31 06:42 [medline]

PHST- 2022/02/24 06:00 [pubmed]

PHST- 2022/02/23 05:30 [entrez]

AID - S109285292200013X [pii]

AID - 10.1017/S109285292200013X [doi]

PST - ppublish

SO - CNS Spectr. 2023 Jun;28(3):319-330. doi: 10.1017/S109285292200013X. Epub 2022 Feb

23.

PMID- 34453506

OWN - NLM

STAT- MEDLINE

DCOM- 20230703

LR - 20230703

IS - 1078-6791 (Print)

IS - 1078-6791 (Linking)

VI - 29

IP - 5

DP - 2023 Jul

TI - Schizophrenia and Homoeopathy: A Review.

PG - 164-169

LID - AT6455 [pii]

AB - CONTEXT: Schizophrenia is a mental condition that is affecting approx. 1.0

percent of the worldwide population, with devastating consequences for affected

individuals and their families. Homoeopathy could be an effective alternative

mode of treatment and can minimize the consequences of it. OBJECTIVE: This study

is done to have a brief review of the condition of Schizophrenia and to evaluate

the role of Homoeopathy as an alternative mode of treatment in patients suffering

from this condition. DESIGN: The research team performed a narrative review by

searching Pubmed, IJRH, ISOR-JDMS, WHO, and Medscape databases. Reference books

related to medicine and homoeopathy were also reviewed. The search used the

keywords like Schizophrenia, Homoeopathy, psychiatry, hallucinations, paranoia,

ICD-10, DSM-5, etc. SETTING: This study is conducted at Faculty of Homoeopathic

Sciences in Jayoti Vidyapeeth Women's University. RESULTS: Schizophrenia alters

the thinking, feeling and behavior of affected person and is presented in form of

delusion, hallucination with social withdrawal. Homoeopathy can be an alternative

mode of treatment to not only help in improving this condition but also treat the

same. There are not much studies that has been conducted to evaluate the role of

Homoeopathy in schizophrenia. Out of few, one study has suggested improvement in

the symptoms of paranoid schizophrenia using Brief Psychiatric Rating Scale

(BPRS) score system. CONCLUSIONS: Schizophrenia is a psychiatric condition not

only affecting routine of daily of life but also the Quality of life. Homoeopathy

is a non-toxic, gentle, permanent treatment which is based on totality of

symptoms (TOS) and individualization. In the process of construction of TOS and

individualization, more importance is given to mental symptoms. As again

pschizophrenia is a psychiatric condition which affects the mental process of

patient, Homoeopathy can be used as an effective method of treatment but to

establish the efficacy of it, more studies including randomized controlled trials

are suggested.

FAU - Gupta, Gaurav

AU - Gupta G

LA - eng

PT - Journal Article

PT - Review

PL - United States

TA - Altern Ther Health Med

JT - Alternative therapies in health and medicine

JID - 9502013

SB - IM

MH - Humans

MH - Female

MH - *Schizophrenia/diagnosis/therapy

MH - *Homeopathy

MH - Quality of Life

EDAT- 2021/08/29 06:00

MHDA- 2023/07/03 06:41

CRDT- 2021/08/28 12:06

PHST- 2023/07/03 06:41 [medline]

PHST- 2021/08/29 06:00 [pubmed]

PHST- 2021/08/28 12:06 [entrez]

AID - AT6455 [pii]

PST - ppublish

SO - Altern Ther Health Med. 2023 Jul;29(5):164-169.